2013 AES Annual Meeting, Washington, D.C

Transcription

PROGRAM
BOOK
67th Annual Meeting
Walter E. Washington
Convention Center
Washington, D.C.
the place to be
for more research
networking
education
special interest groups
exhibitors &
programs for junior members
NEW FORMULATIONS
Now Available
ONFI (clobazam) 10 mg and 20 mg scored tablets & 2.5 mg/mL oral suspension
New Scored Tablets: 10 mg and 20 mg
• New oval shape with a functional score
5 mg tablet is no longer available.
New Oral Suspension: 2.5 mg/mL
• Bottle contains 120 mL
• Berry flavor
Learn more about ONFI
at BOOTH #115
For more information go to ONFIhcp.com
©2013 Lundbeck. All rights reserved.
ONFI is a registered trademark of Lundbeck CLB-B-00002 09/2013
1
WELCOME MESSAGE
Welcome to Washington, D.C., and our 67th AES Annual Meeting. You will find within these pages a broad schedule of
programs, exhibits, social events, and networking opportunities that invite your participation – quality educational
sessions organized by your AES Annual Meeting and Scientific Program Committees targeted to the professional
needs and wide interests of meeting attendees.
New
Suds for Scientists Reception – Meet new friends and enjoy informal networking, appetizers and a cash bar
on Sunday 5:00 p.m. – 6:00 p.m. in Exhibit Hall D, Level Two. A portion of each beverage purchase will aid
AES Lennox and Lombroso Trust.
The following programs are back by the feedback you have given us:
n
Skills Workshops – High interest continues in the limited-attendance, smaller, more focused intensives introduced
two years ago. New among Tuesday’s six intensives is a workshop on the effective use of neurostimulation.
n
Town Hall Meeting: Federal Support of Epilepsy Initiatives – Saturday, December 7 from 7:00 a.m.-8:30 a.m.
in Room 206 on Level Two at the Convention Center.
n
Poster Walking Tours – Enhanced learning opportunities during the authors present times at Poster Sessions 1,
2 and 3 can be enjoyed by joining one of the popular poster walking tours led by AES leadership.
n
Social Networking Groups – SIG, Investigators’ Workshop and symposium participants have a greater opportunity
to meet and continue group discussions during social networking hours on Sunday from 8:00 p.m. – 10:00 p.m.
n
Annual Meeting Mobile App – Keep meeting information conveniently at hand, network with fellow attendees,
exchange private messages, and more, all on your mobile device. To get connected, go to
www.AESnet.org/mobileapp/applist
n
virtualTotebag – The virtualTotebag can connect you to all important meeting information. Use the virtualTotebag
to access, store and share exhibitor and session material. Refer to the flyer in your meeting bag or go to
www.AESnet.org/meetings-and-events for details.
n
Fellows Program – AES is again sponsoring 95 neurology trainees in approved epilepsy fellowships, including 10
Ph.D.s doing epilepsy research, invited to this meeting to pair with mentors for career guidance and support.
The program is made possible by grants from Lundbeck Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc.,
Eisai Inc, Acorda Therapeutics, Cyberonics, Inc, Supernus Pharmaceuticals, Inc., and Questcor Pharmaceuticals, Inc.
Last, but not least, is AES’s commitment to provide Learning Opportunities to Advance and Maintain Professional
Competence. The requirement for MD licensed and certified clinicians to follow Maintenance of Certification (MOC),
and with the advent of the Subspecialty Certification exam in Epilepsy (administered by the American Board of
Psychiatry and Neurology), the American Epilepsy Society has moved in service to its members. For three years now
AES has identified ABPN Core Competencies and secured ABPN review for each annual meeting symposium.
Within recent weeks, the Society has also launched the AES Epilepsy Learning Institute (ELI), a Learning Management
System (LMS). This new LMS will offer American Board of Psychiatry and Neurology (ABPN) authorized epilepsy Part II
Self-Assessment exams for CME credit as well as CME online courses.
Again, welcome to our 67th Annual Meeting. Learn, network and have fun.
Jacqueline A. French, M.D.
President, American Epilepsy Society
In Memory of Two Very Special AES Past Presidents
Cesare T. Lombroso, M.D., Ph.D.
2
Eli S. Goldensohn, M.D.
1917 to 2013
1915 to 2013
AES President 1987
AES President 1968
TABLE OF CONTENTS
FRIDAY
SATURDAY
SUNDAY
MONDAY
TUESDAY
Epilepsy Specialist Symposium ......................................................25
Annual Fundamentals of Epilepsy .................................................25
Advances in the Management of Epilepsy and
the Epilepsy Clinic...................................................................................26
Professional Development in AES ...............................................26
Special Interest Group Meetings ................................................26
Hoyer Lecture ................................................................................................27
Spanish Symposium ..................................................................................27
North American Commission / Commission on
European Affairs Symposium .......................................................28
Mentoring Session for Junior Investigators .....................29
Town Hall Meeting.......................................................................................29
Presidential Symposium........................................................................30
Professionals in Epilepsy Care Symposium ........................30
Translational Research Symposium ...........................................31
Antiepileptic Therapy Symposium ................................................31
Translational Investigators’ Workshops ................................33
Poster Session 1 ........................................................................................34
ASET Technology Course ......................................................................43
Investigators’ Workshops ...................................................................43
Annual Course ................................................................................................44
Reception: Suds for Scientists .....................................................46
Social Networking Groups ..................................................................46
Poster Session 2 ........................................................................................47
Merritt-Putnam Symposium .............................................................55
Lennox and Lombroso Lecture .......................................................56
Investigators’ Workshop ......................................................................57
Pediatric Epilepsy Highlights Session......................................57
Pediatric State of the Art Symposium ..................................58
Platform Sessions ......................................................................................59
Poster Session 3 ........................................................................................60
Scientific Symposium ..............................................................................69
Hot Topics Symposium ...........................................................................70
Skills Workshops ..........................................................................................70
Watch for
these
2014 dates!
TABLE OF CONTENTS
Meeting
Information
Schedule-at-a-Glance ..............................................................................10
Poster Walking Tours ...............................................................................13
Poster Map and Schedule .................................................................14
AES Special Recognition ......................................................................16
Nurse and Grass Awardees .............................................................18
Young Investigator Awardees ..........................................................19
Special Interest Group Schedule .................................................20
Scientific Exhibit Schedule .................................................................21
Exhibitors............................................................................................................72
Abstract Author Index ...........................................................................83
General Information ...............................................................................107
Faculty Ready Room and Photos ..............................................109
Annual Meeting
Call for Abstracts
Available
March 1, 2014
AES Research Recognition
and Distinguished
Achievement Awards
Nominations
August 1, 2014
AES Annual Meeting
and 5th Biennial North
American Epilepsy Congress
December 5-9, 2014
Seattle, WA
4th North American Regional
Caribbean Congress on
Epilepsy (NARCCE)
Registration now open
www.epilepsycaribbean.org
May 22 – 24, 2014
Rodney Bay, St. Lucia
Partners Against Mortality
in Epilepsy (PAME)
June 19 – 22, 2014
Minneapolis, MN
3
“ How do I convince my son I’m
going to be fine when I don’t
always believe it myself?
“
Sponsored by Upsher-Smith Laboratories, Inc.
© 2013 UPSHER-SMITH LABORATORIES, INC. All rights reserved.
108382.01
4
Take a Walk in
SARAH’S
Shoes
At Booth #447
5
6
7
Easy, convenient, green . . .
The AES virtualTotebag is back!
Lighten your load and receive session handouts
and important meeting information electronically!
Accounts have been pre-created for all
pre-registered attendees.
On-site registrants may sign up on-line.
For instructions:
Please refer to the flyer provided in your
meeting bag or for further details go to
www.AESnet.org/meetings-and-events
Questions?
VirtualTotebag Support Desk:
410.402.1062
Email: [email protected]
Go here:
www.AESnet.org/mobileapp/applist
5 Ways to Enhance Your
AES Annual Meeting Experience with
Social Media
1. Join in the conversation – use the Twitter hashtag #AESMTG13, AES LinkedIn group or the AES
Facebook page to follow annual meeting activities, speakers, events and conversations.
2. “Attend” more than one session at a time – seeing posts from various sessions throughout the AES
meeting will allow you to eavesdrop on more than one session at a time.
3. Find New Friends – use the “Social” icon on the Annual Meeting App to communicate with attendees
4. Expand your notes – think about social media as a way to collect your notes and share thoughts about
the sessions with others.
5. Maintain connections – maintain connections virtually with those you meet at the Annual Meeting.
For your convenience, Wi-Fi is available in all the AES meeting and session rooms
at the Convention Center, as well as the Registration Area
Network Name (SSID): AES Attendee Wifi
Password: AES2013DC
American Epilepsy Society
8
is proud to recognize the following supporters
of the 2013 Annual Meeting.
Leader Level
$250,000 – $499,999
Eisai Inc.
Lundbeck Pharmaceuticals, Inc.
UCB, Inc.
Sunovion Pharmaceuticals Inc.
Partner Level
$100,000 – $249,999
Upsher-Smith Laboratories, Inc.
Supporter Level
$50,000 – $99,999
Questcor Pharmaceuticals, Inc.
Cyberonics, Inc.
Supernus Pharmaceuticals, Inc.
Pfizer Inc.
Contributor Level
$25,000 – $49,999
Nihon Kohden America, Inc.
Acorda Therapeutics
Compumedics Limited
Advocate Level
$10,000 – $24,999
NeuroPace
ELEKTA
Natus Neurology Incorporated
GlaxoSmithKline
Cadwell Laboratories, Inc.
Electrical Geodesics, Inc.
Medtronic, Inc.
Patron Level
$5,000 – $9,999
Visualase, Inc.
Ad Tech Medical Instrument Corp.
Lifelines Neurodiagnostic Systems, Inc.
Blackrock NeuroMed
Neuralynx, Inc.
PMT Corporation
Ripple LLC
Epilepsy Foundation
Listing is in order of support level as of October 21, 2013
9
SCHEDULE-AT-A-GLANCE
THURSDAY
5:00 p.m. - 7:00 p.m.
December 5
Registration
Convention Center – L Street Bridge, Level Two
FRIDAY
7:00 a.m. - 6:00 p.m.
December 6
Registration
3:30 p.m. - 5:30 p.m.
8:30 a.m. - 11:30 a.m.
Convention Center – Ballroom C, Level Three
Epilepsy Specialist Symposium:
Treating the New Onset Epilepsy Patient
3:30 p.m. - 6:00 p.m.
12:30 p.m. - 3:00 p.m.
Annual Fundamentals of Epilepsy Symposium:
Neuroimaging in Epilepsy: Focusing On the Focus
and Outside the Focus
Spanish Symposium: Treatment of Epilepsy:
Algorithms for the Selection of Pharmacological
and Non-Pharmacological Therapies
Convention Center – Salon C, Street Level
5:30 p.m. - 6:00 p.m.
1:30 p.m. - 3:00 p.m.
Hoyer Lecture: Pediatric Epilepsy: Small Steps,
Big Challenges
Symposia Break
Convention Center – Foyer – Ballroom C,
Level Three
Professional Development in AES:
A Program for Junior Members and Those in
Transition
6:00 p.m. - 7:30 p.m.
Special Interest Group Meetings
See page 20
Convention Center – Salon A, Street Level
6:00 p.m. - 8:00 p.m.
See page 20
NAC / CEA Symposium:
Big Science: Global Collaborations Improving
Epilepsy Care
SATURDAY
6:30 a.m. - 6:00 p.m.
Registration
December 7
2:30 p.m. - 5:00 p.m.
Professionals in Epilepsy Care Symposium:
Access to Epilepsy Care Across the Spectrum
2:30 p.m. - 5:00 p.m.
Translational Research Symposium:
New Approaches in the Search for a Cure
6:30 a.m. - 7:00 a.m.
Continental Breakfast
Convention Center – Concourse, Level Two
7:00 a.m. - 8:30 a.m.
Mentoring Session for Junior Investigators
Convention Center – Room 203, Level Two
Town Hall Meeting: Federal Support of Epilepsy
Initiatives
Convention Center – Ballroom B, Level Three
5:00 p.m. - 6:00 p.m.
5:15 p.m. - 8:00 p.m.
See page 20
8:30 a.m. - 11:45 a.m.
Presidential Symposium:
The Changing Landscape of Epilepsy Surgery
Noon - 6:00 p.m.
Poster Session 1
Symposia Break
Convention Center – Exhibit Hall D, Level Two
Antiepileptic Therapy Symposium:
One Size Does Not Fit All: Personalized Medical
Care
6:15 p.m. - 7:45 p.m.
See page 20
6:15 p.m. - 8:15 p.m.
Translational Investigators’ Workshop
Exhibits Grand Opening
Lunch: Noon - 1:00 p.m.
SUNDAY
7:30 a.m. - 6:00 p.m.
Registration
December 8
10:00 a.m. - 6:00 p.m.
8:00 a.m. - 5:00 p.m.
Poster Session 2
8:45 a.m. - 4:45 p.m.
Investigators’ Workshops
IW Posters / Boxed Lunch: Noon - 1:30 p.m.
See page 43
8:45 a.m. - 5:15 p.m.
Annual Course: An Algorithmic Approach to
the Diagnosis and Treatment of Non-lesional
Epilepsy
10
Reception: Suds for Scientists 5:00 p.m. - 6:00 p.m.
Scientific Exhibits
See page 21
Exhibit Hall
6:00 p.m. - 7:30 p.m.
See page 20
8:00 p.m. - 10:00 p.m.
Social Networking Groups
Renaissance, Room 8/9
MONDAY
6:30 a.m. - 7:00 a.m.
December 9
2:15 p.m. - 3:00 p.m.
7:00 a.m. - 6:00 p.m.
Registration
7:00 a.m. - 8:30 a.m.
3:45 p.m. - 5:15 p.m.
Poster Session 3
See page 20
3:45 p.m. - 6:00 p.m.
8:00 a.m. - 5:00 p.m.
Scientific Exhibits
Platform Sessions: 3 Concurrent Sessions
See page 59
Merritt-Putnam Symposium:
How We Will Be Treating, Preventing and Curing
Epilepsy in the Year 2025
5:15 p.m. - 6:15 p.m.
6:15 p.m. - 8:45 p.m.
See page 20
10:00 a.m. - 3:30 p.m.
Exhibit Hall
TUESDAY
December 10
Registration
8:30 a.m. - 10:30 a.m.
6:30 a.m. - 7:00 a.m.
Convention Center – Concourse, Room 102B,
Street Level
7:00 a.m. - 8:30 a.m.
Hot Topics Symposium:
New Insights into Basic Mechanisms, Diagnosis
and Treatment of Epilepsy
10:45 a.m. - 12:15 p.m.
See page 20
8:30 a.m. - 10:30 a.m.
Pediatric State of the Art Symposium:
Genetics of Catastrophic Infantile Epilepsies:
From Gene Discovery to Practical Clinical
Applications
7:00 a.m. - 12:30 p.m.
Symposia Break
Convention Center – Foyer, Ballroom B,
Level Three
9:00 a.m. - 10:30 a.m.
Pediatric Epilepsy Highlights Session
See page 21
8:45 a.m. - Noon
Investigators’ Workshop
See page 20
8:00 a.m. - 3:30 p.m.
Lennox and Lombroso Lecture
Psychiatric Comorbidities Through “The Life” of
The Seizure Disorder: A Complex Story With a
Not So Complex Solution
Convention Center – Concourse, Room 102B,
Street Level
Scientific Symposium: Biomarkers for
Epileptogenesis and Neurocognitive and
Neurobehavioral Comorbidities
Skills Workshops #1 (6 Concurrent Sessions)
(separate registration required)
See page 70
12:30 p.m. - 2:00 p.m.
Skills Workshops #2 (6 Concurrent Sessions)
(separate registration required)
See page 70
2013 AES BOARD OF DIRECTORS
PRESIDENT
BOARD MEMBERS
EX-OFFICIO
Janice M. Buelow, RN, Ph.D.
Gregory K. Bergey, M.D. (Epilepsy Currents)
FIRST VICE PRESIDENT
Elson L. So, M.D.
David M. Labiner, M.D.
Douglas A. Coulter, Ph.D. (Research and Training Council)
Page Pennell, M.D.
Brandy Fureman, Ph.D. (NINDS Liaison)
Helen Scharfman, Ph.D.
Robert Edward Hogan, M.D. (Council on Education)
Shlomo Shinnar, M.D., Ph.D.
Cesare T. Lombroso, M.D., Ph.D.
Karen S. Wilcox, Ph.D.
Joseph Sirven, M.D. (Epilepsy Foundation)
SECOND VICE PRESIDENT
Amy Brooks-Kayal, M.D.
TREASURER
Michael D. Privitera, M.D.
ASSISTANT TREASURER
William D. Gaillard, M.D.
PAST PRESIDENT
Frances E. Jensen, M.D.
Dennis D. Spencer, M.D. (Development Council)
Sheryl Haut, M.D. (ILAE Liaison)
William H. Theodore, M.D. (Communications Council)
James Wheless, M.D. (Council on Clinical Activities)
Philip Gattone (Epilepsy Foundation)
11
The American Epilepsy Society
is pleased to announce
INNOVATION PAVILIONS
located inside the Exhibit Hall
Convention Center – Hall D, Level Two
These pavilions offer companies an opportunity to
provide education and training to Annual Meeting attendees
in a convenient and more personal environment.
The Innovation Pavilions will be open on the following days:
Saturday, December 7: 12:00 p.m. - 6:00 p.m.
Lundbeck Pharmaceuticals (A) • Lundbeck Pharmaceuticals (B) •
NeuroPace (C)
New
Suds for Scientists and
Exhibit Hall Reception
Sunday, December 8
5:00 p.m. – 6:00 p.m.
Join your colleagues for appetizers and a
cash bar. A portion of the sale of each
beverage will support the Lennox and
Lombroso Trust.
Sunday, December 8: 10:00 a.m. - 6:00 p.m.
Questcor Pharmaceuticals, Inc. (A) • Lundbeck Pharmaceuticals (B) •
NeuroPace (C)
Monday, December 9: 10:00 a.m. - 3:30 p.m.
Questcor Pharmaceuticals, Inc. (A) • Eisai Inc. (B) •
Sunovion Pharmaceuticals Inc. (C)
Supported in part by Electrical Geodesics, Inc.
and Supernus Pharmaceuticals, Inc.
EQUIPMENT AUCTION TO BENEFIT:
THE LENNOX AND LOMBROSO TRUST FOR RESEARCH AND TRAINING
AND
THE SUSAN S. SPENCER FUND FOR CLINICAL EDUCATION AND RESEARCH
American Epilepsy Society (AES) is pleased to announce that Nihon Kohden participated in the 2013 AES Annual Benefit Auction.
Each year companies can participate in this benefit by either contributing equipment and/or software to be auctioned off, and the
winning bid is announced at the Annual Meeting.
This year Nihon donated a new 1200A Diagnostic and Monitoring Solution, which includes the cart, camera and microphone.
The high bid of $25,120 was submitted and won by Mary Washington Healthcare which includes Mary Washington Hospital in
Fredericksburg, Virginia and Stafford Hospital in Stafford, Virginia.
Nihon Kohden is contributing 100% of the proceeds to the Lennox and Lombroso Trust for Research & Training and the Susan S.
Spencer Fund for Education and Research. Nihon Kohden executives will present a check to the American Epilepsy Society on
Saturday, December 7 at 1:00 p.m. on the floor of the exhibit hall.
AES thanks Nihon Kohden for their continued support and for again participating in the annual equipment auction. We also thank
those that participated in bidding.
AES welcomes more companies participating in this equipment auction. If you know of a company or work for one yourself that
would be interested in participating next year, please let us know. We will be happy to help you with the process! Please contact Jeff
Melin at 203-586-7505 or [email protected] to learn more.
12
There are many ways
to support AES:
AES New Initiatives Fund
The Fritz Dreifuss Epilepsy Fund
Rebecca Goldberg-Kaufman Ethical
Neuropsychiatry Fund
Lennox and Lombroso Trust for Research
and Training
J. Kiffin Penry Fund
Susan S. Spencer Clinical Education and
Research Fund
Support AES today with your gift
www.AESnet.org/contributions
Participate in the AES
PASSPORT
TO PRIZES
PROGRAM
Poster Walking Tours
This program is designed for students, residents, fellows, and junior faculty
to meet with AES mentors and visit interesting, compelling, or novel
posters discussing their perspectives on how the presented data is
meaningful. Poster walking tours will be held on the days noted below and
cover the topics displayed on that day. Mentors and participants will meet
at the Poster Information table near the front of the Poster Hall. The
tours will depart each day during the authors’ present times noted below.
Approximately six posters will be discussed in each category. These
posters have been pre-selected by the mentors. Selections are for
educational purposes only and are not based on merit. Poster Sessions
and authors’ present times are noted below:
Saturday, December 7
Poster Session 1
Authors Present: Noon – 2:00 p.m.
Sunday, December 8
Poster Session 2
Monday, December 9
Poster Session 3
There are daily prize drawings and a Grand Prize
Drawing on Monday in the Exhibit Hall in the Epilepsy
Resource Center.
Prize Drawing Schedule:
SATURDAY, DECEMBER 7
Prize Drawing – 5:30 p.m.
SUNDAY, DECEMBER 8
Prize Drawing – 5:30 p.m.
MONDAY, DECEMBER 9
Prize Drawing & Grand Prize Drawing – 3:00 p.m.
In your AES Annual Meeting bag, as well as the virtualTotebag,
you will find a Passport brochure. To be included in the drawing to
win a variety of great prizes, visit the booths of participating
exhibitors to get your Passport validated. The more exhibitors you
visit, the better the prize.
Please complete your contact information and drop the passport
in the raffle drum located in the Epilepsy Resource Center.
Participants must be present to win. See your Passport for a list
of participating exhibitors.
13
POSTER MAP SESSIONS 1, 2, 3
Walter E. Washington Convention Center
Late Breaking Abstracts
Poster Information Table
Poster Walking Tours begin at the Poster Information table
Questions? Please visit the Poster Information table in front of the poster area.
14
POSTER SCHEDULE
Poster Session 1: Noon – 6:00 p.m. – Convention Center, Hall D, Level Two (see pages 34-42)
Authors Present: Noon – 2:00 p.m. (1.001 – 1.310)
Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 13)
Translational Research
Neurophysiology
Clinical Epilepsy
Neuroimaging
Comorbidity (Somatic and Psychiatric)
Antiepileptic Drugs
Surgery
Behavior / Neuropsychology / Language
Genetics
1.001
1.069
1.125
1.165
1.195
1.203
1.240
1.268
1.292
–
–
–
–
–
–
–
–
–
1.068
1.124
1.164
1.194
1.202
1.239
1.267
1.291
1.310
POSTER SCHEDULE
Sunday, December 8
Poster Session 2: 8:00 a.m. – 5:00 p.m. – Convention Center, Hall D, Level Two (see pages 47-54)
Professionals in Epilepsy Care
Neurophysiology
Clinical Epilepsy
NeuroImaging
Comorbidity (Somatic and Psychiatric)
Antiepileptic Drugs
Surgery
Health Services
Neuropathology of Epilepsy
Epidemiology
Public Health
Case Studies
2.001
2.010
2.024
2.078
2.101
2.116
2.175
2.202
2.230
2.249
2.259
2.281
2.290
–
–
–
–
–
–
–
–
–
–
–
–
–
2.009
2.023
2.077
2.100
2.115
2.174
2.201
2.229
2.248
2.258
2.280
2.289
2.312
Investigators’ Workshop Lunch Poster Session
Noon – 1:30 p.m.
Convention Center – Room 207, Level Two (see pages 43-44)
Monday, December 9
Poster Session 3: 8:00 a.m. – 3:30 p.m. – Convention Center, Hall D, Level Two (see pages 60-67)
Neurophysiology
Clinical Epilepsy
Neuroimaging
Antiepileptic Drugs
Non-AED/Non-Surgical Treatments
Surgery
Genetics
Abstract Author Index – see pages 83-96
3.001
3.075
3.123
3.168
3.200
3.220
3.246
3.253
3.263
3.282
–
–
–
–
–
–
–
–
–
–
3.074
3.122
3.167
3.199
3.219
3.245
3.252
3.262
3.281
3.287
15
AES SPECIAL RECOGNITION
Epilepsy Research Recognition Awards
Saturday, December 7 – 8:30 a.m.
(Immediately preceding the Presidential Symposium)
The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research.
The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for the improved understanding and
treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program.
Award for Basic Science
Award for Clinical Science
Jaideep Kapur, M.D., Ph.D.
Torbjörn Tomson, M.D., Ph.D.
Jaideep Kapur, M.D., Ph.D., is Eugene Meyer III Professor of Neuroscience, Professor of
Neurology, and Director, Neuroscience Center of Excellence, University of Virginia. He
received his medical degree from Maulana Azad Medical College, Delhi University,
completed a fellowship in epilepsy and clinical neurophysiology at the University of
Michigan, and residencies in clinical electrophysiology (University of Michigan), neurology
(Medical College of Virginia), and internal medicine (Eastern Virginia University).
Torbjörn Tomson, M.D., Ph.D., is Professor of Neurology and Epidemiology, Department of
Clinical Neuroscience of Karolinska Institute, Stockholm, Sweden. He received his medical
and neurology training at Karolinska Institute. Dr. Tomson pursued research in
pharmacology at Karolinska’s Soder Hospital. He has served as head of the epileptology
section of the Soder Department of Neurology and currently heads the epileptology section
at Karolinska University Hospital.
Dr. Kapur has made some of the most seminal contributions in epileptology regarding basic
mechanisms of status epilepticus, demonstrating that the brain is not a static structure
during status epilepticus. His early collaborative studies made it clear that benzodiazepine
responsiveness of patients in status epilepticus changes over time and that early treatment
is crucial. In subsequent work Dr. Kapur and his colleagues have made many contributions
regarding molecular and cellular alterations in GABA receptor and, more recently,
glutamate receptors in models of status epilepticus. His studies extend to understanding
neurosteroid regulation of seizures.
Dr. Tomson’s pioneering research in AED pharmacokinetics and metabolism, pregnancy
outcomes in association with AED exposure, and SUDEP have had immediate clinical
relevance and global impact in guiding epilepsy management. He showed for the first time
that people with active epilepsy have an altered variability in heart rate, which correlates
with a higher risk of SUDEP. He was one of the initiators of the international antiepileptic
drugs and pregnancy registry, which he is currently leading. He was among the first to
provide evidence of SUDEP risk factors, that mortality rates are increased three-fold in
people with epilepsy, and that excess mortality occurs across many causes.
Dr. Kapur is widely published in leading journals in neuroscience, neurology, epilepsy and
other professional specialties, and the author of nine book chapters. His service to the
profession includes a term as AES president and more than 15 years’ service on diverse
AES committees, plus memberships on a variety of boards, committees, and workshops for
ILAE, AAN, EF, NIH and other related professional and lay organizations.
Dr. Tomson is a prolific contributor to the scientific literature with over 100 peer-reviewed
papers and a like number of reviews, book chapters and invited commentaries. He is the
co-founder and served as secretary of the Swedish Chapter of ILAE, and has served on
many ILAE Commissions, often in leadership positions.
A $10,000 award is provided by the Lennox and Lombroso Trust Fund
William G. Lennox Award
Monday, December 9 – 8:45 a.m.
(Immediately preceding the Merritt-Putnam Symposium)
René Levy, Ph.D.
Dr. Levy received his bachelor’s degree in pharmacy in 1965 from the University of Paris, France, and his doctorate in pharmaceutical chemistry at the University of California San
Francisco in 1970. Dr. Levy served as chair of the Department of Pharmaceutics at the University of Washington from its creation in 1980 until 2006. Dr. Levy held a concurrent
appointment as professor of Neurological Surgery for over three decades.
Dr. Levy’s epilepsy research program began under the influence of Drs. Arthur Ward (then Chair of Neurological Surgery) and H. Kiffin Penry (then Director of the Epilepsy Branch at the
NINDS). It focused on the optimization of animal models of epilepsy through a thorough understanding of drug disposition and the translation of those approaches to the clinical
evaluation of newer antiepileptic drugs. Later, Dr. Levy became a pioneer in the understanding of the molecular determinants of the metabolism of antiepileptic drugs that allowed a
rational approach to the prediction of drug-drug interactions and to the mechanisms of drug toxicity.
Dr. Levy published more than 300 articles with special emphasis on the disposition, toxicity and interaction potential of antiepileptic drugs. He has co-edited several books including
Metabolism and Antiepileptic Drugs (1984); Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity (1991);
Metabolic Drug Interactions (2000); and multiple editions of the classic epilepsy text Antiepileptic Drugs (2002). Dr. Levy developed the Metabolism and Transport Drug
Interaction Database of the University of Washington (2002) used worldwide by drug discovery and development scientists.
Dr. Levy taught extensively on various aspects of the pharmacological treatment of epilepsy, training scientists and establishing various workshops and conferences. He also served within
the ILAE as member/chair of commissions related to antiepileptic drugs. In 1989, Dr. Levy was named Ambassador for Epilepsy by the International Bureau of Epilepsy. In 2007 he
became Fellow of the American Association for the Advancement of Science. In 2011, Dr. Levy received the Arthur A. Ward Lifetime Achievement Award from the Epilepsy Foundation
Northwest.
16
AES SPECIAL RECOGNITION
AES Service Award
Roger J. Porter, M.D.
Roger J. Porter, M.D. is the Chief Scientific Officer of the Epilepsy Foundation, Adjunct
Professor of Neurology at the Univ. of Pennsylvania, an Adjunct Professor of Pharmacology
at USUHS and he is also a consultant to the pharmaceutical industry, primarily in the
development of antiepileptic drugs and devices. His education includes Eckerd College (BS,
1964), Duke Univ (MD, 1968), UCalifSD (Internship, 1968-69) and UCalifSF (Residency in
Neurology, 1971-74). He spent 20 years at the National Institutes of Health (NIH), in
leadership positions including Chief of the Epilepsy Branch, Chief of the Medical Neurology
Branch, and Deputy Director of the National Institute of Neurological Disorders and Stroke
(NINDS). He left the NIH in 1992 to become Vice President, Clinical Pharmacology at Wyeth
and was promoted to Vice President and Deputy Head of Clinical Research at Wyeth Research
in January 1998. As VP and Deputy Head of Clinical Research, Dr. Porter had worldwide
responsibility for numerous clinical programs including 200 persons in Europe, Canada, Latin
America, and Asia, 65 in Worldwide Clinical Pharmacology and 40 in Global Health
Outcomes Assessment. Dr. Porter retired from Wyeth in 2002. Most of Dr. Porter’s research
has been in epilepsy and the study of antiepileptic drugs; he has published more than 200
articles/chapters and 13 books. His other leadership positions include Chairman of the White
House Committee on Brain and Behavioral Sciences (1990-1992), President, American
Epilepsy Society (1989-1990), and Secretary-General of the International League Against
Epilepsy (1989-1993). He is the past President of the American Society for Experimental
NeuroTherapeutics (ASENT). He is Past-Secretary of the College of Physicians of Philadelphia
and a Fellow of the American Academy of Neurology. He is the recipient of numerous awards
including the Distinguished Alumnus Award from Duke Univ. Medical Center, the USPHS
Distinguished Service Medal, and Doctor of Science (Hon) from Eckerd College.
Lennox and Lombroso Lecturer
Monday, December 9 – 2:15 p.m.
Andres M. Kanner, M.D.
Dr. Andres M. Kanner is a Professor of Clinical Neurology and Psychiatry at the University of
Miami, Miller School of Medicine, which he joined in January 2013. He is also the Head of
the Epilepsy Section in the Department of Neurology and the Director of the Comprehensive
Epilepsy Center. Before moving to Miami, he had been 21 years at Rush Medical College of
Rush University in Chicago, where he was Professor of Neurological Sciences and Psychiatry.
Dr. Kanner's research and publications have focused on pharmacologic, surgical and
psychiatric aspects of treatment-resistant epilepsy. He has edited and co-edited seven
textbooks and has authored and co-authored more than 80 original research articles in peerreviewed scientific journals. Dr. Kanner has served in several committees of the AES and as of
January 1st 2014, he will be chair of the Practice committee and Senior Clinical Editor of
Epilepsy Currents. Dr. Kanner has been the recipient of several awards including the J. Kiffin
Penry Award from the American Epilepsy Society, the Ambassador of Epilepsy from the
International League Against Epilepsy and the Epilepsy Hero's Award from The Epilepsy
Foundation of Chicago.
J. Kiffin Penry Excellence in
Epilepsy Care Award
Saturday, December 7 – 5:15 p.m.
(Immediately preceding the AET Symposium)
Gregory D. Cascino, M.D.
Gregory D. Cascino, M.D. is the recipient of the 2013 J. Kiffin Penry Excellence in Epilepsy
Care Award. Dr. Cascino is the Whitney MacMillan, Jr. Professor of Neuroscience at the Mayo
Clinic College of Medicine and the Chair, Division of Epilepsy at Mayo Clinic, Rochester, MN.
He attended Northwestern University and received his degree in medicine from Rush Medical
College. Dr. Cascino completed an internal medicine residency at Duke University in Durham,
NC and a neurology residency and clinical neurophysiology fellowship at the Massachusetts
General Hospital in Boston, MA. He then became the director of the Francis M. Forster
Epilepsy Center at the William S. Middleton Memorial Veterans Hospital in Madison, WI. In
1988, Dr. Cascino joined the staff of the Mayo Clinic. His interests have included the
identification of surgically remediable epileptic syndromes in patients with medically
refractory seizures. Dr. Cascino and colleagues confirmed the importance of MRI-identified
hippocampal atrophy in patients with medial temporal lobe epilepsy and performed the
initial studies on stereotactic lesionectomy, hippocampal formation volumetry, and subtraction
ictal SPECT co-registered with MRI (SISCOM). He was the William G. Lennox lecturer
“Advances in Imaging” at the 1999 AES Annual Meeting. Dr. Cascino is a site principal
investigator in the NIH-funded multicenter Epilepsy Phenome Genome Project and the Human
Epilepsy Project. He has published over 200 peer-reviewed articles and presented over 350
invited lectures. Dr. Cascino has participated in the training of 75 epilepsy-EEG fellows. He is
currently an Associate Editor of Neurology and is a member of the AAN Board of Directors.
He previously served on the AES Board of Directors, the ACNS Council, and the Professional
Advisory Board Executive Committee of the Epilepsy Foundation of America. He was a past
President of the Section on Epilepsy of the AAN.
AWARDEES
Friday, December 6 – 3:30 p.m.
(Immediately preceding the
Hoyer Lecture)
Extraordinary Contributions Award
Saturday, December 7 – 8:30 a.m.
(Immediately preceding the Presidential
Symposium)
Russell (Rusty) Katz, M.D.
Dr. Katz graduated from the Albert Einstein College of Medicine in New York City in 1977,
and completed his training in Neurology at the Einstein affiliated hospitals in 1982. In 1983
he joined the Food and Drug Administration (FDA) as a medical officer in what was then the
Division of Neuropharmacological Drug Products (DNDP), the unit of the FDA responsible for
the regulation of research with investigational treatments as well as the approval of
treatments for neurologic and psychiatric disease. Several years after joining DNDP, Dr. Katz
became the Deputy Director of DNDP, and in 1999 he became the director of what is now
known as the Division of Neurology Products (which deals solely with treatments for
neurologic disease). Dr. Katz has lectured extensively on all aspects of the development of
treatments for neurologic disease and has written numerous book chapters and articles on
these topics.
17
NURSE AWARDEES
Contact Author
Abstract Title
Jennifer Disabato, DNP, CPNP-PC
Improving Transition To Adult Epilepsy Care: Facilitating Team Communication Using
Clinical Decision Support In The EMR
Poster
2.006
Margo DeVries-Rizzo, M.Sc.N., RN Demonstrating Health Care Savings By Capturing Nurse Practitioner Epilepsy Telephone Care
2.001
Felice Espinosa, B.S.N., RN
Reducing Cycle Time Of EMU Admissions From Arrival To Start Of Hook Up
2.003
Erin Fecske, M.S.N., RN, CNRN
Utilization Of IVs In The Pediatric Epilepsy Monitoring Unit
2.258
Megan Gustafson, RN
The Combined Use Of Clobazam Along With Ketogenic Diet In Children With Refractory Epilepsy
3.228
Kamie McEachran
The Simultaneous Use Of Ketogenic Diet And Vagus Nerve Stimulator In Patients With
Pharmacologically Refractory Epilepsy
3.234
Joellan Mullen, M.S.N., RN, CCRN Preventing Skin Breakdown In EEG Patients
2.004
Tara Myers, CPNP
The Correlation Between Betahydroxybutyrate And Urine Ketone Measurements During
Ketogenic Diet Initiation And The Differences Between Patients Older And Younger
Than 2 Years Of Age
3.235
Joy L. Zajac, M.S.N., PNP
Palliative Resective Epilepsy Surgery: The Cook Children’s Experience
2.186
Acknowledgment: Nurse awards are supported by Eisai Inc.and Upsher-Smith Laboratories, Inc.
GRASS AWARDEES
This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy.
Awardees are selected from young investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined
resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the
American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer
Lecture on Friday, December 6. Congratulations to the following awardees:
18
Contact Author
Abstract Title
Poster / Platform
David Auerbach, Ph.D.
Heart Rate Variability Analysis Reveals Altered Autonomic Tone In
A Mouse Model Of Dravet Syndrome
C.02
Karen Blackmon, Ph.D.
Pre-Surgical Corpus Callosum Midsagittal Cross-Sectional Area Predicts Post-Surgical
Resilience In Working Memory
3.177
David Cantu, Ph.D.
Traumatic Brain Injury Alters Cortical Glutamate Network Function By Compromising
GABAergic Inhibition
C.04
Catherine Christian, Ph.D.
Diazepam Binding Inhibitor Knockout Mice Display Increased Absence Seizures And
Loss Of Thalamic Endozepine Signaling
C.01
Shanti Frausto, B.S.
Epilepsy-Associated Deterioration In Hippocampal Dentate Gyrus Network Firing Properties
1.105
Jochen Meyer
In Vivo 2-Photon Confocal Microscopy Of Cortical Absence Epilepsy
1.102
Lidia Maria Veras Rocha
de Moura, M.D.
Long-Term Outcomes Of Disconnection Vs. Vagal Nerve Stimulation For Drug Resistant Epilepsy
3.247
Ivan Sanchez-Fernandez
Patients With Electrical Status Epilepticus In Sleep And No Macroscopic Abnormalities
On Magnetic Resonance Imaging Have A Smaller Thalamic Volume Than Controls
3.171
YOUNG INVESTIGATOR AWARDEES
Poster /
Platform
Abstract Title
Vincent Alvarez, M.D.
Yield Of Repeated Standard EEGs Versus EEG Monitoring In Comatose Survivors Of
Cardiac Arrest Treated With Hypothermia
2.010
Omar J. Ahmed, Ph.D.
Epileptic Travelling Waves Are Shaped By Local Inhibitory And Excitatory Single Neuron
Activity In Humans
C.08
Elizabeth Andresen, Ph.D.
Mood And Behavior Outcome Following Pediatric Epilepsy Surgery
B.06
Pallavi Bhuyan, M.S.
Scavenging Seizure-Induced Reactive Oxygen Species With A Catalytic Antioxidant Attenuates
Neuroinflammation In Experimental Temporal Lobe Epilepsy
3.025
Christopher Conner
Controlled Retrieval And Domain Specific Parallel Connectivity In The Left Inferior Frontal Convolution
A.06
Hui Gong, M.D.
Risk Factors For Early Seizures, Status Epilepticus And Post-Traumatic Epilepsy In Infants With
Non-Accidental Head Injury
3.158
Mohammed Ilyas, M.D.
Palliative Surgical Resections In Children With Intractable Epilepsy And Bilateral Epileptic Foci:
Surgical Results In The Detroit Series
1.138
Saumya S. Jamuar, M.D.
Targeted Resequencing Identifies De Novo Mutations In Individuals With Epileptic Encephalopathies
1.293
Amy Loughman, B.Sc., B.A.
Cognitive Function In Idiopathic Generalized Epilepsies: A Meta-Analysis
2.226
Amy McTague
KCNT1 Mutations In A National Cohort Of Children With Migrating Partial Seizures Of Infancy
1.292
Negar Memarian, Ph.D.
Neocortical Gray Matter Maps Linked With Two Common Mesial Temporal Lobe Seizure
Onset Patterns
3.174
Rory J. Piper, B.Med.Sci.
Estimating Intracranial Volume Using Intracranial Area In Healthy Pediatric Subjects And
Those With Childhood Status Epilepticus
3.170
Eric Payne, M.D.
Electrographic Seizure Burden Is Associated With Short-Term Outcome In Critically Ill Children
2.011
Alyssa R. Rosen, M.D.
Seizures And Epilepsy In 16p11.2 Deletions And Duplications
1.300
Nicole Van Klink, MSc.
High Frequency Oscillations In Intra-Operative Electrocorticography: Pre- And Postresection
2.192
Zhong Wang, Ph.D.
Voxel-Based Morphometric MRI Post-Processing In “Nonlesional” Pharmacoresistant Focal Epilepsies
A.01
Ruta Yardi, M.D.
Antiepileptic Drug Withdrawal And Long-Term Epilepsy Recurrence After Surgery
B.08
Hongjie Yuan, M.D., Ph.D.
Functional Changes Of A De Novo GRIN2A Mutation In A Patient With Refractory Seizures And
Early-Onset Epileptic Encephalopathy
1.019
AWARDEES
Contact Author
Ackowledgment: Young Investigator Awards are supported by Eisai, Inc., Medtronic, Inc. and Upsher-Smith Laboratories, Inc.
19
SPECIAL INTEREST GROUP SCHEDULE
Friday 1:30 p.m. – 3:00 p.m.
Sunday 8:00 p.m. – 10:00 p.m.
n Basic Neuroscience: Neurocircuitry of Lennox-Gastaut Syndrome:
From Animal Models to Patients
(Convention Center – Room 102B, Street Level)
n Quality, Value and Safety (Convention Center – Room 204C, Level Two)
n Women with Epilepsy Across the Life Cycle: Impact of Genetics and
Brain Physiology (Convention Center – Room 202A, Level Two)
n Social Networking Groups – continuation of SIG discussions
(Renaissance – Room 8/9)
Friday 6:00 p.m. – 7:30 p.m.
n Critical Care EEG Monitoring: Beyond Seizure Detection
(Convention Center – Room 201, Level Two)
n Genetic Testing in the Epilepsy Clinic
(Convention Center – Room 204C, Level Two)
n Neuroimaging: Imaging Epileptogenesis
n SUDEP: Sudden Unexpected Death in Epilepsy
(Convention Center – Room 202A, Level Two)
n Tumor Induced Epilepsy (Convention Center – Room 204A/B, Level Two)
Saturday 7:00 a.m. – 8:30 a.m.
n Children’s Hour: Acute Treatment of Convulsive Seizures in Children
n Epidemiology Applied: Solving Problems in Epilepsy Care Through
Research (Convention Center – Room 204A/B, Level Two)
n Non-Profit Resources For Epilepsy Research: What We Don’t
Know That We Don’t Know About the Availability of Epilepsy Research
Resources (Convention Center – Room 202B, Level Two)
n Sleep in Epilepsy: The Borderland of Sleep and Epileptiform
Neural Activity (Convention Center – Room 204C, Level Two)
n Treating Convulsive Status Epilepticus with the Right Medication at
the Right Time (Convention Center – Salon A, Street Level)
n Why Private Practice Epilepsy (vs. Traditional Academic Epilepsy)? and
Update on Research Collaborations
Saturday 6:15 p.m. – 7:45 p.m.
n AED Pregnancy Registry Outcomes
(Convention Center – Salon A, Street Level)
n Ictal Semiology (Convention Center – Salon C, Street Level)
n Neuroendocrinology: Stress and Exercise in Epilepsy &
Epileptogenesis (Convention Center – Room 206, Level Two)
n Neurostimulation and Neuroengineering
Sunday 6:00 p.m. – 7:30 p.m.
n Basic Mechanisms Underlying Cognitive and Behavioral Deficits
Associated with Epilepsy (Convention Center – Salon A, Street Level)
n Cognitive / Behavioral Approaches for Treatment of Epileptic
Seizures and PNES (Convention Center – Room 101, Street Level)
n Funding Opportunities in the NINDS Phase II Clinical Trial Network,
NeuroNEXT
(Convention Center – Room 102A, Street Level)
n Temporal Lobe Club: Surgical Referrals for Epilepsy – Too Little Too
Late (Convention Center – Room 102B, Street Level)
20
Monday 7:00 a.m. – 8:30 a.m.
n Ketogenic Diet: Supplements and Alternatives
n Neuropharmacology: Clinical Relevance of Mechanisms of Action
(Convention Center – Room 101, Street Level)
n Posttraumatic Epilepsy (Convention Center – Salon A, Street Level)
n Tuberous Sclerosis: Utility and Application of mTOR Inhibitors in
Tuberous Sclerosis Complex: How and When to Start Treatment
Monday 9:00 a.m. – 10:30 a.m.
n EEG: What’s a Hell Conductor in Thalamus?
(Convention Center – Salon C, Street Level)
n Junior Investigators’ Workshop: Finding and Starting Your First
Academic Job (Convention Center – Room 101, Street Level)
n Neonatal Seizures: Do Neonatal Seizures Harm the Brain?
n Neuropsychology: Epilepsy and the Aging Brain —
Neuropsychological Perspectives
n Nursing: Highlighting Current Research
Monday 3:45 p.m. – 5:15 p.m.
n MEG Navigates to Neurosurgeons: A Trajectory of Success
(Convention Center – Room 202A, Level Two)
n Military Epileptologists: VA Telehealth Initiative and How It May Relate
to Epilepsy Care, Sleep Medicine / Epilepsy Comorbility, and Epilepsy
Care in the Elderly
(Convention Center – Room 101, Street Level)
n Psychogenic Nonepileptic Seizures
n Surgical Failures: Non-Lesional Epilepsy Surgery
Tuesday 7:00 a.m. – 8:30 a.m.
n Frontal Lobe Epilepsy: AED and Surgical Treatment Approaches in
Frontal Lobe Epilepsies: Update on Current Practices and
Controversies (Convention Center – Room 102B, Street Level)
n Pediatric Epilepsy Diagnosis and Treatment Opportunities —
Case-Based Discussion (Convention Center – Salon C, Street Level)
n Practice Management Course
(Convention Center – Room 102A, Street Level)
n Psychiatry in Epilepsy: Epilepsy Comorbidity Profiles: Treatment
Targets (Convention Center – Room 101, Street Level)
Help build better programs.
Use the online survey to provide feedback on SIGs
https://www.surveymonkey.com/s/2013SIG.
SCIENTIFIC EXHIBIT SCHEDULE
Scientific exhibits will be on display at this year’s Annual Meeting and will be located in
Room 102AB on the Street Level and Rooms 202B, 203AB and 204AB on Level Two of the
Convention Center. These exhibits will provide meeting attendees an opportunity to update
themselves on the latest research. Authors will be present throughout the exhibit.
Sunday, December 8 • 8:00 a.m. – 11:00 a.m.
Cyberonics, Inc.
VNS Therapy: Building a Foundation for the Treatment of Refractory Epilepsy
Room
102AB
Research Updates for Antiepileptic Therapies Clobazam, Vigabatrin, and IV Carbamazepine
202B
Visualase, Inc.
Clinical Update on MRI-Guided Laser Ablation for Minimally Invasive Neurosurgery
203AB
Supernus Pharmaceuticals Inc.
Trokendi XR™ and Oxtellar XR™: Advancing Patient Therapy with Supernus Technology
204BC
Sunday, December 8 • 2:00 p.m. – 5:00 p.m.
Eslicarbazepine Acetate: Developing a New Treatment for Epilepsy
Clinical Update on Epilepsy Pipeline
202B
204BC
Monday, December 9 • 8:00 a.m. – 11:00 a.m.
UCB, Inc.
Continuing UCB’s Long-Term Commitment to Epilepsy Management
202B
Monday, December 9 • 2:00 p.m. – 5:00 p.m.
Trokendi XR™ and Oxtellar XR™: Advancing Patient Therapy with Supernus Technology
204BC
21
22
Your gateway to educational needs and Maintenance of Certification (MOC)
Now you can access and find what you need for
your professional education on the AES website by
establishing and using your own dashboard:
• Take self-assessment tests
• Index your favorite topic areas
• Cross-reference to Epilepsy Currents
• View archived Annual Meeting symposia
• Link to your record on Medical Education Evaluator
• Link to Professional Connection and start to
participate in an online discussion
It’s all here…starting now!
Log in to the AES Epilepsy Learning Institute at
www.AESnet.org
23
WHY JOIN THE AMERICAN
EPILEPSY SOCIETY?
The American Epilepsy Society serves as a resource for
its membership and the epilepsy community by providing
access to data on the latest breakthroughs, technologies and
methodologies in epilepsy research.
The American Epilepsy Society promotes interdisciplinary
communication, scientific investigation and exchange of
clinical information about epilepsy. Membership in AES opens
doors to educational sessions, networking and knowledge-sharing among its members and Annual Meeting attendees.
AES MEMBERS ARE:
The Journal of the
AMERICAN EPILEPSY SOCIETY
EPILEPSY
CURRENTS
The Journal of the American Epilepsy Society
VOLUME 13
ISSUE 1
January/ February 2014
Current Review in CLINICAL SCIENCE
Epilepsy Care in Developing Countries ..............................................................................105
Gretchen L. Birbeck, MD, MPH
Current Literature in CLINICAL SCIENCE
Beyond the Monthly Seizure Count ....................................................................................111
by Donna C. Bergen, MD
Pharmacokinetic Interactions with Antiepileptic Drugs: ............................................113
Always the Bad Actor or Simply Misunderstood?
by Barry E. Gidal, PharmD
Focal and Generalized: Both Here and There ..................................................................115
by Warren T. Blume, MD
Current Review in BASIC SCIENCE
Primary and Secondary Mechanisms of Epileptogenesis ..............................................118
in the Temporal Lobe: There Is a Before and an After
Yehezkel Ben-Ari, PhD and F. Edward Dudek, PhD
Current Literature in BASIC SCIENCE
Too Much Inhibition Leads to Excitation in ....................................................................131
Absence Epilepsy
by Michael Wong, MD, PhD
Out of (Dis)order? The Dynamics of Seizure Initiation ..............................................133
by Gregory C. Mathews, MD, PhD
Interictal Spikes: Memories Forsaken ..................................................................................135
by Carl E. Stafstrom, MD, PhD
www.AESNET.org
Available on:
www.AESnet.org and www.EpilepsyCurrents.org
to download the app.
www.AESNET.org
24
Office Managers
Pediatric Neurologists
Pharmacists
Pharmacologists
Presidents/CEO’s in
Industry
Industry/Marketing
Professionals
Psychiatrists
Psychologists
Physicians Assistants
Registered Nurses
Residents
Social Workers
Students
Technologists
and Others
AES MEMBERS RECEIVE:
Axon Sprouting and Synaptic Reorganization of ............................................................126
GABAergic Ineterneurons: A Focused Look at a
General Question
by F. Edward Dudek, PhD
Another Look at Early GABAergic Neurotransmission: ............................................128
Maybe It’s Not So Exciting After All!
by Jong M. Tho, MD
Adult Neurologists
Advanced Practice Nurses
Basic Science Researchers
Clinical Researchers
Consultants
Doctors of Osteopathic
Medicine
Doctors of Veterinary
Medicine
Emergency Room Physicians
Epileptologists
Fellows
Government/Regulatory
Internists
Licensed Practical Nurses
Neurosurgeons
Non-Profit Staff
Nutritionists
Epilepsy Currents, the official journal of AES
Epilepsia, the official journal of ILAE
Reduced annual meeting registration fees
Discounted subscriptions to scientific journals
Listing in Find-A-Doctor online directory
Network with members through Professional Connection
Members-only discussion blogs
Research funding opportunities
Distinguished Achievement and Research Recognition
Awards
Weekly e-newsletters with relevant, timely news
Free listing of your employment opportunities on
www.AESNET.org
and much more
• AES 67TH ANNUAL MEETING
Washington, D.C. •
FRIDAY December 6, 2013
www.AESnet.org
AES Fellows Program
8:30 a.m. – 11:30 a.m.
Epilepsy Specialist Symposium:
Treating the New Onset Epilepsy Patient
(3.0 CME Credits)
Overview
While many epilepsy specialists spend much time seeing patients with longstanding disease, the group of new-onset epilepsy patients represents a
distinct population with specific treatment concerns. This symposium will
address the various issues involved in treating those with new-onset epilepsy,
including considerations of when a patient should be treated, the evidentiary
basis for drug choice, treatment prognosis, and specific factors relating to
various subgroups (such as children and the elderly).
Learning Objectives
u
Manage patients with new onset epilepsy across the age spectrum,
based on preferred practices, peer reviewed literature, and published
practice parameters
u
Recognize new-onset epilepsy syndromes and prescribe anti-seizure medications
using published evidence regarding treatment of specific syndromes.
Target Audience
Basic (see page 106 for details)
Program
Nursing Credit
Nurses may claim up to 3.0 contact hours for this session.
Pharmacy Credit
ACPE Universal Activity Number (UAN) is 0073-9999-13-092-L01-P and
provides 3.0 contact hours.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Annual
Course and has approved this program as part of a comprehensive lifelong
learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competencies: Comprehensive Patient Care, Medical Knowledge, and
Professionalism
Acknowledgment
This program is supported by educational grants from Eisai Inc. and
12:30 p.m. – 3:00 p.m.
Annual Fundamentals of Epilepsy
Symposium: Neuroimaging in Epilepsy:
Focusing On the Focus and Outside the Focus
(2.5 CME Credits)
Co-Chairs: Gregory L. Krauss, M.D. and Scott Mintzer, M.D.
8:30 a.m.
Overview
Introduction
Gregory L. Krauss, M.D.
8:45 a.m.
Treating New Onset Epilepsy: The Perspective from a
Longitudinal Study
Bernd Pohlmann-Eden, M.D., Ph.D.
9:15 a.m.
Drug Choice in New-Onset Epilepsy
Tracy A. Glauser, M.D.
9:45 a.m.
New Onset Epilepsy in Children
Dave F. Clarke, M.B.B.S.
The Annual Fundamentals of Epilepsy Symposium will address standard and
novel neuroimaging techniques used in the evaluation of epilepsy. Presentations
will address recent advances in structural and functional MRI, tractography, PET,
SPECT, and MRS. In addition, newer techniques of potential use in epilepsy will
be presented. Two interactive sessions will allow the audience to read MRIs
and submit their answers using Audience Response System.
Learning Objectives
u
Use technical and interpretation key points to improve the quality and
quantity of information extracted from neuroimaging studies in epilepsy
u
10:15 a.m. New Onset Epilepsy in the Elderly
Ilo E. Leppik, M.D.
Use state of the art structural and functional imaging modalities in the
diagnostic work-up of patients with epilepsy
u
10:45 a.m. Treatment Prognosis for New-Onset Epilepsy
Scott Mintzer, M.D.
Use new technologies such as fMRI and diffusion tensor imaging in
presurgical evaluations.
Target Audience
11:15 a.m. Conclusions
Gregory L. Krauss, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
FRIDAY
The American Epilepsy Society is committed to nurturing and supporting fellows in the field of epilepsy. The goal of the AES Fellows Program is to encourage
epilepsy fellows in training to attend the AES Annual Meeting where they will be exposed to the latest updates in clinical and basic science research. A
breakfast and lunch will be held to allow fellows to meet and pair with mentors who can provide guidance regarding career planning, potential research paths,
and clinical endeavors. Following breakfast, the fellows will attend the Epilepsy Specialist Symposium followed by the Annual Fundamentals of Epilepsy
Symposium the Hoyer Lecture and the NAC Symposium. A panel presentation will also be held. Invitations were sent out in July to epilepsy directors and AES
members. This year, 95 fellows were chosen, 10 of whom are Ph.D.s doing epilepsy research. The 2013 AES Fellows Program is supported by Lundbeck
Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., Eisai Inc., Acorda Therapeutics, Cyberonics, Inc., Supernus Pharmaceuticals, Inc. and Questcor
Pharmaceuticals, Inc.
Basic and Intermediate (see page 106 for details)
Program
Co-Chairs: Mohamad Z. Koubeissi, M.D. and Michael R. Sperling, M.D.
12:30 p.m. Introduction
Mohamad Z. Koubeissi, M.D.
25
12:45 p.m. Seizure Protocol MRI
Barbara Dworetzky, M.D.
and outside funding organizations, and most importantly, to make significant
contributions to improve the lives of patients with epilepsy.
1:10 p.m.
PET & SPECT in Epilepsy
William H. Theodore, M.D.
1:35 p.m.
Functional MRI in Epilepsy
Matthias J. Koepp, M.D., Ph.D.
2:00 p.m.
Diffusion Tensor Imaging
Beate Diehl, M.D.
This session will be useful to trainees, basic scientists, clinicians and other health
professionals (nurses, psychologists, Pharm.D.s) who want to know more about
organizational structure or who want to become more involved. The session will
provide an overview of the professional development and volunteering
opportunities within the Society, followed by short presentations by members
active in AES leadership. The session will end with a chance to meet with AES
staff and committee leaders to learn more about available opportunities.
2:25 p.m.
New MRI Techniques in Epilepsy
Graeme D. Jackson, M.D.
2:50 p.m.
Conclusions
Michael R. Sperling, M.D.
Credit Designation
Nursing Credit
Core Competencies: Comprehensive Patient Care and Medical Knowledge
separate registration required — see below for instructions
9:00 a.m. – 4:00 p.m.
27th Annual Advances in the Management of
Epilepsy and the Epilepsy Clinic
This intensive one-day conference is designed for those professionals who
participate in the care of persons with epilepsy. The overall purpose is to
improve services to individuals and families affected by epilepsy. The
conference is presented by the Department of Neurology of Wake Forest
University School of Medicine, Winston-Salem, North Carolina, through an
unrestricted grant committed to the education of health professionals, in an
effort to promote the comprehensive care of those with epilepsy and their
families. Registration for this program is done separately from the AES Annual
Meeting and begins on September 1, 2013. You may register by calling Wake
Forest School of Medicine at 800.642.0500.
Up to 5.5 AMA Category 1 CME credits will be given.
1:30 p.m. – 3:00 p.m.
Professional Development in AES: A Program
for Junior Members and Those in Transition
26
The American Epilepsy Society invites all interested meeting attendees to come
to a special session on volunteer and leadership opportunities within the Society.
The American Epilepsy Society has a variety of programs year-round to improve
the care and treatment of patients with epilepsy. These efforts include education
for basic scientists and clinicians, research grant programs, leadership and
organizational activities, community outreach and advocacy. Greater participation
in the Society offers members extensive career development opportunities by
providing a chance to hone leadership skills, to network with other AES members
1:30 p.m. – 3:00 p.m.
Location listed under each session
Please complete program survey – see page 20
Basic Neuroscience: Neurocircuitry of Lennox-Gastaut
Syndrome: From Animal Models to Patients
Convention Center – Room 102B, Street Level
Coordinators: Martin J. Gallagher, M.D., Ph.D., Laura Jansen, M.D., Ph.D.
Speakers: Aristea Galanopoulou, M.D., Ph.D., Carter O. Snead, M.D.,
John S. Archer, M.B.B.S., FRACP, Ph.D.
Lennox-Gastaut Syndrome (LGS) is a common catastrophic epilepsy condition
that is typically refractory to anticonvulsant drugs, and is usually associated
with cognitive delay and regression. It is critical to identify the cortical and
subcortical brain structures that participate in LGS seizures in order to facilitate
the development of new pharmacological and neurosurgical treatments for this
disease. Therefore, the goal of this year’s basic neuroscience SIG is to review
recent developments in elucidating the neurocircuitry involved in LGS seizures
in both animal models and in human patients. First, Dr. Galanopoulou will
discuss the developmental progression of seizures in rat models that starts
with infantile spasms and then evolves into seizures more typical of LGS.
Second, Dr. Sneed will review his recent work using stereotactic EEG in other
rodent LGS models to identify the subcortical nuclei that participate in LGS
seizures. Finally, Dr. Archer, of the Melbourne functional neuroimaging group,
will discuss their work using fMRI to localize brain regions involved in LGS
seizures in human patients.
Quality, Value and Safety
Convention Center – Room 204C, Level Two
Coordinator: Jeffrey W. Britton, M.D.
Speakers: Jeffrey W. Britton, M.D., F. M. Cutrer, Erik K. St. Louis, M.D.,
Katherine Noe, Ph.D.
This year’s Quality, Value and Safety SIG will discuss a number of topics of
interest. First, a novel system using data entry during history taking will be
demonstrated, which allows simultaneous data-capture and note generation.
Such systems could be used to facilitate quality control and clinical research,
as well as saving on transcription resources. Second, to address confounding
factors affecting Quality of Life measures in epilepsy, results of Quality of Life
data obtained in the interictal state following medication reduction in an EMU
environment will be presented. The speaker will discuss impacts of AED side
effects, mood state, seizures and sleep co-morbidities on quality of life
measures. Third, an update on EMU Safety initiatives will be presented.
Women with Epilepsy Across the Life Cycle: Impact of
Genetics and Brain Physiology
Convention Center – Room 202A, Level Two
Coordinators: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D.
Speakers: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D.,
Ingrid Scheffer, M.B.B.S., Ph.D., FRACP, Cynthia Harden, M.D.
This program will be divided in two parts. In the first section the focus is on
genetic causes of epilepsy in girls and how they are affected throughout their
life cycle. The second part of this SIG will discuss our current knowledge
about the physiologic changes in the brain during a menstrual period and the
role it may play in pathogenesis of seizure exacerbation in women with
catamenial epilepsy and its treatment implications.
In up to 70% of women with epilepsy, seizures exacerbate with menstrual
fluctuation of sex hormones. In the second half of this SIG, the speakers will
discuss the role of sex hormones in pathogenesis of seizure exacerbation in
catamenial epilepsy and whether the response to treatment can be predicted.
They will also address the effects of antiepileptic drugs and seizures on
reproductive function from puberty to menopause. There will be an interactive
discussion regarding how we can use our knowledge of complex interactions
between seizures, sex hormones, seizure medications and brain physiology to
implement meaningful treatment approaches for women with epilepsy.
3:30 p.m. – 5:30 p.m.
11th Judith Hoyer Lecture in Epilepsy:
Pediatric Epilepsy: Small Steps, Big
Challenges
Presentation: Roger T. Porter, M.D., AES Service Award
Lecturer: Jack Pellock, M.D.
The 11th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer
Dr. Jack Pellock, is sponsored by the National Institute of Neurological Disorders
and Stroke. Dr. Pellock’s presentation is the eleventh in a series of lectures
highlighting the promise of epilepsy research. This series is held in memory of
Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy
Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer
spent her life both helping families to cope with epilepsy and promoting
research into a cure and a better quality of life for those with the disorder. The
purpose of the lecture is to raise awareness of epilepsy among researchers and
the public and provide intellectual stimulation that will encourage continuing
progress toward finding a cure for epilepsy.
Target Audience
Basic (see page 106 for details)
Program
Co-Chairs: Patricio E. Abad, M.D., Mario A. Alonso-Vanegas, M.D.
3:30 p.m.
Introduction
Patricio E. Abad, M.D.
3:40 p.m.
Selection of Antiepileptic Drugs in Adults
Carlos S. Acevedo, M.D.
4:10 p.m.
Selection of Antiepileptic Drugs in Children
Roberto Caraballo, M.D.
4:40 p.m.
Refractory Epilepsy: Therapeutic Options
Americo C. Sakamoto, M.D., Ph.D.
5:10 p.m.
Round Table Discussion
Lilia Núñez-Orozco, M.D. and Arnoldo A. Soto, M.D.
5:50 p.m.
Conclusions
Mario A. Alonso-Vanegas, M.D.
Credit Designation
Nursing Credit
Pharmacy Credit
Core Competencies: Medical Knowledge and Practice-Based Learning
6:00 p.m. – 7:30 p.m.
Supported in part by Upsher-Smith Laboratories, Inc. and NINDS
3:30 p.m. – 6:00 p.m.
Spanish Symposium: Treatment of Epilepsy:
Algorithms for the Selection of
Pharmacological and Non-Pharmacological
Therapies
(2.5 CME Credits)
Overview
The symposium will present evidence-based information concerning the
selection of pharmacological and non-pharmacological treatments for children
and adults with recently diagnosed seizures and with refractory epilepsy. An
algorithmic approach to treatment selection will be emphasized on the basis
of available original data and published treatment guidelines.
Learning Objectives
u
Develop a sequential, rational approach to drug selection in children and
adults with newly diagnosed epilepsy
u
Knowledge and implementation of modern concepts of refractory epilepsy
and treatment options to be considered.
FRIDAY
Some forms of epilepsy affect only or predominantly women. These
conditions are mostly genetically determined. Given the recent advances in
genetic technology and genetic testing, the epileptologist is now able to
diagnose such patients more easily. However, most of us did not receive any
training to manage these genetic epilepsies. Dr. Ingrid Scheffer and Dr.
Danielle Andrade will discuss the clinical characteristics of genetically
determined epilepsy affecting women only. When to think of these diagnoses?
How are the seizures in these conditions? What other neurological, psychiatric
and systemic problems are associated? What is the best treatment? These
issues related to genetically determined epilepsy in women will be reviewed
in the first part of the session.
Critical Care EEG Monitoring: Beyond Seizure Detection
Coordinators: Evan Fertig, M.D., Suzette Laroche, M.D
Speakers: Nicolas Abend, M.D., Peter W. Kaplan, M.B., B.S., FRCP,
M. Brandon Westover, M.D., Ph.D.
The primary role of CEEG monitoring in the ICU setting is the detection of
nonconvulsive seizures and status epilepticus. The purpose of this 2013 SIG
is to discuss the potential added clinical value of CEEG for the critically ill
population beyond seizure detection. Speakers will provide updates on new
applications of CEEG monitoring. Topics to be covered are: EEG Monitoring for
Prognostication in Neonates; the Prognostic Significance of EEG Patterns after
Cardiac Arrest Treated with Therapeutic Hypothermia; and EEG Monitoring for
Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage:
Principles and Clinical Practice. Ample time will be allotted for speaker and
audience interaction.
Supported by Questcor Pharmaceuticals, Inc.
27
Genetic Testing in the Epilepsy Clinic
Coordinators: Melodie Winawer, M.D., M.S., Annapurna Poduri, M.D.
Speakers: Ingrid Scheffer, M.B.B.S., Ph.D., FRACP, Beth Sheidley, M.S., CGC,
Ruth Ottman, Ph.D., Tracy Dixon-Salazar, Ph.D.
European Commissions of the International League Against Epilepsy, will focus
on four areas in which big science is playing an important role in epilepsy
research. Areas of collaboration include epilepsy clinical and surgical trials, an
international pregnancy registry, and EEG data sharing through an international
web portal.
We will discuss the evolution of genetic testing for epilepsy in the clinic from
the perspective of a parent of a child with epilepsy, an epileptologist with
genetics expertise, a genetic counselor from an epilepsy genetics program,
and a researcher in epilepsy genetics studying the psychosocial impact of
genetic testing.
Learning Objectives
Neuroimaging: Imaging Epileptogenesis
Target Audience
Coordinator: Matthias Koepp, M.D., Ph.D.
Speakers: Andrea Bernasconi, M.D., Ph.D., Csaba Juhasz, M.D., Ph.D.
Biomarkers in epilepsy are divided into those which reflect a particular stage
of epileptogenesis, with a potential to predict the future development of
epilepsy after a brain insult, and those which rather reflect ictogenicity, i.e., a
state of cortical hyperexcitability sufficient to provoke seizures. In this year’s
Neuroimaging SIG, we will discuss currently available imaging tools (e.g.,
MRI, fMRI, MEG, PET) which are predictors for the risk of future seizures,
progression of the disease, the response to specific AEDs, or the need to
continue such treatment after seizures being controlled for a period of time.
u
Become familiar with and consider all surgical options for management of
intractable childhood epilepsy, resulting in improved outcomes
u
Learners, familiar with limitations of epilepsy / pregnancy databases,
provide well informed counseling to women with epilepsy.
Basic, Intermediate and Advanced (see page 106 for details)
Program
Co-Chairs: Meir Bialer, M.B.A., Ph.D. and Sheryl Haut, M.D.
6:00 p.m.
Introduction
Sheryl Haut, M.D.
6:10 p.m.
Setting Standards: International Collaboration for
Pediatric Epilepsy Surgery Through the ILAE
Gary W. Mathern, M.D.
6:35 p.m.
International Pregnancy Registries: A Global Approach to
a Global Challenge
Coordinators: Lawrence J. Hirsch, M.D., George B. Richerson, M.D., Ph.D.
Speakers: Expert Panel
7:00 p.m.
International Clinical Trials – Threats and Opportunities
Eugen Trinka, M.D., M.Sc.
We will have a panel of experts describe what they think have been the
greatest SUDEP-related advances in the past five years, from the clinical,
basic science, genetic, awareness, prevention and advocacy standpoints. The
audience will then have a chance to provide their own opinions. The panel will
then describe what they think are the top priorities for research and
prevention in the near future, again followed by audience input. Lastly, a panel
will provide tips on how and when to discuss SUDEP with patients and
families.
7:25 p.m.
Epilepsy, Big Data and International Research
Brian Litt, M.D.
7:50 p.m.
Conclusions
Meir Bialer, M.B.A., Ph.D.
SUDEP: Sudden Unexpected Death in Epilepsy
Tumor Induced Epilepsy
Convention Center – Room 204A/B, Level Two
Coordinators: Jeffrey Politsky, M.D., Theodore Schwartz, M.D.
Speakers: Roger J. Packer, M.D., Harry T. Chugani, M.D., Jong M. Rho, M.D.,
Jeffrey P. Greenfield, M.D., Ph.D.
Nursing Credit
The 2013 program will again focus on novel data and research, but will also
include a clinical session. The discussion points will include an expansion on
pre-surgical evaluation, post-surgical follow-up, cognitive impact, and
functional reorganization. We will also utilize the data toward the
development of clinical recommendations, for patients of all ages. AES
members will be invited to submit clinical cases/scenarios for discussion with
the panel.
6:00 p.m. – 8:00 p.m.
North American Commission / Commission on
European Affairs Symposium:
Big Science: Global Collaborations Improving
Epilepsy Care
(2.0 CME Credits)
Overview
With the emerging capabilities for global collaborations and enhanced data
sharing, big science is playing an increasingly important role in epilepsy
research. This symposium, sponsored jointly by the North American and
28
Credit Designation
Pharmacy Credit
Core Competencies: Medical Knowledge, System-Based Practice, and
Practice-Based Learning
Interested in Annual Meeting
CME / CE Credit?
Go to www.AESnet.org
See page 106 for details
SATURDAY December 7, 2013
www.AESnet.org
7:00 p.m. – 8:30 p.m.
Mentoring Session for Junior Investigators
Pre-application required
7:00 a.m. – 8:30 a.m.
Non-Profit Resources for Epilepsy Research: What We Don’t
Know That We Don’t Know About the Availability of Epilepsy
Research Resources
Town Hall Meeting: Federal Support of
Epilepsy Initiatives
Convention Center – Room 202B, Level Two
The purpose of this SIG is to generate focused two-way discussion between
non-profit affiliates of AES and basic and clinical researchers attending the
AES annual meeting. This discussion will educate researchers on how nonprofits set their priorities and fund research or make other resources available,
and it will educate non-profit leaders on what else they could do to support
basic and clinical researchers in the epilepsies. The ultimate goal of this group
is to accelerate research on the epilepsies by more effectively making
valuable resources available to the research community.
NINDS and Anticonvulsant Screening Program
7:00 a.m.
NINDS: Research in Epilepsy and New Initiatives
Brandy Fureman, Ph.D.
7:15 a.m.
Anticonvulsant Screening Program: New Directions
John Kehne, Ph.D.
7:30 a.m.
Town Hall Q & A
Coordinator: Steven Roberds, Ph.D.
Speakers: TBA
FDA and Generic AEDs
Sleep in Epilepsy: The Borderland of Sleep and Epileptiform
Neural Activity
7:45 a.m.
FDA: Action on Insuring Generic Equivalence
Jeff Jiang, Ph.D.
8:00 a.m.
Update on Studies of AED Generic Equivalence
Michael Privitera, M.D.
Coordinators: Mark Quigg, M.D., Erik K. St. Louis, M.D.
Speakers: Iván Sánchez Fernández, M.D., Mark R. Bower, Ph.D,
Mithri R. Junna, M.D.
8:15 a.m.
Town Hall Q & A
7:00 a.m. – 8:30 a.m.
SATURDAY
This program is targeted to fellows, postdoctoral researchers, instructors and
assistant professor level junior faculty. Epilepsy professionals at the Associate
Professor level will volunteer to serve as mentors. Accepted applicants will
meet with their assigned mentors during this time.
developing decision tools, performance indicators, and even guidelines. We
will begin with an overview of how different levels and kinds of
epidemiological and clinical research work together to provide the evidence
needed to change practice. We will hear about the use of focus groups to
identify research priorities, translating those findings to research studies,
closing the gaps between treatment efficacy and implementation, and
studying complex delivery of epilepsy care. Each of four speakers will give a
brief presentation (10-15 minutes) and we will reserve 30-45 minutes for
open discussion and comments from the attendees in the audience.
Recent evidence has defined the impact of structural thalamic brain lesions,
cortical slow wave oscillations, and NREM sleep microarchitectural rhythms
on the frequency of interictal EEG abnormalities and occurrence of seizures
during sleep. This Sleep-Epilepsy SIG will highlight the work of three junior
investigators in relation to the theme of the influence of sleep physiology and
thalamic brain lesions on the frequency of epileptiform neural activity.
Treating Convulsive Status Epilepticus with the Right
Medication at the Right Time
Convention Center – Room Salon A, Street Level
Children’s Hour: Acute Treatment of Convulsive Seizures in
Children
Coordinator: Mary Connolly M.B., B.Ch., FRCP(C), FRCP(I), FRCP(Edin)
Speakers: Richard Chin, M.D., Ph.D., Mary Connolly, M.D., FRCP(C),
Lieven Lagae, M.D., Ph.D.
The 2013 SIG will cover the following topics: 1. Pre-hospital and emergency
treatment of acute seizures; 2. Treatment of convulsive seizures in the ER
after benzodiazepines; 3. Treatment of childhood epilepsy: Do we need 20
anti-seizure drugs or four broad spectrum drugs?
Epidemiology Applied: Solving Problems in Epilepsy Care
Through Research
Convention Center – Room 204A/B, Level Two
Coordinators: Anne Berg, Ph.D., Nathalie Jetté, M.D., FRCP(C)
Speakers: Nathalie Jette, M.D., FRCP(C), Gigi Smith, M.S.N, APRN, CPNP,
Christine Bower-Baca, M.D., Zachary M. Grinspan, M.D.
Coordinators: Tobias Loddenkemper, M.D., Frank Drislane, M.D.
Speakers: Robert Silbergleit, M.D., Jaideep Kapur, M.D., Ph.D.,
Iván Sánchez Fernández, M.D.
Status epilepticus is a life-threatening condition necessitating immediate
medical attention and treatment. Diagnosis, treatment and prognosis of
patients with status epilepticus may be difficult depending on the duration,
etiology and the underlying condition of the patient. One of the single most
effective and modifiable factors in treating convulsive status epilepticus
appears to be time to initiation of treatment and timely escalation of
treatment. This year’s SIG will provide an overview of treatment timing
including so-called first line, second line and third line agents in adult and
pediatric patients presenting with convulsive status epilepticus. Specifically,
Dr. Robert Silbergleit will present first line treatment options and medication
timing from the Rapid Anticonvulsant Medication Prior to Arrival Trial
(RAMPART), Dr. Jaideep Kapur will outline medication considerations and
dose timing on second line agents based on the Established Status Epilepticus
Treatment Trial (ESETT), and Dr. Iván Sánchez Fernández will illustrate
treatment timing and third line treatment choices based on results from the
pediatric Status Epilepticus Research Group (pSERG).
This year’s Epidemiology SIG will consider the role that epidemiological and
other studies play in epilepsy care from identifying gaps and needs to
29
Why Private Practice Epilepsy (vs. Traditional Academic
Epilepsy)? and Update on Research Collaborations
Coordinators: Marcelo Lancman, M.D., Pavel Klein, M.D.
Speakers: Robert Leroy, M.D., Robert Wechsler, M.D., Ph.D.,
Marcelo Lancman, M.D., Pavel Klein, M.D.
The “Epilepsy Care in Private Epilepsy Centers” SIG is a forum for epilepsy
providers in private epilepsy centers as well as those interested in learning
about it or considering transitioning. The group has monthly phone
conferences in which business issues as well as research projects are
discussed. We also communicate through our LinkedIn site. The goal of our
group is to create a consortium of all epilepsy practitioners in the private
setting. One of the main purposes of the SIG is to provide members with a
resource for business questions, advice for providers who are starting in
private practice (i.e., developing a new epilepsy program) and expand our
research possibilities through collaboration among groups.
8:30 a.m. – 11:45 a.m.
11:00 a.m. Perspective of Basic Science: Is There Life Outside the
Hippocampus?
Jeffrey A. Loeb, M.D., Ph.D.
11:25 a.m. Conclusions: Where Do We Go Now?
Credit Designation
Nursing Credit
Presidential Symposium: The Changing
Landscape of Epilepsy Surgery
Core Competencies: Comprehensive Patient Care, System-Based Practice,
and Practice-Based Learning
(2.25 CME Credits)
Presentation: Jaideep Kapur, M.D., Ph.D. and Torbjorn
Tomson, M.D., Ph.D., Research Awards, Russell Katz, M.D.,
Extraordinary Contributions Award, ILAE and NINDS
Updates
Overview
Epilepsy surgery is a very effective intervention for patients with treatment
resistant epilepsy. The most successful epilepsy surgery is temporal
lobectomy, which traditionally has produced seizure freedom in approximately
two-thirds of patients. An AAN / AES guideline recommended temporal
lobectomy as the treatment of choice for treatment resistant temporal lobe
epilepsy. Yet, in a survey of centers with large epilepsy surgery programs, the
number of overall surgeries, as well as the number of temporal lobectomies
had decreased almost universally from their peaks. Moreover, surgeries for
mesial temporal sclerosis have declined by half, whereas non-lesional cases
have increased by a third.
2:30 p.m. – 5:00 p.m.
Professionals in Epilepsy Care Symposium:
Access to Epilepsy Care Across the Spectrum
(2.5 CME Credits)
Overview
This symposium will present the data from various sources that suggest a
shift in epilepsy surgery type and possibly location (from established to
emerging centers) and will provide available evidence for the theories that
may account for these changes. Also, future directions related to these
changes, including basic science considerations (should the neocortex receive
as much attention as the hippocampus?) will be discussed.
Despite progress in diagnosis of epilepsy and associated comorbidities, as
well as an increase in treatment options for epilepsy, limitations to access
have created barriers to appropriate care for persons with epilepsy. Barriers to
access include availability of professionals skilled in treatment of epilepsy;
accurate diagnosis, including identification of comorbidities; cultural and
language barriers; and treatment for psychiatric comorbidities. This
symposium will address these barriers; identify strategies and practical
solutions to overcome the barriers, including those defined by Project Access
and the Managing Epilepsy Well program; and examine the role of advocacy.
A panel discussion will provide the opportunity to address these and other
issues related to access to epilepsy care.
Learning Objectives
Learning Objectives
u
Recognize epilepsy syndromes other than temporal lobe epilepsy and
evaluate such patients for epilepsy surgery
u
Recognize and explicitly address cultural barriers to managing care for
persons with epilepsy
u
Evaluate all patients with refractory epilepsy syndromes including extratemporal and non-lesional epilepsy to provide optimal treatment, identify
surgical candidates, and perform epilepsy surgery for those with
syndromes other than temporal lobe epilepsy when indicated.
u
Provide care for children and youth with epilepsy by utilizing medical
home and telemedicine
u
Collaborate with patients in developing, utilizing, and maintaining selfmanagement skills for psychiatric comorbidities and psychosocial
challenges or recognize the need to refer patient to mental health
professionals for such skills-based intervention.
Target Audience
Intermediate and Advanced (see page 106 for details)
Program
Chair: Jacqueline A. French, M.D.
9:30 a.m.
Introduction
9:45 a.m.
Who Was I Treating Then? Who Am I Treating Now?
Dennis D. Spencer, M.D.
10:05 a.m. The Changing Surgical Landscape in Kids
Howard L. Weiner, M.D.
30
10:30 a.m. What Is the Evidence that the Landscape Is Changing?
Theories of Change
Dale C. Hesdorffer, Ph.D.
Target Audience
Basic and Intermediate (see page 106 for details)
Program
Co-Chairs: Janelle Wagner, Ph.D., Paul M. Levisohn, M.D.
2:30 p.m.
Introduction
Janelle Wagner, Ph.D.
2:45 p.m.
3:15 p.m.
3:25 p.m.
3:45 p.m.
4:05 p.m.
4:45 p.m.
Cultural and Associated Barriers to Epilepsy Care
Lisa Andermann, M.Phil., MDCM
Epilepsy Foundation’s Role in Advocating for Access to
Epilepsy Care
Philip M. Gattone, M.Ed.
Epilepsy Foundation and Access to Care: Overview of
Project Access
Janice M. Buelow, Ph.D., RN
Project Access: Improved Access to Care Through
Medical Home and Telemedicine
Linda Fletcher, M.S., CPNP
Managing Epilepsy Well: Addressing Access to Mental
Healthcare Needs
Nancy J. Thompson, Ph.D.
Conclusions
Paul M. Levisohn, M.D.
Credit Designation
Learning Objectives
u
Learn of new molecular and engineering approaches that may be useful in
controlling epileptogenesis and seizurogenesis
u
Presentation of data concerning new molecular and device-based
therapies for comorbidities of epilepsy will provide new knowledge about
groundbreaking therapeutic approaches that are in development.
Target Audience
Intermediate (see page 106 for details)
Program
Co-Chairs: Daniel H. Lowenstein, M.D., Karen S. Wilcox, Ph.D.
2:30 p.m.
Introduction
Daniel H. Lowenstein, M.D.
2:45 p.m.
Optical Deconstruction and Online Control of
Corticothalamic Circuits Underlying Epilepsy
Jeanne T. Paz, Ph.D.
3:15 p.m.
Optogenetic Dissection of Circuits Underlying AnxietyRelated Behaviors
Steven Petrou, Ph.D.
3:45 p.m.
Focal Cooling for the Prevention and Treatment of
Epilepsy: From Patients to Models (and back again)
Matthew D. Smyth, M.D.
4:15 p.m.
MicroRNAs as Treatment Targets in Epilepsy
David C. Henshall, Ph.D.
4:45 p.m.
Conclusions
Karen S. Wilcox, Ph.D.
Nursing Credit
Pharmacy Credit
Core Competencies: System-Based Practice and Practice-Based Learning,
Communication Skills and Professionalism
Acknowledgment
This program is supported by educational grants from Lundbeck
Pharmaceuticals, Inc. and Eisai Inc.
2:30 p.m. – 5:00 p.m.
Credit Designation
Nursing Credit
Pharmacy Credit
Translational Research Symposium: New
Approaches in the Search for a Cure
Core Competencies: Medical Knowledge
(2.5 CME Credits)
5:15 p.m. – 8:00 p.m.
Overview
SATURDAY
4:25 p.m.
Epidemiologic Research into Access to Care for Epilelpsy
David J. Thurman, M.D., M.P.H.
Antiepileptic Therapy Symposium: One Size
Does Not Fit All: Personalized Medical Care
Research: This symposium will inform the audience about recent advances in
translational, basic research that directly bear on NIH benchmarks and that
could potentially change / improve patient care. Advances in optogenetics
(related to both epileptogenesis and the comorbidities of epilepsy), focal
cooling and molecular targeting will be presented.
(2.5 CME Credits)
Medical Treatment: Medical treatment will be advanced as new
approaches are developed that can selectively target neuronal networks
involved in epileptogenesis and the generation of seizures. These techniques
have already been shown to have an impact in various models of epilepsy,
and it is likely just a matter of time before they are translated into treatments
for human epilepsy.
Overview
Presentation: Gregory D. Cascino, M.D., J. Kiffin Penry
Award
The selection of the optimal therapy for a patient with seizures or epilepsy
depends not only upon the specific epilepsy type but also upon a variety of
individual characteristics of the patient. The goal of this AET symposium will
be to discuss some of these factors and present treatment algorithms that
would allow for more personalized medical care for patients with seizures and
maximize the efficacy and tolerability of the selected treatments. Specifically,
this symposium will discuss how to use genetic tests to select appropriate
31
therapies, select appropriate drug delivery methods to best serve each
patient’s needs, recognize and treat early allergic reactions to anti-seizure
drugs as well as prevent cross-allergies with other drugs, select the optimal
therapies for women with epilepsy to prevent teratogenic or other adverse
effects on their reproductive system, and optimize epilepsy therapies in
patients with HIV. A discussion of the future perspectives to overcome current
barriers in AET implementation will also be presented.
Learning Objectives
u
Develop an algorithmic approach for the selection of optimal antiepileptic
therapy for each individual patient
u
Develop an algorithmic approach for the selection of the optimal
antiepileptic formulation and delivery system for each individual patient
with resulting increased adherence
u
Recognize early adverse drug reactions and the patient populations at risk
for developing them and implement treatment protocols that minimize
such adverse outcomes.
Target Audience
Programs
AED Pregnancy Registry Outcomes
Coordinators: Esther Bui, M.D., FRCP(C), Elizabeth Gerard, M.D.
Speakers: John Craig, M.D., Lewis Holmes, M.D., Kimford Meador, M.D.,
Terrence O’Brien, M.D., FRAC(P), Page Pennell, M.D.,
The AED Pregnancy Registry SIG will continue to present the latest updates
from the six international registries, providing participants with the most
recent and relevant information for counseling and managing women with
epilepsy who are of childbearing age. In addition to presenting pivotal data on
teratogenesis, pregnancy complications and fertility, the investigators will give
their opinions on the management of several case examples demonstrating
how they apply their data and experience to clinical care. This year’s SIG will
pay special tribute to the late Autumn Klein, M.D., Ph.D., and her research on
obstetrical and perinatal outcomes in women with epilepsy will be presented.
Co-Chairs: Aristea Galanopoulou, M.D., Ph.D., Angus A. Wilfong, M.D.
Ictal Semiology
5:30 p.m.
Introduction
Aristea Galanopoulou, M.D., Ph.D.
5:45 p.m.
Genomic Approaches in Selecting AETs: Current State
Norman Delanty, M.D.
6:10 p.m.
Personalizing Drug Delivery
Emilio Perucca, M.D., Ph.D.
6:35 p.m.
Management of Allergic Reactions to AETs
Bernard Cohen, M.D.
7:00 p.m.
Women’s Issues in AET Implementation
Page B. Pennell, M.D.
7:25 p.m.
Management of Seizures in HIV Patients
Gretchen L. Birbeck, M.D., M.P.H.
7:50 p.m.
Conclusions
Angus A. Wilfong, M.D.
Credit Designation
Nursing Credit
Pharmacy Credit
Core Competencies: Practice-Based Learning, Comprehensive Patient Care
and Communication Skills
Acknowledgment
This program is supported by educational grants from Eisai Inc., Sunovion
Pharmaceuticals Inc., and UCB, Inc.
32
6:15 p.m. – 7:45 p.m.
Coordinators: Felix Rosenow, M.D., C. Akos Szabo, M.D.
Speakers: Philip Kahane, M.D., Ph.D., C. Akos Szabo, M.D.,
Felix Rosenow, M.D., Hans Lüders, M.D., Ph.D.
The moderator and members of the faculty will show ictal videos of epilepsy
patients. This will include some typical seizures and also unusual cases. After
showing each video, the presenter will give the audience an opportunity to
discuss the case. Members of the audience will be invited to describe the
ictal semiology and try to deduce the most likely symptomatogenic and
epileptogenic zone. The moderator will then call on the other faculty members
to give their opinion. The format of the conference is interactive, each
presenter engaging the audience for their clinical opinions on the video and
clinical findings in each patient. While the conferences are focused on
semiology, the discussions also include evaluation of EEG, neuroimaging, and
discussion of seizure and functional outcome in epilepsy surgery cases.
Neuroendocrinology: Stress and Exercise in Epilepsy &
Epileptogenesis
Coordinators: D. Samba Reddy, Ph.D., R.Ph., Jana Veliskova, M.D., Ph.D.
Speakers: Michael Privitera, M.D., Nigel Jones, Ph.D., Tallie Z. Baram, M.D.,
Ph.D., D. Samba Reddy, Ph.D., R.Ph.
The Neuroendocrinology SIG will be focused on the impact of stress on epilepsy
and the influence of exercise and environmental enrichment on the
development of epilepsy in persons at risk. Stress is one of the major
precipitating factors in seizures and could exert significant impact on neuronal
plasticity. Stress, stress-induced neurohormones, and underlying molecular
changes could play an important role in the susceptibility to epileptogenesis,
whereby a brain becomes progressively epileptic due to an initial precipitating
event of diverse origin such as brain injury, stroke, infections, or prolonged
seizures. The molecular mechanisms underlying the acquired epilepsy are poorly
understood. Neuroinflammation and neurodegeneration appear to trigger
epileptogenesis following an initial injury. There is an intense search for drugs
that truly prevent the development of epilepsy in people at risk. Exercise and
stress-related hormonal factors may play an important role in adults with
epilepsy. Corticosteroids and neurosteroids have been shown to affect seizure
activity in animal models and in clinical studies. However, the impact of exercise
and stress on epileptogenesis has not been investigated widely. The stress
hormone cortisol or corticosterone has excitatory effects and triggers
epileptogenesis in animal models. There is emerging interest on stress
hormones and environmental enrichment-induced plasticity in regulating the
epileptogenesis. Environmental enrichment and neurosteroids have promising
disease-modifying potential in epileptogenesis. It is hoped that this SIG
discussion may generate new insight on the stress, exercise and environmental
enrichment on epileptic seizures and progression of epileptogenesis.
Neurostimulation and Neuroengineering
Coordinators: Erika E. Fanselow, Ph.D., Chrisopher DeGiorgio, M.D.
Speakers: Marom Bikson, Tay Netoff, M.D.
This year’s program combines the Neurostimulation and Neuroengineering
SIGs. Topics to be covered include: 1) TMS for control of refractory status and
seizures, 2) DC stimulation for control of seizure activity, and 3) Sub-threshold
stimulation methods for reduction of seizure activity.
6:15 p.m. – 8:15 p.m.
Translational Investigators’ Workshop
Translational Neurogenetics of Hemimegalencephaly
Moderator: Peter Crino, M.D., Ph.D.
Speakers: Annapurna Poduri, M.D., Laura Flores-Sarnat, M.D.,
Peter Crino, M.D., Ph.D., Gary Heuer, M.D., Ph.D.
SATURDAY
Plan on Joining Us
December 2014
in Seattle!
2014 ANNUAL
MEETING
5TH Biennial North American Epilepsy Congress
December 5-9, 2014
SEATTLE, WASHINGTON
Washington State Convention Center
•
•
•
•
•
•
FUTURE ANNUAL
MEETING DATES
CME Symposia and Lectures
Platform Sessions
Poster Sessions
Informative Exhibitors
Skills Workshops
2015
2017
Philadelphia, Pennsylvania
Pennsylvania Convention Center
December 4-8
Washington, D.C.
Washington Convention Center
December 1-5
2016
2018
Houston, Texas
George R. Brown Convention Center
December 2-6
New Orleans, Louisiana
Ernest N. Morial Convention Center
November 30-December 4
33
Saturday December 7, 2013
Poster Session 1
Noon - 6:00 p.m.
 Authors Present: Noon – 2:00 p.m.
 Poster Walking Tours (see page 13 for details)
Mechanisms
1.001 A Rapid Inflammatory Process
Following Febrile Status Epilepticus:
A Biomarker Of Epileptogenesis?/
K. Patterson, C. Dubé, M. Choy,
T. Ravizza, A. Vezzani, T. Baram
1.002 Is There A Role For FTO
Inhibition In The Treatment Of
Epilepsy?/J. Rowles, M. Olsen
1.003 A Role For Cytokine Interleukin6 In Posttraumatic Epileptogenesis
J. Boychuk, C. Butler, B. Smith
1.004 Determinants Of Interictal And
Ictal Transitions In A Computational
Model Of An Epileptic Neural Network/
W. Swiercz, K. Lillis, K. Staley
1.005 A Novel T-type Calcium Channel
Antagonist Delays The Progression Of
Epileptogenesis In The Amygdala
Kindling Model Of Temporal Lobe
Epilepsy/P. Casillas-Espinosa, A. Hicks,
A. Jeffreys, E. Tringham, T. P. Snutch,
T. O’Brien, K. Powell
1.006 Structural Differences
Between Granule Cells And Semilunar
Granule Cells: Role In Differential
Post-traumatic Plasticity Of Synaptic
Inputs/F. S. Elgammal, A. Gupta,
A. Proddutur, B. Sweitek,
O. Chika-Nwosuh, V. Santhakumar
1.007 Toll-like Receptor 4 Contributes
To Early Increase In Dentate
Excitability After Concussive Brain
Injury By NMDA Receptor Independent
Mechanisms/Y. Li, A. Korgaonkar,
V. Santhakumar
1.008 The WNT Signaling Pathway Is
Activated During Status Epilepticus
And Epileptogenesis/K. E. Paulson,
A. Yee, K. Saul, A. Pirone, M. Jacob
1.009 Monosynaptic Inputs To
Neonatally- Versus Adult-Born
Dentate Granule Cells In A Rodent
Model Of Temporal Lobe Epilepsy/
X. Du, A. Althaus, H. Zhang, J. Parent
1.010 Development Of JAK/STAT
Inhibitors For Disease Modification In
Epilepsy/A. Carrel, H. L. Grabenstatter,
J. Carlsen, Y. Cruz Del Angel,
S. Russek, M. F. Wempe,
A. Brooks-Kayal
1.011 Neonatal Seizures Diminish
Homeostatic Synaptic Scaling Down In
Cortical Neurons: Evidence From A
Rat Seizure Model And Human
Epilepsy/H. Sun, B. Kosaras, F. Jensen
1.012
IGF-1 And Insulin Contribute To
Epileptogenesis Through Activation Of
AKT-mTor Signaling/Y. Berdichevsky,
Y. Song, K. Staley
1.013 Bioenergetics Of Neuronal
Excitation In Primary Cells And
Zebrafish Embryos/L. Schneider,
S. Rowley, P. Bhuyan, M. Dinday,
K. Artinger, M. Singleton, S. Baraban,
M. Patel
34
1.014 Fibroblast Growth Factor 2
Hyperexpression In Temporal Lobe
Epilepsy Patients/L. D’Souza-Li,
A. E. Ferreira, M. Teocchi, E. Oliveira,
H. Tedeschi
1.015 JAK/STAT Inhibition To Prevent
Post-Traumatic Epileptogenesis/
D. Raible, J. Boychuk, C. Butler,
Y. Cruz Del Angel, S. Russek,
B. Smith, L. Frey, A. Brooks-Kayal
1.016 Activated γδ And Memory αβ T
Lymphocytes Infiltrate The Brain
Parenchyma Of Both Pediatric
Patients With Epilepsy And Mice With
Induced Status Epilepticus/D. Xu,
S. Miller, S. Koh
1.017 Synaptic Alterations During
Post-Traumatic Epileptogenesis In
Vitro/Z. Wang, K. Staley
1.018 Small Numbers Of PTEN
Knockout Dentate Granule Cells Are
Capable Of Driving Epileptogenesis/
I. Rolle, B. Kestler, K. Holland, R. Pun,
S. Danzer
1.019 Functional Changes Of A De
Novo Grin2a Mutation In A Patient
With Refractory Seizures And EarlyOnset Epileptic Encephalopathy/
H. Yuan, T. M. Pierson, C. F. Boerkoel,
W. A. Gahl, S. F. Traynelis
1.020 Transcriptiome Analysis In
Focal Epilepsy Identifies Changes In
Clock Expression In Epileptogenic
Human Tissue/J. Liu, X. Fu, A. Yaun,
W. Gaillard
1.021 Epilepsy Risk Genes Are
Targets Of Aberrant MicroRNAs
Expressed In Epileptogenic Tubers Of
Tuberous Sclerosis Complex Patients/
A. Dombkowski, C. Batista,
D. Cukovic, R. Ranganathan,
U. Shukla, H. Chugani, D. Chugani
1.022 KCNQ2 Targeting To The Axon
Initial Segment Is Disrupted In A
Mutant Form Causing Severe Epilepsy/
B. Tran, M. Xu, E. Cooper
1.023 A Mouse Model With Human
Mutant GABAA Receptor γ2 Subunit
At Q390x Exhibits Reduced Inhibitory
Synaptic Currents In Thalamo-Cortex
Circuitry/C. Zhou, J. Kang, R. Macdonald
1.024 Growth-Associated Protein 43,
A Potential Substrate For Progressive
Epileptogenesis In Type II Focal
Cortical Dysplasia/Z. Ying, I. Najm,
A. Nemes, A. Alexopoulos
1.025 Time Course Of The Neuronal
Sodium Concentration In PostTraumatic Epileptogenesis In Vitro/
T. Balena, K. Staley
1.026 Enhanced AMPA Receptor
Mediated Neurotransmission During
Status Epilepticus Is Due To Increased
Expression Of The GluA1 Subunit/
K. Rajasekaran, S. Joshi, J. Kapur
1.027 Spatially Distinct Patterns Of
Gene Expression Profiles Are Revealed
In The Hippocampus Following Multiple
Early Life Seizures/S. Hu, W. Wan,
A. M. Slomko, J. P. Wongvravit,
Z. Naseer, S. Ali, J. Gill, L. K. Friedman
1.028 Anticonvulsant Efficacy Of
Diuretics During Post-Traumatic
Seizures In Vitro/V. Dzhala,
Y. Saponjian, M. Mail, K. Staley
1.029 Ankyrin-G As A Potential
Molecular Mechanism Linking Epilepsy
And Comorbid Mood Disorder/M. Xu,
E. Cooper
1.030 Increased Superoxide
Dismutase 1 By Lamotrigine
Ameliorates Superoxide Anion-Related
Cell Death After Pilocarpine-Induced
Status Epilepticus In Mice/Y. Cho,
K. Heo, I. Cho, H. Kim, B. Lee, W. Kim
1.031 High-frequency Stimulation Of
The Anterior Nucleus Of The Thalamus
Increases Brain-derived Neurotrophic
Factor (BDNF) Expression And
Neurogenesis In The Rat Dentate
Gyrus/T. Selvakumar, T. Tierney
Models
1.032 Therapeutic Effect Of
Lacosamide And Levetiracetam In
Generalized Seizures, As
Demonstrated In A Rodent Model Of
Cortical Dysplasia/A. Nemes,
R. O’Dwyer, Z. Ying, I. Najm,
A. Alexopoulos
1.033 Development Of Chronic
Depression And Cognitive Deficits In A
Rat Model Of Organophosphate
Paraoxon Toxicity/L. Deshpande,
K. F. Phillips, B. A. Huang, R. DeLorenzo
1.034 A Flexible Cre-Dependent
GCaMP5 Reporter Mouse For
Investigation Of Mouse Models Of
Epilepsy/J. Gee, M. N. Economo,
M. Rothermel, S. C. Morris,
M. Wachowiak, M. R. Capecchi,
K. Wilcox, J. White, P. Tvrdik
1.035 Cognitive Dysfunction And
Hippocampal Damage Induced By
Prolonged Febrile Convulsion And
Hypoxic-Ischemia In Immature Rat/
J. Byeon, B. Eun, G. Kim
1.036 Development Of An Etiologically
Relevant Model Of Carbamazepineresistant Epilepsy For The Early
Evaluation Of Novel Anti-Seizure
Drugs/K. Thomson, C. H. Rueda,
A. Modi, T. Glauser, H. White
1.037 Effects Of Acute Vs Chronic
Sleep Disruption On Flurothyl-Induced
Seizure Susceptibility In Mice/
E. Wallace, M. Jones, J. Rho,
R. Maganti
1.038 The NS-PTEN Ko Mouse Model
Of Cortical Dysplasia With Epilepsy Is
Associated With Inflammation/
A. Brewster, L. Nguyen, A. Anderson
1.039 Hippocampal Circuitry
Disruptions Following Diffuse Brain
Injury In Swine/J. A. Wolf, K. Browne,
M. Grovola, D. K. Cullen, A. V. Ulyanova
1.040 The Significance Of Craniofacial
Trauma In A Baboon Colony: A Clinical
Marker Of Seizures?/C. Szabo,
K. Knape, M. Leland, C. Bauer,
J. Williams
Human Studies
1.047 Study Of Seizure Onset And
Propagation Using Intracranial EEG
Recorded Using Micro-Electrodes/
I. Basu, W. S. Anderson
1.048 Vagus Nerve Stimulation
Triggered By Cardiac-based Seizure
Detection, A Prospective Multicenter
Study/P. Boon, K. van Rijckevorsel,
C. Elger, N. Mullatti,
A. Schulze-Bonhage, K. Vonck,
G. Wagner, W. Van Grunderbeek,
J. Begnaud, R. McGuire
1.049 GABA Imbalance In Temporal
Neocortex Of Patients With
Pharmacoresistant Temporal Lobe
Epilepsy And Mood Disorders/
L. Rocha, M. Alonso-Vanegas,
S. Orozco-Suárez, C. Zavala-Tecuapetla,
M. Masao-Buentello, J. Cienfuegos,
J. Cisneros-Franco
1.050 Driving With Epilepsy: A
Prospective Study Using A Driving
Simulator During Clinical And
Subclinical Seizures/W. Chen,
A. Bauerschmidt, M. W. Youngblood,
C. Cunningham, N. Li, R. Gebre,
M. Johnson, E. Chen, P. Vitkovskiy,
Y. Baykara, D. Kluger, C. Ezeani,
Z. Kratochvil, J. Bronen, J. Thomson,
K. Riordan, J. Yoo, R. Shirka,
L. Manganas, L. Hirsch, H. Blumenfeld
1.051 Taurine Intervention In Succinic
Semialdehyde Dehydrogenase
(SSADH) Deficiency/P. Pearl,
J. Shreiber, W. Theodore,
R. McCarter, E. Wiggs, T. Bottiglieri,
J. He, E. Barrios, K. M. Gibson
1.052 Established And Novel CellSurface Autoantibodies In RecentOnset Cryptogenic Adult Epilepsies/
T. Moloney, J. Adcock, S. R. Irani,
H. Kramer, A. Vincent, B. Lang
Noon - 6:00 p.m.
1.053 Stop SUDEP Program:
Application Of Visual Automated
Fluorescence Electrophoresis In The
Qualitative Profiling Of Archived
SUDEP Samples/T. L. Klassen,
T. Tomson, O. Sveinsson,
U. von Dobeln, J. Drabek, J. Noebels,
M. Diaz, STOP SUDEP Program
Network, A. Goldman
1.054 Spectrum Of Abnormalities In
GABAergic Phenotype In Epileptogenic
Cortical Malformations/L. Jansen,
W. H. Roden, S. A. Gunter,
L. M. Viltz, J. Ojemann
1.055 Dysregulated Metabotropic
Glutamate Receptor Expression In
Tuberous Sclerosis Complex And Focal
Cortical Dysplasia/P. Dilsiz, A. Salah,
H. Weiner, Y. Ding, O. Devinsky,
D. Talos
Devices, Technologies, Stem Cells
1.056 Efficacy Of Electric Conduction
On Rats With Penicillin-Induced
Neocortical Epilepsy/S. Liang, S. Zhang
1.057 Vagus Nerve Stimulation In
Patients Under One Year Of Age/
W. Gump, K. Skjei
1.058 Linear Model Of The Ketogenic
Diet For Algorithmic Diet Planning/
H. Li, C. Bergqvist, J. Jauregui,
C. Chee, C. Fenton
1.059 Human Neural Stem Cells
Generate Functional Neurons In
Mouse Neocortex/F. Zhou, T. Zheng,
J. Fortin, C. Kuang, B. Reynolds,
D. Steindler, Y. Xiao, D. Hondmann,
S. Roper
1.060 Vagus Nerve Stimulation In
Medically Refractory Epilepsy 15 Year
Outcome: Reduction Of Seizure
Frequency Sustained/J. C. Dean,
R. Pavelock, C. Allen
1.061 Sympatho-Vagal Balance
Derived From Heart Rate Variability
During ECG Monitoring May “Reveal”
The Underlying Cause Of Blackouts/
P. Cooper, N. Virag, A. Anwar,
R. Sutton, A. Fitzpatrick, M. de Melis
1.062 GABA-ergic Cell Therapy
Greatly Diminishes Spontaneous
Seizures And Alleviates Cognitive And
Mood Dysfunction In Chronic Temporal
Lobe Epilepsy/A. Shetty, B. Hattiangady,
B. Shuai, X. Rao
Biomarkers
1.063 24h Quantitative-EEG And InVivo Glutamate Biosensor Detects
Activity And Circadian Rhythm
Dependent Biomarkers Of
Pathogenesis In MeCP2 KO Mice/
S. Kadam, S. Ammanuel, C. ODriscoll,
A. Wozniak, C. Eyring, M. E. Blue,
C. M. Crainiceanu, M. Johnston
1.064 Wigner-Hough Transform For
Chirp Signals Detection During
Seizure Periods/W. Besio, A. Feltane,
G. F. Boudreaux-Bartels,
I. E. Martínez-Juárez, Y. Boudria
1.065 Can We Predict Depression In
Individuals With Temporal Lobe
Epilepsy? Insights From An Animal
Model/C. Dubé, M. Choy, J. Molet,
S. Quddusi, Y. Chen, T. Baram
1.066 An Examination Of Cognitive
Deficits Following Experimental Febrile
Status Epilepticus In Rat Pups:
Neurobiology And Biomarkers/J. Barry,
A. Robbins, K. R. Jenks, R. Scott,
P. Lenck-Santini, M. Choy, C. Dubé,
T. Baram, G. L. Holmes
1.067 The Role Of Autoimmune
Antibodies In Cryptogenic Epilepsy/
C. Ozkara, G. Gozubatik-Celik, S. Delil,
N. Yeni, E. Tuzun
1.068 Increased Aquaporin 4 In The
Rat Splenium After PilocarpineInduced Status Epilepticus/H. Song,
D. Shin
Neurophysiology
Video EEG Epilepsy-Monitoring
1.069 Use Of Prolonged VEEG
Monitoring In Children With First
Unprovoked Seizure/A. Hashim,
M. Salam, J. Singh
1.070 Analysis Of Ictal And Interictal
Infraslow Activity (ISA) By
Stereoelectroencephalography (SEEG)/
S. Thompson, B. Krishnan, J. Bulacio,
J. Mosher, R. Burgess
1.071 Role Of VEEG Monitoring In
Neonates With HIE Undergoing
Therapeutic Hypothermia With
Correlation Of Seizures And
Neurodevelopmental Outcome/
S. Kaushal, M. Salam, J. Singh,
A. Hashim
1.072 Inter-Rater Reliability Of The
Assessment Of Hypsarrhythmia/
G. Kwong, J. Matsumoto, J. Lerner,
J. Wu, R. Sankar, S. Hussain
1.073 Safety In The Epilepsy
Monitoring Unit (EMU). A Survey Of
The “Safety In EMU” Task Force In
Europe/G. Rubboli, S. Beniczky,
M. Canevini, S. Claus, P. Kahane,
H. Stefan, W. Van Emde Boas,
H. Van Hemert, D. Velis, A. Gil-Nagel,
B. J. Steinhoff, E. Trinka, P. Ryvlin
1.074 Nocturnal Sympathetic Surges
Of Electrodermal Activity Lateralize
Ipsilaterally To The Seizure Onset
Zone/D. Vannan, R. Sarkis,
S. Thome-Souza, M. Poh, J. Klehm,
R. Picard, T. Loddenkemper,
C. Reinsberger
1.075 Automated Detection Of
Electrographic Seizures In Pediatric
EMU Patients Through Analysis Of
Scalp EEG/D. Shiau, K. Schnabel,
J. Desrochers, R. Kern, J. Sackellares,
J. Halford
1.076 Photic Induced Seizures And
Photoparoxysmal Response/
N. Shahdad, A. Weinstock, M. Bilal,
B. Teter
1.077 Utilization And Yield Of The
Epilepsy Monitory Unit In Pediatric
Age Group/K. Pawar, D. Jarosz,
H. Ahmann, B. Kinnaman,
S. Abdelmoity, A. Abdelmoity
1.078 Rationale And Diagnostic Yield
Of Repeat Video-EEG In Presurgical
Epilepsy Patients/C. Eze, J. Schreiber,
I. Dustin, J. Greenfield, M. Duran,
P. Tyer, S. Sato, W. Theodore, S. Inati
SATURDAY
1.041 Revisiting Arterial Occlusion
As An Animal Model Of Poststroke
Epilepsy/E. R. Miller, E. A. Kharlamov,
V. Yenugadhati, K. M. Kelly
1.042 Hyperthermia-Induced Seizures
Are Potentiated By Lipopolysaccharide
And Reduced By L-Type Calcium
Channel Blocker, Nimodipine/
L. M. Mlsna, S. Koh
1.043 Can Seizure Threshold Tests In
Epileptic Mice Be Used As A Model
For Pharmacoresistant Epilepsy?/
F. Twele, K. Töllner, C. Brandt,
W. Loscher
1.044 Cortical Recruitment Paterns
During Mediodorsal Kindling:
Comparison Of Sprague-Dawley And
WAG/RIJ Rats/M. Kendirli, T. Eryigit,
E. Bertram, F. Onat
1.045 Time-Dependent Diazepam
Insensitivity In The DFP Model Of
Status Epilepticus/D. Reddy,
R. Kuruba, X. Wu
1.046 Status Epilepticus Induces Cell
Proliferation But Not Neuronal Cell
Death In The Developing Rat
Cerebellum/M. López-Meraz,
A. Lanes-Durán, M. Miquel, J. Manzo
Poster Session 1
35
1.079 Characteristics Of Postictal
Generalized EEG Suppression (PGES)
In Children/K. Okanari, H. Otsubo,
K. Elizabeth, A. Ochi, T. Okanishi,
S. Sakuma, C. Go, Y. Eguchi,
M. Tsunoda, Y. Mori, E. Donner
1.080 The Value Of Video
Electroencephalography In
Psychogenic Syncope In Children/
R. Stowe, V. Puri
1.081 Infraslow Activity And Ictal
Onset Baseline Shifts: Report Of Five
Paediatric Cases/L. Bello-Espinosa,
M. Scantlebury, J. Rho, J. Buchhalter,
A. Datta
MEG
1.082 Coherence Aids In Localization
Of Infraslow Brain Activity (ISA)
Detected Prior To Ictal MEG In
Patients With Focal Epilepsy/
A. Zillgitt, V. Shvarts, G. Barkley,
J. Moran, K. M. Mason, N. Tepley,
S. Bowyer
1.083 Relationship Between Temporal
Lobe Epilepsy Surgical Outcome And
The Direction Of Coherent Brain
Networks Detected By MEG/
B. Assaad, M. Elsayed, K. M. Mason,
A. Zillgitt, L. R. Schultz, G. Barkley,
J. Moran, S. Bowyer
1.084 MEG Source Analysis And
Directional Information Flow For Noninvasive Interictal Epileptogenic Focus
Localization In Patients With Nonlesional MRI And Neocortical Epilepsy/
B. Krishnan, I. Vlachos, Z. Wang,
J. Mosher, L. Iasemidis, R. Burgess,
A. Alexopoulos
1.085 Patterns Of Cortical Activation
Following Median Nerve Stimulation In
Patients With Intractable Epilepsy: An
MEG Study/P. Klaas, J. Mosher
1.086 Magnetoencephalography With
Temporal Spread Image Method Could
Show Propagation Of Epileptic
Activities/S. Shibata, M. Matsuhashi,
T. Kunieda, Y. Yamao, R. Inano,
T. Kikuchi, H. Imamura, S. Takaya,
R. Matsumoto, A. Ikeda, R. Takahashi,
T. Mima, H. Fukuyama, N. Mikuni,
S. Miyamoto
1.087 Comparison Of MEG Inverse
Modeling Algorithms With Intracranial
EEG, Resection Area, And Seizure
Outcome/J. Tenney, H. Fujiwara,
D. Rose
1.088 A Comparison Of Dipolar And
Distributed Source Estimation
Methods In The Analysis Of Interictal
Epileptic Spikes Observed In MEG
Recordings/A. Alareddy, M. Raghavan,
Z. Li, W. Mueller, S. Baillet, E. Bock
1.089 Comparison Of Expertly
Selected Vs Standard Subarray
Analysis For Current Dipole Source
Localization Of Magnetoencephalograms
In Epilepsy Patients/R. Burgess,
O. Nazarenko, J. Fong, S. Ito,
J. Mosher, A. Alexopoulos
36
Poster Session 1
Noon - 6:00 p.m.
1.090 The Role Of Magnetic Source
Imaging (MSI) In Non-Lesional
Neocortical Pediatric Epilepsy/
W. Zhang, J. Doescher, D. Dickens,
M. Frost, T. Passe, M. Dunn,
F. Ritter
1.091 Comparison Of
Magnetoencephalography And
Intracranial Electroencephalography In
Patients With Epilepsy/D. Kim,
K. J. Hwang, J. Kim, Y. H. Lee,
H. S. Park, S. Hong
1.092 Auditory Evoked Fields (AEFs)
During Sedation: Exploring The Effect
Of Dexmedetomidine (PRECEDEX)/
T. Kleineschay, M. Korostenskaja,
E. Castillo
Brain Stimulation
1.093 Can Single Pulse Stimulation
Help To Discriminate Between
Pathological And Physiological High
Frequency Oscillations?/
M. van’t Klooster, C. Ferrier,
N. van Klink, K. Braun, F. Leijten,
G. Huiskamp, M. Zijlmans
1.094 Increased Polyphasia In The
Motor Evoked Potential Of Patients
With Epilepsy And Their First-degree
Relatives/A. D. Pawley, B. Ceronie,
F. Chowdhury, L. Nashef, R. Elwes,
M. P. Richardson
1.095 Cardiac Autonomic Nervous
System Activity Changes Associated
With Generalized Tonic-Clonic Seizures
In Electroconvulsive Therapy (ECT)/
Y. Suzuki, M. Miyajima, K. Ohta,
N. Yoshida, M. Okumura,
M. Nakamura, T. Sasano, T. Kawara,
M. Matsuura, M. Matsushima
1.096 Electrical Brain Stimulation
And The Human Insular Functional
Connectivity/T. Almashaikhi,
S. Rheims, K. Ostrowsky-Coste,
A. Montavont, J. Jung,
J. De Bellescize, A. Arzimanoglou,
P. Keo Kosal, M. Guenot, O. Bertrand,
P. Ryvlin
1.097 Early Responses Evoked By
Single Pulse Electrical Stimulation: A
Physiological Or Epileptic Phenomenon?/
B. Mouthaan, M. van’t Klooster,
M. Zijlmans, F. Leijten, C. Ferrier,
G. Huiskamp
1.098 Safety Of Cortico-Cortical
Evoked Potentials By Low-Frequency
Stimulation Of Intracranial Electrodes/
P. Mégevand, M. S. Goldfinger,
D. Groppe, C. Keller, S. Bickel,
S. Hwang, C. Harden, L. Entz,
A. Mehta
1.099 Mapping Cortical Excitability
Using Single Pulse Electrical
Stimulation In Sereoelectroencephalographic Studies/
A. Barborica, C. Donos, J. Ciurea,
A. Rasina, B. Balanescu, I. Mindruta
1.100 Cortical Excitability Difference
In Postictal State Of Epileptic Seizure
And Syncope Associated With Loss Of
Consciousness/H. J. Nam, W. Shin,
Y. N. Kwon, J. S. Lee
1.101 Increased Cortical Silent
Period In Patients With Extratemporal
Epilepsy In Comparison To Healthy
Controls/B. Ceronie, A. D. Pawley,
M. Orth, M. P. Richardson
Animal Studies
1.102 In Vivo 2-photon Confocal
Microscopy Of Cortical Absence
Epilepsy/J. F. Meyer, A. Maheshwari,
J. Noebels, S. Smirnakis
1.103 A Novel Mechanism Underlying
Stress-induced Seizure Susceptibility/
G. MacKenzie, J. Maguire
1.104 AMPA Receptor
Desensitization After Early Life
Seizures/H. O’Leary, A. M. Castano,
T. Benke
1.105 Epilepsy-Associated
Deterioration In Hippocampal Dentate
Gyrus Network Firing Properties/
S. F. Frausto, C. Dengler, H. Takano,
D. Coulter
1.106 GIRK2 Channel Function Is
Necessary For Infantile Spasms-like
Seizures Induced By GABA(b)
Receptor Agonists/M. Blichowski,
A. Shephard, L. Shen, M. Cortez,
O. Snead
1.107 Hippocampal Interneurons
From Epileptic KCNA1-null Mice
Exhibit Differential Physiological
Properties And Responses To
Metabolic Supplementation/
C. Gavrilovici, Z. W. Zhang, J. M. Rho
1.108 Neuron Type-Specific
Optogenetic Stimulation Of The Medial
Septum For The Treatment Of
Epilepsy/N. Laxpati, M. Chiruvella,
J. Tung, C. A. Gutekunst, R. Gross
1.109 NMDA Receptors And L-Type
Ca2 Channels Mediate Activitydependent Regulation Of K Channel
Genes During The Expression Of
Homeostatic Intrinsic Plasticity/
K. Lee, S. Royston, M. Vest, D. Ley,
E. Kim, L. Y. Jan, H. Chung
1.110 Long Term Changes In The
Mechanisms Of mGluR Mediated Long
Term Depression Following A Single
Episode Of Early Life Seizures/
P. Bernard, A. M. Castano, T. Benke
1.111 Serotonin Signaling Regulates
Heat-induced Seizures In Knock-in
Drosophila Models Of Epilepsy/
S. S. Schutte, R. J. Schutte,
J. Algara, E. Barragan, J. Gilligan,
C. Staber, Y. Savva, M. A. Smith,
R. Reenan, D. O’Dowd
Computational Analysis & Modeling
Of EEG
1.112 Resection Of Cortex With
Interictal Fast Ripples Correlating
With Seizure Outcome In Patients
With Wide-Spread Epileptic Networks
In Tuberous Sclerosis Complex/
T. Okanishi, T. Akiyama, A. Ochi,
H. Otsubo
Noon - 6:00 p.m.
Clinical Epilepsy
Clinical Diagnosis
1.125 Rotavirus Infection Can Cause
Seizures Accompanied By Diffuse
Cerebral White Matter Injury In FullTerm Newborns: Is It Fifth Day Fits?/
K. Lee, K. Oh, C. Moon
1.126 Risk Factors For Drug
Resistant Epilepsy In Adult Patients
With Generalized Epilepsy Case
Control Study Nested Within A
Cohort/L. Hernandez Ronquillo,
S. Buckley, J. Tellez-Zenteno
1.127 Is Early Discontinuation Of
AED Therapy During EEG Telemetry
Safe And Efficacious?/S. A. Rizvi,
J. Tellez-Zenteno, L. Hernandez Ronquillo
1.128 Cingulate Epilepsy Manifesting
As Panic Disorder: Multimodal
Approach To Diagnosis/M. K. Tall,
M. Korostenskaja, T. Grace,
M. Westerveld, J. Seo, J. Cook,
P. Chen, C. Salinas, K. Lee
1.129 Characterization Of Microarray
Chromosomal Analysis For Clinical Use
In A Cohort Of Patients With
Childhood Absence Epilepsy/E. Sell,
A. Stanek, E. Lewis
1.130 Characteristics Of LennoxGastaut Syndrome In Adults/
U. Menon, F. Khan, E. Ramsay
1.131 Electrographic Status
Epilepticus Of Sleep (ESES) In 21
Children/D. Depositario-Cabacar,
P. Pearl, S. Weinstein, J. Conry,
T. Tsuchida, A. Kao, W. Gaillard,
T. Zelleke
1.132 The Presence Of Non-Epileptic
Seizures In An Epilepsy Monitoring
Unit (EMU)/O. Farooq, N. Agarwal,
P. Li, R. Jani, M. Boudreau, S. Kerr,
S. Finnegan, A. Weinstock
1.133 The Diagnostic Value Of Serum
Prolactin Levels In The Epilepsy
Monitoring Unit/S. Nasir, A. Abubakr
1.134 Clinical Manifestations Of AntiLGI1 Encephalitis In Korea/J. Shin,
S. Lee, J. Moon, K. Jung, K. Lee,
S. Lee, K. Chu
1.135 Cardiac Diagnoses In The
Epilepsy Monitoring Unit/L. Ngo,
J. Zhu, J. Hopp
1.136 Incidence Of Oxygen
Desaturation In Psychogenic NonEpileptic Seizures/E. Teasdale,
C. Derry, R. Brotherstone, S. Duncan
1.137 Idiopathic Generalized Epilepsy
Vs Frontal Lobe Epilepsy: A Common
Dilemma At Epilepsy Centers/
N. Rincon Flores, A. Bozorg,
A. Frontera, F. Vale, S. Benbadis,
V. Kelly
Clinical Treatments
1.138 Palliative Surgical Resections
In Children With Intractable Epilepsy
And Bilateral Epileptic Foci: Surgical
Results In The Detroit Series/M. Ilyas,
H. Chugani, L. Sivaswamy, E. Asano,
S. Sood
1.139 The Pediatric Epilepsy
Research Consortium: Organization
And Preliminary Experience/A. Berg,
E. Wirrell, K. Knupp, D. Nordli,
S. Khan
1.140 Assessment Of Liver Toxicity In
Perampanel-Treated Subjects: Pooled
Results From Phase III Clinical Trials/
A. Laurenza, H. Yang, B. Williams,
S. Zhou, J. Ferry
1.141 Lack Of Effect Of Perampanel
On QT Interval Duration: Results
From A Thorough QT Analysis And
Pooled Phase III Clinical Trials/H. Yang,
A. Laurenza, B. Williams, A. Patten,
Z. Hussein, J. Ferry
1.142 Efficacy And Safety Of
Perampanel In The Subgroup Of
Elderly Patients Included In The Phase
III Epilepsy Clinical Trials/B. Williams,
R. Wechsler, A. Laurenza, H. Yang,
S. Zhou, I. Leppik
1.143 Pharmacokinetics Of
Perampanel: Results From Phase I
Clinical Pharmacology Studies/B. Gidal,
D. A. Verbel, J. Ferry
1.144 GABA Vs Non-GABA
Mechanism Of Action Of Concomitant
Antiepileptic Drugs: Post-Hoc Analysis
Of Pooled Perampanel Phase III
Studies/M. Muller, H. Yang,
B. Williams, T. Ma, A. Laurenza,
S. S. Chung
1.145 Subgroup Analysis By Gender
In Perampanel Phase III Studies Of
Patients Diagnosed With PartialOnset Seizures/B. Vazquez, H. Yang,
B. Williams, S. Zhou, A. Laurenza
1.146 Review Of Psychiatric And
Behavioral Events In Perampanel
Clinical Studies/A. Ettinger,
A. LoPresti, H. Yang, B. Williams,
S. Zhou, R. Fain, A. Laurenza
1.147 Pooled Perampanel Phase III
Trials: Time To Onset And Duration For
Most Common Adverse Events/D. Ko,
H. Yang, B. Williams, D. Xing,
A. Laurenza
1.148 Obesity As A Common
Comorbidity In Patients With
Generalized Epilepsy And
Developmental Delay/L. D. Ladino,
L. Hernandez Ronquillo,
J. Tellez-Zenteno
1.149 The National Infantile Spasms
Consortium (NISC), A US Multicenter
Initiative To Improve Treatment And
Outcomes Of Infantile Spasms:
Etiologies, Initial Therapies And Early
Follow Up/K. Knupp, E. Wirrell,
A. Berg, S. Khan
1.150 Cannabinoids Are Not
Associated With Better Control Of
Epilepsy/C. Garcia Gracia, K. Kurako,
A. Rodriguez, C. Malpe, N. Galvez
1.151 Further Reduction In Clinical
Seizures With Addition Of
Levetiracetam In Subjects Receiving
Responsive Neurostimulation/
T. Crowder Skarpaas, F. Sun,
M. Morrell
SATURDAY
1.113 Gamma Activity Modulated By
Picture And Auditory Naming Tasks:
Intracranial Recording In Patients
With Focal Epilepsy/K. Kojima,
E. C. Brown, N. Matsuzaki,
R. Rothermel, D. Fuerst, A. Shah,
S. Mittal, S. Sood, E. Asano
1.114 Absence Of Auditory SteadyState Responses In Dravet
Syndrome Patients/E. Urrestarazu,
S. Cieza Ortiz, M. Alegre, F. Escobar,
J. Artieda, J. Iriarte,
R. Sanchez Carpintero
1.115 Dynamic Modulation Of
Epileptic High Frequency Oscillations
By The Phase Of Slower Cortical
Rhythms/G. Ibrahim, R. Anderson,
G. Singh-Cadieux, T. Akiyama, A. Ochi,
H. Otsubo, T. Okanishi, E. Donner,
J. Rutka, O. Snead, S. Doesburg
1.116 Pathological And Physiological
High Frequency Oscillations In Focal
Human Epilepsy/A. Matsumoto,
B. Brinkmann, M. Kucewicz,
J. Cimbalnik, M. Stead, J. Matsumoto,
R. Marsh, F. Meyer, G. Worrell
1.117 Automated Localization Of
Seizure Onset Zone Based On NonLinearity In The High Frequency
Components Of Interictal Intracranial
EEGs/E. Geertsema, M. Zijlmans,
D. Velis, S. Claus, G. Visser, S. Kalitzin
1.118 A Comparison Of Dynamic
Measures Applied To The EEG Findings
Of Spikes, Sleep, And Artifact In
Routine EEG Data/M. Schwabe,
K. Hecox
1.119 Peri-Ictal Broadband
Electrocorticography Including InfraSlow And High-frequency Activities
And Postoperative Seizure Outcomes
In 23 Medically Intractable Epilepsy
Patients/S. Park, S. Lee, C. Chung
1.120 Characteristic Abnormalities
Identified Using Automated Analysis
Of ECG During Seizures/D. Goldenholz,
M. Seyal
1.121 Epileptogenicity Of
Schizencephaly: Current Source
Analysis Using Standardized LowResolution Brain Electromagnetic
Tomography/O. Kwon, T. Yang, D. Kim,
S. Jung
1.122 Electrocorticographic
Correlates Of Overt Articulation Of
44 English Phonemes: Intracranial
Recording In Children With Focal
Epilepsy/G. Toyoda, E. Brown,
N. Matsuzaki, K. Kojima, E. Asano
1.123 Preictal Decrements Of Highfrequency Activities In The
Electrocorticography Of Intractable
Epilepsy Patients/S. Park, S. Lee,
C. Chung
1.124 Defining Electrophysiologic
Resting State Networks Associated
With Focal Epilepsy/S. Bandt,
D. Bundy, K. Ayoub, N. Szrama,
E. Leuthardt
Poster Session 1
37
1.152 Long-term Experience With
Lacosamide In Pediatric Epilepsy
Patients – A Retrospective European
Multicentre Report/M. Feucht,
E. Haberlandt, H. Ošlejšková,
G. A. Ramos Rivera
1.153 Cysticercal Calcifications Are
Not A Common Cause Of Drug-Resistant
Epilepsy In Neurocysticercosis/
S. Shaw, D. Millett, L. Chen, P. Kim,
C. Liu, L. Kalayjian, D. Ko, C. Heck
1.154 Evaluation Of Abuse Potential
Of Perampanel/J. Ferry, H. Yang,
B. Williams, K. Bradshaw, R. V. Fant,
A. Laurenza
Prognosis
1.155 EEG Power Predicts Seizure
Burden In The First 24 Hours In
Neonatal Hypoxic Ischemic
Encephalopathy Treated With
Hypothermia/S. Jain, A. Mathur,
P. Srinivaskumar, M. Wallendorf,
J. Zempel
1.156 Treatment Resistant Seizures
In Childhood Absence Epilepsy/
A. Michoulas, M. Gainza, D. Schrader,
M. Demos, M. Connolly
1.157 Practices Of Health Care
Providers In Discussing SUDEP With
Patients With Epilepsy/W. Miller,
J. Buelow, D. Friedman, O. Devinsky
1.158 The Impact Of Marital Habits
In Seizure Control Of Patients With
Temporal Lobe Epilepsy/M. Al Saluli,
F. Babtain, S. Al Ghamdi, H. Bhatia,
M. Velmurugan
1.159 Outcomes Of Genetic
Generalized Epilepsy At A
Comprehensive Epilepsy Center/
M. Elsayed, B. Assaad, L. R. Schultz,
V. Wasade, T. Howard, E. Muma,
J. Snyder, S. Gaddam, N. Mahmood,
L. Schuh, J. Constantinou, G. Barkley,
M. Spanaki, A. Zillgitt
1.160 Absence Epilepsy: The
Significance Of Intermittent Rhythmic
Delta Activity/A. Shaw, M. Michelson,
I. Sen-Gupta, A. Berg, C. Stack
1.161 Risk Of Epilepsy Following
Neonatal Seizures Secondary To
Hemorrhagic Stroke In Term Neonates/
C. Venkatesan, J. Millichap,
D. G. Ritacco, S. Nangia, C. Stack,
D. Nordli
1.162 Clinical Markers Of Postictal
Generalized EEG Suppression In
Children/E. Kouzmitcheva, K. Okanari,
H. Otsubo, E. Donner
1.163 Features Associated With
Refractoriness In Patients With
Primary Generalized Epilepsy/
A. Gomez, R. McLachlan,
S. Mirsattari, D. Diosy, J. Burneo
1.164 Discordance Between
Functional Magnetic Resonance
Imaging (fMRI) And WADA Test For
Language Lateralization/K. Ding,
Z. Yetkin, P. Van Ness, M. Agostini,
R. Hays, P. Gupta, J. J. Konikkara,
B. Mickey, C. Madden, P. Modur
38
Neuro Imaging
Poster Session 1
Noon - 6:00 p.m.
Structural Imaging
1.165 Increased Anxiety In Temporal
Lobe Epilepsy Is Associated With
Augmented Hippocampal-Amygdala
Connectivity/J. Riley, J. Lin
1.166 Differential Hippocampal And
Extrahippocampal Predictors Of
Verbal And Visual Memory In Right
And Left TLE Patients/M. Connolly,
J. Riley, M. Sazgar, L. Mnatsakanyan,
A. Linane, F. P. Hsu, J. Lin
1.167 Diffusion And Morphovolumetry
Abnormalities In Subcortical
Structures Of Patients With MRI
Negative Focal Neocortical Seizures/
S. Yang, Y. Hsin
1.168 White Matter Alteration In
Patients With Focal Non-Lesional
Epilepsy Correlates Highly With Onset
Age, Duration Of Epilepsy And
Pharmacoresistance/Y. Hsin, S. Peng,
T. Harnod
1.169 Lateralization Of Temporal
Lobe Epilepsy By Analysis Of
Asymmetric Fractional Anisotropy In
The Cingulum/M. Nazem-Zadeh,
J. M. Schwalb, K. V. Elisevich,
H. Bagher-Ebadian, H. Soltanian-Zadeh
1.170 Predicting When MRI And
FDG-PET Will Exhibit Epilepsy-Related
Findings/W. Kerr, A. Trefler,
K. R. Raman, E. S. Hwang, J. Stern,
N. Salamon, M. S. Cohen
1.171 Diffusion Tensor Imaging In
Cryptogenic West Syndrome: TractBased Spatial Statistics Analysis At
Onset/C. Ogawa, J. Natsume,
T. Fukasawa, H. Yamamoto,
H. Kidokoro, S. Yokoi, T. Takeuchi,
Y. Azuma, N. Ishihara, N. Ando,
T. Kubota, T. Negoro, K. Watanabe
1.172 Longitudinal Changes Of
Structural Neural Networks And
Cognitive Function In Benign Childhood
Epilepsy With Centrotemporal Spikes/
S. Kim, H. Hong, H. Jung, J. Lee,
H. Lee
1.173 Microsurgical Anatomy Of The
Dorsal Hippocampal Commissure:
Correlations With Diffusion Tensor
Imaging Fiber Tracking And Clinical
Relevance/A. Becerra Zegarra,
A. Khan, S. De Ribaupierre,
J. G. Burneo, A. Parrent, T. Peters,
D. Steven
1.174 Diffusion Tensor Imaging And
Tractography Identify Structural
Changes In Cryptogenic Focal Epilepsy/
C. Vollmar, J. Remi, E. Hartl,
C. Catarino, A. Loesch, S. Noachtar
1.175 Cognitive And Brain
Developmental Trajectories In NewOnset Juvenile Myoclonic Epilepsy/
J. Lin, K. Dabbs, J. Riley, J. Jones,
D. Jackson, D. Hsu, C. Stafstrom,
M. Seidenberg, B. Hermann
1.176 Abnormal White Matter
Correlates With Neuropsychological
Impairment In Children With
Localization-Related Epilepsy/
E. Widjaja, J. Skocic, C. Go,
O. C. Snead, D. Mabbott, M. L. Smith
1.177 Hippocampal Volume Is
Predicted By Number Of Years Since
Seizure Onset/K. Hanson, C. Pearson,
H. Seif Eddeine, S. Gale
1.178 Anxiety In Children With
Epilepsy: Amygdala-Prefrontal Cortex
Abnormalities/D. Jackson,
K. Chambers, J. Jones, K. Dabbs,
D. Hsu, C. Stafstrom, M. Seidenberg,
B. Hermann
1.179 How Concordant Are MRI, PET,
EEG, ECOG. MEG And Neuropsychology
For Hemispheric And Lobar
Localization Of Epileptogenic
Tissue?/U. Uysal, M. Popescu,
I. Osorio
1.180 Birth Weight And FrontoTemporal Volumes In Children With
Epilepsy/S. Gurbani, P. Siddarth,
J. Levitt, R. Caplan
1.181 The Spectrum Of Structural
Brain Abnormalities In
Pharmacoresistant Epilepsy: An MRI
Study On Consecutive 60 Patients/
T. Kobulashvili, G. Lomidze,
M. Okujava, G. Kuchukhidze,
S. Kasradze
1.182 Nonconvulsive Status
Epilepticus Presenting As Broca’s
Aphasia/D. A. Vargas-Mendez,
Y. Matuk-Pérez, I. Rodriguez-Leyva
Functional Imaging
1.183 Interictal Epileptiform
Discharge Mapping Based On Local
Synchronization Of fMRI Signal/
J. V. Liu, E. J. Kobylarz, G. P. Thomas,
B. Jobst
1.184 Prediction Of Post-Operative
Naming Outcome In Temporal
Lobectomy Patients Using Resting
State Intrinsic Connectivity
Distribution/F. Winstanley,
D. Scheinost, J. Arora, G. Yang,
D. Spencer, T. Constable
1.185 Association Between
Functional Connectivity Of The Medial
Temporal Structures And Depression
Symptomatology In Temporal Lobe
Epilepsy/N. Kemmotsu, N. Kucukboyaci,
C. Cheng, H. Girard, C. McDonald
1.186 Assessment Of The Mesial
Temporal Lobe With 7T MRSI For The
Consideration Of Dual Pathology/
P. Farooque, R. Duckrow, L. Hirsch,
D. Spencer, J. Pan
1.187 Epileptic Networks Using Scalp
And Intracranial EEG-fMRI And
Postsurgical Outcome/U. J. Chaudhary,
S. Perani, D. Carmichael, R. Rodionov,
S. Vulliemoz, R. Thornton,
M. Pugnaghi, C. Micallef, A. McEvoy,
C. Scott, B. Diehl, M. Walker,
J. Duncan, L. Lemieux
1.188 Primary Cortex And Pons
Behave Differently During Spike And
Wave Discharges Of Genetic
Generalized Epilepsy Versus LennoxGastaut Syndrome/P. Carney,
J. Archer, A. Warren, D. F. Abbott,
G. D. Jackson
Cormorbidity (Somatic And
Psychiatric)
Psychiatric Conditions
1.195 The Neurological Disease And
Depression Study (NEEDS) – Epilepsy
Cohort: A Study Of The Burden,
Course And Impact Of Depressive
Disorders In Persons With Epilepsy/
N. Jette, K. Fiest, A. G. Bulloch,
S. Wiebe, L. Blaikie, C. Atta,
C. Carroll, K. Dobson, S. Macrodimitris,
S. Patten
1.196 Effects Of Vagal Nerve
Stimulation On Depressive Symptoms
In Patients With Difficult-To-Treat
Epilepsies/K. Bohlmann, A. L. Friedo,
U. Wolff, H. B. Straub
1.197 Major Stressful Life Events In
Pediatric And Adult Patients With
Psychogenic Nonepileptic Seizures/
K. Valente, R. Alessi
1.198 Life Satisfaction Of People
With Epilepsy/N. Thompson, A. Patel,
L. Selwa, S. Stoll, C. Begley,
E. Johnson, R. Fraser
1.199 Screening For Depression,
Anxiety, And Interictal Dysphoric
Disorder In Epilepsy/M. Amiri, P. Bech,
C. P. Hansen
1.200 The Prevalence Of Psychiatric
Comorbidity And Recreational Drug
Use In Epileptic And Nonepileptic
Events Is High/A. Rodriguez,
C. Garcia Gracia, K. Kurako, C. Malpe,
N. Galvez
Noon - 6:00 p.m.
1.201 Design And Feasibility Of A
Memory Intervention With Focus On
Self-Management For Cognitive
Impairment In Epilepsy/B. Jobst,
T. Caller, K. Secore, R. J. Ferguson,
F. P. Alexandre, J. Harrington,
R. M. Roth
Animal Studies
1.202 Sudden Unexpected Death In A
Mouse Model Of Dravet Syndrome/
F. Kalume, R. E. Westenbroek,
C. S. Cheah, F. H. Yu, J. C. Oakley,
T. Scheuer, W. Catterall
Antiepileptic Drugs
Mechanisms of Action
1.203 Human Nav1.1 And Nav1.2
Show Differential Slow Inactivation
Properties And Response To Phenytoin/
Z. Zeng, S. Miller, C. French
1.204 Anticonvulsant Properties Of
Brivaracetam Are Not Mediated By
Its Effects On Voltage-gated Sodium
Channels/I. Niespodziany, V. André,
N. Leclère, P. Ghisdal, C. Wolff
1.205 An In Vitro Screen For
Antiepileptogenic Compounds Utilizing
Organotypic Hippocampal Slice
Cultures/Y. Saponjian, Y. Berdichevsky,
W. Swiercz, K. Staley
1.206 Lamotrigine Suppresses
Thalamic Epileptiform Oscillations Via
A Blockade Of The Persistent Sodium
Current/A. Alexander, J. Huguenard
1.207 Brivaracetam Is Superior To
Levetiracetam In Decreasing
Excitatory Synaptic Transmission/
X. Yang, S. Rothman, J. Dubinsky
1.208 Effective Treatment Of Typical
Absence Seizures With Ezogabine: A
Case Report/D. Vossler, U. Yilmaz
Animal Studies
1.209 Eslicarbazepine Acetate Is
Antiepileptogenic In The Pilocarpine
Mouse Model Of Temporal Lobe
Epilepsy/N. Pires, M. Bonifácio,
L. Wright, H. Beck, P. Soares Da Silva
1.210 Treatment With Pregnanolone
Is Effective Against Seizures Induced
By Whole Body Exposure To Sarin/
M. Furtado, D. B. Miller,
J. E. Schwartz, W. T. Muse,
M. K. Schultz, M. F. Stone,
D. L. Yourick, C. E. Whalley,
L. A. Lumley
1.211 PharmacoEEG Profiling Of The
Most Commonly Used AEDs In The
MTLE Mouse Model/C. Roucard,
B. Pouyatos, C. Bouyssières,
C. Dumont, R. Maury, V. Duveau
1.212 Effects Of Recurrent Neonatal
Status Epilepticus And Stress On
Learning And The Anticonvulsant
Phenobarbital Effects/O. Akman,
S. L. Moshé, A. S. Galanopoulou
1.213 Profile Of Retigabine-Induced
Neuronal Apoptosis In The Developing
Rat Brain/A. Kondratyev, L. Brown,
C. Soper, C. Kulick, K. Gale, P. Forcelli
1.214 Efficacy Of Retigabine On
Acute Limbic Seizures In Adult Rats/
L. K. Friedman, J. P. Wongvravit,
A. M. Slomko, S. Hu, W. Wan, S. Ali,
Z. Naseer
1.215 Comparison Of The
Anticonvulsant Efficacy Of
Phenobarbital, Imepitoin And Abecarnil
In The Pentylenetetrazole Seizure Test
In Mice And Dogs/K. Töllner,
K. Hoffmann, F. Twele, H. Potschka,
W. Loscher
1.216 Retigabine Calms SeizureInduced Behavior Following Status
Epilepticus/A. M. Slomko,
L. K. Friedman, Z. Naseer
Clinical Trials
1.217 First Clinical Experiences With
Perampanel – The Kork Experience In
74 Patients/B. J. Steinhoff,
M. Bacher, T. Bast, L. Keller,
R. Kornmeier, K. Mathews, J. Scholly,
A. M. Staack, I. Wisniewski
1.218 Lacosamide Added To An
Existing Monotherapy In Epilepsy
Patients With Partial Onset Seizures:
Outcome Of 2nd Interim Analysis Of
The Vitoba Study (Vimpat Added To
One Baseline AED)/M. Noack-Rink,
T. Mayer, S. S. Arnold, U. Runge
1.219 Safety And Tolerability Of
USL255 In Subjects With Refractory
Partial-onset Seizures: Results From
The Randomized, Phase 3 Prevail
Clinical Trial/R. E. Hogan, S. Arnold,
T. A. Fakhoury, B. Anders, D. Laine,
W. M. Todd, B. Lawson
1.220 Comparison Of The
Pharmacokinetics Of USL255, An
Extended-release Topiramate, When
Sprinkled Onto Food Or Swallowed
Intact/A. M. Clark, B. Anders,
M. B. Halvorsen
1.221 USL255, A Once-daily,
Extended-release Topiramate, Is
Efficacious As An Adjunctive Therapy
For Refractory Partial-onset Seizures:
Results From The Randomized Phase
3 Prevail Clinical Trial/S. S. Chung,
T. A. Fakhoury, B. Anders, D. Laine,
S. Arnold, M. B. Halvorsen
1.222 Time To Onset Of Efficacy And
Sustained Treatment Effects Of
USL255: Results From The Phase 3
Prevail Clinical Trial/B. Lawson,
S. S. Chung, A. M. Clark,
M. B. Halvorsen, I. Blatt
1.223 USL255, A Once-Daily,
Extended-release Topiramate, Has
Positive Effects On Clinical Outcomes
And Quality Of Life: Results From The
Phase 3 Prevail Clinical Trial/S. Arnold,
I. Blatt, A. M. Clark, M. B. Halvorsen,
V. N. Nagaraddi
1.224 Clinical Experience Of
Lacosamide Therapy In 148 Infants
And Children Less Than 12 Years/
M. Gustafson, D. Arkilo, F. Ritter
1.225 Cognitive Effects Of Extendedrelease, Once-daily Trokendi XR™ Vs
B.I.D. Immediate-release Topiramate
(TPM-IR, Topamax®) In Healthy
Volunteers/S. Schwabe, S. Brittain
SATURDAY
1.189 Sensorimotor Cortical
Reorganization In Epilepsy Patients
With Malformations Of Cortical
Development/J. G. Burneo,
S. Nikolova, R. Bartha
1.190 Usefulness Of Random Forest
Classifier For Predicting Surgery
Outcome In Epilepsy With
Hippocampal Sclerosis From FDG And
[11C]flumazenil PET/J. Yankam Njiwa,
K. Gray, F. Mauguiere, P. Ryvlin,
A. Hammers
1.191 Hemodynamic Response
Function In Patients With Focal
Cortical Dysplasia Vs. Mesial Temporal
Sclerosi/S. Watanabe, D. An,
M. Safi-Harab, F. Dubeau, J. Gotman
1.192 BOLD Response From Focal
Epileptiform Discharges On
Intracranial EEG/Y. Aghakhani,
C. Beers, D. J. Pittman, I. Gaxiola
Valdez, P. Federico
1.193 PET Imaging Of Inflammation In
Epilepsy/P. Zanotti-Fregonara,
I. Dustin, J. Hong, V. Pike, K. Jenko,
S. Zoghbi, D. Rallis-Frutos, C. Eze,
K. Zaghloul, J. Schreiber, S. Inati,
R. Innis, W. Theodore
1.194 EEG Amplitude Is Related To
Ictal Task Performance In Childhood
Absence Epilepsy/J. Guo, R. Kim,
S. Jhun, H. Mistry, W. R. Xiao,
A. Kundishora, G. Castellucci,
S. Braun, J. Rodríguez-Fernandez,
X. Bai, M. Negishi, C. Bailey,
M. J. Crowley, T. Constable,
L. C. Mayes, H. Blumenfeld
Poster Session 1
39
1.226 Dosing Feasibility And
Pharmacokinetics By Seizure Type And
Status, And Tolerability Of Intranasal
Diazepam In Adults With Epilepsy/
M. Sperling, H. Seif Eddeine, K. Haas,
G. Krauss, H. R. Henney III,
A. L. Rabinowicz, G. Bream,
E. Carrazana
1.227 Lacosamide Conversion To
Monotherapy For The Treatment Of
Partial-onset Seizures: Results From
A Historical-Controlled, Multicenter,
Double-blind, Randomized Trial/
R. Wechsler, G. Li, J. A. French,
T. O’Brien, O. D’Cruz, P. Williams,
M. Brock
1.228 Conversion To Monotherapy
With Eslicarbazepine Acetate In
Adults With Partial-Onset Seizures/
L. Pazdera, M. P. Jacobson, P. Bhatia,
D. Blum, T. Grinnell
1.229 Identification Of The Most
Disparate Generic Lamotrigine Tablets
Based On In Vitro Screening/E. Elder,
K. Jones, A. Schuelke, V. Echeverria,
J. Walton, B. Gidal, T. Welty, P. Bolger,
M. Berg, R. Alloway, M. Privitera
1.230 Efficacy And Safety Of Adjunct
Perampanel Based On Number Of
Antiepileptic Drugs At Baseline And
Baseline Predictors Of Efficacy: Phase
3 Post Hoc Analysis/T. Glauser,
T. Ma, R. Fain
1.231 Effect Of Adjunctive
Lacosamide On Complex Partial
Seizures And Partial Seizures With
Secondary Generalization In Adults:
Pooled Analysis Of Three Open-Label
Extension Trials/S. Dimova,
C. McShea, P. Doty, K. Werhahn,
M. De Backer
Cohort Studies
1.232 Stiripentol In Dravet
Syndrome: Results Of A Retrospective
US Study/E. Wirrell, L. Laux,
D. N. Franz, J. E. Sullivan,
R. P. Saneto, R. P. Morse,
O. Devinsky, H. Chugani, A. Hernandez,
L. D. Hamiwka, M. Mikati, I. Valencia,
M. E. Le Guern, L. Chancharme,
M. Sotero de Menezes
1.233 Short-Term And Long-Term
Outcomes Of Rufinamide Treatment:
A Single Pediatric Center Experience/
N. E. Kadish, S. Thome-Souza,
S. Ramgopal, I. Sánchez Fernández,
A. Bergin, J. Bolton, C. Harini,
M. Libenson, H. Olson, J. Peters,
A. Poduri, A. Rotenberg, M. Takeoka,
S. Kothare, B. Bourgeois,
T. Loddenkemper
1.234 An Spanish Collection Of
Patients With Eslicarbazepine In
Clinical Practice/J. Serratosa,
E. Guillamon, E. López-Gomáriz,
M. Toledo, J. Salas,
J. Rodriguez Uranga, F. López,
A. Castillo, J. Mauri, P. Giner,
N. Torres, J. Palau Bargues, A. Molins
Albanell, M. Garcés,
B. Gonzalez Giraldez,
V. Villanueva Haba
40
Poster Session 1
Noon - 6:00 p.m.
1.235 Safety And Utility Of
Stiripentol In The Treatment Of
Epilepsy In Dravet Syndrome/C. Press,
K. Chapman, K. Knupp
Clobazam In A Pediatric Refractory
Epilepsy Population: A Retrospective
Study At A Tertiary Care Center/
S. Thome-Souza, J. Klehm,
I. Sánchez Fernández, A. Bergin,
J. Bolton, C. Harini, M. Libenson,
J. Peters, A. Poduri, A. Rotenberg,
M. Takeoka, T. Loddenkemper
1.237 Risk Of Recurrent Seizures
And Duration Of Antiepileptic Therapy
After Suspected Childhood
Encephalitis/J. Gold, J. Crawford,
H. Sheriff, C. Glaser, M. Nespeca,
S. Wang
1.238 Efficacy And Tolerability Of
Intravenous Lacosamide In Children/
D. Arkilo, M. Gustafson, F. J. Ritter
1.239 Control Of Seizures In
Different Stages Of Partial Epilepsy:
Laco-Exp A Spanish Retrospective
Study Of Lacosamide/V. Villanueva Haba,
F. López, J. Serratosa,
B. Gonzalez Giraldez, D. Campos Blance,
A. Molins Albanell, J. Rodriguez Uranga,
J. Mauri, J. Salas Puig, M. Toledo,
J. Sanchez-Alvarez, A. Moreno,
P. Serrano, J. González de la Aleja,
R. Saiz Diaz, P. De La Pena Mayor,
M. Asensio
Surgery
Adult
1.240 Seizure Onset Localization And
Post-Surgical Outcomes In Patients
Undergoing Both Ictal SPECT And
Intracranial Monitoring/H. Dave,
K. Haas
1.241 Epilepsy Surgery In Mesial
Temporal Sclerosis With Ictal Scalp
Video-EEG Topographically NonConcordant: The Relevance Of
Minimally Invasive Records/N. Canas,
A. R. Pinto, H. Delgado, C. Romero,
J. C. Ferreira, P. Cabral
1.242 Is Memory Outcome Following
Temporal Lobe Surgery Related To
Age?/I. Tyrlikova, Z. Hummelova,
R. Kubikova, S. Telecka, M. Tyrlik,
R. Kuba, M. Brazdil, J. Chrastina,
J. Hemza, I. Rektor
1.243 Surgical Laser Ablation In NonMesial Temporal And Temporal Mesial
Sclerosis Cases In Six Adult Patients/
M. Chez, S. Ciricillo, A. Ghassemi,
C. Lepage
1.244 Medical And Surgical
Management Of Neurocysticercosis
With Intractable Epilepsy In The Same
Patient/J. Oster, F. M. Machado,
G. Cosgrove
1.245 Minimizing And Managing
Complications From Subdural
Electrode Implantation For
Localization Of Seizure Foci/N. Tandon,
Y. Esquenazi Levy, R. Knowlton,
O. Hope, G. Kalamangalam, J. Slater
1.246 Changes In
Electroencephalography After
Bilateral Chronic Stimulation Of
Anterior Thalamic Nucleus In Patients
With Intractable Epilepsy/W. Kim,
C. Im, S. Kim, S. Lim, Y. Kim, Y. Shon
1.247 Functional Hemispherectomy In
Adults For Refractory Status
Epilepticus/N. Andrade, C. Szabo,
L. Morgan, K. Karkar, J. Caron,
A. Papanastassiou
Pediatrics
1.248 Multifocality In Tuberous
Sclerosis As Viewed By Different
Diagnostic Tools In Relation To
Surgical Outcome/P. Krsek, M. Kyncl,
A. Jahodova, M. Kudr, P. Jayakar,
I. Miller, T. Resnick, M. Duchowny
1.249 Outcomes Following Multiple
Subpial Transection In Landau-Kleffner
Syndrome/B. Neville, M. Clark,
J. Fernando, N. Jolleff, M. Downes,
W. Harkness, R. Selway, R. Greenaway
1.250 Stepwise Surgeries With A
Combination Of Callosotomy And
Unilateral Resective/Disconnective
Surgery For Medically Refractory
Infantile Spasms/T. Ono, H. Baba,
K. Toda
1.251 Outcome Of Resective Surgery
In Childhood Onset Refractory
Temporal Lobe Epilepsy/D. Yalnizoglu,
M. Karakaya, B. Konuskan, D. Genc
Acikgoz, E. Erdogan Bakar, G. Duzgun,
K. Karli Oguz, F. Soylemezoglu,
B. Bilginer, N. Akalan, M. Topcu,
G. Turanli
1.252 Outcomes And Safety Profile
Of Stereotactic Laser Ablation For
Treatment-Resistant Epilepsy In The
Pediatric Population/A. Wilfong,
A. Shetty, D. Curry
1.253 2011 ILAE Classification Of
Focal Cortical Dysplasia (FCD) In
Temporal Lobe Epilepsy In Children:
Influence On Outcome/E. Anghelina,
A. Michoulas, C. Sanguansermsri,
L. Huh, G. Hendson, C. Dunham,
A. Singhal, P. Steinbok, M. Connolly
1.254 Atonic Seizures In Children
With Surgically Remediable Epilepsy:
Electro-Clinical Features,
Neuroimaging And Surgical Results/
J. Scholly, M. P. Valenti-Hirsch,
K. Strobl, A. De Saint-Martin,
C. Boulay, P. Kehrli, I. J. Namer,
T. Bast, J. Zentner, E. Hirsch
1.255 Longitudinal Anatomical
Assessment Of Stereotactic Laser
Ablation For Hypothalamic
Hamartomas/S. Vadivelu, S. Desai,
A. Wilfong, D. Curry
1.256 A Novel Multistage Procedure
Using Bilateral Intracranial EEG And
Complete Corpus Callosotomy May
Help To Localize A Seizure Focus In
Unlocalizing Intractable Epilepsy/
K. Lee, P. Chen, J. Seo,
M. Korostenskaja, J. Baumgartner
1.257 SISCOM In Nonlocalizing MRI:
An Unselected Pediatric Series/
L. Wong-Kisiel, K. Nickels, E. Wirrell
1.258 Interhemispheric Vertical
Hemispherotomy For Infants With
Hemispheric Epilepsy/M. Iwasaki,
S. Osawa, Y. Shimoda, M. Uematsu,
K. Jin, N. Nakasato, T. Tominaga
Behavior / Neuropsychology /
Language
Adult
1.268 Global Assessment Of
Epilepsy-related Disability Scale: A
New Measure Of Disability In Patients
With Epilepsy/T. Sajobi, N. Jette,
S. Wiebe, S. Patten, J. Engbers,
K. Fiest, M. Lowerison
1.269 The Left Temporal Pole Is A
Multimodal Convergence Region For
Proper Name Retrieval: Evidence
From Electrocorticography Of Famous
Person Picture And Voice Naming/
T. J. Abel, A. E. Rhone, K. V. Nourski,
H. Oya, H. Kawasaki, M. Howard,
D. Tranel
Noon - 6:00 p.m.
1.270 Contralateral Impact Of
Interictal And Ictal EEG Is Associated
With Accelerated Forgetting In
Unilateral Mesial Temporal Sclerosis
Patients/L. Pinto, C. Adda, L. A. Silva,
N. H. Banaskiwitz, C. Jorge,
R. Valerio, L. Castro
1.271 Interictal Epileptic Activity
Interferes With Frontal Lobe Function
In Temporal Lobe Epilepsy/
V. Dinkelacker, X. Xin, M. Baulac,
S. Samson, S. Dupont
1.272 Construct Validity Of Global
Assessment Severity Of Epilepsy
(GASE) Scale In Adult Epilepsy Patient
Population/S. Wiebe, T. Sajobi,
N. Jette, S. Patten, J. Engbers,
K. Fiest, M. Lowerison
1.273 Naming Outcome Following
Epilepsy Surgery In Adults: Effects Of
Side And Site Of Surgery/R. Busch,
D. P. Floden, B. Prayson, J. Chapin,
W. Bingaman, I. Najm
1.274 Interictal Spikes Outside The
Epileptic Network Disrupt Cognitive
Function/D. Becker, A. C. Nanivadekar,
K. Davis, J. Pollard, S. Schmitt,
G. Baltuch, T. Lucas, B. Litt,
M. J. Kahana
1.275 Does The Left Medial Temporal
Region Mediate Naming?/
M. Hamberger, A. C. Williams
1.276 Hippocampal Volume Does Not
Predict Cognitive Outcome Following
Subtemporal Selective
Amygdalohippocampectomy/
C. Pearson, K. D. Hanson, S. W. Hill,
S. Gale
1.277 Wechsler Adult Intelligence
Scale-4th Edition Performance In Left
Versus Right Temporal Lobe Epilepsy/
S. Packwood, C. Pearson
1.283 Adaptive Functioning In
Children With Focal Versus
Generalized Intractable Epilepsy/
C. Salinas, A. Carbonell,
M. Westerveld, K. Lee
1.284 Mapping The Landscape Of
Cognitive Development In Children
With Epilepsy/L. Bonilha, J. Lin,
C. Stafstrom, D. Hsu, K. Dabbs,
B. Hermann
1.285 Lateralizing And Localizing
Significance Of Design Fluency
Performance In Pediatric Epilepsy
Patients/A. Hempel
1.286 Attentional Deficits Of
Children And Adolescents With
Temporal Lobe Epilepsy/P. Rzezak,
C. A. Guimarães, M. Guerreiro,
K. Valente
1.287 Mental Health Among
Adolescents With Epilepsy: Parents
And Teens Disagree/L. Carbone,
A. Leftridge, M. Plegue, R. Shellhaas
1.288 Birth Weight And IQ In Children
With Epilepsy/P. Siddarth, J. Levitt,
S. Gurbani, R. Caplan
1.289 The Impact Of Behavior
Problems On The Health-Related
Quality Of Life Of Children And
Adolescents With Epilepsy/H. Choi,
E. Kim, S. Kim, H. Lee
1.290 Select Improvement In
Neurobehavioral Status Of Two
Patients Following High Dose
Clobazam For Treatment Of CSWS/
C. Vega, I. Sánchez Fernández,
J. Klehm, J. Peters, S. Thome-Souza,
C. Harini, G. Wilkening, K. Chapman,
T. Loddenkemper
1.291 Social Difficulties Among
Children With Epilepsy/R. Trobliger,
E. Segal, M. E. Lancman, M. Lancman
Pediatrics
1.278 High Gamma Network For
Expressive Language In Typically
Developing Children – A Possible Tool
To Evaluate Altered Language
Networks In Children With Epilepsy/
H. Fujiwara, D. Kadis, D. Rose
1.279 Atypical Language Localization
In Pediatric Temporal Lobe Intractable
Epilepsy/A. Maulisova, B. Korman,
G. Rey, P. Krsek, V. Novak, B. Bernal,
M. Duchowny
1.280 Impaired Sleep-Related
Consolidation Of Declarative Memory
In Focal Idiopathic Epilepsies Of
Childhood/S. Galer, C. Urbain,
X. De Tiege, M. Emeriau, R. Leproult,
G. Deliens, A. Nonclercq, P. Peigneux,
P. Van Bogaert
1.281 Impact Of Maternal Education
And Seizure-related Factors On
Wechsler Intelligence Scale Scores/
K. Evankovich, L. Chapieski
1.282 mTOR-dependent Learning And
Memory Deficits In The Pilocarpine
Seizure Model/A. Carter, A. Brewster,
J. Lugo, W. L. Lee, A. Anderson
Genetics
SATURDAY
All Ages
1.259 Epilepsy Surgery In Patients
With NF-1/A. D. Rothner, J. Wexler,
M. Moodley, W. Bingaman
1.260 Impact Of Vagal Nerve
Stimulation On Adult Patients With
Refractory Seizures At A Tertiary
Epilepsy Clinic/C. Le, A. Issa,
U. Menon
1.261 Altered Seizure Profiles After
Failed Temporal Lobectomy For
Intractable Epilepsy/D. Englot,
P. A. Garcia, E. F. Chang
1.262 Factors Contributing To The
Yield Of Asymmetric Bilateral
Implantations Of Intracranial
Electrodes/R. Lee, J. Mandrekar,
G. Worrell, G. Cascino, N. Wetjen,
F. Meyer, E. Wirrell, R. Marsh, E. So
1.263 Surgical Treatment Of
Refractory Status Epilepticus/
C. Torres Muller, L. Fabres, F. Solari,
L. Rios, F. Otayza, J. Pavlov,
M. Campos
1.264 Statistically Validated
Localizing Signs In Frontal Lobe
Epilepsy: A Systematic Review/
J. White, P. Penovich, F. Ritter
1.265 Utilization Of Corpus
Callosotomy To Decrease Frequency
Of Seizures Associated With Apnea/
S. Wolf, S. Ghatan, P. McGoldrick,
H. Kang, D. Tovar, M. La Vega-Talbott,
W. Gao, R. Goodman, K. Khodabakhsh
1.266 Surgical Treatment For
Medically Refractive Focal Epilepsy In
A Patient With Fragile X Syndrome/
C. Kenmuir, M. Richardson,
G. Ghearing
1.267 Cerebral Tumors: Experience
Of A Portuguese Epilepsy Surgery
Centre/J. Pimentel, I. Cordeiro,
A. Campos, A. Gonçalves Ferreira
Poster Session 1
Human Studies
1.292 KCNT1 Mutations In A National
Cohort Of Children With Migrating
Partial Seizures Of Infancy/
A. McTague, E. Meyer, R. Appleton,
K. Lascelles, A. Desurkar, R. Kneen,
M. A. Kurian
1.293 Targeted Resequencing
Identifies De Novo Mutations In
Individuals With Epileptic
Encephalopathies/S. Jamuar,
C. LaCoursiere, H. Olson, C. Shain,
E. Martin, B. Sheidley, S. Heavin,
T. W. Yu, I. Scheffer, C. Walsh,
A. Poduri
1.294 Whole Exome Sequencing
Reveals A Novel Mutation In A Novel
Gene (Myclonin 3) For JME/D. Bai,
M. Medina, J. Bailey, M. Alonso,
T. Suzuki, M. Tanaka,
I. E. Martínez-Juárez, J. Serratosa,
K. Yamakawa, A. Delgado-Escueta
1.295 Gene Discovery And Highthroughput Resequencing Of
Candidate Genes In Epileptic
Encephalopathy/H. Mefford, E. Sherr,
I. Scheffer, A. Poduri, D. Dlugos, EpiK
Investigators
41
1.296 DEPDC5 Epilepsies: Sporadic
Subjects And Small Families Reveal An
Extended Phenotypic Spectrum/
D. Crompton, B. L. Hodgson,
B. Regan, L. Licchetta, S. Mullen,
M. Pandolfo, S. Kivity, L. Dibbens,
S. Berkovic, I. Scheffer
1.297 High Frequency Of Copy
Number Variants Found In Genetic
Generalized Epilepsy With Intellectual
Disability/S. Mullen, G. Carvill,
S. Bellows, M. A. Bayly, S. Berkovic,
L. Dibbens, I. Scheffer, H. Mefford
1.298 Early-onset Epileptic
Encephalopathies Caused By PIGA
Gene Mutation/M. Kato, H. Saitsu,
Y. Murakami, K. Kikuchi,
S. Watanabe, R. Matsuura,
R. Takayama, S. Hamano, T. Kinoshita,
K. Hayasaka, N. Matsumoto
1.299 Genetic Testing In Drug
Resistant Epilepsy: Clinical Utility And
Predictors Of Higher Yield/M. Ream,
M. McDonald, M. Mikati
1.300 Seizures And Epilepsy In
16p11.2 Deletions And Duplications/
A. R. Rosen, S. Kessler, C. Ackhar,
A. Poduri, E. Sherr, for the SVIP
Consortium
1.301 Malformations Of Human
Cerebral Cortex: Role Of Rare Copy
Number Variations (CNV)/
I. Lopes-Cendes, F. Torres,
D. A. Souza, C. Santos, V. Terra,
M. Kauffman, A. Sakamoto,
M. Guerreiro, M. A. Montenegro,
F. Cendes
Noon - 6:00 p.m.
1.302 Hippocampal Malrotation Is
Associated With Chromosome
22q11.2 Microdeletion/A. S. Bassett,
T. Krings, E. W. C Chow, T. Kiehl,
D. Andrade
1.303 Myoclonic Occipital
Photosensitive Epilepsy With Dystonia
(MOPED): A Novel Familial Autosomal
Dominant Epilepsy Syndrome/
L. Sadleir, K. Smith, S. Paterson,
N. Redshaw, A. Ranta, R. Kalnins,
S. Berkovic, M. Hildebrand, M. Bahlo,
I. Scheffer
1.304 Identifying The Clinical,
Environmental And Genetic Predictive
Factors For Epilepsy Management:
The Dice Study/C. Cara, A. Gil-Nagel,
J. Poza, M. Carreno, J. Gonzalez,
P. Serrano, J. Sanchez-Alvarez
1.305 Linkage Analysis Combined To
Whole Exome Sequencing To Identify
New Genes In Consanguineous
Families With Juvenile Myoclonic
Epilepsy/B. Ouled Amar Bencheikh,
F. Lahjouji, J. Gauthier, L. Jouan,
K. Khaldi, H. Lamghari,
P. Lachance-Touchette, D. Spiegelman,
A. Dionne-Laporte, H. Daoud,
F. Hamdan, H. Belaidi, P. Dion,
R. Ouazzani, G. Rouleau, P. Cossette
1.306 Clinical Diagnostic Exome Is A
Highly Effective Testing Option For The
Identification Of Phenotypically
Variable Single Gene Disorders
Associated With Seizures/S. Gandomi,
K. D. Farwell Gonzalez, L. Shahmirzadi,
S. Tang
Get Started:
• Go to http://connect.AESnet.org
• Click Login
• Enter your Member login ID# and Password
• Click Go
42
Poster Session 1
1.307 Clinical Course Of Epilepsy In
Patients With STXBP1 Related
Epileptic Encephalopathy/Y. Ueda
1.308 Copy Number Variant (CNV)
Analysis Of 21 Families With
Autosomal Dominant Lateral Temporal
Epilepsy/C. Nobile, M. Fanciulli,
E. Pasini, R. Loeb, R. Ottman,
R. Michelucci
1.309 Autosomal Dominant Epilepsy
With Auditory Features: A New LGI1
Family Including A Phenocopy With
Cortical Dysplasia/K. Klein,
M. Pendziwiat, R. Cohen,
C. G. de Kovel, F. Rosenow,
B. P. Koeleman, G. Kuhlenbäumer,
Z. Afawi, I. Helbig
1.310 Genetic Testing Preferences
Among Individuals With Epilepsy And
Unaffected Family Members: Impact
Of Penetrance And Clinical Utility/
J. O. Okeke, S. Sorge, V. Tangel,
S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
You can use AES Professional Connection to:
• Connect with colleagues year round
• Build your network
• Discuss current issues
• Volunteer for Committees
• Participate in Committee and SIG discussion groups
• Share documents
• And more!
SUNDAY December 8, 2013
www.AESnet.org
Separate registration required — on site registrations accepted
7:30 a.m. – 5:00 p.m.
ASET Course:
Making an LTM/ICU Monitoring Program
Work: Technical Aspects
1. Translating Clinical Research into Clinical Practice and Back Again
Moderators: Anne Berg, Ph.D., Brandy Fureman, Ph.D.
Speakers: Lorie Hamiwka, M.D., Tobias Loddenkemper, M.D.,
Russell Saneto, D.O., Ph.D.
Recommended Reading: Leviton A, Loddenkemper T, Pomeroy SL, Clinical
practice guidelines and practice parameters for the child neurologist, J
Child Neurol 2013; 28: 917-925.
2. Dendritic Injury in Epilepsy: Mechanisms and Consequences
Moderator: Michael Wong, M.D., Ph.D.
Speakers: Joaquin Lugo, Ph.D., John Swann, Ph.D., Michael Wong,
M.D., Ph.D.
3. Mitochondrial Abnormalities in Malformations of Cortical Development
Moderator: Michael Miles, Pharm.D.
Speakers: Hansel Greiner, M.D., Lili Miles, M.D.,
Michael Miles, Pharm.D.
Break: 10:15 a.m. - 10:30 a.m.
8:45 a.m. – 4:45 p.m.
Investigators’ Workshop Chair: Michael Wong, M.D., Ph.D.
Clinical Investigators’ Workshop Chair: Hal Blumenfeld, M.D., Ph.D.
Overview
These workshops, conducted informally and designed to encourage
interaction, will address several important areas of rapidly-emerging
knowledge in clinical and basic research in epilepsy. The workshops are
intended to identify challenges in current research, propose methods to
overcome those challenges, and encourage areas for future investigation.
The Basic Science Investigator Workshops will highlight a number of research
areas that have been developing rapidly over the last year. Participants include
both established and junior epilepsy investigators as well as researchers
outside the epilepsy community who have specialized expertise that may be
applied to epilepsy basic science. In addition, one of the workshops features
presentations by Junior Investigators in cutting-edge areas of research.
The Clinical Investigators’ Workshops provide a series of working seminars in
matters of active clinical investigation and controversy. Speakers present
results from their ongoing research and place their findings in the context of
current understanding. One of these workshops has been selected as a
Translational Investigators’ Workshop. This two-hour session will present a
particularly broad overview of basic and clinical research on an important
problem in epilepsy.
Most of the workshops run as concurrent sessions on Sunday, with the
translational workshop Saturday afternoon and a single workshop on Monday
afternoon. A separate Investigators’ Workshop Poster Session will occur
starting at noon on Sunday in proximity to the IW Platform Sessions.
Target Audience
Basic scientists, neurologists, neuroscientists, pharmacologists,
neuropsychologists and neurosurgeons who are performing research in
epilepsy
Use the online survey to provide feedback on
https://www.surveymonkey.com/s/IWevals
Morning Session II – 10:30 a.m. - Noon
4. The Big Picture: How Changes in Global Brain Connectivity Facilitate
Epileptic Seizures and Cognitive Deficits
SUNDAY
This is a one-day course taking place in conjunction with the AES 67th Annual
Meeting. The goal of the course is to ensure that participants are able to provide
an ideal environment for a comprehensive epilepsy evaluation. To accomplish this
goal, caregivers must have an in-depth understanding of the features of
EEG/video recording equipment and techniques that will optimize the process
and increase the efficiency and accuracy of the recording session. Our course
objectives will enable caregivers in the Epilepsy Monitoring Unit and the
Neurological Intensive Care Unit to provide the highest quality patient experience.
Our target audience is neurodiagnostic technologists, nurses who work with
patients in long term monitoring (LTM) and neurological intensive care units, and
physicians with an interest in setting up and managing an LTM or neuro ICU
telemetry unit. The registration fee is $120. Please visit www.aset.org to view
the meeting schedule, registration form, faculty profiles and course objectives.
Morning Session I – 8:45 a.m. - 10:15 a.m.
Moderator: Jack J. Lin, M.D.
Speakers: Leonardo Bonilha, M.D., Ph.D., Bruce Hermann, Ph.D.,
Marcus Kaiser, Ph.D.
5. Engaging Basic Scientists in the Early Stages of Drug Discovery
Moderators: Manisha Patel, Ph.D., Helen Scharfman, Ph.D.
Speakers: Ray Dingledine, Ph.D., Kevin Staley, M.D.,
Manisha Patel, Ph.D.
6. What’s Next? A Young Investigators Workshop: A Series of
Research Talks by Young Investigators in the Epilepsy Community
Moderator: Chris Dulla, Ph.D.
Speakers: Esther Krook-Magnuson, Ph.D. (UCI), Omar Ahmed, Ph.D.
(Harvard), Jianxiong Jiang, Ph.D. (Emory), Robert Hunt, Ph.D. (UCSF)
Noon - 1:30 p.m. Poster Session (Lunch)
Note: Number below refers to poster assignment
1.001 A Rapid Inflammatory Process Following Febrile Status Epilepticus:
A Biomarker Of Epileptogenesis?/Katelin Patterson
1.002 Is There A Role For FTO Inhibition In The Treatment Of
Epilepsy?/Joie Rowles
1.003 A Role For Cytokine Interleukin-6 In Posttraumatic
Epileptogenesis/Jeffery Boychuk
1.005 A Novel T-Type Calcium Channel Antagonist Delays The Progression
Of Epileptogenesis In The Amygdala Kindling Model Of Temporal Lobe
Epilepsy/Pablo Casillas-Espinosa
1.007 Toll-Like Receptor 4 Contributes To Early Increase In Dentate
Excitability After Concussive Brain Injury By NMDA Receptor Independent
Mechanisms/Ying Li
1.008 The Wnt Signaling Pathway Is Activated During Status Epilepticus
And Epileptogenesis/K. Paulson
1.009 Monosynaptic Inputs To Neonatally- Versus Adult-Born Dentate
Granule Cells In A Rodent Model Of Temporal Lobe Epilepsy/Xi Du
43
1.011 Neonatal Seizures Diminish Homeostatic Synaptic Scaling Down In
Cortical Neurons: Evidence From A Rat Seizure Model And Human
Epilepsy/Hongyu Sun
1.012 IGF-1 And Insulin Contribute To Epileptogenesis Through Activation
Of AKT-mTOR Signaling/Yevgeny Berdichevsky
1.015 JaK/STAT Inhibition To Prevent Post-Traumatic Epileptogenesis/
Daniel Raible
1.018 Small Numbers Of PTEN Knockout Dentate Granule Cells Are
Capable Of Driving Epileptogenesis/Isaiah Rolle
1.019 Functional Changes Of A De Novo GRIN2A Mutation In A Patient
With Refractory Seizures And Early-Onset Epileptic
Encephalopathy/Hongjie Yuan
1.020 Transcriptiome Analysis In Focal Epilepsy Identifies Changes In
Clock Expression In Epileptogenic Human Tissue/Judy Liu
1.021 Epilepsy Risk Genes Are Targets Of Aberrant microRNAs Expressed
In Epileptogenic Tubers Of Tuberous Sclerosis Complex Patients/
Alan Dombkowski
1.022 KCNQ2 Targeting To The Axon Initial Segment Is Disrupted In A
Mutant Form Causing Severe Epilepsy/Baouyen Tran
1.023 A Mouse Model With Human Mutant GABAA Receptor γ2 Subunit
At Q390X Exhibits Reduced Inhibitory Synaptic Currents In ThalamoCortex Circuitry/Chengwen Zhou
1.042 Hyperthermia-Induced Seizures Are Potentiated By
Lipopolysaccharide And Reduced By L-Type Calcium Channel Blocker,
Nimodipine/L. Mlsna
1.102 In Vivo 2-Photon Confocal Microscopy Of Cortical Absence
Epilepsy/Jochen Meyer
1.294 Whole Exome Sequencing Reveals A Novel Mutation In A Novel
Gene (Myclonin 3) For JME/Dongsheng Bai
3.006 Intracerebral Interleukin-1beta Injection Causes Infantile Spasms In
Neonatal Rats Without Behavioral Deficits/Stephen Briggs
3.024 Antiepileptic Action Of c-Jun N-Terminal Kinase (JNK) Inhibition/
T. Tai
3.025 Scavenging Seizure-Induced Reactive Oxygen Species With A
Catalytic Antioxidant Attenuates Neuroinflammation In Experimental
Temporal Lobe Epilepsy/Pallavi Bhuyan
3.026 Chronic Progesterone Treatment Increases Seizure Frequency And
Glutamatergic Neurotransmission/Suchitra Joshi
3.027 Hypothalamic Paraventricular Nucleus – A Brain Structure At The
Intersection Of Stress And Cryptogenic Infantile Spasms/Tamar Chachua
3.029 Cardiac Alterations And Increased Susceptibility For Ventricular
Tachycardia In A Model Of Acquired Epilepsy/Yi-Chen Lai
3.032 Acute Cell-Specific Alterations In Synaptic Transmission During
Status Epilepticus: Further Evidence Of Diminished Inhibition And
Increased Excitation Of Principal Neurons/H. Sun
3.038 Role Of Adenosine In Seizure-Induced Death In DBA/2 Mice And
Genetically Epilepsy-Prone Rats (GEPRs): Potential Relevance To
SUDEP/Carl Faingold
3.039 The NS-PTEN Knockout Mouse Model of Cortical Dysplasia with
Epilepsy is Associated with Alterations in the Kv1.1 Potassium
Channel/Lena Nguyen
3.042 Reduced Strength Of Inhibitory Synaptic Connections In
Experimental Cortical Dysplasia/Steven Roper
3.044 Controlled Cortical Impact As A Model Of Traumatic Brain Injury For
The Generation Of Experimental Post-Traumatic Epilepsy/David Treiman
3.046 Ganaxolone & Cryptogenic Infantile Spasms/Mi-Sun Yum
3.051 Activation Of 5-HT2 Receptors Prevents Seizure-Related Respiratory
Arrest And Death In Wild-Type And 5-HT Neuron Deficient Mice/
Gordon Buchanan
3.067 Optogenetic Stimulation Of Superior Collicus/Patrick Forcelli
3.070 Thalamo-Hippocampal Connectivity In Medial Temporal Lobe
Epilepsy/Daniel Barron
3.071 Gene Expression Signature Of Activated Microglia In Infantile
Spasms: Implications For Novel Drug Development/Senthil Sundaram
3.182 Does Childhood Convulsive Status Epilepticus (CSE) Result In LongTerm Hippocampal Damage? A Quantitative Hippocampal Volumetric
Analysis/Suresh Pujar
3.185 Hypoglycemic Brain Injury In Neonates And Seizure
Occurrence/Katherine Muir
44
3.241 The Ketogenic Diet Attenuates Both Seizure Severity And Increases
In Glial Fibrillary Acidic Protein Expression Following Kainic Acid
Administration In Mice/Mohammed Abdelwahab
3.244 D-Leucine, An Amino Acid That Protects Against Seizures/
Adam Hartman
3.279 The Role Of Mutated GABA(A) Receptor In The Pathogenesis Of
Idiopathic Generalized Epilepsy/Ana Stoica
Afternoon Session I – 1:30 p.m. - 3:00 p.m.
7. Seizures Among Critically Ill Children: Epidemiology, Treatment and
Outcomes
Moderator: Cecil Hahn, M.D.
Speakers: Nicholas Abend, M.D., Cecil Hahn, M.D., Michael Bell, M.D.
8. Controlling Seizures With Electrical Light Orchestra
Moderators: Christophe Bernard, Ph.D., Ivan Soltesz, Ph.D.
Speakers: Antal Berenyi, M.D., Ph.D., John Huguenard, Ph.D.,
Dimitri Kullmann, M.D., Ph.D.
9. The KCNQ2-Associated Epilepsy and Encephalopathy Spectrum:
Bedside to Bench and Back
Moderator: Ed Cooper, M.D., Ph.D.
Speakers: John Millichap, M.D., Mala Shah, Ph.D.,
Mark Shapiro, Ph.D.
Break: 3:00 p.m. - 3:15 p.m.
Afternoon Session II – 3:15 p.m. - 4:45 p.m.
10. Translating Seizure Terminology and Modeling from Rodents to
Humans: Is Consensus Possible?
Moderators: Solomon Moshé, M.D., Alexis Arzimanoglou, M.D.
Speakers: Aristea Galanopoulou, M.D., Ph.D., Karen Wilcox, Ph.D.
11. Neurocysticercosis-Related Epilepsy
Moderator: Jorge G. Burneo, M.D.
Speakers: David Millet, M.D., Ph.D., Alejandro L. Escalaya, M.D.,
Gagandeep Singh, M.D.
12. Astrocyte Control of the Extracellular Environment – Pathological and
Therapeutic Implications
Moderators: Chris Dulla, Ph.D., Alex Rotenberg, M.D., Ph.D.
Speakers: Chris Dulla, Ph.D., Daniela Kaufer, Ph.D.,
Harald Sontheimer, Ph.D.
8:45 a.m. – 5:15 p.m.
Annual Course: An Algorithmic Approach
to the Diagnosis and Treatment of
Non-lesional Epilepsy
(6.0 CME Credits)
Overview
Non-lesional epilepsy refers to the absence of a potentially epileptogenic lesion
on magnetic resonance imaging (MRI). These cases are particularly challenging
and time consuming to the epilepsy team as the apparent lack of a visual cue
results in doubts regarding validity of the diagnosis as well as whether surgery
can even be considered due to the uncertainty of the extent of the
epileptogenic zone. It is estimated that 20% to 30% of patients with medically
refractory epilepsy will have a normal MRI. Moreover, most neurologists and
comprehensive epilepsy centers report an increase in non-lesional epilepsy case
referrals resulting in an increase in noninvasive and invasive diagnostic
evaluations in order to verify the diagnosis and then to ultimately assess
surgical candidacy.
11:50 a.m.
Algorithm for Diagnosis of Non-lesional Epilepsy
Jorge Burneo, M.D.
This year’s annual course will delve into the management of non-lesional
epilepsy, a heterogeneous collection of complex epilepsies that most adult and
pediatric clinicians face daily. The course is divided into two sessions with the
morning session devoted to diagnostic issues and the afternoon to treatment.
Each session will be framed by common clinical scenarios and will be used to
discuss epileptogenic mechanisms, highlighting novel diagnostic and both
medical and surgical treatment modalities. A multidisciplinary approach will be
emphasized. The goal of the course is to highlight clinical management while
illuminating basic science and practice gaps. Each session will end with a
summary and offer an algorithm for the clinical management of non-lesional
epilepsy.
Noon - 2:00 pm.
Lunch Break
Treatment Challenges
Case Presentation
Daniel Friedman, M.D.
2:05 p.m.
Lecture: Pharmacologic Management of
Michael Privitera, M.D.
2:25 p.m.
Flash Panel: Presurgical Evaluation in
Gregory Cascino, M.D. – SPECT
Terrence O’Brien M.D. – PET
Robert Knowlton, M.D. – MEG
2:40 p.m.
Case Presentation
Amy Crepeau, M.D.
2:45 p.m.
Lecture: Intracranial Evaluation and Outcomes in
William Bingaman, M.D.
3:10 p.m.
Debate: How Far Do You Go in the Treatment of
Non-lesional Epilepsy? – Case Management
Orrin Devinsky, M.D., Greg Krauss, M.D.
3:40 p.m.
Break
3:55 p.m.
Case Presentation
Christi Heck, M.D.
4:00 p.m.
Lecture: Dietary Approaches to Non-lesional
Epilepsy
Eric Kossoff, M.D.
4:25 p.m.
Lecture: Existing Devices for Therapy of
Non-lesional Epilpesy
Andrew Cole, M.D.
4:40 p.m.
Lecture: Possible Future Devices for Therapy of
Robert Fisher, M.D., Ph.D.
Learning Objectives
u
Develop an algorithmic approach for the diagnostic work-up of nonlesional
patients presenting with “spells” with improved diagnosis and better
treatment outcomes
u
Apply state of the art imaging and electrophysiological modalities in both
the diagnostic work-up and pre-surgical evaluations of non-lesional
epilepsies
u
Understand the pathophysiology of epilepsy in patients with normal
imaging and effectively manage their care
u
Utilize recent developments in pharmacological and non-surgical
treatment approaches to non-lesional epilepsy
u
Develop and utilize an algorithmic approach for the process of pre-surgical
evaluation of patients with non-lesional drug-resistant epilepsy with
improved seizure control and quality of life.
Target Audience
Basic, Intermediate and Advanced (see page 106 for details)
Program
Chair: Joseph I. Sirven, M.D.
Diagnostic Challenges
8:45 a.m.
Introduction
Joseph Sirven, M.D.
8:55 a.m.
Case Presentation
Jennifer DeWolfe, D.O.
5:00 p.m.
Algorithm for Treatment of Non-lesional Epilepsy
Lara Jehi, M.D.
9:00 a.m.
Lecture: Advanced Imaging Techniques – PET,
MRI, MRS, MSI, SPECT, DTI
Robert Knowlton, M.D.
5:15 p.m.
Course Ends
SUNDAY
2:00 p.m.
Credit Designation
9:25 a.m.
Flash Panel: Ictal Semiology and Diagnosis
Selim Benbadis, M.D., Jeffrey Buchhalter, M.D., Ph.D.,
Prakash Kotagal, M.D.
The American Epilepsy Society designates this live activity for a maximum
of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
9:40 a.m.
Lecture: Advanced EEG Techniques – HFOs and
EEG fMRI
Jean Gotman, Ph.D.
Nursing Credit
10:05 a.m.
Break
10:20 a.m.
Case Presentation
Randa Jarrar, M.D.
10:25 a.m.
Lecture: Genomic Testing in the Setting of
Alica Goldman, M.D., Ph.D.
10:50 a.m.
Lecture: Understanding Epilepsy Networks
William Stacey, M.D., Ph.D.
11:15 a.m.
Case Presentation
David Spencer, M.D.
11:20 a.m.
Debate: Extent of Diagnostic Evaluations for
Non-lesional Epilepsy – Case Management
Practice vs. Economic Considerations
Richard Zimmerman, M.D., Charles Begley, Ph.D.
Pharmacy Credit
Core Competencies: Medical Knowledge, System-Based Practice and
Comprehensive Patient Care
Acknowledgment
This program is supported by educational grants from Eisai Inc., UCB, Inc.,
Sunovion Pharmaceuticals Inc. and Cyberonics, Inc.
45
5:00 p.m. – 6:00 p.m.
Reception: Suds for Scientists
Join your colleagues in the Exhibit Hall for complimentary appetizers and a
cash bar. A portion of the sale of each beverage will support the Lennox and
Lombroso Trust. The Trust supports fellowships and early career grants for
postgraduates and newly independent faculty.
6:00 p.m. – 7:30 p.m.
Basic Mechanisms Underlying Cognitive and Behavioral
Deficits Associated with Epilepsy
Coordinators: Amy L. Brewster, Ph.D., Dane Chetkovich, M.D., Ph.D.
Speakers: Helen Scharfman, Ph.D., Farah Lubin, Ph.D., Mauro Costa-Mattioli, Ph.D.
Cognitive and behavioral deficits are often seen in individuals with epilepsy.
This session will cover molecular mechanisms at the epigenetic and protein
translation level that are associated with the regulation of memory and
behavior under physiological conditions and in epilepsy. Research in this area
provides insight into potential novel mechanisms that can be targeted for
treatment of comorbidities in epilepsy.
Supported by Sunovion Pharmaceuticals Inc.
Cognitive / Behavioral Approaches for Treatment of Epileptic
Seizures and PNES
Convention Center – Room 101, Street Level
Coordinators: Steve Schachter, M.D., Siegward Elsas, M.D.,
Rosa Michaelis, M.D., Lauren Frey, M.D., Marcio Sotero De Menezes, M.D.
Speakers: W. Curt LaFrance, Jr., M.D., M.P.H.
To date, about one-third of individuals with epilepsy continue to have medically
intractable epileptic seizures despite high-dose polytherapy; even the new
generation of anticonvulsive drugs has failed to bring significant change to this
situation. Uncertainty about when a seizure might occur may be more
disabling than the actual number of seizures if it decreases the individual’s
sense of self-control. Treatment options for psychogenic non-epileptic seizures
are few, despite the high prevalence and disabling nature of the disorder.
Although basic principles of behavioral approaches to epileptic and
psychogenic nonepileptic seizures have been discussed in the literature for
many years, specialty clinics have not integrated behavioral therapy into their
treatment programs.
Literature suggests that adjunctive behavioral treatment approaches that
investigate multiple factors underlying seizure activity can lead to proactive
strategies for avoiding seizure triggers, which may also facilitate the transition
of an individual’s sense of self-identity from “chronically ill” to “normal” and
“being in control.”
This group session aims at offering a platform which gives practitioners an
opportunity to exchange tools that will allow them to implement elements of
cognitive behavioral interventions in their clinical practice. In expectation of the
Funding Opportunities in the NINDS Phase II Clinical Trial
Network, NeuroNEXT
Convention Center – Room 102A, Street Level
Coordinators: Brandy Fureman, Ph.D., Deborah G. Hirtz, M.D.
Speakers: Elizabeth McNeil, Shanta Rajaram, Ph.D., Tracy Glauser, M.D.
The NINDS recently launched the “Network for Excellence in Neuroscience
Clinical Trials” known as NeuroNEXT. NeuroNEXT provides a robust,
standardized, and accessible infrastructure to facilitate rapid development and
implementation of protocols in neurological disorders affecting adult and / or
pediatric populations. The network includes multiple Clinical Sites, one Clinical
Coordinating Center (CCC) and one Data Coordinating Center (DCC). The
Network website is www.neuronext.org. A unique feature of this network is
that you DO NOT need to be part of the NeuroNEXT infrastructure to apply to
conduct a study within the network. Applications from academic investigators,
advocacy groups / foundations, small businesses and the pharmaceutical
industry are welcomed. This NIH SIG session will feature brief talks about
applying for NeuroNEXT funding from the NINDS Scientific Program Director,
the Scientific Review Officer coordinating NeuroNEXT application reviews, and
a member of the NeuroNEXT Executive Committee. The session will include
ample time for questions and discussion.
Temporal Lobe Club: Surgical Referrals for Epilepsy —
Too Little Too Late
Coordinator: Jerome Engel, Jr., M.D., Ph.D.
Speakers: Edward Chang, M.D., Jerome Engel, Jr., M.D., Ph.D.,
Jacqueline A. French, M.D., David Millett, M.D., Ph.D., Philip M. Gattone, M.Ed.
This year’s session will address the possible reasons for the treatment gap in
epilepsy surgery and approaches to correct this. Eddie Chang will present data
from his study published in Neurology last year (Englot et al., Neurology
2012;78:1200-1206) indicating an increase in hospital admissions for epilepsy
but no change in number of surgeries between 1990 and 2008. More patients
were referred to smaller hospitals without surgical facilities. Pete Engel will
present data indicating that the delay from diagnosis to referral to an epilepsy
surgery program for MTLE has not changed as a result of the Wiebe RCT, and
the AAN practice parameter recommending surgery as the treatment of choice
for temporal lobe epilepsy (Haneef et al., Neurology 2010;75:699-704). Jackie
French is collecting data indicating a reduction in referrals of MTLE with
hippocampal sclerosis and will argue that this represents a decrease in the
prevalence of surgical candidates.
registration is not required
8:00 p.m. – 10:00 p.m.
Social Networking Groups
Renaissance – Room 8/9
Informal gathering and networking for SIG participants. Space is limited so
participants are welcome on a first-come, first-served basis. Roundtable topics
include: Epilepsy and Sports; Evidence Based Behavioral Assessment and
Intervention; and Autism and Epilepsy..
You’re invited to attend
Sunday, December 8
AES ANNUAL
BUSINESS MEETING
8:00 a.m. – 8:30 a.m.
All AES members are encouraged
Renaissance Hotel – Grand Ballroom, South
Coffee will be available
46
publication of the workbook “Taking Control of Your Seizures,” authored by the
Andrews / Reiter Epilepsy Treatment Program in collaboration with
Dr. Curt LaFrance, Dr. LaFrance will review this standardized workbook as an
on-going step by step guideline of a systematic, multi-modal counseling
intervention that aims at assisting the individual in improving seizure frequency
and overall self-defined quality of life.
to attend this yearly meeting.
Sunday December 8, 2013
Poster Session 2
8:00 a.m. – 5:00 p.m.
Professionals in Epilepsy Care
Nursing
2.001 Demonstrating Health Care
Savings By Capturing Nurse
Practitioner Epilepsy Telephone
Care/M. DeVries-Rizzo
2.002 Incidence And Risk Factors For
Electrode-Related Skin Irritation
During Video-EEG Monitoring/
C. Drees, M. Makic, A. Hill, S. Limon,
M. Mancuso, P. Walczak, K. Biesecker,
K. Wikler, K. Bravo, L. Frey
2.003 Reducing Cycle Time Of EMU
Admissions From Arrival To Start Of
Hook Up/F. B. Espinosa, J. Jones,
S. C. Marcion
2.004 Preventing Skin Breakdown In
EEG Patients/J. Mullen, W. Morton,
R. Vara
Education
2.008 Can Medical Students Learn To
Differentiate Epileptic Seizures From
Non-Epileptic Seizures?/J. Wagoner,
M. P. Jacobson, V. Poukas
2.009 Testing Responsiveness During
Seizures: Current Practice Amongst
Neurology Residents And Nurses/
A. Stino, C. Maideniuc, P. Kulwicki,
R. Dupuy, M. Basha
Neurophysiology
ICU EEG
2.010 Yield Of Repeated Standard
EEGs Versus EEG Monitoring In
Comatose Survivors Of Cardiac
Arrest Treated With Hypothermia/
V. Alvarez, A. Sierra-Marcos,
M. Oddo, A. O. Rossetti
2.011 Electrographic Seizure Burden
Is Associated With Short-term
Outcome In Critically Ill Children/
E. Payne, X. Zhao, H. Frndova,
K. McBain, R. Sharma, J. Hutchison,
C. Hahn
2.012 Burst-suppression With
Identical Bursts: A Distinct EEG
Pattern With Poor Outcome In
Postanoxic Coma/J. Hofmeijer,
M. Cloostermans, M. J. Van Putten
2.013 Early Outcome Prediction In
Comatose Patients After Cardiac
Arrest With Continuous EEG/
M. J. van Putten, J. Hofmeijer,
M. Cloostermans
Clinical Epilepsy
Classification and Syndromes
2.024 From Atypical Rolandic
Epilepsy To Encephalopathy With
Electrical Status Epilepticus During
Sleep: Where Is The “Cutoff”?/
A. De Saint-Martin, C. Seegmuller,
P. Valenti-Hirsch, C. Boulay,
M. A. Spitz, E. Hirsch
2.025 Subcortical Atrophy In
Patients With IGE And Their
Asymptomatic First-degree
Relatives/M. P. Richardson, S. Keller,
A. D. Pawley, L. Nashef, R. Elwes,
F. Chowdhury
2.026 Seizure Semiology In Brain
Tumor Patients Presenting With
Nonconvulsive Seizure And Status/
J. Kennedy, W. Sherman, I. Garic,
P. Kumthekar, M. Macken, E. Gerard,
J. Raizer, S. Schuele
2.027 A Potential Localising Sign;
The Characteristics Of Ictal Head
Turning In Posterior Quadrant
Epilepsy/M. Wijayath, C. Wong,
M. Bartley, M. Dexter, A. Bleasel
2.028 Lennox-Gastaut Syndrome
Associated With Dysgenesis Of
Corpus Callosum/M. U. Khan,
A. B. Janati, N. S. Alghassab,
M. Sammour, M. Alzeir
2.029 The Incidence Of Epilepsy
Among Pediatric Patients With NF-1/
P. Kotagal, M. Moodley, A. D. Rothner,
J. Wexler, A. Gupta
2.030 A Comparison Of Seizure
Semiology Between Autoimmune
Encephalitis And Autoimmune Epilepsy
Paediatric Patients/S. Wright,
Y. Hacohen, A. Geerts, M. Lim,
O. Brouwer, A. Vincent
2.031 What Are The Commonest
Causes Of Epilepsy Seen In An
Epilepsy Clinic? An Indian Viewpoint/
A. Haldar
2.032 Systematic Review Of The
Impact Of Rapid Eye Movement Sleep
On Seizure Frequency/M. Ng,
M. Pavlova
SUNDAY
Psychosocial
2.005 Evidence That American
Mental Health Organizations Are Not
Interested In Psychogenic
Symptoms/S. Benbadis
2.006 Improving Transition To Adult
Epilepsy Care: Facilitating Team
Communication Using Clinical Decision
Support In The EMR/J. A. Disabato,
P. Levisohn, L. Hutton, N. McDougall
2.007 Improving Mental Health
Services For Children And Youth With
Epilepsy: Practical Solutions From
Project Access/P. Levisohn,
J. Wagner, T. Falcone, L. Cook,
G. Uchegbu
2.014 Overall Yield And Predictors Of
Seizure Occurrence In A Large
Intensive Care Unit Video-EEG
Monitoring Experience/T. Walczak,
S. Patel, I. Leppik, E. G. Walczak,
R. Gumnit
2.015 Periodic And Rhythmic
Patterns During EEG Monitoring Of
Critically Ill Children/K. Chapman,
N. Abend, D. Arndt, J. Carpenter,
K. Cornett, D. Dlugos, W. Gallentine,
C. Giza, C. Hahn, J. Lerner,
T. Loddenkemper, J. Matsumoto,
K. McBain, K. Nash, E. Payne,
I. Sánchez Fernández, S. Sanchez,
K. Williams, J. Goldstein
2.016 EEG Seizures During
Hypothermia And Neurodevelopmental
Outcome In Neonates With Hypoxicischemic Encephalopathy/M. Balestri,
M. L. Lispi, D. Longo, S. Pro,
E. Castelli, F. Vigevano, M. R. Cilio
2.017 Assessment Of Automated
EEG Analysis And Trending For
Critically Ill Patients/F. Fürbass,
J. J. Halford, C. Baumgartner,
K. Schnabel, M. Weinkopf,
M. Hartmann, A. Gruber, J. Koren,
J. Herta, H. Perko, T. Kluge
2.018 The Diagnostic Accuracy Of
Electrographic Seizure Detection In
The Adult Neuro-ICU Using A Panel Of
Quantitative EEG Trends/C. Swisher,
S. Sinha
2.019 Use Of Bispectral Index In
Monitoring Depth Of Sedation In The
Neuro-ICU: Correlation With
Quantitative EEG/P. Korb,
J. Ehrenberg, H. Arif, S. Al Kasab,
P. Kandiah, L. Rudzinski, S. Cholleti,
P. Garcia, S. Laroche
2.020 Seizure Burden And Clinical
Outcome In Critically Ill Patients/
K. Mims, A. Tumkur, S. Sinha,
A. Husain
2.021 Named Coma Patterns During
EEG Monitoring Of Critically Ill
Children/J. Goldstein, N. Abend,
D. Arndt, J. Carpenter, K. Cornett,
D. Dlugos, W. Gallentine, C. Giza,
C. Hahn, J. Lerner, T. Loddenkemper,
J. Matsumoto, K. McBain, K. Nash,
E. Payne, S. Sanchez,
I. Sánchez Fernández, K. Williams,
K. Chapman
2.022 The Value Of Long-Term-EEGmonitoring (LTM) In Neuro-ICU
Patients With Altered Mental Status
(AMS) Of Different Severity/M. Tom,
M. Fiol
2.023 New-Onset Refractory Status
Epilepticus: Early Clinical And
Electroencephalographic Clues To The
Identification Of Etiology/N. Gaspard,
B. Foreman, K. Haas, A. Jongeling,
P. Kaplan, J. Lee, S. Schmitt,
J. Szaflarski, M. Westover, L. Hirsch,
S. Laroche
Clinical Diagnosis
2.033 SUDEP Disclosure In Young
Adults With Epilepsy: Patients’
Reaction, Perception Of Risk, Views
On Timing And Behavioural Change/
S. Duncan, A. Tonberg, J. Harden,
A. McLellan, R. Chin
2.034 Duster Abuse: A Recurrent
Spell/K. Orjuela, V. Patil
2.035 Language Laterality
Assessment Through MEG Under
Sedation/A. Papanicolaou,
S. Narayana, R. Rezaie, L. Birg,
A. McGregor, K. Van Poppel,
S. Fulton, B. Mudigoudar, F. Boop,
J. Wheless
2.036 Cerebellar Dysfunction In
Adults With Dravet Syndrome Related
To SCN1A Mutation/C. Dentel,
G. Rudolf, M. Fleury, D. Rohmer,
E. Hirsch
47
2.037 EMG-Based Seizure Detector:
Interim Results Comparing A
Generalized Tonic-Clonic Seizure
Detection Algorithm To Video-EEG
Recordings/M. Girouard, C. Szabo,
L. Morgan, K. Karkar, L. Leary, O. Lie,
J. Cavazos
2.038 AED Withdrawal In A Pediatric
Epilepsy Monitoring Unit: A
Prospective Study/M. Goyal, P. Parks,
H. Kim, P. Kankirawatana
2.039 Pattern Analysis Of Seizure
Clustering During EEG Monitoring/
V. Ferastraoaru, S. Haut, M. Ihle,
M. Dumpelmann, A. Schulze-Bonhage
2.040 Continuous Epileptiform
Discharges Are Common In Elderly
Patients With Delirium: A Prospective
Study With Continuous EEG
Monitoring/N. Gilles, C. Meeus,
C. Depondt, T. Pepersack, B. Legros
2.041 Does The Phenotype Of SCN1A
Mutation Negative Dravet Syndrome
Patients Differ From Those Who Are
Mutation Positive? Analysis Of 262
Cases/A. Brunklaus, R. Ellis,
E. Reavey, S. Zuberi
2.042 Diagnoses Of Neurobehavioral
Paroxysms In Veterans Of Operation
Enduring Freedom/Operation Iraqi
Freedom (OEF/OIF) - Experiences
From A VA Epilepsy Center/
S. Satpute, R. Franks, D. Chen
2.043 Pattern Of Brain Injury
Predicts Long Term Epilepsy Following
Neonatal Encephalopathy/Q. Xu,
V. Chau, S. P. Miller, K. J. Poskitt,
A. Hill, S. Belanger, J. Rigney,
E. Roland
2.044 Pericentral Ulegyria With
Ipsilateral Hippocampal Sclerosis/
G. Kuchukhidze, I. Unterberger,
J. Dobesberger, J. Hãfler, G. Walser,
E. Trinka
2.045 The Cerebral Syncope Is Other
Differential Diagnostic Cause Of Loss
Of Consciousness From Seizures/
J. Lee
2.046 Sleep Apnea Scale Of The
Sleep Disorders Questionnaire (SASDQ) As A Screening Tool For
Obstructive Sleep Apnea In Adults
With Epilepsy/N. Economou,
N. Andrews, D. Dikeos,
N. Foldvary-Schaefer
2.047 Prevalence And Clinical
Significance Of Unilateral Wicket
Rhythms/R. Azzam, A. Arain, N. Azar
Clinical Treatments
2.048 Lesional Vs Non-Lesional
Partial Epilepsy: Post-Hoc Analysis Of
Pooled Perampanel Phase III
Studies/S. Marsh, H. Yang,
B. Williams, S. Huang, A. Laurenza,
S. S. Chung
Perampanel In Patients With
Neurologic & Psychiatric
Comorbidities: Post-Hoc Analysis Of
Phase III Epilepsy Trials/D. Squillacote,
H. Yang, B. Williams, S. Zhou,
A. Laurenza, V. Biton
48
Poster Session 2
8:00 a.m. – 5:00 p.m.
2.050 Analysis Of Aggression In
Perampanel Phase III Epilepsy Clinical
Trials/A. LoPresti, A. Ettinger,
H. Yang, B. Williams, S. Zhou, R. Fain,
A. Laurenza
2.051 Quality Assessment Of
Epilepsy Treatment Using A Registry
Of Clinical Data/C. Hansen
2.052 What’s In A Guideline? The
Treatment Of Infantile Spasms At A
Tertiary Care Center/D. Thodeson,
Y. Sogawa
2.053 Immunomodulation Therapy In
Three Cases Of Late-onset
Rasmussen Encephalitis/G. Timarova,
I. Lisa, K. Dudasova, V. Belan,
M. Jezberova, E. Pristasova,
J. Andrisova
2.054 Surgical Treatment Of Patients
With Rasmussen’s Encephalitis/
Y. Guan, G. Luan, J. Zhou
2.055 Developmental Outcome In
Children With Infantile Spasms
Treated With High Dose Oral
Steroids/S. Adhami, C. Harini
2.056 Pre-hospital And Emergency
Management Of Afebrile Pediatric
Status Epilepticus/S. Seinfeld,
J. Pellock, R. DeLorenzo
2.057 Phenytoin/Fosphenytoin Is The
Most Prescribed But Least Effective
Anti-Epileptic Medication For Second
Line Treatment Of Status
Epilepticus/J. Langer, N. Fountain
2.058 Changes In Seizure Patterns
And Tolerability After Interruption Of
Vagal Nerve Stimulation Duty Cycle/
V. Woodard, J. Boggs, D. Couture,
C. O’Donovan
2.059 New Treatment Strategy For
Infantile Spasms: Short Course Of
Vigabatrin With Early Switch/B. Lim,
H. Ryu, G. Jeong, H. Kim, H. Hwang,
J. Chae, J. Choi, Y. Hwang, K. Kim
2.060 Visualase For Medically
Refractory Epilepsy: The Wake Forest
Comprehensive Epilepsy Center
Experience/G. Popli, D. Couture,
J. Boggs, A. Laxton, M. Wichter,
J. Hutchens, V. Woodard,
C. O’Donovan
2.061 Current Attitudes Towards
Treatment Of Neonatal Seizures/
R. Garcia-Sosa, K. Kelley, O. Khan,
J. Hageman
2.062 Major Health Issues In A
Cohort Of Epilepsy Patients Treated
With Vagus Nerve Stimulation
Therapy/S. Tobochnik, C. Gutierrez,
M. Jacobson
2.063 Effect Of Ketoconazole On
Perampanel Pharmacokinetics/
R. Maganti, A. Laurenza, H. Yang,
B. Williams, D. A. Verbel, E. Schuck,
J. Ferry, B. Gidal
2.064 Benzodiazepine Use For
Emergency Treatment Of Seizures: A
Review/J. Pellock, S. Haut, S. Seinfeld
2.065 Effectiveness Of Intravenous
Levetiracetam As An Adjunctive
Treatment In Pediatric Refractory
Status Epilepticus/H. Kim, H. Ryu,
B. Lim, J. Chae, J. Choi, K. Kim,
Y. Hwang, H. Hwang
2.066 Daily Diaries In Epilepsy
Research: Does Electronic Format
Improve Adherence?/E. Polak, A. Apfel,
M. Privitera, D. Buse, S. Haut
2.067 The EpiNet-first Trials; Call For
Participants/P. Bergin, B. Legros,
M. Tripathi, S. Beretta, W. D’Souza,
H. J. Tan, J. G. Burneo, N. Dang,
C. Zanchi
Prognosis
2.068 Heart Rate Variability And
Baroreflex Sensitivity In Epilepsy: Do
They Play A Role In Sudden
Unexpected Death In Epilepsy?/
A. Laffan, C. Doherty, R. A. Kenny,
Y. Langan
2.069 Autonomic Changes Following
Generalized Tonic Clonic Seizures: An
Analysis Of Adult And Pediatric
Patients With Epilepsy/R. Sarkis,
S. Thome-Souza, M. Poh, J. Klehm,
D. Vannan, J. Madsen, R. Picard,
T. Loddenkemper, C. Reinsberger
2.070 Psychogenic Seizures In US
Veterans; Outcome Following
Diagnosis/M. Salinsky, D. Storzbach,
C. Evrard, E. Goy
2.071 Newly Developed Nocturnal 2’
Generalized Tonic Clonic Seizure After
Temporal Lobectomy/S. Park, S. Kim,
D. Lee, M. Lee
2.072 Management Outcomes In
Elderly Patients With Epilepsy (EPWE)
In A Tertiary Care Epilepsy Center/
S. Bandyopadhyay, N. Bangalore
Vittal, P. Singh, A. Arain
2.073 Antiepileptic Drug Type And Its
Association With Outcome In Status
Epilepticus/S. Kumari, J. Cheng
2.074 Clinical Characteristics In
Children With Recurrent Febrile
Seizures/J. Noh, B. Cha
2.075 Most Adults With Childhood
Onset Epilepsy And Their Parents
Have Incorrect Or Highly Improbable
Ideas Of The Cause 20-30 Years
Later: A Population-Based Study/
P. Camfield, C. S. Camfield
2.076 Success Of Postoperative
Anti-Epileptic Medication Reduction In
Children Following Surgery For
Intractable Epilepsy/K. Nickels,
E. Wirrell, L. Wong-Kisiel
2.077 Predictors Of Outcome In A
Large Cohort Of Infantile Spasms Of
Unknown Cause/M. Madou,
C. Yuskaitis, K. Howell, E. Sherr,
A. Poduri, EPGP Investigators and
EpiK Investigators
Neuro Imaging
Functional Imaging
2.078 Functional MRI Of Neuronal
Activation In Epilepsy Patients With
Malformations Of Cortical
Development/S. Nikolova, R. Bartha,
J. G. Burneo
2.079 Resting-State Motor
Networks In Frontal Lobe Epilepsy/
K. E. Woodward, I. Gaxiola Valdez,
B. Goodyear, P. Federico
8:00 a.m. – 5:00 p.m.
2.093 Epileptic Network Associated
With Hypothalamic Hamartoma: An
EEG-fMRI Study/K. Usami,
R. Matsumoto, N. Sawamoto,
H. Murakami, M. Inouchi, T. Fumuro,
A. Shimotake, T. Kato, T. Mima,
H. Masuda, H. Fukuyama,
S. Kameyama, A. Ikeda
2.094 Using Control Stimuli To
Isolate Language-Specific Responses
In MEG Language Assessments In The
Presurgical Evaluation Of Patients
With Epilepsy/Z. Li, S. Baillet,
E. Bock, M. Raghavan
Other Emerging Techniques
2.095 MEG-Guided Tractography
(MEG-GT): A New Protocol To
Characterize Transcallosal Patterns
Of Seizure Propagation/E. Castillo,
T. Kleneschay, P. Chen,
M. Korostenskaja, P. Salazar, J. Cook,
J. Baumgartner, J. Seo, K. Lee
2.096 Simultaneous Intracranial
Electrical Stimulation And fMRI
(SEEG-fMRI) For Improved PostOperative Seizure Outcome/
J. Gonzalez-Martinez, S. E. Jones,
J. Bulacio, R. Enatsu, D. Nair, I. Najm
2.097 Structure Meets Function
Meets Neuropsychology: Factor-driven
Integration Of Multimodal Data/
N. Kucukboyaci, N. Kemmotsu,
H. Girard, C. Cheng, E. Tecoma,
V. Iragui-Madoz, C. McDonald
2.098 Tumor Associated Seizures
Are Affected By Gene Expression In A
Region-Specific Manner: A Genomic
Imaging Study/J. Lee, A. Norden,
K. Ligon, D. Maetzold, J. Snyder,
P. Wen
2.099 Clustering And Localizing
Interictal Epileptiform Discharges To
Predict Seizure Onset/T. Gilbert,
J. Hou, P. Luu, M. Holmes, D. Tucker
2.100 How Long Does The
Hippocampus Take To Settle Down
After MRI-guided Laser Ablation For
Refractory Epilepsy? Proof Of Concept
Using A Multi-Parametric Analysis Of
MRI Markers/P. Tiwari, S. Danish,
A. Madabhushi
Cormorbidity (Somatic And
Psychiatric)
Medical Conditions
2.101 High Risk Of Venous
Thromboembolism In Persons With
Epilepsy And Seizure Disorders
Relative To Persons With Migraine/
G. Martz, A. Selassie, D. A. Wilson
2.102 The Spectrum Of Clinical And
Immunological Features Of Status
Epilepticus (SE) Associated With
Systemic Lupus Erythematosus
(SLE)/A. Krumholz, T. Ting, J. Mikdashi
2.103 The Hazard Of Subsequent
Stroke In Adult-Onset Epilepsy/
A. Malek, D. A. Wilson, B. Wannamaker,
D. T. Lackland, A. Selassie
2.104 Patterns Of Pre-Existing And
Concurrent Multimorbidity In Persons
With Epilepsy/K. Kaiboriboon,
P. Bakaki, S. Koroukian
2.105 Central Auditory Processing
Disorders In Children With Temporal
Lobe Epilepsy/M. Guerreiro,
M. Boscariol, M. Amaral, R. Casali,
C. G. Matas, C. A. Guerreiro,
M. F. Collela-Santos
2.106 The Impact Of Seizures On
Cognition And Health Related Quality
Of Life In Primary Brain Tumours/
A. Bleasel, Z. Rahman, C. Wong,
M. Wong
2.107 Comorbidity Burden Among
Medicaid Beneficiaries With
Epilepsy/A. Chandran Pillai, P. Bakaki,
S. Koroukian, K. Kaiboriboon
2.108 Bone Health Screening
Practices Amongst Boston Children’s
Hospital Neurologists In Patients On
Anti-Epileptic Medications: A Quality
Improvement Project/M. Schomer,
A. Patel, C. Elitt, K. Spencer,
J. Heath, K. Julich, C. Ackhar,
E. Hart, N. S. Ma, S. An, M. Putman,
E. Allred, T. Loddenkemper
Psychiatric Conditions
2.109 Patient Health Questionnaire
(PHQ-9) As A Depression Screening
Tool In Epilepsy Patients: A Validation
Study/J. Rathore, G. Tesar, R. Busch,
Y. Fan, N. Obuchowski, L. Jehi
2.110 Correlates Of Lifetime Suicidal
Ideation In The Community-Based
Connecticut Study Of Epilepsy/
E. Baldin, D. C. Hesdorffer, R. Caplan,
A. Berg
2.111 Factors Associated With PostIctal Psychosis/R. Doss, J. White
2.112 Working Memory Mediates The
Association Among The Comorbidities
Of Pediatric Epilepsy/R. Caplan,
P. Siddarth, S. Gurbani, R. Sankar
2.113 Coping, Behavior And
Emotional Problems In Adolescents
With Epilepsy Participating In The
Project Cope (Collaboration For
Outreach And Prevention Education
For Children/Adolescents With
Epilepsy)/T. Falcone, J. Timmons
Mitchell, R. Butler, L. Sperry,
E. Pestana Knight
2.114 Psychiatric Disorders In Youth
With Epilepsy: A Comparison To
Healthy Controls/J. Wagner, G. Smith,
D. A. Wilson, A. Selassie
2.115 Antiepileptic Drugs In Patients
With Psychogenic Nonepileptic
Seizures: Lack Of Response Is Not
Mandatory And May Delay
Diagnosis/R. Alessi, K. Valente
SUNDAY
2.080 Differential Reduction In
Activation Of Language And Executive
Function Networks In Right And Left
Mesial Temporal Sclerosis Patients In
A Language-Based Decision fMRI
Paradigm/B. Martins-Castro,
J. de Almeida, P. R. Arantes,
C. Jorge, R. Valerio, E. Amaro Jr,
L. Castro
2.081 Automated Voxel-Based SPMSpect Analysis In MRI-negative
Temporal Lobe Epilepsy/V. Sulc,
B. Brinkmann, D. Hanson, D. Jones,
D. Horinek, G. Cascino, L. Wong-Kisiel,
J. Britton, E. So, G. Worrell
2.082 Effect Of Age Of Seizure
Onset And Mesial Temporal Sclerosis
On Brain Functional Organization In
Temporal Lobe Epilepsy/G. Doucet,
C. Skidmore, D. Pustina, A. Sharan,
M. Sperling, J. Tracy
2.083 Global Functional Connectivity
Analysis With Resting State fMRI For
Planning Epilepsy Surgery: Case
Report/Y. Nakai, Y. Kaneoke,
H. Nishibayashi, T. Donishi, M. Terada,
M. Ogura, N. Nakao
2.084 Lateralization And Localization
Of Epilepsy Related Hemodynamic Foci
Using Presurgical fMRI/H. Zhang,
Y. Lu, B. Brinkmann, G. Worrell, B. He
2.085 Default Mode Network
Dysfunction In A Patient With Epilepsy
In The Precuneus/M. Centeno,
S. Perani, K. St Pier, L. Lemieux,
J. Clayden, C. Clark, R. Pressler,
J. Cross, D. Carmichael
2.086 Resting State Network In
Idiopathic Generalized Epilepsy: A
Graph-theoretical Analysis Of MEG
Data/A. Elshahabi, S. Klamer, J. Giehl,
H. Lerche, C. Braun, N. Focke
2.087 Evidence Of Functional
Network Evolution In TLE/V. Morgan,
A. S. Dagley, R. Xu, B. Abou-Khalil
2.088 The Microstructural Change Of
The Corpus Callosum In Children With
Medically Intractable Neocortical
Epilepsy: A Diffusion Tensor Imaging
Study/H. Kim, W. J. McQuitty,
A. Harrison, A. Oh, P. Kankirawatana,
C. Rozzelle, J. Blount
2.089 Noninvasive Mapping Of The
High Frequency Brain Activity In Focal
Epilepsy Patients/Y. Lu, G. Worrell,
H. Zhang, B. Brinkmann, C. Nelson,
B. He
2.090 Verbal And Visual Memory
Function In Temporal Lobe Epilepsy:
Results Of A Blocked Versus Eventrelated Analysis/S. Bonelli,
M. Yogarajah, R. Powell, P. Thompson,
R. Samson, M. Symms, M. Koepp,
J. Duncan
2.091 Characterization Of The PreIctal State In Focal Epilepsy Using
Near Infrared Spectroscopy/
S. Vinette, E. Slone, J. Dunn,
P. Federico
2.092 Impact Of PET Scan On
Epilepsy Surgery Evaluation/E. Oberst,
O. Tesoro, C. Patterson, S. Williams,
Y. Sogawa, J. Mountz, M. Tamber,
S. Gedela
Poster Session 2
Antiepileptic Drugs
Clinical Trials
2.116 USL255 Is Efficacious Across
All Partial-Onset Seizure Types And
With A Variety Of Concomitant
Antiepileptic Drugs: Results From
Subgroup Analyses Of The Phase 3
Prevail Clinical Trial/I. Blatt,
V. N. Nagaraddi, B. Anders,
A. M. Clark, M. B. Halvorsen,
R. E. Hogan
49
2.117 Long-Term Open-Label
Extension (OLE) Study Evaluating The
Safety And Efficacy Of USL255,
Once-Daily Extended-Release
Topiramate, In Patients With PartialOnset Seizures: Interim Analysis
From Prevail OLE/T. A. Fakhoury,
S. S. Chung, B. Anders, D. Laine,
I. Blatt
2.118 Open-Label Continuation Of
The Effectiveness And Safety Of
Diazepam Auto-Injector Administered
By Caregivers In An Out-Patient
Setting To Patients With Epilepsy For
Episodes Of Acute Repetitive
Seizures/J. Rogin, J. Wheless,
B. Abou-Khalil, K. Wolter, G. Pixton,
N. Sherman, R. Shukla, C. Roland,
K. Sommerville K, V. Goli
2.119 Steady-State Bioequivalence
Of Extended-Release, Once-Daily
Trokendi XR™ (SPN-538) To
Immediate-Release Topiramate (TPMIR, Topamax®)/J. Johnson, S. Brittain,
J. Dugan Stocks, P. Baroldi
2.120 Pharmacokinetic Rationale For
Mg-For-Mg Overnight Switch From
Twice-Daily Immediate-Release
Topiramate (TPM-IR) To Once-Daily,
Extended-Release Trokendi XR™ (SPN538)/J. Dugan Stocks, J. Johnson,
S. Brittain, P. Baroldi
2.121 Linearity And Dose Strength
Equivalence Of Once-Daily, ExtendedRelease Topiramate (Trokendi XR™,
SPN-538)/E. Roers, S. Brittain,
J. Dugan Stocks, P. Baroldi
2.122 Once-Daily Trokendi XR™ (SPN538) Vs. Twice-Daily Topamax®: Impact
Of Nonadherence On Topiramate
Concentrations/S. Brittain
2.123 Long-Term Response To
Clobazam In Relation To Baseline
Seizure Frequency In Patients With
Lennox-Gastaut Syndrome/
J. Wheless, J. Isojarvi, D. Lee
2.124 Long-Term Efficacy Of
Clobazam For Drop Attacks In
Patients With Lennox-Gastaut
Syndrome Is Consistent Across The
Age Spectrum/J. Buchhalter, D. Lee,
V. Shen, J. Isojarvi
2.125 Tolerability Of
Ezogabine/Retigabine, Using A Flexible
Dosing Regimen, As Adjunctive
Therapy To Specified, Individual
Antiepileptic Drug Treatments In
Adults With Partial-Onset Seizure/
S. DeRossett, H. Lerche, J. Daniluk,
N. Lotay, S. Edwards
2.126 Eslicarbazepine Acetate As
Adjunctive Treatment For Refractory
Partial-Onset Seizures: Pooled
Analysis Of Safety Data From Three
Phase III Controlled Trials/J. Rogin,
B. Abou-Khalil, D. Blum, R. Sousa,
T. Grinnell
2.127 Efficacy Of Eslicarbazepine
Acetate In Patients With Refractory
Partial Onset Seizures: A Pooled
Analysis Of Three Phase III Controlled
Studies/V. Biton, G. Krauss, D. Blum,
R. Sousa, T. Grinnell
50
Poster Session 2
8:00 a.m. – 5:00 p.m.
2.128 Eslicarbazepine Acetate As
Adjunctive Therapy In Patients With
Refractory Partial-Onset Seizures:
Safety Results Of A 12-Week
Randomized Placebo-Controlled Study
On Behalf Of The 304 Study Team/
B. Abou-Khalil, J. B. Rogin,
A. Biraben, C. Galimberti, P. Kowacs,
S. B. Hong, D. Blum, T. Nunes,
P. Soares Da Silva, T. Grinnell,
H. Cheng
2.129 Lacosamide For Uncontrolled
Primary Generalized Tonic-Clonic
Seizures: An Open-Label Extension
Study/S. Yates, R. Wechsler, C. Beller
2.130 The Impact Of Lacosamide On
Functioning And Quality Of Life/
E. Fertig, R. Trobliger, M. Lancman,
M. Malik, K. Perrine, L. Myers,
M. Bonafina
Cohort Studies
2.131 Usage Patterns Of Clobazam
Vs. Clonazepam In Epilepsy: Results
From The UK CPRD Database/
J. Isojarvi, M. Cossecq,
A. Guiraud-Diawara, D. Jones,
V. Shen, P. Verpillat
2.132 Response Of Seizures And
Epileptiform Activity To High-Dose
Clobazam Treatment/J. Klehm,
I. Sánchez Fernández, J. Peters,
S. Thome-Souza, C. Harini, C. Vega,
G. Wilkening, K. Chapman,
T. Loddenkemper
2.133 Clinical Experience With
Lacosamide In Institutionalized
Mentally Retarded And Refractory
Epileptic Patients/P. Bermejo, A. Cruz
2.134 Early Experience With Add-on
Treatment Of Patients With Focal
Epilepsy With Perampanel/
A. Schulze-Bonhage
2.135 Rufinamide Retention Rate In
Pediatric Epilepsy/A. McCarthy,
S. Kessler
2.136 Laco-IV Study: Intravenous
Lacosamide Experience In Clinical
Practice/M. Garces, F. López,
A. Castillo, P. Giner, N. Torres,
I. Escalza, A. Del Villar Igea,
M. Bonet, E. Noé, V. Villanueva Haba
2.137 Resource Utilization Among
Epilepsy Patients With And Without
Breakthrough Seizures In A U.S.
Managed Care Population/
A. A. Petrilla, F. Velez, V. Bollu,
V. Divino, S. Hallinan, Y. Fang,
A. Ettinger, C. Makin
2.138 Clinical Experience Of
Lacosamide Monotherapy In Patients
With Partial Epilepsy/B. Gonzalez
Giraldez, J. Zurita Santamaría,
J. Serratosa
Drug Interaction
2.139 Effects Of Eslicarbazepine
Acetate On Serum Lipids In Statin
Users And Non-users: Pooled Analysis
Of Placebo-controlled Trials/D. Blum,
S. Mintzer, R. Wechsler, J. Rogin,
B. Gidal, M. Schwab, R. Sousa,
T. Grinnell
2.140 Antiepileptic Drugs And
Comedications In Elderly Nursing
Home Patients With Epilepsy/J. Lee,
I. Leppik, B. M. Kistner, J. Rarick,
T. C. McCarthy, A. Birnbaum
2.141 Impact Of Planned Reduction
Of Concomitant Antiepileptic Drugs
On Tolerability In Patients With
Partial-onset Seizures Receiving
Lacosamide/J. Fong, J. Bena,
S. Morrison, N. Foldvary-Schaefer
Drug Side Effects
2.142 Psychiatric Adverse Events
After Levetiracetam Use In Korean
Adults: Independent From Serum
Drug Level/K. Lee, J. Moon, J. Shin,
J. I. Byun, J. A. Lim, T. J. Kim,
Y. Shin, Y. Kim, B. Kang, S. Lee,
K. Jung, K. Chu, S. Lee
2.143 Short-Term Impact Of EnzymeInducing Antiepileptic Drugs On
Vascular Disease And Use Of LipidLowering Agents/S. Mintzer, V. Maio,
K. Foley
2.144 Cross-Sensitivity Of Adverse
Cognitive Effects With Antiepileptic
Drug Use/B. Chen, K. Detyniecki,
A. Javid, R. Buchsbaum, H. Choi,
L. Hirsch
2.145 Lacosamide Has No Negative
Effect On Sleep Parameters In
Healthy Subjects: Results From An
Open-Label Study/J. Hudson,
S. Yates, P. Williams, J. Guptill,
K. Simontacchi, W. Byrnes, O. D’Cruz
2.146 Impact Of TreatmentAssociated Adverse Events On
Healthcare Resource Utilization And
Costs Among Patients With Partial
Onset Seizures: A Longitudinal
Analysis/V. Bollu, F. Velez, M. Cloutier,
A. Guerin, V. Carter, J. Heroux,
K. Dea, E. Q. Wu
2.147 The Economic Burden Of
Central Nervous System Events
Among Patients With Partial Onset
Seizures Treated With Antiepileptic
Drugs/F. Velez, V. Bollu, M. Cloutier,
A. Guerin, V. Carter, J. Heroux,
R. Nitulescu, E. Q. Wu
2.148 Exploration Of Adverse Events
By Region, And Detailed Focus On
Psychiatric Events, With Long-Term
Open-Label Perampanel Treatment/
E. Ben-Menachem, G. Krauss,
M. Gee, M. Bagul, D. Kumar
2.149 Antiepileptic Drug Risks In
Patients With Heart Failure And
Heart Block/S. Merrill, R. L. Page,
J. Bainbridge
2.150 Objective Self-measurement Of
The Subjective Side Effect Of
Dizziness On Sodium Channel Blocking
AEDs/S. D. Dunlap, K. Lervik,
J. Bainbridge, L. Strom
2.151 Neurology Resident Knowledge
And Screening Practices Of AED Side
Effects/G. Narwani, R. Nanjireddy,
A. Shah, M. Basha
2.152 Antiepileptic Drugs And
Movement Disorders: A Frequently
Neglected Story/F. Zaheer, K. Jones,
M. Bensalem-Owen, J. Slevin
2.153 Levetiracetam May Aggravate
Generalized Epilepsy Syndromes In
Pregnancy/P. Tseng, F. Bannout
2.154 Auditory Hallucinosis
Associated With The Use Of
Ezogabine/Retigabine/J. Asconape,
D. I. Thomas, J. McGee
2.155 Urinary Retention With
Clobazam/P. McGoldrick, S. M. Wolf,
R. Olasin, D. Tovar, H. Guinan
8:00 a.m. – 5:00 p.m.
2.167 Efficacy And Tolerability Of
Intravenous Levetiracetam In
Children/W. Hastings, O. Khan,
E. D. Crisp, A. Aceves, R. Castillo,
B. Kirmani
2.168 Levetiracetam Monotherapy Is
As Effective As Valproate In Newly
Diagnosed Cases With Juvenile
Myoclonic Epilepsy (JME)/F. Babtain,
M. Al Hamrany, H. Bhatia,
M. Velmurugan
2.169 Angel-Dust And The AED:
Lamotrigine Leads To PCP False
Positives In Dose-dependent
Manner/M. El-Hagrassy, R. Beach
2.170 A Survey Of Retail Pharmacist
Knowledge And Practice Regarding
Manufacturer Changes Of
Antiepileptic Drugs/L. Garrity,
A. Hessling, M. Turner
2.171 Pharmaco-Adherence In
Patients With Epilepsy And Neurologic
Tumors/M. Spitz, C. Drees, L. Frey,
J. Fleming, J. Bainbridge, S. Pearson,
A. Shrestha, L. Strom
2.172 Retrospective Study Of
Lacosamide In The Elderly (> 60)/
J. Bainbridge, M. Spitz, L. Frey,
D. McDermott, C. Drees, C. O’Brien,
L. Strom, A. Shrestha, S. Pearson
2.173 Clearance Of Valproic Acid By
Continuous Renal Replacement
Therapy In A Patient With Status
Epilepticus/F. Khan, U. Menon,
R. Sagastume, R. Ramsay
2.174 Most Commonly Used
Antiepileptic Drugs (AEDs) In Children
With Intractable Epilepsy/O. Muthaffar
Surgery
Adult
2.175 Comparison Of Short-Term
Healthcare Utilization After Standard
Temporal Resection To Stereotactic
Laser Ablation For Mesial Temporal
Lobe Epilepsy/E. Faught,
S. L. Helmers, R. Gross, J. Willie
2.176 Mesial Temporal Lobe Epilepsy
Surgery: Reasons Of Failures And The
Role Of MEG/I. Mohamed,
A. Pouladian, A. Bouthillier, D. Nguyen
2.177 Ictal And Interictal Intracranial
EEG Patterns In Non Lesional
Temporal And Temporal ‘Plus’ Epilepsy
Correlated To Outcomes And
Histopathology/I. Noviawaty,
C. Nievera, E. Kutluay, W. Mueller,
M. Raghavan
2.178 Hippocampal Volume And
Postsurgical Outcome In Intractable
Temporal Lobe Epilepsy/Y. Goh,
J. C. Schoene-Bake, A. Marson,
M. P. Richardson, B. Weber, S. Keller
2.179 Hemispherectomy In Adults
With Intractable Epilepsy: The Barrow
Neurological Institute Experience In
The Context Of The Literature
Review/C. Schusse, K. Smith,
C. Drees
2.180 Predictors Of Postoperative
Seizure Outcome: A Longitudinal
Study Of Temporal And Extratemporal
Resections/H. Chen, M. Agostini,
K. Ding, P. Gupta, R. Hays, P. Van
Ness, P. Modur
2.181 Super-Selective
Amygdalohippocampectomy In
Patients Treated By Laser Ablation/
W. Tatum, V. Gupta, J. Shih,
R. Wharen
Pediatrics
2.182 Epilepsy Surgery In Pediatric
Stroke Patients/A. Kao, K. Havens,
S. Magge, P. Pearl, W. Gaillard
2.183 Hemispherectomy For
Intractable Epilepsy In The Pediatric
Age Group: Systematic Review And
Meta-analysis/S. Salam, C. Watson,
C. Griessenauer, J. Blount
2.184 Acute And Mid-Term Outcomes
Of Refractory Epilepsy And
Neurocognitive Comorbidities
Following MRI-Guided Laser-Induced
Thermal Ablation Of Cortical
Dysplasia/D. Carter, S. Hess,
K. Tornabene, K. Donato, S. Huckins,
Z. Tovar-Spinoza, Y. Eksioglu
2.185 Outcomes Of Refractory
Epilepsy And Neurocognitive
Comorbidities Following SequentialStaged MRI-Guided Laser-Thermal
Ablation In Pediatric Patients With
Tuberous Sclerosis Complex/
Y. Eksioglu, S. Hess, K. Tornabene,
K. Donato, S. Huckins, D. Carter,
Z. Tovar-Spinoza
2.186 Palliative Resective Epilepsy
Surgery: The Cook Children’s
Experience/J. Zajac, E. Smith,
L. Bailey, A. Hernandez, S. Malik,
D. Donahue, C. Keator, M. Perry
2.187 Depth Electrodes Provide
Essential Data On Intracranial EEG, In
Children With Refractory Epilepsy
From Deep Malformations Of Cortical
Development And Developmental
Tumors/C. Moufawad El Achkar,
C. Harini, A. Poduri, M. Libenson,
J. R. Madsen, M. Takeoka
2.188 Utility Of ECD-SPECT After
Corpus Callosotomy For Children With
Refractory Epilepsy/K. Toda, H. Baba,
T. Ono
2.189 Psychiatric Functioning In
Pediatric Patients Pre- And Postepilepsy Surgery/J. Doss, E. Adams,
L. Buck, J. Doescher
2.190 Repeat Resective Surgery In
Pediatric Epilepsy/R. Bower, E. Wirrell,
N. Wetjen
Of Refractory Gelastic Seizures And
Neurocognitive Comorbidities
Following MRI-Guided Laser-Induced
Thermal Ablation Of Hypothalamic
Hamartoma/Z. Tovar-Spinoza,
S. Hess, K. Tornabene, K. Donato,
S. Huckins, D. Carter, Y. Eksioglu
SUNDAY
Other
2.156 High Brain Permeability
Differentiates Brivaracetam From
Levetiracetam And Reveals Promising
Potential As Acute Intervention
Against Prolonged And LifeThreatening Seizures/J. Nicolas,
D. Tytgat, A. Matagne, L. Staelens,
H. Klitgaard, S. Kervyn
2.157 Impact Of Delayed-dose
Administration Of USL255, An
Extended-release Topiramate
Formulation/B. Anders, Q. Lu,
E. Ludwig, A. M. Clark,
M. B. Halvorsen
2.158 Risk Of Seizures Following
Surgical Resection Of Newly
Diagnosed Meningiomas/M. Daras,
M. Hsu, T. Kaley, R. Curry,
K. Panageas, E. Avila
2.159 Effectiveness And Positioning
Of Lamotrigine In The Treatment Of
Epilepsy – Retrospective Study At
One Epilepsy Center In Japan/
T. Yamamoto, T. Yamazoe, A. Fujimoto,
R. Kobayashi, T. Yokota, H. Enoki
2.160 Correlation Of Serum And CSF
Levels Of Lacosamide (LCM)/A. Shah,
M. Basha, D. H. Rhoney, S. Mittal
2.161 Clobazam As An Adjunctive
Treatment In Refractory Seizures:
One Year Followup In The Clinical
Setting/G. Deck, G. Montouris
2.162 Variability Of Lamotrigine And
Carbamazepine Concentrations In
Elderly Community Dwelling
Patients/C. Lim, B. Prasittisopin,
R. Ramsay, J. F. Collins, I. Leppik,
A. Birnbaum
2.163 Galaco Study: Experience With
Lacosamide In Focal Epilepsies In
Galicia, Spain/X. Rodriguez Osorio,
F. López, A. Pato, G. Fernández-Pajarín,
E. Corredera, E. Rubio-Nazábal,
E. Cebrián
2.164 Ketamine In Refractory Status
Epilepticus – A Retrospective Study
On 16 Patients/J. Höfler, A. Zerbs,
J. Dobesberger, G. Pilz, M. Leitinger,
H. Novak, E. Trinka
Felbamate In Adults With Intractable
Epilepsy & Static Encephalopathy/
S. Singh, R. R. Sankaraneni,
M. Faulkner, S. Karimi
2.166 Additive Drug Treatment And
Duration Of Status Epilepticus And
Persistent Repetitive Seizures/
M. Hegazy, T. Ruble, S. Lam,
C. Ahrens, N. So
Poster Session 2
51
All Ages
2.192 High Frequency Oscillations In
Intra-operative Electrocorticography:
Pre- And Postresection/N. van Klink,
M. van’t Klooster, G. Huiskamp,
F. Leijten, R. Zelmann, M. Zijlmans
2.193 Intracranial Localization For
Planning Laser Interstitial Thermal
Ablation For Treatment Of Temporal
Lobe Epilepsy/M. Witcher, D. Couture,
G. Popli, C. O’Donovan
2.194 Long-term Seizure Outcome
Following Resective Surgery For
Epilepsy In A Japanese Epilepsy
Center/T. Kunieda, N. Mikuni,
S. Shibata, R. Inano, Y. Yamao,
T. Kikuchi, R. Matsumoto,
J. Takahashi, A. Ikeda, H. Fukuyama,
S. Miyamoto
2.195 Epilepsy Surgery In The United
States: Analysis Of Data From The
National Association Of Epilepsy
Centers (NAEC)/A. M. Alkhachroum,
K. Kaiboriboon, A. Zrik, A. Daif,
D. Labiner, S. Lhatoo
2.196 Location Of Epileptogenic Zone
May Affect The Resection
Completeness Rate And Thus The
Surgical Outcome In The Refractory
Focal Epilepsy/J. Seo, P. Chen,
M. Korostenskaja, J. Baumgartner,
K. Lee
2.197 An Algorithmic Approach To
Lesional Temporal Lobe Epilepsy/
F. Vale, S. Benbadis, A. Vivas
2.198 Stereotactic Laser
Amygdalohippocampotomy For Mesial
Temporal Lobe Epilepsy: Results Of
Multicenter Experience At 6 Months
And 1 Year/R. Gross, J. Willie,
S. Helmers, A. Mehta, C. Harden,
D. Couture, G. Popli, A. Sharan,
M. Sperling, R. Marsh, G. Worrell,
G. Cascino, M. Weinand, D. Labiner,
S. Danish, S. Wong, R. Wharen,
J. Shih, D. Curry, A. Wilfong,
J. Ojemann, E. Novotny, N. Tandon,
J. Slater, A. Golby, J. Madsen,
M. Takeoka, D. Drane
2.199 Focal Resection Following
Anterior Corpus Callosotomy For
Refractory Epilepsy/D. Chuang,
M. Sperling, A. Sharan, M. Nei
2.200 Seizure Onset Zone
Connectivity With Intracranial EEG/
D. Madhavan, H. Kyllo, M. Puccioni,
T. Wilson
2.201 Technical Points In VNS
Implantation And Its Complications/
T. Yamazoe, T. Yamamoto, A. Fujimoto,
R. Kobayashi, T. Yokota, H. Enoki
Language
Adult
2.202 Predicting Neuropsychological
Outcome From Selective Temporal
Lobectomy Using The Wechsler
Memory Scale-4th Ed. (WMS-IV) And
Other Verbal And Visual Memory
Tests/M. Schoenberg, E. Rinehardt,
M. Mattingly, A. Bozorg,
N. Rodgers-Neame, F. Vale,
S. Benbadis
52
Poster Session 2
8:00 a.m. – 5:00 p.m.
2.203 Examining The Relationship
Between Subjective And Objective
Memory In Patients With Epilepsy/
J. McAuley, N. Passen, C. Prusa,
J. Jih, B. Shneker, S. Hart
2.204 Quality Of Life In A Cohort Of
Men With Epilepsy, Compared With A
UK Control Population And Seven
Chronic Medical Conditions/Y. Leavy,
L. Greenway, D. Ahern, S. Duncan
2.205 Neuropsychological Functioning
In Patients With Psychogenic NonEpileptic Seizures (PNES): Those With
Comorbid PTSD Compared To Those
With No Trauma/L. Myers,
M. E. Lancman, S. Szuster,
K. Lebeau, R. Trobliger,
M. E. Lancman
2.206 Practical Implications Of
Methodological Differences In The
WADA Test Protocols/J. J. Konikkara,
A. B. Frol, M. Agostini, K. Ding,
P. Gupta, R. Hays, P. Van Ness,
P. Modur
2.207 Mood Disorder In Patients
With Multiple Sclerosis And
Epilepsy/K. L. Medin, P. Patel,
N. Mirchandani, L. B. Krupp,
R. Spiegel
2.208 You’re Seeing Right; Right
Hemispheric Language Lateralization
In A Right Handed Patient/D. Eliashiv,
R. Marawar, S. Dewar, M. Polczynska,
C. Benjamin, S. Bookheimer,
B. Moseley
2.209 Use Of The iPad For Assessing
Postoperative Memory Functioning
After Selective WADA/A. Herges,
C. Pearson, I. Stroescu
2.210 Anger Expression And How It
Relates To Mood And Coping
Strategies In Patients With
Epilepsy/K. Lebeau, L. Myers,
M. Evans, J. Politsky, M. Lancman,
M. E. Lancman, M. Fleming
2.211 Adherence To Lacosamide
Among Predominantly AfricanCaribbean Patients With Epilepsy/
L. Nakhutina, S. D. Kunnakkat,
V. Arnedo, C. Lushbough, N. Soni,
A. Grant
Pediatrics
2.212 The Chess Study: A
Population-Based Study Of Behaviour
And Cognition In School-Aged Children
With ‘Active’ Epilepsy/C. Reilly,
P. Atkinson, R. Chin, C. Gillberg,
R. Scott, S. Aylett, B. Neville,
V. Burch, K. Das
2.213 Antiepileptic Drug Exposure
During Breastfeeding And Cognitive
Outcomes At Age 6 Years/K. Meador,
G. Baker, N. Browning, M. Cohen,
R. Bromley, J. Clayton-Smith,
L. Kalayjian, A. Kanner, J. Liporace,
R. May, P. Pennell, M. Privitera,
D. Loring
2.214 Real-Time Effect Of
Centrotemporal Spikes Upon Cognitive
Performance In BECTS/K. Patel,
J. Tenney, K. Hibbard, T. Maloney,
D. Morita, T. Glauser, J. Vannest
2.215 Post-Surgical Cognitive
Prognosis In Children With Epilepsy:
Duration As A Primary Risk Factor/
E. Adams, C. Opperman, J. Doss,
L. Buck, J. Doescher, F. Ritter
2.216 Routine Developmental,
Autism, Behavioral And Psychological
Screening In Epilepsy Care Settings/
S. Eom, B. Fisher, C. Dezort, A. Berg
2.217 Does Duration Of Epilepsy
Impact Self-concept And Knowledge
Of Epilepsy In Children?/D. Terry,
M. Eversole, L. Hamiwka
2.218 Significant Impact Of Past
Trauma On Behavioral Problems And
Quality Of Life In A Hispanic Pediatric
Cohort With Epilepsy/A. Partikian,
E. Florendo, C. J. Lane, S. B. Stewart,
A. Sandoval
2.219 Establishing A Computerized
Tool For Clinical Evaluation Of
Cognitive Function In Children With
New-Onset Epilepsy/M. Asato,
R. Triplett, J. Pardini, D. Magovern,
P. Beem
2.220 Cognitive Outcome Of Temporal
Lobe Resection In Children With
Temporal Lobe Epilepsy/H. Yu, J. Lee,
M. Lee
2.221 Socioeconomic Deprivation Is
An Independent Risk Factor For
Behavioural Problems In Children With
Epilepsy/J. Carson, A. Weir,
A. McLellan, R. Chin
2.222 Effects Of EPA Enriched
Phosphatidylserine-Omega-3 (Vayarin)
On Epileptic Children With Symptoms
Of ADHD/C. N. Nguyen, S. T. Nguyen,
J. M. Chang, R. T. Nguyen,
R. Chudnow, A. R. Riela, G. So,
P. Mireles, V. S. Miller
2.223 Longitudinal Investigation Of
Social Competence And Behavioral
Problems In Children With New-Onset
Epilepsy/D. Almane, Q. Zhao,
P. J. Rathouz, J. Jones, D. Jackson,
D. Hsu, C. Stafstrom, M. Seidenberg,
B. Hermann
2.224 Cognitive Functioning In New
Onset Pediatric Epilepsy: Evidence Of
Decline Within The First Year?/
B. Van Meurs, E. Adams,
C. Opperman, L. Schnabel, F. Ritter
2.225 Intellectual Functioning After
Epilepsy Surgery In A Pediatric
Cohort/M. Thompson, M. Goyal,
T. Cartwright, P. Kankirawatana,
H. Kim, C. Rozzelle, J. Blount
All Ages
2.226 Cognitive Function In Idiopathic
Generalized Epilepsies: A MetaAnalysis/A. Loughman, S. C. Bowden,
W. D’Souza
2.227 Partial Seizures Show Bimodal
Distribution Of Impaired
Consciousness/C. Cunningham,
W. Chen, A. Shorten, M. McClurkin,
T. Choezom, C. Schmidt, V. Chu,
A. Bozik, C. Best, M. Chapman,
M. Furman, K. Detyniecki, J. Giacino,
H. Blumenfeld
2.228 Electrocorticographic Mapping
Of Self And Object Mental
Rotations/M. Cervenka,
A. Korzeniewska, J. Yoke, M. Fifer,
Y. Wang, D. McMullen, G. Milsap,
J. Corines, D. Boatman,
P. Franaszczuk, N. Crone
2.229 Longitudinal Feasibility Testing
Of The Mindset Vers 2.1: A ClinicBased Decision Support System For
Epilepsy Self-Management/C. Begley,
R. Shegog, A. Harding, M. Newmark,
C. Goldsmith, O. Hope
Health Services
Access to Care
2.239 Health Disparities In Access To
Epilepsy Monitoring Unit In Puerto
Rico Based On Health Insurance
System: Private Versus Medicaid/
L. Sanchez, I. Pita
8:00 a.m. – 5:00 p.m.
2.240 Comprehensive Medical And
Surgical Care For Epilepsy Across The
Life Span: A Canadian Strategy/
O. Snead, J. Bowen, T. Valiante,
J. G. Burneo, L. Levin, E. Ferguson,
M. A. Neary, S. Whiting,
R. Ramachandran Nair, F. Wagner,
A. Chambers, R. Goeree
2.241 Improving Access To Care For
Children With Medically Refractory
Epilepsy Through Systems Modeling/
M. Lim, J. Bowen, O. Snead,
R. Goeree, A. Worster, J. Tarride
2.242 Predicting Frequent
Emergency Department Users Among
People With Epilepsy, Via Health
Information Exchange/Z. Grinspan,
J. S. Shapiro, E. L. Abramson,
G. Hooker, L. M. Kern, R. Kaushal
2.243 Are Seizure Patients Avoiding
Us?/L. Kaplan
2.244 Integration Of Medical
Counseling For Epilepsy Patients In
Routine Medical Care/I. S. Klotz
Health Care Models
2.245 Time To Target Event: PreSurgical Versus Non-Surgical
Admissions And Impact On Epilepsy
Monitoring Unit Length Of Stay/
S. Thawani, C. Carlson, O. Agbe-Davies,
P. Sabharwal, T. Berk, D. Gazzola
2.246 Integration Of Genetic
Counseling Services Into The
Comprehensive Epilepsy Center At
Cincinnati Children’s Medical
Center/C. Spaeth, E. King, H. Greiner
2.247 Was Transition Of Care A
Priority For Families Of Adolescents
With Epilepsy Participating In The
Project Cope?/E. Pestana Knight,
J. Timmons Mitchell, R. Butler,
L. Sperry, T. Falcone
2.248 Factors Impacting Epilepsy
Monitoring Unit Length Of Stay/
D. Gazzola, S. Thawani, O. Agbe-Davies,
P. Sabharwal, T. Berk, C. Carlson
In vitro Studies
2.249 Polarized Axonal Surface
Expression Of Neuronal KCNQ
Potassium Channels Is Regulated By
Calmodulin Interaction With KCNQ2
Subunit/J. Cavaretta, K. Sherer,
K. Lee, E. Kim, R. Issema, H. Chung
2.250 Quantitative Analysis Of
Neocortical Architecture In
Refractory Temporal Lobe Epilepsy/
C. Blinston, R. Hammond, M. Goubran,
A. Parrent, J. G. Burneo,
S. De Ribaupierre, D. Steven,
T. Peters, A. Khan
2.251 Delayed Maturation Of
GABAergic Signaling In Hippocampal
And Cortical Neurons In The SCN1B
Null Mouse Model Of Dravet
Syndrome/Y. Yuan, H. A. O’Malley,
P. Mason, C. Chen, L. Isom
Practice Resources
2.252 How Long Is Long Enough? The
Utility Of Prolonged Inpatient Video
EEG Monitoring/B. Moseley, S. Dewar,
Z. Haneef, J. Stern
2.253 Cost Efficacy Of Continuous
Ambulatory EEG Vs Routine EEG In
The Diagnosis Of Epilepsy In
Veterans/J. Pathmanathan,
K. Upchurch, E. Baker, D. McCarthy
2.254 Epilepsy And Driving. Vew Of
Adolescent And Young Adult With
Epilepsy/C. Miziara, V. G. Serrano,
S. L. Gois, D. H. Nakanishi,
M. G. Manreza
2.255 Usefulness Of Emergent
Electro-Encephalogram In Known
Epileptic Patients/M. Chochoi,
M. Girot, X. Lenne, P. Williate,
S. Leblanc, P. Derambure, L. Tyvaert
2.256 Patient’s Perspective On
Disclosure Of Sudden Unexpected
Death In Epilepsy: A Pilot Study/
F. Pascual, A. Hakimi, Y. Ng
2.257 Transitions In Care: Improving
The Hospital Discharge Process For
Epilepsy Patients/K. Secore, T. Caller,
R. Rosenbaum, J. Kleen, J. Kaspar,
J. Harrington, B. Jobst
2.258 Utilization Of IVS In The
Pediatric Epilepsy Monitoring Unit/
E. Fecske, A. Abdelmoity
Epidemiology
2.259 Prevalence And Societal
Impact Of Epilepsy In Rwanda: Results
Of A Cross-Sectional Survey/F. Sebera,
B. Uwacu, N. Munyandamutsa,
J. Gatali, D. Teuwen, I. Ndiaye,
A. Gallo, P. Dedeken
2.260 Seizures And Outcomes Study
In Children (SOS-Kids): Rationale,
Design And Impact/S. Shih, B. Kroner,
M. A. Ardini, S. Cushner Weinstein,
J. Salpekar, D. C. Hesdorffer,
K. Havens, T. Zelleke, D. Cabacar,
W. Gaillard
2.261 Emergency Department
Utilization For Known Epileptic
Patients/L. Tyvaert, M. Girot,
S. Leblanc, P. Williate, X. Lenne,
H. Hubert, P. Goldstein, E. Wiel,
M. Chochoi, P. Derambure
2.262 Epilepsy Prevalence, Incidence
And Socioeconomic Deprivation In
Wales, UK/W. Pickrell, A. S. Lacey,
R. Thomas, P. Smith, R. A. Lyons,
M. Rees, M. Kerr
2.263 Epilepsy In The Veteran Health
Administration: Demographics And
Disease Frequencies/T. Tran,
R. Rehman, P. Kelly, A. Husain
2.264 Early Onset Epilepsy: Then &
Now/S. Khan, J. Millichap, D. Nordli,
A. Berg
2.265 Generalized Convulsive Status
Epilepticus In Patients With Traumatic
Brain Injury: A United States
Population-based Study/M. Dhakar,
S. Sivakumar, A. Shah, M. Basha
2.266 The Best Tool To Screen For
Depression In Persons With
Epilepsy/K. Fiest, S. Patten,
A. G. Bulloch, S. Wiebe, N. Jette
2.267 Longitudinal Course Of Epilepsy
In Rett Syndrome/D. C. Tarquinio,
W. Kaufmann, J. B. Lane,
S. A. Skinner, K. J. Motil, J. L. Neul,
A. K. Percy, D. G. Glaze
SUNDAY
Delivery of Care
2.230 Healthcare Utilization Among
Patients With Uncontrolled Epilepsy:
A Retrospective Study In A
Commercially-Insured U.S.
Population/M. Malmenas, V. Bollu,
T. Pattipaka, F. Velez
2.231 Risk Factors For Emergency
Department Visits And/Or Unplanned
Hospitalization For Children With
Epilepsy/A. Patel
2.232 Epilepsy/Seizure Burden In The
ED – A Retrospective Analysis In The
UNMH Emergency Department/
G. Lakshminarayan, B. Fisch
2.233 Initial Evaluation By Primary
Care Providers Referring Children To A
Pediatric Epilepsy Center/C. T. Tran,
S. N. Dalal, M. D. Pernell, S. Arnold
2.234 Admission To A Seizure
Monitoring Unit Is Associated With A
Decrease In Utilization Of HospitalBased Care In A Large Health
Region/M. Lowerison, N. Jette,
K. Sauro, S. Macrodimitris, S. Dean,
C. DeCoster, A. Leszczynski, S. Wiebe
2.235 Does Nursing Training Improve
The Management Of Generalized TonicClonic Seizures In The Epilepsy
Monitoring Unit?/K. Sauro,
H. Dhaliwal, M. Suddes, F. Abdulla,
S. Wiebe, C. Krassman,
S. Macrodimitris, P. Federico,
N. Pillay, W. Murphy, Y. Agha-Khani,
N. Jette
2.236 Evaluating Caregiver
Satisfaction After First Visit To A
Pediatric Epilepsy Center/S. N. Dalal,
C. T. Tran, E. A. Burch, S. Arnold
2.237 Implementation Of A Spells
Workup, Assessment, And Treatment
Team For Nonepileptic Spells/
C. Shunney, A. De Marco, L. Thomas
2.238 PNEE-related Falls In The EMU
Occur More Often At Night:
Implications For Safety Monitoring/
E. Acton, A. Krause, A. Thaler,
C. Anderson, J. Pollard
Poster Session 2
53
2.268 An Evaluation Of The
Association Between An FDA
Suicidality Warning And Antiepileptic
Drug Prescription Claims In A State
Medicaid Program/Y. Ng, M. Mittal,
D. Harrison, M. J. Miller,
K. C. Farmer, D. M. Thompson
2.269 Validation Of An Epilepsy
Specific Risk Adjustment Index For
Mortality Research/J. Roberts,
M. Liu, C. Smith, H. Quan, S. Wiebe,
N. Jette
2.270 Traumatic Brain Injury In
Patients With Generalized Convulsive
Status Epilepticus: A United States
Population-Based Study/S. Sivakumar,
M. Dhakar, M. Basha, A. Shah
2.271 Clinical Characteristics Of
Patients With Epilepsy In Korea; A
Nationwide Epidemiologic Study/
D. Kim
2.272 Acute Traumatic Brain Injury In
Persons With Epilepsy And Seizure
Disorders/D. A. Wilson, A. W. Selassie
2.273 Validation Of An Algorithm For
The Identification Of Epilepsy Patients
In The Veterans Health Administration
(VHA)/R. Rehman, A. Everhart,
A. Figueroa-Garcia, A. Frontera,
D. Riley, D. Schooff, M. Lopez
2.274 Incidence Of Seizures In ICUEEG Monitoring May Be Higher Than
Previously Thought: Effect Of Using
Kaplan-Meier Estimator/L. Olson,
C. McCracken, A. Vats
2.275 Long-Term Cohort Studies:
Keeping In Touch Over The Years/
C. Rios, C. Hurst, M. Consolatore,
A. Berg
2.276 Quality Of Life In Children With
Epilepsy: Development And
Assessment Of A Shorter Version Of
The Quality Of Life In Childhood
Epilepsy Questionnaire (QOLCE)/
S. Goodwin, A. Lambrinos, M. Ferro,
K. Speechley
2.277 Low Prevalence Of Mesial
Temporal Lobe Epilepsy May Account
For Decline In Temporal Lobectomy/
H. H. Afeefy, U. Uysal, N. Fountain
2.278 Validating A Natural Language
Processing Tool To Exclude
Psychogenic Non-Epileptic Seizures In
Electronic Medical Record Based
Epilepsy Research/H. Hamid,
S. Fodeh, G. A. Lizama, R. Czlapinski,
M. Pugh, W. LaFrance, C. Brandt
2.279 A Unique Partnership For
Research In Epilepsy Outcomes: The
Emory University And UCB
Collaboration/S. Helmers, F. Cox,
D. Thurman, R. Faught, A. Patel,
T. Durgin, P. Fritz, K. Simontacchi,
L. Waller, H. Superak
2.280 Prevalence Of Prone Body
Position In Patients With SUDEP/
J. Liebenthal, J. Tao
54
Poster Session 2
8:00 a.m. – 5:00 p.m.
Public Health
2.281 Population Health Management
(PHM) For Refractory Epilepsy And
Psychiatric Co-Morbidities: Deploying
A PHM Delivery Model For Amplifying
Patient Outreach/M. Rossi, D. Ehrens,
N. Monica
2.282 The Effectiveness Of Visiting
Epilepsy Clinics: A Caribbean
Experience/D. Clarke, A. Ali,
K. A. Bramble-Browne, K. W. Moon,
S. M. LeSure, N. Dick, J. Bird
2.283 Caregiver Burden In Epilepsy:
Determinants And Impact/I. Karakis,
A. J. Cole, G. D. Montouris,
M. San Luciano, K. J. Meador,
C. Piperidou
2.284 Treatment Gap In Epilepsy:
New Insight From Analysis Of
Diagnosis Gap/L. M. Li, C. M. Genari
2.285 Alignment Of Self-management
Support Between Adults With
Epilepsy And Their Primary Support
Persons/E. Walker, G. Engelhard,
N. Thompson
2.286 A Survey Of Exercise In People
With Epilepsy/R. Sharon, A. Neils,
J. Cohen
2.287 Pressure Ulcers With EEG
Electrodes In A Pediatric Epilepsy
Monitoring Unit/T. Long-Henson,
R. O’Leary
2.288 A Comparison Of Facebook
Pages Related To Epilepsy And Breast
Cancer/G. Ghearing
2.289 Does Knowledge About
Epilepsy Reduce Depression, Anxiety,
And Stigma In Adolescents With
Epilepsy?/H. Ryu, B. Kim, H. Kim,
S. Eom, S. Lee
Case Studies
2.290 Towards Long-Term Home
Monitoring Of Epileptic Children/
M. Milosevic, A. Van de Vel,
K. Cuppens, B. Bonroy, B. Ceulemans,
L. Lagae, B. Vanrumste, S. Van Huffel
2.291 Different Localizations
Underlying Neocortical Gelastic
Epilepsy/Y. T. Tran, M. Wilk, T. Tayah,
A. Bouthillier, I. Mohamed, D. Nguyen
2.292 Primary Sleep Disorders:
Presentation And Diagnosis In An
Epilepsy Monitoring Unit/A. Sanchez,
A. Kabir, A. Krumholz
2.293 Cryptogenic Phantosmia And
Treatment Response With
Lamotrigine – A Case Series/S. Ye,
D. Friedman
2.294 An Atypical Presentation Of
BECTS/I. Hughes, D. Ghoneim,
E. Tuttle, A. Paciorkowski
2.295 Ictal SPECT Activation In A
Case Of Gelastic Seizures Caused By
A Low Grade Glioma In The
Posteriolateral Temporal Lobe/
M. Boudreau, P. Li, R. Miletich, V. Li,
A. Weinstock
2.296 Electroclinical Presentations
Of Cingulate Epilepsies/X. Wang,
A. Papanastassiou, J. Caron,
K. Karkar, L. Leary, O. Lie, L. Morgan,
C. Szabo
2.297 Right Hemispheric Ictal
Asystole – Report Of Two Cases/
J. Chu, S. Majmudar, D. Chen
2.298 Hippocampal Malrotation And
Its Relation To Temporal Lobe Epilepsy:
A Series Of 11 Patients/I. Escudero,
C. Arenas Cabrera, P. Martinez Agredano,
L. Mauri Fábregas
2.299 Seizure Alert Dog As An
Effective ‘Seizure Detection Device’ In
Refractory-Symptomatic Localization
Related Epilepsy: A Case Report/
P. D. Lyons, M. F. Bodamer,
E. J. Lyons, L. P. Harry
2.300 Ictal Asystole In Patients
Undergoing Video-EEG Monitoring/
A. Herlopian, J. Greenfield,
B. Shihabuddin
2.301 Seizure-Induced Cerebral
Edema Mimicking Ischemic Stroke/
T. Yang, O. Kwon
2.302 Facio-Brachio-Crural Dystonic
Seizures As The First Manifestation
Of Limbic Encephalitis/R. Gandhi,
C. Garcia Gracia, A. Rodriguez,
C. Malpe
2.303 Successful Epilepsy Surgery In
A Child With ‘Forme Fruste’ Aicardi
Syndrome – Infantile Spasms With
Unilateral Ocular And Cerebral
Involvement/S. Malone, S. Calvert,
G. Gole, M. Gabbett, M. Wood
2.304 Relapsing Anti-NMDAR NonParaneoplastic Encephalitis/P. Breia,
P. Pereira, N. Ferreira, C. Guarda
2.305 Child-To-Parent Violence: Two
Cases Of V-EEG Confirmed PNES
Associated With Hidden Abuse/
J. Bortz, K. Noe, J. Sirven,
J. Drazkowski, M. Hoerth
2.306 Co-Existence Of Coenzyme
Q10 Deficiency And A MCM4
Mutation: Report Of A Second Case
And Review Of The Literature/K. Ng,
M. Mikati, D. Koeberl, M. McDonald,
E. Arehart
2.307 The Etiologic Role Of
Neurocysticercosis In Drug-Resistant
Epilepsy: A Systematic Review/
A. Escalaya, M. Villafuerte Espinoza,
G. Singh, J. G. Burneo
2.308 Unusual EEG-presentation Of
Epileptic Nystagmus/C. Stephani,
J. Park
2.309 Tumors Of Tuberous Sclerosis
Complex A Challenge That Requires
New Therapies?/E. Victoria Costa
Caetano, P. Cerqueira, M. G. Manreza,
E. Garzon, J. Andrade, U. C. Reed
2.310 Seizure Prodromes With
Associated EEG Changes In Focal And
Generalized Epilepsy/A. Crepeau,
J. Britton, B. Westmoreland
2.311 Vagus Nerve Stimulator In A
Patient With Lennox-Gastaut
Syndrome – Four Year Follow Up/
I. D’Andrea-Meira, A. Baltar,
M. Souza, V. Pereira, S. Alves-Leon
2.312 Unusual Case Of Diencpehalic
Autonomic Seizure In A Patient With
Leukemia: A Case Report And Review
Of The Literature/A. M. Feyissa,
S. Tummala
• AES 67TH ANNUAL MEETING Washington, D.C. •
MONDAY December 9, 2013
www.AESnet.org
7:00 a.m. – 8:30 a.m.
Ketogenic Diet: Supplements and Alternatives
Coordinators: Elizabeth A. Thiele, M.D., Ph.D., Susan A. Masino, Ph.D.,
Christina Bergqvist, M.D.
Speakers: Richard L. Veech M.D., Ph.D., Dominic D’Agostino Ph.D.,
Robin S. B. Williams Ph.D., Karin Borges, Ph.D.
Coordinator: Peter Crino, M.D., Ph.D.
Speakers: Peter Crino, M.D., Ph.D., Darcy A. Krueger, M.D., Ph.D.,
Tanjala Gipson, M.D.
The SIG would cover the current indications for mTOR inhibitor therapy, how
to start sirolimus / everolimus (dose), what to follow (labs, EEG), potential
risks and serious adverse events (SAE), what to do in the setting of SAEs,
dealing with insurance and cost issues, when to stop therapy, and special
cases and clinical scenarios (renal failure, organ transplant, cancer history,
prenatal use, interactions with AEDs). The SIG would end with a panel
discussion of specific cases or uses, comparing sirolimus versus everolimus,
and then an information sheet that can be emailed to all SIG participants that
ask for it.
8:45 a.m. – Noon
Merritt-Putnam Symposium: Future
Therapies: How We Will Be Treating,
Preventing and Curing Epilepsy in the Year
2025
(3.0 CME Credits)
Presentation: René Levy, Ph.D., William G. Lennox Award
Overview
Please join our SIG for a spirited discussion about the role mechanisms of
action play in determining efficacy, side effects, and developing new agents
for the treatment of epilepsy. Each speaker will provide a short presentation
and audience members are encouraged to engage in the discussion. Time will
also be allocated for addressing SIG business and networking.
Multiple strategies are being forwarded for prevention and treatment of
epilepsy, some of which raise the possibility of providing an eventual cure for
the disorder. Signaling pathways and inflammatory processes offer promising
targets for novel treatment strategies, some of which use existing
medications. As stem cell research progresses, cell replacement therapy is
considered a potential option to replace lost or dysfunctional neurons in the
epileptic brain. Optogenetics may provide unique strategies for potential
treatment of brain diseases, particularly epilepsy. Seizure detection and
prediction devices suggest possible non-medication-related approaches for
treatment of epilepsy. This symposium will review these topics and provide
insight into emerging treatment options.
Supported by Sunovion Pharmaceuticals, Inc.
Learning Objectives
Posttraumatic Epilepsy – NEW
u
Utilize novel therapies for treatment of patients with difficult to control
epilepsy with resulting improved seizure control
u
Assess patients for inflammatory processes which are causing
uncontrolled seizures and treat with anti-inflammatory and immune
therapies when appropriate.
Neuropharmacology: Clinical Relevance of Mechanisms
of Action
Coordinators: Jeannine Conway, Pharm.D., Scott Mintzer, M.D.
Speakers: Nathan Fountain, M.D., Mikiko Yamada, Pharm.D., John Kehne, Ph.D.
Coordinators: Enrique A. Feoli, M.D., Joseph Drazkowski, M.D.
Speakers: Asla Pitkanen, M.D., Joseph Drazkowski, M.D., Enrique A. Feoli, M.D.
The primary point of this SIG is to bring together specialists who care for
patients with TBI and PTE and in so doing to improve our understanding of the
underlying causes and our approach to the care of these patients. Multiple
questions about TBI and PTE remain unanswered and deserve coordinated
focus and discussion, including but not limited to antiseizure drug prophylaxis,
the value of electroencephalography, novel treatments in the acute setting
such as hypothermia, epileptogenicity of various forms of TBI, prevalence and
impact of early seizures and status epilepticus, interplay between AEDs,
seizures, and cognitive function. Topics will include the following discussion
points: a. Consensus on AED prophylaxis and benefit of early (first week) AED
therapy; b. Prevalence of status epilepticus and utility of continuous EEG in
early TBI; c. Existing animal models of PTE; and d. Case presentations
MONDAY
The 2013 Ketogenic Diet Special Interest Group (KD-SIG) will focus on
supplements and alternatives to ketogenic diet therapy. There has been
intense interest in supplements that might make a dietary approach more
effective or more palatable, and in alternatives which may avert the need for
an extremely strict diet. This year’s session will feature four speakers who are
focusing on ketone esters and alternative oils (triheptanoin and medium chain
triglyceride [MCT] variants): Richard L. Veech, National Institutes of Health,
Dominic D’Agostino, University of South Florida, Robin S. B. Williams, Royal
Holloway, University of London, and Karin Borges, University of Queensland.
Each speaker will offer a short 10-12 minute talk to briefly outline basic
science of mechanisms and metabolism, the potential use for epilepsy with or
without dietary treatments, and any data on current clinical use (unrelated to
epilepsy), as appropriate. After the presentations, there will be ample time to
discuss what further basic science knowledge and potential clinical trials are
needed to establish effectiveness and bring these compounds to patients and
for questions and answers. With attendees representing all the major centers
worldwide, the KD-SIG has the potential to become a launching board for a
multicenter trial and collaborative laboratory work.
Tuberous Sclerosis: Utility and Application of mTOR
Inhibitors in Tuberous Sclerosis Complex: How and When to
Start Treatment
Target Audience
Program
Chair: Amy Brooks-Kayal, M.D.
9:00 a.m.
Introduction
9:15 a.m.
Cell Signaling Modulators as Novel Disease Modifying
Therapies
Anne Anderson, M.D.
55
9:45 a.m.
Anti-Inflammatory Therapy
Annamaria Vezzani, Ph.D.
10:15 a.m. Cellular Therapies
Scott C. Baraban, Ph.D.
10:45 a.m. Optogenetic Therapy
Ivan Soltesz, Ph.D.
11:15 a.m. Seizure Detection / Prediction Devices and Therapies
Gregory A. Worrell, M.D., Ph.D.
Credit Designation
Nursing Credit
Pharmacy Credit
Core Competencies: Medical Knowledge and System-Based Practice
9:00 a.m. – 10:30 a.m.
EEG: What’s a Hell Conductor in Thalamus?
Coordinator: Hiroshi Otsubo, M.D.
Speakers: O. Carter Snead, M.D., Pete Halasz, Hiroshi Otsubo, M.D.
We focus on the role of thalamus in epilepsy. Epileptic discharges of
continuous spike and wave during sleep and 3 Hz spike and waves in children
are well known as abnormal discharges with thalamo-cortical epileptic
network. Sleep spindles and awake alpha rhythm are also thalamo-cortical
functional network. We discuss these EEG and clinical findings of abnormal
and normal thalmo-cortical network to explore the mechanism of thalamus in
conducting cortex in epilepsy.
Junior Investigators Workshop: Finding and Starting Your
First Academic Job
Coordinator: William Stacey, M.D., Ph.D.
Speakers: Brian Litt, M.D., John Huguenard, Ph.D., John Greenfield, M.D., Ph.D.
Making the leap into your first faculty position is a daunting task, but there are
many opportunities available. Our panel, composed of both senior and
recently-hired faculty, will discuss how to approach this process, from initial
contact to negotiating a contract to getting started once you are there. This
informal discussion will allow junior investigators to ask questions and get
advice about finding and starting your first job. In addition, a list of current
academic job openings will be available for all attendees.
Neonatal Seizures: Do Neonatal Seizures Harm the Brain?
Coordinators: Adam Hartman, M.D., Renee Shellhass, M.D.
Speakers: Maria Roberta Cilio, M.D., Ph.D., Carl Stafstrom, M.D., Ph.D.
For 2013 we are modifying the format a bit to make this SIG even more
interactive. In addition to our traditional debate, we are including a “data blitz”
segment. The organizers will select several of the best neonatal seizurerelated abstracts accepted for presentation at AES. The authors of these
papers will be invited to briefly present their work and respond to questions
from the audience. Following the data blitz, we will again employ a debate
format, highlighting the question “Do neonatal seizures harm the brain?” Our
debaters, Dr. Roberta Cilio (UCSF) and Dr. Carl Stafstrom (University of
Wisconsin, Madison), are both known for their eloquence and rational
approaches to the literature. We anticipate this thought-provoking debate will
engender spirited discussion from the audience!
Neuropsychology: Epilepsy and the Aging Brain —
Neuropsychological Perspectives
Coordinator: Philip Fastenau, Ph.D.
Speakers: Gail L. Risse, Ph.D., Marilyn Jones-Gotman, Ph.D.,
Michael Seidenberg, Ph.D.
Three renowned neuropsychologists will present recent and emerging data
examining changes in cognitive functioning, psychiatric comorbidities, and
brain imaging associated with aging in people with epilepsy. Dr. Gail L. Risse
will introduce the topic with a brief review of the latest research on
neuroanatomic and cognitive changes in the brain during normal aging and
will consider how these changes may be affected by chronic seizures,
epilepsy surgery and the longitudinal effects of AEDs. Dr. Marilyn JonesGotman will share preliminary data from her longitudinal study comparing
people with temporal lobe epilepsy (TLE) who had undergone surgical
management of their seizures, a comparison group of people with chronic TLE
who had not undergone surgery, and a control group of healthy adults who
were matched to the patients on age and years of education. They
investigated whether cognitive changes with aging are greater after surgery
versus long-term medical management alone versus normal aging.
Dr. Michael Seidenberg will summarize a series of studies from his group,
including a four-year longitudinal study that examined MRI volumetrics,
cognition, and psychiatric status in adults with TLE compared to healthy
individuals. This collection of presentations will summarize what is known, set
the stage for discussion with the audience about implications for patient
education, assessment, and management and will highlight the gaps in
knowledge to direct future research with our aging epilepsy populations.
Nursing: Highlighting Current Research
Coordinators: Madona D. Plueger, APRN, ANCS-BC,
Georgette Smith, M.S.N., APRN, CPNP
Speakers: TBA
The 2013 Nursing SIG will highlight nursing awardee poster presentations. We
continue to choose this approach for the third year to provide further
opportunities for nurses to share current quality improvement and research
projects with one another. This forum fosters the development of ongoing
nursing participation and collaboration in the field of epilepsy. The experience
provides the nurses and participants more time to discuss posters than time
allotted in the conference hall. In addition, a discussion on education and
competency will be led by the moderator.
2:15 p.m. – 3:00 p.m.
Lennox and Lombroso Lecture:
Psychiatric Comorbidities Through "The Life"
of The Seizure Disorder: A Complex Story
With a Not So Complex Solution
Lecturer: Andres M. Kanner, M.D.
Tribute to Cesare T. Lombroso, M.D., Ph.D.
56
3:45 p.m. – 5:15 p.m.
Investigators’ Workshop
Antiepileptic Drug and Device Development — What
Does the Future Hold?
Moderators: H. Steve White, Ph.D., Nicholas Poolos, M.D., Ph.D.
Speakers: Henrik Klitgaard, Ph.D., Martha Morrell, M.D.,
Stephen Collins, M.D., Ph.D.
3:45 p.m. – 5:15 p.m.
MEG Navigates to Neurosurgeons: A Trajectory of Success
Coordinator: Anto Bagić, M.D., Ph.D.
Speakers: Andreas Alexopoulos, M.D., M.P.H., Stefan Rampp, M.D.,
Jorge Gonzalez Martinez, M.D., Ph.D.
Military Epileptologists: VA Telehealth Initiative and How It
May Relate to Epilepsy Care, Sleep Medicine / Epilepsy
Comorbidility, and Epilepsy Care in the Elderly
Coordinators: Jonathan Halford, M.D., Hamada Hamid, M.D.
Speakers: Martin Salinsky, M.D., Glen Graham,
William Curt LaFrance, Jr., M.D., M.P.H., Stephanie Chen
The VA Healthcare System has traditionally served as a leader in healthcare
service technology and innovation. In the last three years, the VA Epilepsy
Centers of Excellence (ECOE) has incorporated and developed video telehealth
services across several regions. Unique services developed by the VA include:
Specialty Care Access Network-Extension for Community Healthcare
Outcomes (SCAN-ECHO), in which epilepsy specialists provide video
conferencing consultation to general neurologists as well as primary care
providers within the VA system; Tele-Cognitive Behavioral Therapy for
Psychogenic Nonepileptic Seizures, in which neuropsychiatrists provide direct
treatment for patients with PNES across centers; Tele-Home Seizure Clinic, in
which patients who have difficulty reaching VA clinics may video conference
with clinicians from their homes; and Tele-Electroencephalograph services, in
which VA neurologists access and interpret EEG data remotely. This panel will
provide an overview of existing and emerging clinical video telehealth
technologies offered by the ECOE and describe how to access and establish
these services.
Coordinator: Markus Reuber, M.D., Ph.D., FRC(P)
Speakers: Matthias J. Koepp, M.D., Ph.D., W. Curt LaFrance, Jr., M.D.,
M.P.H., Laura H. Goldstein, Ph.D., M.Phil., Markus Reuber, M.D., Ph.D., FRC(P)
This SIG will focus on two topics related to (Psychogenic) Nonepileptic
Seizures (NES).
1) Brain imaging studies of nonepileptic seizures. The last two decades have
seen remarkable progress in the development of structural and functional
brain imaging technology. Methods such as automated morphometric analysis
of magnetic resonance imaging (MRI) data, functional MRI and resting state
fMRI have provided important clues about the etiology of conditions which
were previously thought “idiopathic,” “medically unexplained” or
“psychogenic.” Professor Matthias Koepp will summarize the state of
knowledge with respect to NES. He will take account of cohort studies
describing MRI abnormalities in patients with NES and more recent work
using structural MRI and resting state fMRI analyses to move forward our
understanding of nonepileptic seizure disorders (as well as the limitations of
these studies). He will also look at imaging studies conducted in disorders
which overlap clinically with NES such as posttraumatic stress, conversion
and personality disorders, to demonstrate the potential of imaging technology
in the unraveling of previously mysterious conditions.
2) Treatment of nonepileptic seizures. While we are still waiting for Class 1
evidence of the effectiveness of treatments for NES, significant progress has
been made with the development of a number of different psychotherapies for
NES. In this part of the SIG a number of experienced therapists working in
different settings and in different countries will demonstrate how they
approach a typical case and how their own therapeutic approach would work
in practice. Having outlined their therapeutic approaches, the experts will
discuss treatment options for cases brought along by members of the
audience.
Surgical Failures: Non-Lesional Epilepsy Surgery
Coordinators: Saadi Ghatan, M.D., Gerald Grant, M.D.
Speakers: TBA
Participants are asked to present cases of surgical failure, where there was
no recognizable MRI abnormality. Speakers will be recruited over the course
of the year by the SIG coordinators, in response to earlier criticisms regarding
case selection.
MONDAY
Clinical MEG has evolved dramatically from its beginnings as an exotic
research tool to a practical workhorse for epilepsy localization and for
mapping of functional areas. Practice guidelines have been developed by
ACMEGS, then endorsed and published by ACNS. Nevertheless, there is still
diversity in the way that MEG is interpreted and reported, as well as variability
among neurosurgeons in the way that they perceive and use the results of
these reports. And the effect on patient care of even the most polished report
will not be maximized unless properly integrated into the surgical planning.
The speakers in this Special Interest Group will address the continuum of MEG
care from optimal indications through clinically informative and technologically
versatile reporting to advanced incorporation into preoperative planning and
neuronavigation. This dynamic exchange between medical and surgical
specialties is expected to help clarify the best possible use of MEG in the care
of epilepsy patients.
Psychogenic Nonepileptic Seizures
3:45 p.m. – 6:00 p.m.
Pediatric Epilepsy Highlights Session
Note: Number below refers to poster assignment
This session will showcase selected scientific abstracts focused on topics in
clinical care and research in pediatric epilepsy. Authors will present a six-minute
overview of their work. Presentations are chosen from all submitted abstracts.
Participants will be able to view posters and meet the authors at the end of the
program.
1.112 Resection Of Cortex With Interictal Fast Ripples Correlating With
Seizure Outcome In Patients With Wide-Spread Epileptic Networks In
Tuberous Sclerosis Complex/Tohru Okanishi
1.252 Outcomes And Safety Profile Of Stereotactic Laser Ablation For
Treatment-Resistant Epilepsy In The Pediatric Population/Angus Wilfong
1.292 KCNT1 Mutations In A National Cohort Of Children With Migrating
Partial Seizures Of Infancy/Amy McTague
2.006 Improving Transition To Adult Epilepsy Care: Facilitating Team
Communication Using Clinical Decision Support In The EMR/
Jennifer Disabato
57
2.007 Improving Mental Health Services For Children And Youth With
Epilepsy: Practical Solutions From Project Access/Paul Levisohn
Learning Objectives
u
2.076 Success Of Postoperative Anti-Epileptic Medication Reduction in
Children Following Surgery For Intractable Epilepsy/Katherine Nickels
Recognize the right test for the right patient and to better interpret and
use the resulting findings
u
2.077 Predictors Of Outcome In A Large Cohort Of Infantile Spasms Of
Unknown Cause/Maura Madou
Present the different methods and resources available for genetic testing
and illustrate how to use them.
Target Audience
2.112 Working Memory Mediates The Association Among The
Comorbidities Of Pediatric Epilepsy/Rochelle Caplan
Program
2.189 Psychiatric Functioning In Pediatric Patients Pre- And Post-Epilepsy
Surgery/Julia Doss
Chair: Mohamad Mikati, M.D.
6:15 p.m.
2.251 Delayed Maturation Of GABAergic Signaling In Hippocampal And
Cortical Neurons In The Scn1b Null Mouse Model Of Dravet
Syndrome/Yukun Yuan
Introduction
Mohamad Mikati, M.D.
6:30 p.m.
Recent Discoveries of Epilepsy Related Genes: A
Preview of the Future
Erin Heinzen, Pharm.D., Ph.D.
3:45 p.m. – 6:00 p.m.
7:00 p.m.
Clinical Phenotypes of Mutations Causing Catastrophic
Epilepsies in Infancy
Ingrid E. Scheffer, M.B.B.S., Ph.D.
7:30 p.m.
Typical and Atypical Epilepsy Phenotypes of Amenably
Treatable Epilepsies: Therapeutic Implications
8:00 p.m.
Pediatric State of the Art Symposium:
Genetics of Catastrophic Infantile Epilepsies:
From Gene Discovery to Practical Clinical
Applications
Gene, Panel, Exome or Genome Sequencing for Infants
with Epileptic Encephalopathies? How Do We Diagnose,
and How Do We Interpret?
Heather C. Mefford, M.D., Ph.D.
8:30 p.m.
Conclusions
(2.5 CME Credits)
Credit Designation
Platform Sessions: 3 Concurrent Sessions
See page 59 for locations
There will be three concurrent sessions consisting of selected key scientific
abstracts. Authors will present a 10-minute overview of their work followed
by a five-minute Q & A.
6:15 p.m. – 8:45 p.m.
Overview
Recent years have witnessed an explosion of knowledge about genetic
causes of catastrophic epilepsy syndromes that were previously considered
symptomatic of unknown etiology or simply cryptogenic. These discoveries
are providing insights into the underlying pathophysiology of these epileptic
syndromes and are providing novel opportunities for better diagnosis,
prognostication, genetic counseling and even therapies. There is, thus, an
increasingly apparent gap in our knowledge of the full range of recent
discoveries, their clinical correlates, when and how to test for the underlying
genetic etiologies, how to interpret the results of the genetic testing and how
to use these results to prognosticate and to treat.
This symposium aims to address the above gaps in our knowledge and to
achieve the following goals: 1) Review the recent discoveries of genes that
result in catastrophic infantile epilepsies and of the increasingly powerful
methods and strategies used to make these discoveries and that will shape
discoveries of the future. 2) Define the clinical and radiological manifestations
of genetic mutations that could cause catastrophic epilepsy syndromes
whether or not associated with brain malformations. Describe clinical and
radiological clues that should lead to the suspicion of certain malformation
syndromes or of syndromes without associated brain malformation that would
have otherwise been considered “cryptogenic”. 3) Describe the expanding
range of EEG and seizure semiology presentations of genetic-metabolic
vitamin and diet responsive syndromes emphasizing the sometimes atypical
features that should raise the suspicion of these amenably treatable entities.
4) Present the currently available resources for clinical genetic testing ranging
from specific gene sequencing to whole exome sequencing and analyze their
use and discuss their utility in the clinical situations of infantile epileptic
encephalopathies.
58
Nursing Credit
Pharmacy Credit
Core Competencies: Medical Knowledge, System-Based Practice, PracticeBased Learning and Comprehensive Patient Care
Acknowledgment
This program is supported by educational grants from Questcor
Pharmaceuticals, Inc. and Lundbeck Pharmacueticals, Inc.
Monday December 9, 2013
A. Diagnosis / Biomarkers
Platform Sessions
3:45 p.m. - 6:00 p.m.
B. Treatment
C. Translational
Moderators: Orrin Devinsky, M.D.,
Sandra Helmers, M.D.
Moderators: Andres Kanner, M.D.,
Mohamad Koubeissi, M.D.
Moderators: Steve Danzer, Ph.D.,
Susan Masino, Ph.D.
B.01 Anesthetic Drugs In Status Epilepticus In The
ICU – Risk Or Rescue? Results From A Six-Year Cohort
Study/P. Kaplan, R. Sutter, S. Marsch, P. Fuhr,
S. Ruegg
C.01 Diazepam Binding Inhibitor Knockout Mice
Display Increased Absence Seizures And Loss Of
Thalamic Endozepine Signaling/C. Christian,
J. Huguenard
4:00 p.m. A.02 Lateralization Of Temporal Lobe Epilepsy
With Long-Term Ambulatory Intracranial Monitoring
Using The RNS™ System: Experience In 82
Patients/D. King-Stephens, E. Mirro, P. Weber, K.
Laxer, P. Van Ness, V. Salanova, D. Spencer, C.
Heck, A. Goldman, B. Jobst, W. Shields, G. Bergey,
S. Eisenschenk, G. Worrell, M. Rossi, R. Gross, A.
Cole, M. Sperling, D. Nair, R. Gwinn, Y. Park, P.
Rutecki, N. Fountain, R. Wharen, L. Hirsch, I.
Miller, G. Barkley, J. Edwards, E. Geller, M. Berg,
T. Sadler, F. Sun, M. Morrell
B.02 Management Of Pediatric Refractory
Convulsive Status Epilepticus In Clinical Practice.
Pediatric Status Epilepticus Research Group
(pSERG)/T. Loddenkemper, N. Abend, S. Agadi, S. An,
R. Arya, J. Carpenter, K. Chapman, W. Gaillard,
T. Glauser, H. Goodkin, M. Mikati, K. Peariso,
M. Ream, I. Sánchez Fernández, R. Tasker, pSERG
C.02 Heart Rate Variability Analysis Reveals Altered
Autonomic Tone In A Mouse Model Of Dravet
Syndrome/D. S. Auerbach, B. C. Clawson, I. Ogiwara,
K. Yamakawa, M. Meisler, J. Parent, L. Isom
4:15 p.m. A.03 Identification Of High Frequency
B.03 Electrographic Seizures Following Convulsive
Status Epilepticus In Children. A Retrospective
Multicenter Study Of The Pediatric Critical Care
Electroencephalogram Group (PCCEG)/N. Abend,
I. Sánchez Fernández, D. Arndt, J. Carpenter,
K. Chapman, K. Cornett, D. Dlugos, W. Gallentine,
C. Giza, J. Goldstein, C. Hahn, J. Lerner,
T. Loddenkemper, J. Matsumoto, K. McBain,
K. Nash, E. Payne, S. Sanchez, K. Williams
B.04 Folic Acid Use By Women With Epilepsy: Interim
Analysis Of The Epilepsy Birth Control Registry/
A. Herzog, H. B. Mandle, K. E. Cahill, K. M. Fowler,
A. R. Davis, W. A. Hauser
C.03 Generalized Periodic Discharges After Acute
Cerebral Ischemia: Reflection Of Selective Synaptic
Failure?/M. Cloostermans, R. Hindriks, J. Hofmeijer,
M. J. van Putten
3:45 p.m. A.01 Voxel-Based Morphometric MRI Post-
Processing In “Nonlesional” Pharmacoresistant
Focal Epilepsies/Z. Wang, S. E. Jones, Z. Jaisani,
A. Murugesan, A. Ristic, C. Wong, B. Krishnan,
R. Burgess, J. Mosher, I. Najm, A. Alexopoulos
selected for the Fritz Dreifuss Award
Oscillations During Intraoperative
Electrocorticography In Patients With Temporal
Lobe Epilepsy/A. Bermeo-Ovalle,
D. Ehrens, T. Hoeppner
4:30 p.m.
A.04 Differences In Thalamic Nuclei Responses
During Epileptiform Activity Of Lennox Gastaut
Syndrome/J. Archer, A. Warren, D. F. Abbott,
G. D. Jackson
C.04 Traumatic Brain Injury Alters Cortical Glutamate
Network Function By Compromising GABAergic
Inhibition/D. Cantu, K. Walker, L. Andresen,
A. Taylor, D. Hampton, G. Tesco, C. Dulla
B.05 Long-Term Safety And Efficacy Of Responsive
Brain Stimulation In Adults With Medically Intractable
Partial Onset Seizures/M. Morrell, F. Sun,
D. King-Stephens, A. Murro, G. Barkley, R. Gwinn,
K. Noe, G. Bergey, C. Heck, A. Massey, R. Duckrow,
R. Wharen, M. Smith, C. Bazil, P. Van Ness, D. Nair,
B. Jobst, V. Salanova, A. Cole, G. Worrell,
J. Edwards, D. Spencer, C. Skidmore, M. Duchowny,
E. Geller, M. Berg, P. Rutecki, E. Mizrahi, R. Gross,
D. Shields, S. Eisenschenk, N. Fountain, D. Labar,
P. Olejniczak, C. O’Donovan
C.05 Viral Encephalitis Causes Epilepsy Due To
IL-6-Producing Macrophages/R. S. Fujinami,
M. F. Cusick, J. E. Libbey, D. C. Patel
5:00 p.m. A.06 Controlled Retrieval And Domain Specific
B.06 Mood And Behavior Outcome Following
Pediatric Epilepsy Surgery/E. N. Andresen,
M. Ramirez, A. B. Dorfman, K. Kim, P. Klaas,
J. Haut, C. Kenney, W. Bingaman, R. Busch
C.06 miR146a-Mediated Control Of Brain
Inflammation: A New Therapeutic Opportunity In
Epilepsy/T. Ravizza, V. Iori, A. M. Iyer, E. Aronica,
A. Vezzani
5:15 p.m. A.07 Targeted Resequencing Of 101 Known And
Candidate Epilepsy Genes In 600 Patients With
Severe Epilepsies Identifies Recurrently Mutated
Genes/G. Carvill, S. Heavin, J. McMahon, B.
O’Roak, S. Berkovic, J. Shendure, I. Scheffer, H.
Mefford
B.07 Temporal Lobe Epilepsy Surgical Patients
Undergoing MRI-Guided Stereotactic Laser Ablation
Exhibit Better Episodic Memory Outcome As Compared
To Standard Surgical Approaches/D. Drane, D. Loring,
N. Voets, A. M. Saindane, M. Price, M. Ivanisevic,
J. Willie, K. Meador, R. Gross
C.07 Role Of Decreased Cholinergic
Neurotransmission In Reduced Corticothalamic Arousal
During Complex Partial Seizures/W. Li, J. Motelow,
G. Liu, A. Gummadavelli, Z. Zayyad, J. Chin, H. Lee,
Q. Zhan, A. Mishra, R. N. Sachdev, B. Sanganahalli,
M. Furman, D. Englot, F. Hyder, H. Blumenfeld
5:30 p.m. A.08 New Insights Into The Spectrum Of
B.08 Antiepileptic Drug Withdrawal And Long-Term
Epilepsy Recurrence After Surgery/R. Yardi, A. Irwin,
D. Nair, A. Gupta, J. Gonzalez-Martinez, W. Bingaman,
I. Najm, L. Jehi
C.08 Epileptic Travelling Waves Are Shaped By Local
Inhibitory And Excitatory Single Neuron Activity In
Humans/O. J. Ahmed, W. Truccolo, E. N. Eskandar,
G. R. Cosgrove, N. S. Potter, A. Blum, L. Hochberg,
S. Cash
C.09 Frontal Hemodynamic Changes Precede Onset Of
Temporal Lobe Seizures. Scalp Recordings Using NearInfrared Spectroscopy/M. Seyal
Function And Organization In Children With
BECTS/T. Maloney, J. Tenney, K. Hibbard, D.
Morita, T. Glauser, J. Vannest
Parallel Connectivity In The Left Inferior Frontal
Convolution/C. Conner, N. Tandon
MONDAY
4:45 p.m. A.05 Centrotemporal Spikes Affect Language
selected for Goldberg Kaufman Award
Pathogenic Variation In Epilepsy Gained From
Analysis Of 1600 Individuals/C. Downtain, E.
Butler, D. McKnight, A. Shanmugham, A.
Entezam, G. Richard, S. Aradhya
A.09
Towards Home Monitoring Of
5:45 p.m.
Anticonvulsant Levels: A Pilot Study Using BioNano-Chip Technology/G. Kalamangalam, N.
Christodoulides, N. Ali, J. Hohenstein, R. Farid, J.
Lindo-Gibbs, A. Dasgupta, J. Wentworth, E.
Lykissa, J. McDevitt
B.09 FDA Black Box Warning On Risk Of Aseptic
Meningitis With Use Of Antiepileptic Drug Lamotrigine:
Comparative Risk Of Alternative Medications/
C. Teigland, P. Chen, A. Parente, R. Bhattacharjee
59
Poster Session 3
8:00 a.m. – 3:30 p.m.
Mechanisms
3.001 Altered Neocortical Networks
Revealed By Multielectrode
Recordings In A Chronic Epilepsy
Model /R. Serafini, S. Dettloff, J. Loeb
3.002 Deficits In Sirtuin Function
And Bioenergetics In
Chemoconvulsant-Induced
Epileptogenesis/L. B. Gano, K. Ryan,
L. Liang, S. Rowley, P. Bhuyan,
M. Patel
3.003 Metabolic Dysfunction During
Seizure Development In Mouse
Pilocarpine Model/K. Tan, T. McDonald,
O. Smeland, U. Sonnewald, K. Borges
3.004 Electrophysiological Properties
Of Age-defined Dentate Granule Cells
In A Rat Temporal Lobe Epilepsy
Model/J. Parent, A. Althaus,
G. Murphy, H. Zhang, E. A. Messenger
3.005 Chronic Monitoring Of Posttraumatic Epileptogenesis In Vitro/
K. Lillis, W. Swiercz, M. Mail,
H. Mullan, B. Bacskai, K. Staley
3.006 Intracerebral Interleukin-1Beta
Injection Causes Infantile Spasms In
Neonatal Rats Without Behavioral
Deficits/S. Briggs, A. S. Galanopoulou
3.007 Duration Of Status Epilepticus
Induced By Intrahippocampal
Pilocarpine: Effect On Hippocampal
Neuronal Degeneration/
O. Galvis-Alonso, R. I. Pongeluppi,
J. Mejia, B. P. Martins, R. L. Oliveira,
M. F. Mattos, B. F. Dutra-Andrade,
R. D. Graciani
3.008 Disruption Of Glial-Based
Adenosine Homeostasis In Human
Rasmussen’s Encephalitis: A New
Pathogenic Mechanism/T. Li, G. Luan
3.009 High-Dose Rapamycin Blocks
Mossy Fiber Sprouting But Not
Seizures In A Mouse Model Of
Temporal Lobe Epilepsy/P. Buckmaster,
K. Heng, M. Haney
3.010 Effects Of Kainic Acid In Mice
With Impaired Cleavage Of
Proneurotrophins/H. E. Scharfman,
J. J. LaFrancois, M. W. VonDran,
T. Marinic, V. Padow, S. S. Iyengar,
W. Friedman, B. L. Hempstead
3.011 Increased NRSF Expression
During Epileptogenesis Derives From
A Reduction In MIR-124 Expression/
G. P. Brennan, S. McClelland, S. Iyers,
T. Baram
3.012 The GluN2B-Selective NMDAR
Antagonist, Ro25, 6981 Reduced
Posttraumatic Seizure Susceptibility
And Improved Neurobehavioral
Deficits/L. Shao, S. Lindo,
W. B. Rittase, S. Bausch
3.013 Selective Neuronal Expression
Of The System XC-Glutamate-Cystine
Antiporter In Two Mouse Models Of
Temporal Lobe Epilepsy/J. Loewen,
M. Barker-Haliski, E. Dahle, H. White,
K. Wilcox
60
3.014 Changes In Neuronal
Cytoplasmic CL-Dynamics Triggered
By Two Photon Laser-Induced
Necrosis Of Neighboring Neurons/
K. Egawa, K. Lillis, V. Dzhala,
K. Staley
3.015 Altered Neural Stem Cell
Regulation After Status Epilepticus:
Role Of Notch Signaling/M. Korn,
J. Parent
3.016 Anti-Epileptogenic Effect Of
AKT Inhibitor Perifosine On A Temporal
Seizure Model In Rats/L. Zeng,
H. Zhang, M. Wong
3.017 Characterization Of Acute
PROBDNF Activation After Seizures
In The Mouse/A. Thomas,
Y. Cruz Del Angel, B. L. Hempstead,
S. Russek, A. Brooks-Kayal
3.018 Network Analysis Of
Multielectrode Data Implies
Reorganization In The Chronic
Epileptic Rat Hippocampus/M. Zions,
D. McCloskey
3.019 Synchrony Dynamics During
Seizure Onset And Termination Are
Similar In Acute And Chronic Rodent
Models Of Limbic Epilepsy/D. Mogul,
T. Sobayo
3.020 Chronic Hyperexcitability Of
Reticular Thalamic Neurons After An
Early Exposure To General Anesthesia/
M. DiGruccio, H. Goodkin, S. Todorovic
3.021 Optimization Of Early Seizure
Detection Algorithm Using Continuous
In-vivo Monitoring In Pilocarpine Rat
Model/Y. Choi, H. Chung, S. Kim,
E. Kim, S. Yang, J. Park, S. Lee,
S. Jun, C. Ji, J. Kim, B. Lee, H. Lee
3.022 Pore Loop KCNQ2 Mutations
Causing Epileptic Encephalopathy
Strongly Suppress Wild Type KCNQ2
Currents When Co-Expressed In
Mammalian Cells/L. Li, B. Tran, M. Xu,
J. Millichap, B. Porter, E. Cooper
3.023 Activation Of M1 Muscarinic
Acetylcholine Receptors On
Parvalbumin-positive Interneurons
Contributes To Pilocarpine-Induced
Seizures/E. D. DeCan, F. Yi,
E. Marceau, K. Stoll, K. Deisseroth,
D. Gerber, S. Tonegawa, J. Lawrence
3.024 Antiepileptic Action Of C-JunN-Terminal Kinase (JNK) Inhibition/
T. Y. Tai, L. N. Warner, T. D. Jones,
S. Jung, D. W. Skyrud, N. P. Poolos
3.025 Scavenging Seizure-Induced
Reactive Oxygen Species With A
Catalytic Antioxidant Attenuates
Neuroinflammation In Experimental
Temporal Lobe Epilepsy/P. Bhuyan,
L. Liang, B. J. Day, M. Patel
3.026 Chronic Progesterone
Treatment Increases Seizure
Frequency And Glutamatergic
Neurotransmission/S. Joshi,
K. Rajasekaran, J. Sun, J. Williamson,
J. Kapur
3.027 Hypothalamic Paraventricular
Nucleus – A Brain Structure At The
Intersection Of Stress And
Cryptogenic Infantile Spasms/
T. Chachua, C. Goletiani, M. Yum,
G. Sidyelyeva, J. Veliskova, L. Velisek
3.028 Transcription Of STAT3-target
Genes In Dentate Gyrus Following
Pilocarpine-induced Status
Epilepticus/H. L. Grabenstatter,
Y. Cruz Del Angel, S. Russek,
A. Brooks-Kayal
3.029 Cardiac Alterations And
Increased Susceptibility For
Ventricular Tachycardia In A Model Of
Acquired Epilepsy/Y. Lai, N. Li,
W. Lawrence, X. H. Wehrens,
A. Anderson
3.030 5-HT6 Receptor Antagonists
Differentially Affect GABAergic
Synaptic Transmission In A Mouse
Model Of Familial Alzheimer’s Disease
With Comorbid Seizures/P. J. West
3.031 Vagal Nerve Stimulation
Modifies Firing Rate And The Synaptic
Proteome Of Amygdala/piriform Cortex
Neurons/Y. Huang, G. Alexander,
E. Soderblom, X. He, A. Moseley,
J. McNamara
Models
3.032 Acute Cell-Specific Alterations
In Synaptic Transmission During
Status Epilepticus: Further Evidence
Of Diminished Inhibition And Increased
Excitation Of Principal Neurons/
H. Sun, H. Goodkin
3.033 Altered Intrathalamic
GABAergic Circuitry In A Genetic
Mouse Model Of A Human Absence
Epilepsy Syndrome/M. Gallagher,
C. Zhou, M. Deel, L. Ding
3.034 Modeling Of Dysfunctional Ion
Channels Reveals Combinations That
Underlie Predisposition To Neuronal
Hyperexcitability In Epilepsy/
T. L. Klassen, T. T. Chen
3.035 Temporal- And LocationSpecific Alterations Of The GABAergic
System In MECP2 Mutant Mouse
Brains/S. Kang, S. T. Kim, C. Eyring,
M. Johnston, S. Kadam
3.036 Seizure Directionality Across
The Corpus Callosum/G. Aaron,
R. Cotter, M. Van Zandt, S. Winnik
3.037 Novel Heart Rate Anaylsis
Distinguishes TLE Patients From
Patients With Non-Epileptic
Seizures/R. O’Dwyer, U. Zuercher,
R. Burgess
3.038 Role Of Adenosine In SeizureInduced Death In DBA/2 Mice And
Genetically Epilepsy-Prone Rats
(GEPRs): Potential Relevance To
SUDEP/C. Faingold, M. Randall,
S. P. Kommajosyula
8:00 a.m. – 3:30 p.m.
Human Studies
3.053 Specific HFO Features
Correlate With Seizure Onset Zone In
Human EEG/S. Gliske, Z. Irwin,
W. Stacey
3.054 Single Unit Recordings During
Virtual Navigation Tasks In Patients
With Temporal Lobe Epilepsy/
A. Robbins, A. Titiz, R. Scott,
G. Holmes, P. Lenck-Santini, B. Jobst
3.055 Predisposing Factors Of
Posterior Reversible Encephalopathy
Syndrome In Acute Childhood
Leukemia/I. Lee, S. Kim, J. Hahn,
J. Lee, N. Chung, B. Cho, H. Kim
3.056 Can Epilepsy Induce
Progressive Brain Damage?
Converging Evidence From Human
FCD And A Rat Model/A. Finardi,
F. Colciaghi, P. Nobili, M. Bramerio,
G. Battaglia
3.057 Long Term Behavioural
Outcomes In Children Following
Convulsive Status Epilepticus
(CSE)/M. Martinos, S. Pujar,
C. Gillberg, B. Neville, M. de Haan,
R. Scott, R. Chin
3.058 Serotonin Levels In The
Hippocampal Tissue Of Patients With
Refractory Temporal Lobe Epilepsy
Caused By Mesial Temporal
Sclerosis/N. Fonseca, H. P. Joaquim,
L. L. Talib, S. Vincentiis, W. F. Gattaz,
K. Valente
3.059 Mitochondrial Respiratory
Chain Dysfunction In Children With
Epilepsy/D. Khurana, M. Goldenthal,
I. Valencia, S. Damle, C. Fernandez,
K. Carvalho, H. Hardison, W. Yorns,
R. Jethva, J. Melvin, A. Legido
3.060 Postictal Increase Of ICAM-1
In Human Epilepsy/M. Hagge,
M. Oster, S. Bauer, D. G. Olmes,
W. Oertel, F. Rosenow, H. Hamer
Devices, Technologies, Stem Cells
3.061 The Contribution Of Sphenoidal
Electrodes Placed Under Fluoroscopy,
To The Lateralization In Bilateral
Refractory Temporal Lobe Epilepsy:
A Clinical Trial/A. Kilit Yilmaz,
G. Guvenc, S. Ture, G. Akhan,
N. Yuceer
3.062 Use Of A Cloud-based EEG
Database To Measure The Inter-Rater
Reliability Of Intracranial EEG
Interpretation/B. Oommen,
J. Wagenaar, B. Litt
3.063 Far-Field Radio-frequency
Powering (FFRFP) Of Devices For
Implantable Neuromodulation/E. Chow,
O. Abdel-Latief, D. Thompson,
M. Morris
3.064 Brain Computer Interface For
Modulation Of Temporal Lobe Seizures
Utilizing Cognitive Feedback/
D. Ehrens, M. Rossi
3.065 Evaluation Of A New Card
Device For The Medication Adherence
Checking In Epilepsy/I. Takumi, H. Ura,
K. Sadamoto, H. Takamori, T. Bizen,
Y. Kishi, A. Morita
3.066 RF Heating Effect Study Of
VNS Lead Under MRI With RF Head
Coil/D. Li, J. Chen, J. Begnaud
3.067 Optogenetic Stimulation Of
The Superior Colliculus Attenuates
Seizures Evoked By
Pentylenetetrazole/P. Forcelli,
C. Soper, K. Gale
Biomarkers
3.068 Long Intracortical Inhibition
Can Be Reliably Measured With
Transcranial Magnetic Stimulation
Evoked EEG Potentials/S. Kessler,
M. Wiener, C. Gorman, H. B. Coslett,
R. H. Hamilton
3.069 Enhancement Of The P300
Positively Correlates With The
Therapeutic Effect Of Vagus Nerve
Stimulation In Patients With
Refractory Epilepsy/L. De Taeye,
K. Vonck, P. Boon, A. Meurs,
V. De Herdt, E. Carrette, L. Mollet,
I. Dauwe, S. Gadeyne, M. Van Bochove,
T. Verguts, G. Pourtois, R. Raedt
3.070 Thalamo-hippocampal
Connectivity In Medial Temporal Lobe
Epilepsy/D. Barron, N. Tandon,
J. Lancaster, J. Cavazos, P. T. Fox
3.071 Gene Expression Signature Of
Activated Microglia In Infantile
Spasms: Implications For Novel Drug
Development/S. Sundaram, H. Chugani,
J. S. Maksabo, D. Chugani
3.072 Cortical Excitability In Patients
With Succinic Semialdehyde
Dehydrogenase (SSADH) Deficiency
Treated With Chronic Taurine
Therapy/J. Schreiber, P. Pearl,
I. Dustin, Y. Yu, P. Reeves-Tyer,
E. M. Wassermann, K. M. Gibson,
W. Theodore
3.073 In-Vivo Measurement Of Brain
Inflammation With [11C]-[R]-PK11195 Positron Emission Tomography
In Children With Epileptic Disorders/
A. Kumar, V. Tiwari, O. Muzik,
P. K. Chakraborty, H. Chugani
3.074 Early-life Seizures Cause A
Reduction Of Adult Dopamine D4
Receptors In The Prefrontal Cortex Of
The Rat/T. A. Shohatee, A. Willner,
D. McCloskey
MONDAY
3.039 The NS-PTEN Knockout Mouse
Model Of Cortical Dysplasia With
Epilepsy Is Associated With
Alterations In The KV1.1 Potassium
Channel/L. Nguyen, A. Brewster,
A. Anderson
3.040 Repeated Low Dose Of Kainate
Produces A Reliable Model Of
Epileptogenesis In C57BL6/J Mouse/
T. Thippeswamy, S. Puttachary
3.041 Age At Traumatic Brain Injury
Affects Excitability And Seizure
Susceptibility/A. Reid, A. Bragin,
J. Engel, R. Staba, C. Giza
3.042 Reduced Strength Of Inhibitory
Synaptic Connections In Experimental
Cortical Dysplasia/S. Roper, F. Zhou
3.043 Efficacy Of Flupirtine To Treat
Hypoxia-Ischemia Induced Neonatal
Seizures/D. Sampath, Y. Raol,
A. White
3.044 Controlled Cortical Impact As
A Model Of Traumatic Brain Injury For
The Generation Of Experimental PostTraumatic Epilepsy/D. Treiman,
J. White-James, J. W. McDorman,
S. Marsh, L. Treiman
3.045 The Canine Translational
Platform: Proof Of Concept Study Of
Fosphenytoin For Status Epilepticus
In Canine Clinical Patients/
E. Patterson, L. Coles, J. Cloyd,
M. Podell, C. VIte, B. Bush,
A. Rendahl, I. Leppik
3.046 The Effect Of Ganaxolone On
Animal Model Of Cryptogenic Infantile
Spasms/M. Yum, M. Lee, D. Kim,
L. Velisek, T. Ko
3.047 Sex-Specific Behavioral
Changes In Murine BRD2 Model Of
Juvenile Myoclonic Epilepsy/L. Velisek,
J. Veliskova, C. Goletiani,
G. Maglakelidze, T. Chachua,
G. Sidyelyeva, E. Shang,
D. Wolgemuth, D. Greenberg
3.048 Restoring Normal Cortical
Activity During Complex Partial
Seizures: A Novel Use For Thalamic
Deep Brain Stimulation/J. Motelow,
A. Gummadavelli, W. Li, Q. Zhan,
B. Sanganahalli, M. Furman, F. Hyder,
H. Blumenfeld
3.049 In Vivo 1h MRS Can Detect
Regional GABA Changes In A Mouse
Model Of Epilepsy/E. Powell,
R. F. Martin, A. Marshall, R. Gullapalli,
S. Xu
3.050 Alterations In Neuronal And
Glial Compartment Triggered By
Epilepsy In A Rat Model Of Cortical
Dysplasia/P. Nobili, F. Colciaghi,
A. Finardi, G. Battaglia
3.051 Activation Of 5-HT2 Receptors
Prevents Seizure-related Respiratory
Arrest And Death In Wild-type And 5HT Neuron Deficient Mice/
G. Buchanan, M. A. Hajek,
G. Richerson
3.052 Carpe Datum! Enzyme Based
Microelectrode Arrays Offer Novel
Insights Into Mechanics Of Epilepsy/
V. Davis, M. L. Stephens,
S. R. Batten, R. Alcala, H. McKee,
G. Gerhardt, J. Slevin
Poster Session 3
Neurophysiology
Other Clinical EEG
3.075 High Frequency Oscillations On
Scalp Electroencephalograms: A
Preliminary Study In Physiologically
Normal Volunteers/E. Papathanasiou,
M. Elpidorou, S. Papacostas
3.076 Cortiq-Based Real-Time
Functional Mapping For Epilepsy
Surgery/M. Korostenskaja, C. Kapeller,
R. Prueckl, P. Chen, K. Lee,
M. Westerveld, J. Cook,
J. Baumgartner, C. Guger
3.077 Pediatric Anti-N-Methyl-DAspartate Receptor Encephalitis – A
Review Of EEG Findings In Children/
J. Munoz, A. Lowden, S. Arnold,
D. Graves
61
3.078 High Frequency Oscillations In
Non-Epileptogenic Cortex/
R. Alkawadri, N. Gaspard, H. Zaveri,
I. Goncharova, D. Spencer,
A. Alexopoulos, N. So, L. Hirsch
3.079 Brainstem-Cranial NerveMediated Microreflexes For Possible
Uses To Investigate Affect Control/
F. Matsuo
3.080 EEG In First Complex Febrile
Seizure/C. Harini, K. Singh, R. Marin
de Carvalho, A. Kimia, S. An,
A. Bergin, M. Takeoka,
T. Loddenkemper
3.081 Continuous EEG Monitoring In
Preterm Neonates Using MicroEEG® –
A New Portable EEG Device/G. Chari,
Z. Ibrahim, R. Kim, R. Parris,
S. A. Baki, J. Cracco, J. Aranda
3.082 Overlap Of Absence Seizures
And Focal Spikes On EEG/C. Herren,
D. Gossett, D. Sirsi
3.083 Real-Time Functional Mapping
(RTFM) For Epilepsy Surgery:
Converging Results From Three
Imaging Modalities/A. Schaal,
M. Korostenskaja, P. Chen,
M. Westerveld, C. Salinas, G. Schalk,
P. Brunner, J. Cook, J. Baumgartner,
K. Lee
3.084 Quality Assessment Of
Electroencephalography Obtained
From A “Dry Electrode” System In
Veterans/J. Halford, C. G. Waters,
G. Martz, E. Kutluay, B. C. Dean,
W. Soussou
3.085 Early Ictal High Frequency (70175 Hz) Power Increases Identifying
The Seizure Onset Zone/
A. Korzeniewska, P. Franaszczuk,
M. Cervenka, C. Jouny, G. Bergey,
N. Crone
3.086 Utility Of Prolonged EEG Of
Over 40 Minutes Compared To The 20
Minute Standard/C. Miskin,
K. Carvalho, I. Valencia, A. Legido,
D. Khurana
3.087 Spike Timing, Location, And
Temporal Patterns May Improve
Seizure Onset Localization In
Pediatric Patients Undergoing
Epilepsy Surgery/E. Marsh,
C. Bermudez, C. Conley, S. Tomlinson,
B. Porter
3.088 Spike Frequency In Benign
Focal Epilepsy Of Childhood With
Centrotemporal Spikes/M. Takeoka,
K. Boyer, C. Harini
3.089 Impact Of Interictal
Epileptiform Discharges On Occipital
Lobe Cortical Function: An EEG-fMRI
Study/J. Remi, F. Sales, S. Noachtar,
M. Castelo-Branco
3.090 Effect Of Cognitive Stimulation
On Hippocampal Ripples In Epileptic
Patients/M. Brazdil, J. Cimbalnik,
R. Roman, M. Stead, P. Daniel,
J. Halamek, P. Jurak
3.091 Comparing Dense Array EEG
And Intracranial EEG For Source
Localization Of Interictal Spikes In
Patients With Neocortical Epilepsy/
M. Yamazaki, M. Terrill, A. Fujimoto,
T. Yamamoto, D. Tucker
62
Poster Session 3
8:00 a.m. – 3:30 p.m.
3.092 Estimation Of Skull Table
Electrical Capacitance Using Ictal
Recording Of High Frequency Onset To
Reconcile Electrophysical Property Of
Scalp Recorded High Frequency
Activities As Low Pass Filter
Recording/H. Hasegawa
3.093 Diagnostic Utility Of Sedated
Electroencephalography In Pediatric
Autistic Population/C. Jacob,
S. Karkare
3.094 Characteristics Of Routine
EEG Performed In Adults At A Typical
Tertiary Academic EEG Laboratory/
L. Rong, A. Bozorg, A. Frontera,
S. Benbadis
3.095 Comparison Of Features Of
Suppression-burst
Electroencephalographic Pattern With
Different Etiologies/T. Fukasawa,
T. Kubota, T. Negoro
3.096 Atypical EEG Pattern Of
Absence Status Epilepticus: A Report
Of Two Cases/N. Murr, C. Mysore,
R. Zabad
3.097 Focal Rhythmic Artifact During
Electroencephalography/V. Patil,
E. Crisan, P. Martinez, B. Kocol
3.098 The Diagnostic Utility Of
Ambulatory EEG/J. McCormick
Animal Studies
3.099 Epilepsy And Aberrant
Synaptic Plasticity Is Epigenetically
Regulated In Tuberous Sclerosis
Complex/T. Basu, K. O’Riordan,
A. Kirchner, B. Schoenike, A. Roopra
3.100 The Effect Of Peripheral
Inflammation On Hippocampal
Glutamatergic Synaptic Transmission:
A Possible Mechanism For Changes In
Central Nervous System
Excitability/K. Riazi, K. A. Sharkey,
Q. Pittman
3.101 Cell Type-specific
Responsiveness Of Hippocampal
Dentate Gyrus Neurons To Perforant
Path Stimulation/E. Goldberg,
D. Coulter
3.102 Interneuron Firing Patterns In
High Frequency Activity/G. Morris,
A. D. Powell, P. Jiruska, J. Jefferys
3.103 Research Of WAG/RIJ Rats
Offspring Behavior During First Month
Of Life/E. Rogozinskaya, A. Malyshev,
E. Razumkina, V. Dubynin, K. Sarkisova
3.104 Transient Disruption Of The
Epileptic Network With Intracranial
Electrodes/K. Davis, D. Wulsin, C. Wu,
B. Litt
3.105 State Representation Using
Subspace Projection Of Ca1- Ca3
Local Field Potentials In A Rat Model
Of Focal Epilepsy/B. Mahmoudi,
S. Arcot Desai, N. Laxpati, R. Gross
3.106 Highly Specific
Channelrhodopsin-2 Expression In
Cholinergic Mesopontine Neurons In A
Rat Model Of Complex Partial
Seizures/Q. Zhan, M. Furman,
B. A. Lerner, J. Meng, J. Motelow,
C. Ma, W. Li, I. B. Witten,
K. Deisseroth, J. A. Cardin,
H. Blumenfeld
3.107 Restoring Fast Cortical
Activity In A Rat Model Of Complex
Partial Seizures Using Optogenetic
Stimulation/M. Furman, Q. Zhan,
B. A. Lerner, J. Meng, J. Motelow,
C. Ma, W. Li, I. B. Witten,
K. Deisseroth, J. A. Cardin,
H. Blumenfeld
3.108 Effects Of DC IELD On
Synaptic Plasticity And Seizure In
Thalamocingulate Circuitry/W. Chang,
B. Shyu
3.109 Results Of Video-EEG
Monitorization In The Rats Treated
With Kainic Acid In Acute Term/
C. Gurses, E. Taskiran, C. Yilmaz,
N. Orhan, M. Bahceci, M. Kaya,
N. Arican, M. Kucuk, B. Ahishali
Computational Analysis & Modeling
Of EEG
3.110 Remote Inhibition Of Cortical
Activity In The Attention And
Executive Networks By Interictal
Spikes In Patients With Mesial
Temporal Lobe Epilepsy/H. Zaveri,
R. Alkawadri, I. Goncharova,
N. Gaspard
3.111 Automated Detection Of IEDs
Using Smart Templates And Iterative
Reviewing/S. Lodder, M. J. van Putten
3.112 Delineation Of Eloquent Cortex
Via Resting-State Functional
Connectivity As Measured By
Functional Magnetic Resonance
Imaging And The Electrocorticogram/
D. Groppe, P. Mégevand, S. Bickel,
C. Keller, A. Mehta
3.113 Mapping Mental Calculation
Systems With Electrocorticography/
K. Ueda, E. Brown, K. Kojima,
E. Asano
3.114 Relationship Between
Resection Extents Of Broadband
Interictal Electrocorticography
Including Infra-Slow And Highfrequency Activities And Seizure
Outcomes/S. Park, S. Lee, C. Chung
3.115 Dynamic EEG Source Analysis
Of Seizure Propagation Patterns
Using Intracranial Recording/J. Ochoa,
D. Naritoku
3.116 Software Analysis Of Seizure
Severity And Post-Ictal Duration/
R. McGuire, M. Frei, R. Kern,
D. Shiau, J. Halford, B. Olin,
J. Begnaud
3.117 Spatiotemporal Dynamics Of
Epileptic Network From Intracranial
EEG Recordings/H. Chung, Y. Choi,
S. Kim, S. Yang, J. Park, S. Lee,
S. Jun, C. Ji, J. Kim, B. Lee, H. Lee
3.118 Markov Modeling Of Sleepwake Dynamics Following Acute
Neural Injury/F. Yaghouby, T. Zhang,
M. Striz, C. Schildt, K. Donohue,
B. O’Hara, S. Sunderam
3.119 Effect Of Vigilance State On
Clinical Seizure Predictability: A Pilot
Analysis/S. Sunderam, F. Yaghouby,
P. Modur
3.120 Characterization Of
Hypsarrhythmia Using EEG Spectral
Analysis/L. Seltzer, K. Thio, M. Berg,
A. Paciorkowski
3.121 Detection Of Epileptic Spikes
In The EEG With High Precision Using
Clustering Methods/M. Weinkopf,
H. Perko, M. Hartmann, G. Gritsch,
F. Fürbass, T. Kluge
3.122 Characteristics Of The High
Frequency Oscillations (80-200 And
200-400 Hz) In The Seizure Onset
Zone: Assessment By Automatic
Detection/U. Malinowska, G. Bergey,
M. Cervenka, C. Jouny
Clinical Epilepsy
8:00 a.m. – 3:30 p.m.
3.135 When Atypical Cases Requires
Atypical Management: Case
Presentation Of Type III Sturge Weber
Syndrome/S. Proteasa, J. Lajoie,
J. Maytal
3.136 Video EEG Monitoring In The
Pediatric Intensive Care Unit/
S. Manganaro, L. A. Bello-Espinosa,
M. Andriola
3.137 Clinical And
Electroencephalographic Patterns
Associated With Electrodecremental
Activity In Pediatric Patients/
J. M. Pérez, M. Gutierrez Ceniseros
Clinical Treatments
3.138 Complications Of Invasive
Electrode Monitoring In Epilepsy
Surgery. A Prospective Study Based
On The Swedish National Epilepsy
Surgery Register 1996-2010/
B. Rydenhag, E. Hedegärd, R. Flink,
K. Malmgren
3.139 Retrospective Review Of
Juvenile Myoclonic Epilepsy Patients
At A Tertiary Center/R. Yu, H. Kim,
J. Lee, H. Kang
3.140 Expert Opinion On Treatment
Of Pediatric Status Epilepticus In
Poland/B. Steinborn, D. Dunin-Wasowicz,
M. Mazurkiewicz-Beldzinska,
M. Balcerzak, A. Jus, J. Wheless,
S. Jozwiak
3.141 Expert Opinion On Treatment
Of Idiopathic Generalized Epilepsy
Syndromes Of Childhood And
Adolescence In Poland/
M. Mazurkiewicz-Beldzinska,
D. Dunin-Wasowicz, B. Steinborn,
M. Balcerzak, A. Jus, J. Wheless,
S. Jozwiak
3.142 Effects Of Antiepileptic Drug
Therapy On Vitamin D Status Among
The Children With Epilepsy In Korea:
Prevalence And Risk Factors/Y. Lee,
K. Park, Y. Kim, S. Nam
3.143 Sleep-Related Breathing
Abnormalities In Children Receiving
Vagus Nerve Stimulation/
R. J. Schultz, P. Marquette,
A. A. Wilfong
3.144 The Response To ACTH Is
Determined Early In The Treatment Of
Infantile Spasms/J. R. Mytinger,
A. Weber, G. L. Heyer
3.145 Bromide For Severe Epileptic
Encephalopathies In Early Infancy/
K. Sugai, E. Nakagawa, Y. Saito,
T. Saito, A. Ishiyama, H. Komaki,
M. Sasaki, T. Otsuki
3.146 Effective Use Of Low Dose Of
Rufinamide After An Initial Worsening
Effect In Lennox-Gastaut Patients/
J. Corny, A. Papon, V. Bellavoine,
T. Storme, A. Ilea, O. Bourdon,
S. Auvin
3.147 A Pilot Study Addressing The
Executive Dysfunction In Pediatric
Population With Paroxysmal NonEpileptic Events And Epilepsy/
G. Krigbaum, R. Bunch, J. Buchhalter
3.148 Surgical Resections For
Posttraumatic Epilepsy Following
GSWs To The Brain/Y. Esquenazi Levy,
G. Kalamangalam, O. Hope, J. Slater,
N. Tandon
Clobazam As Adjunctive Therapy In
The Treatment Of Medically
Refractory Absence Seizures/
M. La Vega-Talbott, S. M. Wolf,
P. McGoldrick
3.150 Experience With Vigabatrin In
Patients <18 Years Of Age With
Refractory Complex Partial
Seizures/M. Frost, P. Penovich,
C. Hoskin, C. Monette
3.151 Experience With Vigabatrin
Over The Years/P. Penovich, M. Frost,
J. Brunn, C. Monette
3.152 The Predictive Marker Of
Response To Levetiracetam In Focal
Epilepsy Patients/S. Lim, S. Kim,
W. J. Kim, Y. Kim, Y. Shon
3.153 Improving Time To Treatment
And Resolution Of Status
Epilepticus/D. McDermott, L. Frey,
M. Faithe, J. Bainbridge, C. O’Brien,
C. Oh, S. Pearson, A. Shrestha,
L. Strom, M. Spitz, C. Drees
3.154 Induction Of Bust-Suppression
Or Coma By Intravenous Anesthetics
And Outcome Of Refractory Status
Epilepticus/B. Kang, K. Jung, J. Shin,
J. Moon, J. I. Byun, J. A. Lim,
H. Moon, Y. Kim, S. Lee, K. Chu,
S. Lee
3.155 Epilepsy Self Management
Behaviors In An Outpatient Clinical
Setting: Preliminary Findings/
D. Friedman, S. Ye
3.156 Nonconvulsive Status
Epilepticus: A Case Cohort/B. Bittel,
U. Uysal, N. Hammond
3.157 The Clinical Relevant Of Source
Location In FLES And Prediction Of
Postoperative Outcome/H. Stefan,
J. Mu, E. Carrette, K. Roessler,
H. Hamer, P. Boon, E. Pauli,
I. Bluemcke, M. Buchfelder, S. Rampp
MONDAY
Clinical Diagnosis
3.123 Can A Clinical Questionnaire
Completed By Patients Prior To Video
EEG Help In Identifying Those At
Highest Risk For Non Epileptic
Seizure Like Events?/M. Gahlot,
C. Schramke, J. P. Valeriano,
K. M. Kelly, A. Synowiec
3.124 Pathophysiology Of Peri-Ictal
Water Drinking (PIWD): 3 Cases
Report/P. Laoprasert, A. White,
N. Stence, D. Mirsky
3.125 Nonconvulsive Seizures In
Abusive Head Trauma/H. Greiner,
M. V. Greiner, K. Holland
3.126 The Characteristics Of Infantile
Spasms Associated With
Mitochondrial Disorders/J. Lee,
H. Kang, J. Lee, H. Kim
3.127 The Resting State fMRI Study
In NLE Patients/X. Fu, R. Qian, X. Wei,
Y. Qi, Y. Fu
3.128 Diagnostic Utility Of The
Routine Electroencephalogram In
Patients Admitted To The Psychiatry
Inpatient Service/J. Marcus,
N. K. Sethi, G. Solomon
3.129 Localization Value Of Ictal
Turning Prone Along The Horizontal
Body Axis/A. Arain, N. Azar, P. Singh,
M. Al-Kaylani, B. Abou-Khalil
3.130 Partial Epilepsy As The Single
Manifestation Of Spontaneous
Meningoencephalocele, A Rare
Etiology, A Series Of 7 Patients/
A. Biraben, V. Lassalle, A. Nica,
B. Carsin-Nicol, C. Haegelen
3.131 Norovirus Is A Culprit Of
Benign Convulsions Associated With
Mild Gastroenteritis/G. Kim, J. Byeon,
M. Kim, B. Eun
3.132 The Accuracy Of Seizure
Diagnosis Based On Semiology:
Seizure Type Matters/S. Wang, B. Jin
3.133 Bisynchronous Spike-And-Wave
Activity In Frontal Lobe Epilepsy: A
Possible Role For Primary Bilateral
Synchrony In Focal Epilepsy/
F. Williams, F. Torres Delgado,
F. Khursheed, E. Mader,
N. Villemarette-Pittman, P. Olejniczak
3.134 Early Onset Absence Epilepsy:
One Center’s Review Of Clinical
Features, Therapy And Outcomes/
K. Havens, J. Conry, P. Pearl,
W. Gaillard, D. Depositario-Cabacar
Poster Session 3
Prognosis
3.158 Risk Factors For Early
Seizures, Status Epilepticus And
Post-traumatic Epilepsy In Infants
With Non-Accidental Head Injury/
H. Gong, M. Grigg-Damberger,
M. I. Johnson
3.159 Prognostic Value Of Video-EEG
Monitoring During Therapeutic
Hypothermia In Neonatal HypoxicIschemic Encephalopathy/R. Morse,
W. Edwards, G. Holmes, J. Filiano
3.160 Early Prediction Of Refractory
Status Epilepticus: An International
Two-Center Study/W. Ziai, P. Kaplan,
S. Marsch, S. Rueeg, R. Sutter
Children With Recurrent Episodes Of
Convulsive Status Epilepticus/S. An,
I. Sánchez Fernández, J. Klehm,
D. Jillella, T. Loddenkemper
63
3.162 Can Ictal Scalp EEG Predict
Diagnosis And Outcomes Of Bilateral
Independent Temporal Lobe Epilepsy:
A Systematic Review/X. Liu,
Y. Aghakhani, N. Jette, S. Wiebe
3.163 Seizure Trajectories In DrugResistant Epilepsy: A Cohort Study/
H. Choi, L. Hirsch, M. Hayat, A. Javid,
R. Zhang, G. Heiman
3.164 Relationship Between HealthRelated Quality Of Life (HR-QOL) And
The Proportions Of Responders Who
Achieve A Minimal Clinically Important
Difference (MCID): A Pooled Analysis
Of Three Phase III Trials Of
Perampanel (PER) In The Treatment Of
Refractory Partial Onset Seizures
(POS)/R. Simons, C. O’Brien,
H. Kraemer, R. Sheffield,
D. Squillacote
3.165 Impact Of Severity Of Epilepsy
On Health-related Quality Of Life In
Children With Newly-diagnosed
Epilepsy: Presence Of Cognitive
Problems Matters/M. Ferro,
S. Wiebe, M. Smith, C. Camfield,
G. Zou, S. Levin, K. Speechley
Children With Febrile Seizure Plus On
Jeju Island, South Korea/S. Kim
3.167 Time To Initial Treatment Of
Status Epilepticus And Its
Association With Clinical Outcome/
J. Cheng
Neuro Imaging
Animal Studies
3.168 Structural And Metabolic
Changes In The Intrahippocampal
Kainic Acid Model Of Temporal Lobe
Epilepsy/V. Keereman, P. van Mierlo,
I. Dauwe, P. Boon, S. Vandenberghe,
C. Vanhove, R. Raedt
3.169 Resting-State fMRI
Demonstrates Functional Connectivity
Differences In Epileptic And Control
Non-Human Primates/F. Salinas,
K. Karkar, C. Szabo
Structural Imaging
3.170 Estimating Intracranial Volume
Using Intracranial Area In Healthy
Paediatric Subjects And Those With
Childhood Status Epilepticus/R. Piper,
M. Yoong, S. Pujar, R. Chin
3.171 Patients With Electrical
Status Epilepticus In Sleep And No
Macroscopic Abnormalities On
Magnetic Resonance Imaging Have A
Smaller Thalamic Volume Than
Controls/I. Sánchez Fernández,
A. Akhondi-Asl, J. Klehm, S. Warfield,
J. Peters, T. Loddenkemper
3.172 TBSS Analysis Of Diffusion
Tensor Imaging In Cryptogenic West
Syndrome: Comparison With PET
Hypometabolism/J. Natsume,
C. Ogawa, T. Fukasawa, H. Yamamoto,
H. Kidokoro, S. Yokoi, T. Takeuchi,
Y. Azuma, N. Ishihara, N. Ando,
T. Kubota, T. Negoro, K. Watanabe
64
Poster Session 3
8:00 a.m. – 3:30 p.m.
3.173 Prevalence Of Hippocampal
Malrotation (HIMAL) Is Not Higher In
Children With Prolonged Febrile
Seizures (PFS) Compared To AgeMatched Controls: A PopulationBased Study/R. Chin, S. Pujar,
A. Krishnan, K. Chong, B. Neville,
R. Scott
3.174 Neocortical Gray Matter Maps
Linked With Two Common Mesial
Temporal Lobe Seizure Onset
Patterns/N. Memarian, S. Madsen,
S. Kim, K. Nalbandian, P. Macey,
S. Dewar, J. Engel, P. Thompson,
R. Staba
3.175 Multimodal Analysis
Demonstrates White Matter
Abnormalities In Drug Resistant
Epilepsies/B. M. Campos, A. Coan,
C. Yasuda, G. C. Beltramini, M. Liu,
C. Beaulieu, D. Gross, F. Cendes
3.176 Tractographic Analysis Of The
Uncinate Fasciculus For Investigating
Frontotemporal Spike Propagation/
N. Tanaka, E. Takahashi, J. Madsen,
S. Stufflebeam
3.177 Pre-Surgical Corpus Callosum
Midsagittal Cross-sectional Area
Predicts Post-Surgical Resilience In
Working Memory/K. Blackmon,
R. Kuzniecky, W. Barr, T. Thesen,
W. Doyle, O. Devinsky, B. Ardekani,
H. Pardoe
3.178 Gray Matter Atrophy Is
Influenced By Time Of Active Disease
In Mesial Temporal Lobe Epilepsy With
And Without Hippocampal Sclerosis/
A. Coan, B. M. Campos, C. Yasuda,
F. Cendes
3.179 Relationship Between
Processing Speed And Brain Volume In
Children With Benign Childhood
Epilepsy With Centro-Temporal Spikes
(BECTS)/S. Woods, T. Maloney,
M. Altaye, D. Morita, J. Vannest
3.180 Computerized MRI Processing
To Detect Focal Lesions In Intractable
Epilepsy/T. Akiyama, K. Kobayashi,
K. Ida, T. Morita, N. Shimizu,
S. Kanazawa, H. Yoshinaga
3.181 TBSS Analysis Of Diffusion
Tensor Imaging In Children With
Temporal Lobe Epilepsy/H. Yamamoto,
J. Natsume, Y. Kajita, H. Kidokoro,
N. Ishihara, T. Negoro, K. Watanabe
3.182 Does Childhood Convulsive
Status Epilepticus (CSE) Result In
Long-Term Hippocampal Damage? A
Quantitative Hippocampal Volumetric
Analysis/S. Pujar, M. Martinos,
B. Neville, C. Clark, R. Scott, R. Chin
3.183 Reduced Structural
Connectivity Strength Between Left
And Right Hippocampus In Temporal
Lobe Epilepsy/R. Xu, Z. Ding,
A. S. Dagley, A. W. Anderson,
B. A. Landman, B. Abou-Khalil,
V. Morgan
3.184 White Matter Changes In
Lesion-Negative Temporal Lobe
Epilepsy Are Different To Those Seen
In Hippocampal Sclerosis/D. Vaughan,
D. Raffelt, J. Tournier, G. Jackson,
A. Connelly
3.185 Hypoglycemic Brain Injury In
Neonates And Seizure Occurrence/
K. Muir, E. W. Tam, Q. Xu, D. S. Wong,
S. P. Miller, K. J. Poskitt, E. Roland,
A. Hill, V. Chau
3.186 Subcortical Shape Analysis In
Temporal Lobe Epilepsy/S. Keller,
J. O’Muircheartaigh, C. Traynor,
K. Towgood, G. Barker,
M. P. Richardson
3.187 Analysis Of The Neocortex In
Mesial Temporal Lobe Epilepsy Using
Dipole Source Imaging And Cortical
Surface Analysis/L. P. Ferreira,
R. P. Paschoalato, S. Yamashita,
L. Betting
Functional Imaging
3.188 Favorable Post-Resective
Outcomes In MRI-negative Refractory
Extratemporal Localization-Related
Epilepsy Using Subtraction Ictal
SPECT Co-registered To MRI
(SISCOM)/A. Jalota, M. Rossi,
R. Byrne
3.189 Hippocampal Functioning In A
Language And A Verbal Memory
Paradigm In Children With Epilepsy/
L. Sepeta, M. Berl, B. Xu,
V. Roopchansingh, L. Barrett,
W. Theodore, W. Gaillard
3.190 Simultaneous Intracranial EEG
And fMRI Of A Seizure/D. Carmichael,
U. J. Chaudhary, R. Thornton,
R. Rodionov, S. Vulliemoz, A. McEvoy,
B. Diehl, M. Walker, J. Duncan,
L. Lemieux
3.191 Magnetoencephalographic
Representation Of Language Activity
In Patients With Intractable Epilepsy:
Effect Of Noise Covariance/N. Suzuki
3.192 Probing Intracranial EEGCharacterized Seizure Propagation
Networks With Resting State
Functional MRI/K. Karkar, O. Lie,
H. Y. Wey, F. Salinas, J. L. Lancaster,
P. T. Fox, C. Szabo, T. Q. Duong
3.193 Seizure Propagation In A
Patient With Musicogenic Epilepsy – A
Multimodal Imaging Study/S. Klamer,
A. Elshahabi, C. Braun, H. Lerche,
N. Focke
3.194 Impaired Attention Is
Associated With Greater fMRI Signal
Changes During Absence Seizures/
R. Kim, J. Guo, S. Jhun, H. Mistry,
W. R. Xiao, A. Kundishora,
G. Castellucci, S. Braun,
J. Rodríguez-Fernandez, X. Bai,
M. Negishi, C. Bailey, M. J. Crowley,
T. Constable, L. C. Mayes,
H. Blumenfeld
3.195 Bold Signal Changes
Associated With Temporal Lobe
Interictal Discharges Examined With
Simultaneous IEEG-fMRI/C. Beers,
I. Gaxiola Valdez, D. J. Pittman,
A. Kang, Y. Aghakhani, P. Federico
3.196 18FDG-PET May Give A
Diagnostic Clue For Patients With
Febrile Infection-Related Epileptic
Syndrome/J. Kim, H. Kang, H. Kim,
M. Oh, J. Lee
3.197 Morphology-Based SemiAutomatic Analysis Of Interictal EEGfMRI In The Presurgical Work-Up Of
Refractory Focal Epilepsy/S. Tousseyn,
P. Dupont, K. Goffin, S. Sunaert,
W. Van Paesschen
3.198 The Pre-Operative Evaluation
Of Intractable Mesial Temporal Lobe
Epilepsy Without Hippocampal
Sclerosis/N. Tsuyuguchi, M. Morino,
T. Uda, K. Ohata
3.199 Prospective Florbetapir F 18
PET/CT To Evaluate Perfusion Patterns
And Amyloid Deposition In Chronic
Temporal Lobe Epilepsy/B. K. Day,
R. E. Hogan, J. McConathy,
L. Maccotta
Antiepileptic Drugs
8:00 a.m. – 3:30 p.m.
3.209 Abuse Potential Assessment
Of Eslicarbazepine Acetate In Healthy
Male And Female Recreational
Sedative Users/N. Levy-Cooperman,
D. Blum, H. Cheng, B. Chakraborty,
T. Hopyan, J. Faulknor, K. A. Schoedel
3.210 Adjunctive Eslicarbazepine
Acetate In Patients With Refractory
Partial-Onset Seizures: Efficacy
Results Of A 12 Week Randomized
Placebo-Controlled Study On Behalf Of
The 304 Study Team/M. Sperling,
J. Harvey, A. Biraben, C. Galimberti,
P. Kowacs, S. B. Hong, H. Cheng,
D. Blum, T. Nunes, P. Soares-da-Silva
3.211 Long-Term Retention, And
Reasons For Discontinuations, With
Perampanel Treatment In
Pharmacoresistant Focal Seizures/
J. Shih, E. Perucca, M. Gee,
M. Bagul, D. Kumar
3.212 Comparison Of Bioavailability
And Dissolution Data For Generic
Lamotrigine Tablets In The Equigen
Trial/T. Welty, E. Elder, A. Schuelke,
K. Jones, B. Gidal, P. Bolger,
R. Alloway, M. Privitera, M. Berg
3.213 Effectiveness And Tolerability
Of Perampanel After 3 Months Of
Treatment In Children And
Adolescents With Refractory Epilepsy
– First European Experience/A. Biro,
A. Müller, U. Stephani, T. Tarallo,
K. Schlachter, T. Bast, G. Kurlemann,
B. Fiedler, S. Leiz, M. Nikanorova,
M. Wolff, E. Haberlandt, C. Selch,
A. Fiedler, M. Staudt, G. Kluger
3.214 Use Of Investigator Training To
Improve Seizure Classification In
Prevail—A Phase 3, Global Study
Evaluating USL255, Once-daily
Extended-Release Topiramate, In
Adults With Partial-Onset Seizures/
B. DiVentura, J. A. French, B. Anders,
D. Laine, M. B. Halvorsen
3.215 Clobazam-Treated Patients
With LGS Experienced Fewer SeizureRelated Injuries Than Placebo Patients
During The Contain Trial/D. Lee,
M. Sperling, J. Isojarvi
3.216 Feasibility Of Assessing
Antiepileptic Drug Bioequivalence In
Patients With Epilepsy Under Clinical
Use Conditions/T. Ting, W. Jiang,
A. Krumholz, J. Polli
3.217 Intravenous Levetiracetam
Efficacy In Children With Acute
Repetitive Seizures And Effective
Factors/R. Isguder, O. Guzel, H. Agin,
S. Akarcan, U. Yilmaz, A. Unalp,
N. Unal
3.218 Perampanel Use Over 3 Years
In Partial Onset Seizures: Canadian
Experience/N. Pillay, P. Hwang,
R. McLachlan
Of Adjuvant High Dose Nocturnal
Diazepam Treatment For Electrical
Status Epilepticus Of Sleep/
R. C. Gunasekara, D. Francois,
S. Hess, K. Tornabene, K. Mehrotra,
C. Mohan, L. Probst, Y. Eksioglu
Non-AED / Non-Surgical
Treatments (Hormonal,
Ketogenic, Alternative, Etc.)
Adult
3.220 Adjunctive Use Of Verapamil In
Patients With Refractory Temporal
Lobe Epilepsy/A. Asadi-Pooya,
A. Razavi, A. Abdi, M. R. Sperling
3.221 Ketogenic Diet For Adults In
Super-Refractory Status Epilepticus/
J. Probasco, K. Thakur, S. Hocker,
K. Roehl, B. Henry, E. Kossoff,
P. Kaplan, R. Geocadin, A. Venkatesan,
M. Cervenka
3.222 Impact Of Sensorimotor
Rhythm (SMR) Neurofeedback On
Quality Of Life In Patients With
Epilepsy: A Case Series/L. Frey,
L. Friedlander, L. Strom
3.223 Medical Marijuana For Epilepsy:
A Case Series Study/J. Tellez-Zenteno,
L. D. Ladino, L. Hernandez Ronquillo
Pediatrics
3.224 Bone Health In Children
Treated With Ketogenic Diet: A
Retrospective Matched Cohort
Study/M. Gainza, A. Michoulas,
F. Zanotto, C. Simonson, A. Ferguson,
L. Huh, K. Selby, M. Connolly
3.225 Comparison Of Ketogenic Diet
And Modified Atkins Diet In Children
With Epilepsy: A Randomized
Controlled Trial/J. Yoon, E. Lee,
H. Kim, J. Lee, H. Kang
3.226 Growth And Energy Intake In
Infants And Children Treated With The
Ketogenic Diet/L. Thompson,
H. Kayyali, M. Gustafson, M. AhMu,
T. Myers, E. Fecske, A. Abdelmoity
3.227 The Impact Of The Ketogenic
Diet Treatment On The Frequency Of
Emergency Room Visits, Number Of
Hospitalizations And The Length Of
Hospitalizations Related To Epilepsy/
A. Luniova, S. Abdelmoity, H. Kayyali,
A. Abdelmoity
3.228 The Combined Use Of
Clobazam Along With Ketogenic Diet
In Children With Refractory Epilepsy/
M. Gustafson, E. Fecske, T. Myers,
A. Abdelmoity
3.229 The Effects Of Ketogenic Diet
Treatment On The Immunoglobulin
Levels And On The Infection Frequency
And Severity In Children Diagnosed
With Epilepsy/O. Guzel, R. Isguder,
N. Arslan, H. Agin, N. Unal
3.230 Carnitine Deficiency Exists In
Children On The Medium Chain
Triglyceride (MCT) Ketogenic Diet/
Y. Liu, H. Lowe, M. Zak, J. Kobayashi,
V. Chan, E. Donner
3.231 Comparison Of Treatment
Effect Between Ketogenic Diet And
Oral Steroid For Patients With
Infantile Spasm/B. H. Noh, H. Kim
3.232 Efficacy Of Ketogenic Diet In
Dravet Syndrome/K. Imai, E. Ishihara,
H. Ikeda, T. Yamaguchi, R. Takayama,
Y. Ueda, Y. Takahashi, Y. Inoue
MONDAY
Clinical Trials
3.200 What A “Drop-Out” Reveals
About The Impact Of The Nocebo
Effect In Patients With Epilepsy/
J. Polli, T. Ting, W. Jiang
3.201 Safety/Tolerability Of Adjunctive
Intravenous (IV) Brivaracetam (BRV)
As Infusion Or Bolus In Patients With
Epilepsy/P. Klein, V. Biton, D. Dilley,
M. L. Barnes, J. Schiemann, Z. Lu
3.202 Interactions Between
Concomitant Antiepileptic Drugs And
Eslicarbazepine Acetate: A Population
Pharmacokinetic Analysis/
M. Jacobson, B. Gidal, D. Blum,
3.203 Safety And Tolerability Of
Adjunctive Brivaracetam Administered
As Oral Solution In Pediatric Patients
Aged >1 Month To 16 Years With
Epilepsy/E. Liu, A. Hepner, D. Dilley,
A. Stockis, A. Daniels
Clobazam For LGS Patients Who
Completed All 15 Weeks Of The
Phase III Contain Trial/J. Conry, Y. Ng,
G. Peng, D. Lee, J. Isojarvi
3.205 Response To Clobazam Among
Benzodiazepine-experienced LGS
Patients During The Contain Trial/
W. Rosenfeld, J. Isojarvi, K. Nichol,
D. Lee
3.206 Pharmacokinetics Of Oncedaily, Extended-release Trokendi XR™
(SPN-538) In The Elderly/W. O’Neal,
S. Brittain, J. Dugan Stocks,
J. Johnson, P. Baroldi
3.207 Efficacy Of Ezogabine/
Retigabine, Using A Flexible Dosing
Regimen, As Adjunctive Therapy To
Specified, Individual Antiepileptic Drug
Treatments In Adults With PartialOnset Seizure/H. Lerche, J. Daniluk,
N. Lotay, S. DeRossett, S. Edwards
3.208 Adverse Event Profile Of
Eslicarbazepine Acetate During Dose
Titration In Phase III Controlled
Studies Of Patients With Refractory
Partial-Onset Seizures/G. Krauss,
V. Biton, J. Harvey, D. Blum,
Poster Session 3
65
3.233 The Effects Of Changes In
Duty Cycle On The Efficacy Of Vagal
Nerve Stimulation Therapy In Children
With Intractable Epilepsy/O. Guzel,
A. Kilit, R. Isguder, H. Agin, N. Unal
3.234 The Simultaneous Use Of
Ketogenic Diet And Vagus Nerve
Stimulator In Patients With
Pharmacologically Refractory
Epilepsy/K. McEachran, M. Gustafson,
E. Fecske, T. Myers, A. Abdelmoity
3.235 The Correlation Between
Betahydroxybutyrate And Urine
Ketone Measurements During
Ketogenic Diet Initiation And The
Differences Between Patients Older
And Younger Than 2 Years Of Age/
T. Myers, M. Gustafson, E. Fecske,
Z. Hawa, A. Abdelmoity
3.236 Pericardial Effusion And
Cardiac Tamponade During ACTH
Treatment For Infantile Spasms/
A. M. Brian, J. D. Sparks, K. Skjei
3.237 A Comparison Between
Enterally Fed Patients And Orally Fed
Patients Following The Ketogenic
Diet/M. Joy, M. Ybarra, J. Kane,
D. Clarke
3.238 A Ketogenic Diet Quality
Improvement Initiative/M. I. Ciobanu,
D. Hale, M. Irwin, C. Lee
All Ages
3.239
Vagus Nerve Stimulation (VNS)
Therapy In 46 Patients With LennoxGastaut Syndrome (LGS) In
Venezuela/A. Soto, G. Contreras,
V. Sainz, E. Rubio, H. Scholtz,
O. Hernandez, F. Duran
3.240 Impact On Quality Of Life In
Patients With Refractory Epilepsy
Submitted To Therapy With VNS/
A. M. Estevo, L. Nakaharada,
M. B. Guaranha, L. A. Soster,
E. Garzon
Animal
3.241 The Ketogenic Diet Attenuates
Both Seizure Severity And Increases
In Glial Fibrillary Acidic Protein
Expression Following Kainic Acid
Administration In Mice/M. Abdelwahab,
J. M. Rho, D. Kim
3.242 Hippocampal Glucose
Metabolism Altered By Medium Chain
Triglycerides/T. McDonald, K. Tan,
M. P. Hodson, K. Borges
3.243 Fructose-1,6-diphosphate
Protects Against Epileptogenesis By
Modifying Cation-chloride
Cotransporters In A Model Of
Amygdaloid Kindling Temporal
Epilepticus/Y. Ding, S. Wang, M. Ding
3.244 D-Leucine, An Amino Acid That
Protects Against Seizures/
A. Hartman, P. Santos, J. M. Hardwick
66
Poster Session 3
8:00 a.m. – 3:30 p.m.
3.245 Validation Of The Rat Tetanus
Toxin Model Of MTLE For The
Assessment Of Responsive
Neurostimulation Therapy/J. Goodman,
A. Saghyan, C. Wang, N. Nathwani,
M. Breeden, N. Hasulak, T. Crowder
Skarpaas, K. Cicora, T. Monroe,
W. Wan, T. Tcheng
Surgery
Adult
3.246 Patient Centered Priorities For
Post-Surgical RCT Enrollment:
Barriers, Motivations, And Ethics/
P. Ford, D. Patton, K. Yee, D. Miller,
J. Gonzalez-Martinez, L. Jehi
3.247 Long-Term Outcomes Of
Disconnection Vs. Vagal Nerve
Stimulation For Drug Resistant
Epilepsy/L. Moura, A. Cole, D. Hoch
3.248 Stereotactic Radiofrequency
Amygdalohippocampectomy: Two Years
Of Good Neuropsychological
Outcomes/H. Malikova, L. Kramska,
Z. Vojtech, J. Lukavsky, R. Liscak
3.249 Long-Term Post-Operative
Psychosocial Outcomes After
Resective Surgery For Epilepsy/
V. Wasade, R. Tahir, L. R. Schultz,
B. Smith, K. Elisevich, J. Schwalb,
M. Spanaki
3.250 Intractable Focal Epilepsy In
Women Of Childbearing Age:
Reproduction And The Effect Of
Epilepsy Surgery/R. Fabris, R. Marsh,
F. Meyer, J. Mandrekar, T. Griffin
Cascino, G. Cascino
3.251 Intracranial Monitoring And
Surgical Outcomes In Temporal Lobe
Epilepsy With Bilateral Hippocampal
Atrophy/W. Hu, V. Sulc, Z. Nedelska,
J. Choi, L. Ren, G. Ghearing,
J. Britton, G. Worrell
3.252 Safety, Efficacy, And Life
Satisfaction Following Resective
Epilepsy Surgery In Older Patients/
S. Dewar, B. Moseley, D. Eliashiv
Language
Adult
3.253 Prospective Memory After
Mesial Temporal Lobe Resection For
Mesial Sclerosis Associated
Epilepsy/C. Adda, A. P. Santos,
C. Jorge, R. Valerio, L. Castro
3.254 Functional And Structural
Abnormalities In Patients With
Idiopathic Generalized Epilepsy/
L. Betting, J. C. Marchette,
W. P. Blasque, A. M. Braga,
S. Yamashita, A. T. Cerqueira
3.255 Basal Temporal Language Area
Revisited In Japanese – Its Anatomy,
Function And Connectivity/
R. Matsumoto, T. Kunieda,
A. Shimotake, H. Imamura,
K. Kobayashi, K. Usami, T. Kikuchi,
H. Fukuyama, R. Takahashi, N. Mikuni,
S. Miyamoto, A. Ikeda
3.256 Obesity And Epilepsy: Possible
Factors Affecting Co-Morbidity/
G. Risse, P. Penovich, E. Prazak,
M. Jones-Gotman
3.257 Empathy Ability And Emotion
Recognition In Temporal Lobe Epilepsy
And Idiopathic Generalized Epilepsy/
L. Zummo, O. Daniele
3.258 Theory Of Mind Disorders In
Temporal Lobe Epilepsy Patients:
Demographic, Clinical, Quality Of Life
And Psycho-Affective Relationship/
S. Hennion, X. Delbeuck, R. Lopes,
L. Tyvaert, P. Derambure, W. Szurhaj
3.259 A Comparison Of MMPI
Results Of Patients Having No Events
During Video EEG Monitoring With
Patients With Epileptic Events And
Non Epileptic Seizure Like Events/
C. Schramke, J. P. Valeriano,
K. M. Kelly
3.260 Socialization Patterns In
Patients With Psychogenic NonEpileptic Seizures (PNES)/U. Vaidya,
L. Myers, M. E. Lancman, S. Szuster,
M. Lancman, E. Feoli
3.261 Effects Of Amygdala Lesion In
The Right Hemisphere On Higher
Brain Functions Among Intractable
Temporal Lobe Epilepsy Patients/
K. Usui, K. Terada, N. Usui,
K. Matsuda, K. Araki, Y. Araki,
H. Hosoyama, T. Tottori, K. Baba,
Y. Inoue
3.262 Predictors Of Severity In
Psychogenic Non-Epileptic Seizures/
J. Pritchard, M. Cohen, J. Zhu,
S. Testa, J. Hopp
Genetics
Human Studies
3.263 Genetic Testing Preferences
Among Individuals With Epilepsy And
Unaffected Family Members: Testing
Modalities/S. Sorge, J. O. Okeke,
V. Tangel, S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
3.264 Whole Exome Sequencing
Reveals Recessive Mutations In CUL7
And TBCD In Two Siblings With
Landau-Kleffner Syndrome/V. Tiwari,
S. K. Sundaram, J. S. Maksabo,
A. M. Huq, H. Chugani
3.265 Exome Sequencing Of Two
Families With Familial Adult Myoclonic
Epilepsy/M. Cadieux-Dion,
E. Andermann, F. Andermann,
M. Gravel, D. Nguyen, P. Cossette
3.266 Unravelling The Genetics Of
The Common Epilepsies Using
Discordant Monozygotic Twins/
M. Hildebrand, S. Petrovski,
J. Damiano, B. Regan, I. Scheffer,
E. Heinzen, D. Goldstein, S. Berkovic
3.267 Dissecting The Genetic
Architecture Of Focal Epilepsy
Through Genomic Heritability Analysis/
M. Johnson, D. Balding, A. Marson,
D. Speed
8:00 a.m. – 3:30 p.m.
3.281 Dentate Gyrus Transcriptome
Analyzes By High-throughput Next
Generation Sequencing In A Chronic
Epilepsy Animal Model Without Status
Epilepticus/A. S. Vieira, A. Matos,
M. G. Borges, C. S. Rocha,
B. S. Carvalho, V. Pascoal,
I. Lopes-Cendes
Human Studies
3.282 Histopathology Of New Onset
Refractory Status Epilepticus
(NORSE)/K. Suchdev, M. Basha,
W. Kupsky, A. Shah, S. Mittal
3.283 Increased Aquaporin 4 (AQP4)
Is Not Correlated With T2 MRI In
Temporal Lobe Epilepsy/
J. E. Peixoto-Santos, T. R. Velasco,
J. A. Assirati, C. G. Carlotti,
C. G. Salmon, R. C. Scandiuzzi,
C. Santos, J. Leite
3.284 Invasive EEG Patterns And
Clinical Characteristics Of Various
Types Of Focal Cortical Dysplasia/
A. Pinheiro-Martins, R. Busch,
J. Bulacio, J. Gonzalez-Martinez,
W. Bingaman, I. Najm
3.285 Increased Oligodendroglial-Like
Cells In Subcortical Areas Correlating
With Epileptic Spasms In Intractable
Pediatric Epilepsy/S. Sakuma,
W. Halliday, A. Ochi, H. Otsubo
3.286 Encephalitis Outcomes And
Management: A Retrospective
Study/A. Jongeling, E. E. Meyers,
B. Foreman
Animal Studies
3.287 Lithium Pilocarpine-Induced
Status Epilepticus In The Immature
Rat Results In Age-Specific
Neurodegeneration: A Comparison Of
Three Ages Using Fluoro-Jade B And
A Novel Miniature Video-EEG
Telemetry System/E. Scholl,
M. Lehmkuhle, F. Dudek, J. Ekstrand
MONDAY
3.268 Mild Case Of UnverrichtLundborg Disease Mimicking Juvenile
Myoclonic Epilepsy In Adulthood/
E. Andermann, F. Andermann,
D. Amrom, A. Lehesjoki
3.269 LGI1 Mutation Presenting As
D. Amrom, E. Andermann,
F. Andermann
3.270 Genetics And Reproductive
Decision-Making In Families With Two
Or More Individuals With Epilepsy/
V. Tangel, S. Sorge, J. O. Okeke,
S. Shostak, J. C. Phelan, J. Goldsmith,
M. Winawer, D. Hesdorffer,
W. K. Chung, R. Ottman
3.271 Hemimegalencephaly: Adult
Evolution/N. Wu, A. Ali, T. Krings,
D. Andrade
3.272 Contribution Of Molecular
Genetics In The Investigation Of
Epileptic Encephalopathies/
L. Nakaharada, E. Garzon,
C. A. Takeuchi, F. B. Piazzon,
M. B. Guaranha, F. Kok
3.273 NDE1 Gene Deletion
Presenting With Aicardi Syndrome/
C. Boelman, D. Chitayat, B. Minassian
3.274 Aicardi Syndrome: Long-Term
Evolution/A. Ali, D. Andrade, N. Wu
3.275 Deep Brain Stimulation For The
Management Of Seizures In MECP2
Duplication Syndrome/
F. A. Nascimento, H. Faghfoury,
T. Krings, A. Ali, J. D. Fridhandler,
A. Lozano, R. Wennberg, D. Andrade
3.276 An Uncommon Presentation Of
A MECP2 Mutation: Malignant
Migrating Partial Epilepsy Of Infancy
With Cataracts And Upper Motor
Neuron Deficits/E. Segal, E. Fertig,
S. Parisotto, H. Pedro
3.277 Mutations In PLCB1 In Early
Infantile Epileptic Encephalopathy:
Expansion Of The Phenotypic And
Genotypic Disease Spectrum/A. Ngoh,
I. Wentzensen, A. McTague, E. Meyer,
C. Applegate, D. Batista, E. Kossoff,
T. Wang, M. A. Kurian
Poster Session 3
Animal Studies
3.278 Seizure Predisposition After
Perinatal Hypoxia: Effects Of
Subsequent Age And Of An Epilepsy
Predisposing Gene Mutation/
M. Mikati, A. Leonard, E. Arehart
3.279 The Role Of Mutated GABA(a)
Receptor In The Pathogenesis Of
A. Stoica, P. Lachance-Touchette,
M. Choudhury, G. Di Cristo,
P. Cossette
3.280 Identification Of Quantitative
Trait Loci For Susceptibility To
Pilocarpine-induced Cell Death In
Inbred Strains Of Mice/
P. Schauwecker
67
THE EPILEPSY RESEARCH BENCHMARKS
2014 NINDS Benchmarks for Epilepsy Research
On April 17-19, 2013, the National Institute of Neurological Disorders and Stroke (NINDS) hosted Curing the Epilepsies
2013: Pathways Forward, the third in a series of Curing the Epilepsies conferences held in partnership with epilepsy
advocacy and professional organizations to assess progress in epilepsy research and help set an agenda for future years. As
an important outcome, these conferences have led to development and revision of Benchmarks for Epilepsy Research, which
reflect shared priorities across the epilepsy community for research toward clinically meaningful advances in understanding
and treating the epilepsies, and ultimately toward prevention and cures. Since their initial development in 2000, the
Benchmarks have helped to galvanize the research community around broad goals and bring attention to emerging
opportunities, such as preventing epileptogenesis, understanding and addressing aspects of the epilepsies beyond seizures,
and confronting the challenge of sudden unexpected death in epilepsy (SUDEP) — all of which are now vibrant areas of
epilepsy research.
With input from the April 2013 conference and the wider epilepsy community, NINDS has now developed 2014
Benchmarks for Epilepsy Research as a framework for focusing research and benchmarking progress over the next five to
ten years. Please visit http://www.ninds.nih.gov/research/epilepsyweb to read more about the new Benchmarks.
AES / NINDS Epilepsy Research Benchmarks Stewards
The Benchmarks Stewards are a group of epilepsy researchers who have volunteered to track and promote progress in
areas highlighted by the NINDS Benchmarks for Epilepsy Research. To broaden visibility and participation, this group will be
an AES committee beginning in 2014. New Stewards will be added each year from among interested AES members to serve
three-year terms. The full roster of 2014 Stewards will be announced prior to the 2013 AES Annual Meeting.
NINDS gratefully acknowledges the following outgoing stewards, who have provided many years of service. Their dedication
and expertise have been invaluable for monitoring research advances and opportunities and for making the Benchmarks an
integrated part of the epilepsy research community.
Matthew Anderson, M.D., Ph.D., Beth Israel Deaconess Medical
Jocelyn Bautista, M.D., Cleveland Clinic
Anne Berg, Ph.D., Children’s Memorial Hospital Chicago
Edward Bertram, M.D., University of Virginia
Amy Brooks-Kayal, M.D., University of Colorado Denver
Marc Dichter, M.D., Ph.D., University of Pennsylvania
Jerome Engel, M.D., Ph.D., University of California Los Angeles
Tracy Glauser, M.D., Cincinnati Children’s Hospital
Bruce Hermann, Ph.D., University of Wisconsin Madison
Molly Huntsman, Ph.D., University of Colorado Denver
Ruben Kuzniecky, M.D., New York University
John Langfitt, Ph.D., University of Rochester Medical Center
Brian Litt, M.D., University of Pennsylvania
Solomon Moshé, M.D., Albert Einstein College of Medicine
Patricia Shafer, RN, M.N., Beth Israel Deaconess Medical
Alexander Rotenberg, M.D., Ph.D., Children’s Hospital Boston
Elson So, M.D., Mayo Clinic, Rochester
John Swann, Ph.D., Baylor College of Medicine
Carl Stafstrom, M.D., University of Wisconsin
H. Steve White, Ph.D., University of Utah
Karen Wilcox, Ph.D., University of Utah
Story C. Landis, Ph.D.
Director, NINDS
Stewards
Chair, Benchmarks Stewards
University of California, San Francisco
Raymond J. Dingledine, Ph.D.
Vice-Chair, Benchmarks Stewards
Emory University
Cara Long, Ph.D.
Co-Chair, Benchmarks
NINDS
For more information about the Benchmarks and to view past Stewards’ reports, please visit:
http://www.ninds.nih.gov/research/epilepsyweb/2007_benchmarks.htm
68
• AES 67TH ANNUAL MEETING Washington, D.C. •
TUESDAY December 10, 2013
www.AESnet.org
7:00 a.m. – 8:30 a.m.
Frontal Lobe Epilepsy: AED and Surgical Treatment
Approaches in Frontal Lobe Epilepsies: Update on Current
Practices and Controversies
Dr. Caplan will briefly describe how to screen for the comorbidity profile
across the ages and identify patients most in need of intervention. Drs. Lin
and Barry will talk about cognitive rehabilitation and psychiatric treatment,
respectively, in adults with epilepsy. Dr. Berl will discuss cognitive
rehabilitation for working memory deficits, and Dr. Jones will describe CBT in
children with epilepsy with anxiety disorders. After these brief presentations,
how best to treat two complex cases, one adult and one child, will be the
focus of discussion by the speakers and audience.
Coordinator: Fernando Cendes, M.D., Ph.D.
Speakers: TBA
Advances in knowledge and technology pose new challenges and controversies.
Frontal lobe epilepsy is the second most common type of localization-related
epilepsy that undergoes surgical treatment, but probably the most challenging in
terms of medical and surgical management. The causes are diverse and often
undetected by current standards of neuroimaging investigation, and a large
proportion of patients need invasive EEG investigation. Despite advances in
technology, many patients with frontal lobe epilepsy cannot undergo surgery
either due to seizure onset zone being close to or involving eloquent areas (motor
and language) or because there is a lack of clear localization of epileptogenic
lesion / seizure focus. We will discuss the promising approaches to improve
investigation and surgical outcome and also the AED and other therapeutic
alternatives in those for whom surgery is not indicated.
Pediatric Epilepsy Diagnosis and Treatment Opportunities –
Case-Based Discussion
Coordinator: Elaine Wyllie, M.D.
Speakers: TBA
Six dynamic faculty members will each present an exciting case from his or
her clinical experience that teaches an important clinical point and advances
our field of pediatric epilepsy. Topics will be diverse and touch on
controversies in EEG, seizure semiology, genetics, neurometabolism,
neuroimaging, antiepileptic drug therapy, and epilepsy surgery. Audience
interaction is encouraged and welcome.
Convention Center – Room 102A, Street Level
Coordinator: Gregory Barkley, M.D.
Annual update on ICD and CPT coding plus an open forum to discuss
Electronic Health Record (EHR) issues, tips, and tricks. Participants are
encouraged to submit suggestions of problems or tips from their own
practices ahead of time. Submit to [email protected].
Psychiatry in Epilepsy: Epilepsy Comorbidity Profiles:
Treatment Targets
Coordinators: Rochelle Caplan, M.D., John Barry M.D.
Speakers: Rochelle Caplan, M.D., Jack J. Lin, M.D., John Barry, M.D.,
Madison Berl, Ph.D., Jane Jones, Ph.D.
Despite extensive evidence on the comorbidities of epilepsy and their impact
on quality of life, resources are limited to conduct comprehensive assessment
and treatment of the interrelated psychiatric, cognitive, linguistic, and social
comorbidities of many epilepsy patients. To address these unmet needs, this
year’s Psychiatry in Epilepsy SIG has two main goals. The first goal is to
inform the audience about the different comorbidity profiles and how to
determine which individuals are in most need of treatment for the
comorbidities. The second goal is to introduce participants to cognitive
rehabilitation techniques and cognitive behavior treatments (CBT) that modify
the comorbidity profile and improve the functioning and quality of life of
epilepsy patients across the ages.
(2.0 CME Credits)
Overview
This symposium will bring together emerging knowledge and ongoing
investigations into the emergence of epilepsy and associated neurocognitive
and neurobehavioral comorbidities in a number of syndromes that demonstrate
such an association. The study of biomarkers to be considered will involve
clinical neurophysiological markers as well as neuroimaging-based approaches.
Interventional possibilities based on mechanism-based identification of
therapeutic targets in animal models will also be highlighted.
Learning Objectives
u
Recognize biomarkers for epilepsy-related comorbidities which help direct
management of patients
u
Use neuroimaging and neurophysiology to supplement neurocognitive
tests and screens for HRQoL to assess the etiology and extent of
neurocognitive deficits in patients with epilepsy.
Target Audience
Advanced (see page 106 for details)
Program
Chair: Raman Sankar, M.D., Ph.D.
8:30 a.m.
Introduction
Raman Sankar, M.D., Ph.D.
8:40 a.m.
Longitudinal Neurophysiological Study of Children with
Tuberous Sclerosis, TBI, and HIE
Joyce Wu, M.D.
9:05 a.m.
Relative Value of Structural vs Functional Imaging in
Cognitive Comorbidities
Carrie McDonald, Ph.D.
9:30 a.m.
Neuroimaging in Behavioral (Affective) Comorbidities of
Epilepsy
Frank Gilliam, M.D., M.P.H.
9:55 a.m.
Therapeutic Target Identification, Potential Biomarkers
from Animal Models
Andrey Mazarati, M.D., Ph.D.
TUESDAY
Practice Management
8:30 a.m. – 10:30 a.m.
Scientific Symposium: Biomarkers for
Epileptogenesis and Neurocognitive and
Neurobehavioral Comorbidities
Raman Sankar, M.D., Ph.D.
69
Credit Designation
Credit Designation
Nursing Credit
Nursing Credit
Pharmacy Credit
Pharmacy Credit
Core Competencies: Medical Knowledge
Core Competencies: Medical Knowledge and Practice-Based Learning
8:30 a.m. – 10:30 a.m.
Hot Topics Symposium: New Insights into
Basic Mechanisms, Diagnosis and Treatment
of Epilepsy
(2.0 CME Credits)
Overview
Separate registration and ticket required
10:45 a.m. – 12:15 p.m. and 12:30 p.m. – 2:00 p.m.
Skills Workshops
Each workshop will run during both times
Basic EEG in Epilepsy: Fundamentals and Interpretation
Moderator: Greg Cascino, M.D.
u
Through the process of “staging,” define the likely prognosis for patients
at the time of initial presentation with seizures, and make management
decisions based on this assessment
The routine EEG recording remains essential in the care and management of
individuals with seizures and suspected epilepsy. The EEG is used for
diagnosis, classification of seizure type and identification of a specific epileptic
syndrome. EEG findings may be of prognostic importance and be used to
assess the efficacy of treatment. Use of appropriate EEG methodology and
recognition of artifact and benign variant patterns are essential for satisfactory
clinical studies. This workshop will review basic methodologies of EEG for the
evaluation and treatment of pediatric and adult patients with seizure
disorders. This will include use of appropriate EEG techniques and
fundamentals of EEG recordings. Recognition of benign variant alterations and
ictal-interictal epileptogenic discharges will be addressed. The presentations
will also discuss the importance of EEG to identify characteristics of specific
epilepsies and epileptic syndromes.
u
Establish “staging” of patients with refractory epilepsy in order to help
define prognosis and inform treatment decisions.
Essentials of the Epilepsy Monitoring Unit: Basics for
Setting up Video EEG and Related Services
Staging of epilepsy, based on clinical history and diagnostic testing, allows
better prognostication and informs treatment decisions, be it at initial
presentation or when patients are being evaluated for refractory epilepsy.
Animal data regarding epileptogenesis may aid in defining the process of
epileptogenesis in humans, helping establish appropriate management. New
NIH benchmarks will help in prioritizing both basic and clinical research
efforts, including a better understanding of epileptogenesis.
Learning Objectives
Target Audience
Program
Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D., R. Edward Hogan, M.D.
8:30 a.m.
Introduction
R. Edward Hogan, M.D.
8:45 a.m.
Staging and Translational Aspects of Animal
Models of Epilepsy
Frances E. Jensen, M.D.
9:10 a.m.
9:35 a.m.
Clinical Issues and Seizure Severity
R. Edward Hogan, M.D.
Staging of Seizures According to Current Classification
Systems
Elinor Ben-Menachem, M.D., Ph.D.
10:00 a.m. Update on the New NIH Benchmarks
Elinor Ben-Menachem, M.D., Ph.D.
70
Moderator: Ed Hogan, M.D.
Technological advances have enhanced our capabilities for advanced
neurodiagnostic testing for epilepsy, enabling acquisition of video EEG and
ictal SPECT studies for clinical diagnostic purposes. This skills workshop will
review the basic indications and guidelines for establishing and maintaining an
epilepsy monitoring unit, as well as basic safety issues in the EMU. The
discussion will include practical information for set up and maintenance of
video EEG equipment as well as issues in acquisition and processing of ictal /
interictal SPECT studies.
Genetics: The Usefulness of Genetics in Patient Care
Moderators: Christina Gurnett, M.D., Ph.D.
Knowledge of genetics is becoming increasingly important for the diagnosis
and treatment of patients with epilepsy. In this skills workshop, we will
discuss the following questions: Do you need to test for HLA genetic variants
before starting carbamazepine or phenytoin? What is the role of
chromosomal microarray analysis in idiopathic generalized epilepsies or in
pediatric epileptic encephalopathies? What are the merits of single gene
testing vs. gene panels vs. comprehensive genetic testing (i.e. exomes) for
patients with epilepsy? How are genetic tests billed? How do you interpret
the results of genetic testing?
Intracranial Electrode Studies: How Do You Choose a
Technique for Optimum Localization?
Moderator: Dennis Spencer, M.D.
Over the past thirty years, resection for medically intractable epilepsy has
become a standard treatment option. However, in many instances successful
surgery is not possible without defining the potential respective volume by
intracranial electrophysiology. Imaging and stereotactic navigation have made
great strides since the 1990s and epilepsy centers have many choices
regarding types of electrodes, number of contacts needed, and how they are
delivered. This workshop will look at three centers with different solutions to
intracranial studies. Common problematic cases will be presented and each of
the three surgeons will provide a rationale for their solution to a standard
study.
Optimal Use of Neuroimaging in Diagnosing and Treating
Epilepsy
Moderator: Michael R. Sperling, M.D.
Neuroimaging is an essential tool in the diagnosis and treatment of epilepsy.
It has opened a window on the pathological substrate underlying epilepsy,
ranging from subtle gliotic lesions and cortical malformations to larger, more
extensive structural disturbances. This workshop will review the techniques
used to diagnose epilepsy, emphasizing both basic MRI customized for
epilepsy and advanced neuroimaging techniques. We will review a rational
approach to the use of neuroimaging and highlight specific techniques that
enhance diagnostic ability, along with newer fMRI and other functional
imaging methods. Interpretation of scans and various findings will be
reviewed in this practical session.
Practical Vagus Nerve Stimulation
Moderator: Elinor Ben-Menachem, M.D., Ph.D.
Neurostimulation is now an accepted treatment option for patients with
refractory epilepsy. At this point only vagus nerve stimulation (VNS) is
approved by the FDA for patients with epilepsy. This workshop will discuss
and instruct on how to use VNS effectively. After the workshop participants
should be able to identify appropriate patients, understand how implantation
is carried out and how to program the device. Side effects and how to
practically manage them will be discussed as well. If other neurostimulating
devices will be approved by the FDA during the months before the Annual
Meeting, the information on how to proceed with those devices will also be
addressed.
TUESDAY
71
EXHIBITOR FLOOR PLAN
Late Breaking Abstracts
Cyber Cafe
Poster Information Table
Poster Walking Tours begin at the Poster Information table
Exhibit Hall Hours:
Saturday, December 7 ..................................................Noon - 6:00 p.m.
Sunday, December 8 ........................................10:00 a.m. - 6:00 p.m.
Monday, December 9 ......................................10:00 a.m. - 3:30 p.m.
72
EXHIBITOR LOCATIONS
Booth
Acorda Therapeutics, Inc. ...........................................143
Booth
*GLUT1 Deficiency Foundation .......................................14
ADInstruments, Inc. ...................................................159
Integra LifeSciences Corporation.................................249
Ad-Tech Medical Instrument Corp.................................231
John Libbey EUROTEXT ...............................................118
AED Pregnancy Registry .............................................348
*LGS (Lennox-Gastaut Syndrome) Foundation...................9
Ambu Inc. ..................................................................509
Lifelines Neurodiagnostic Systems, Inc. .......................256
*American Board of Clinical Neurophysiology, Inc. (ABCN)...17
Lippincott Williams & Wilkins.......................................431
American Board of Psychiatry and Neurology ................533
Lundbeck Pharmaceuticals ..................................114, 115
*American Board of Registration of EEG and EP Technologies
(ABRET).....................................................................18
Medikidz ....................................................................536
*American Clinical Magnetoencephalography Society
(ACMEGS) ...................................................................6
MVAP Medical Supplies, Inc.........................................457
*American Clinical Neurophysiology Society (ACNS) ...........7
*American Epilepsy Society .............................................2
*Angel Wings Foundation ..............................................12
*Anita Kaufmann Foundation,The....................................16
*ASET – The Neurodiagnostic Society ............................20
Athena Diagnostics, Inc. .............................................132
BIOPAC Systems, Inc..................................................138
Blackrock NeuroMed...................................................437
Cadwell Laboratories, Inc. ...........................................337
Carolinas HealthCare System......................................350
*Charlie Foundation, The & ICE Epilepsy..........................11
Child Neurology Foundation .........................................336
Clever Sys, Inc. ..........................................................142
Compumedics Limited .................................................243
Courtagen Life Sciences, Inc. ......................................253
*CURE (Citizens United for Research in Epilepsy)..............3
Cyberonics, Inc. .........................................................315
*DClamp Software and IEEG Portal ..................................8
Demos Medical Publishing ...........................................415
DigiTrace EEG Services ...............................................333
*Dravet Syndrome Foundation .......................................13
Eisai Inc. ...................................................................203
Electrical Geodesics, Inc.....................................343, 444
ELEKTA Oy.................................................................215
Elsevier, Inc. ..............................................................110
Emfit, Corp. ...............................................................542
emka TECHNOLOGIES INC...........................................443
Emory Genetics Laboratory.........................................530
*Epilepsy Foundation...............................................1, 505
Epilepsy Life Links ......................................................152
*EpiNet Study Group ....................................................19
EUROIMMUN US........................................................251
GeneDx .....................................................................146
GlaxoSmithKline .........................................................123
National Association of Epilepsy Centers......................511
National Institute of Neurological Disorders &
Stroke (NINDS)........................................................556
Natus Neurology Incorporated.....................................423
Neuralynx, Inc ............................................................222
Neuro Quest LLC .......................................................257
NeuroPace, Inc...........................................................523
Nihon Kohden America, Inc. .........................................223
Novartis Pharmaceuticals ...........................................456
Nuro Pharma Inc. .......................................................116
Optima Neuroscience, Inc. ..........................................442
Oxford University Press ..............................................112
*PCDH19 Alliance.........................................................10
Persyst .....................................................................156
Pinnacle Technology, Inc...............................................130
PMT Corporation ........................................................122
Questcor Pharmaceuticals, Inc............................330, 432
Rhythmlink International, LLC ......................................514
Ripple LLC .................................................................237
Rogue Research Inc....................................................459
RSC Diagnostic Services ............................................157
*SeizureTracker.com .....................................................15
Smart Monitor Corp. ..................................................531
Sunovion Pharmaceuticals Inc. ....................................323
Supernus Pharmaceuticals, Inc. ..................................131
Sutter Health ............................................................128
Tenet Hospital System – South Florida.........................458
Texas Children’s Hospital.............................................356
Transgenomic, Inc.......................................................126
Triangle BioSystems, Inc. ............................................148
*Tuberous Sclerosis Alliance............................................5
UCB, Inc. ...................................................................101
Upsher-Smith Laboratories, Inc. .........................447, 513
Visualase, Inc.............................................................527
Vitaflo USA ................................................................158
Wiley .........................................................................338
EXHIBITORS
*Epilepsy Centers of Excellence, Department of Veterans
Affairs.........................................................................4
Multi Channel Systems ...............................................144
Global Neuro-Diagnostics............................................358
*Please see Epilepsy Resource Center participants on page 82
73
Stop by the EPILEPSY RESOURCE CENTER
at the Entrance of the Exhibit Hall
2013 Epilepsy Resource Center
— Participants —
Table # ERC Participants:
17 American Board of Clinical Neurophysiology
(ABCN)
18 American Board of Registration of EEG and
EP Technologies (ABRET)
6 American Clinical Magnetoencephalography
Society (ACMEGS)
7 American Clinical Neurophysiology Society
(ACNS)
2 American Epilepsy Society
12 Angel Wings Foundation
16 Anita Kaufmann Foundation, The
20 ASET - The Neurodiagnostic Society
11 Charlie Foundation And Ice Epilepsy
3 CURE (Citizens United for Research in
Epilepsy)
8 DClamp Software
13 Dravet Syndrome Foundation
4 Epilepsy Centers of Excellence, Department
of Veterans Affairs,
1 Epilepsy Foundation
19 EpiNet Study Group
14 GLUT1 Deficiency Foundation
9 LGS (Lennox-Gastaut Syndrome) Foundation
10 PCDH19 Alliance
15 SeizureTracker.com
5 Tuberous Sclerosis Alliance
New Therapies - New this Year!
As a result of the great presentations that took place
earlier this year at the 12th Conference on Antiepileptic
Drug Trials in Miami, AES has encouraged participation of
new therapies at our meeting to increase the knowledge
of meeting attendees. New Therapies will have
presentation time slots in our Epilepsy Resource Center.
New Therapies company participants and table
locations to follow.
74
Many of the ERC participants will be offering miniworkshops dedicated to the education, awareness
and research for people with epilepsy worldwide. All
participants of AES, including exhibitors, are invited to
attend the mini-workshops. The schedule will be
posted daily outside the ERC.
The Epilepsy Resource Center is a comprehensive
one-stop resource for patients, researchers and
clinicians specializing in the area of epilepsy.
EXHIBITORS
as of October 21, 2013
Exhibit Schedule
Saturday, December 7: Noon-6:00 p.m.
Lunch: Noon-1:00 p.m.
Symposia Break: 5:00 p.m.-6:00 p.m.
Prize Drawing: 5:30 p.m.
Sunday, December 8:10:00 a.m.-6:00 p.m.
Suds for Scientists: 5:00 p.m.-6:00 p.m.
Prize Drawing: 5:30 p.m
Acorda Therapeutics, Inc.
Booth #143
420 Saw Mill River Rd
Ardsley, NY 10502
Phone: 914-326-5787
Fax: 914-606-9608
Website: www.acorda.com
Contact: Ms. Crystal Friend
Website: www.aedpregnancyregistry.org
Contact: Ms. Caitlin Smith
Acorda’s mission is to develop therapies to
restore neurological function and improve the
lives of people with multiple sclerosis, spinal
cord injury and other disorders of the
nervous system.
Ambu Inc.
Booth #509
6740 Baymeadow Dr
Glen Burnie, MD 21060
Phone: 800-262-8462
Toll Free: 800-262-8462
Fax: 800-262-8673
Website: www.ambuUSA.com
Contact: Ms. Brittany Wilhelm
ADInstruments, Inc.
Booth #159
2205 Executive Cir
Colorado Springs, CO 80906
Phone: 719-576-3970
Toll Free: 888-965-6012
Fax: 719-576-3971
Website: www.adinstruments.com
Contact: Mr. Matthew Dilworth
ADInstruments provides computer-based
data acquisition systems for research. Our
multichannel PowerLab data acquisition
systems and LabChart 7 software provide
outstanding data acquisition, display and
analysis features for a wide range of life
science experimental applications. PowerLab
is USB 2.0 ready and compatible with the
latest Windows and Macintosh OS.
Ad-Tech Medical Instrument Corp.
Booth #231
1901 William St
Racine, WI 53404
Phone: 800-776-1555
Toll Free: 800-776-1555
Fax: 262-634-5668
Website: www.adtechmedical.com
Contact: Ms. Heidi Schultz
AED Pregnancy Registry
Booth #348
121 Innerbelt Rd - Ste 220 Massachusetts
General Hospital
Somerville, MA 02143
Phone: 617-724-9550
Toll Free: 888-233-2334
Fax: 617-726-1911
processes. ABPN also oversees the
certification process for physicians seeking
certification in child and adolescent psychiatry.
American Board of Registration of EEG and
EP Technologies (ABRET)
Booth #18
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Website: www.abret.org
Contact: Ms. Janice Walbert
The American Board of Registration of
Electroencephalographic and Evoked Potential
Technologists (ABRET) is the national
credentialing board for Neurodiagnostic
Technologists (R. EEG T., R. EP T., CNIM,
CLTM) and laboratory accreditation programs,
LAB-EEG, LAB-NIOM, and LAB-LTM. Learn
more about laboratory accreditation and other
resources.
Ambu is dedicated to the development of
innovative products that help save lives and
simplify workflow of the anesthetists to the
benefit of the patients.Within the field of
anesthesia Ambu offers a wide range of
American Clinical Magnetoencephalography
products from resuscitators, face masks and
Society (ACMEGS)
laryngeal masks to the highly innovative
Booth #6
single use flexible intubation scope.
555 E Wells St - Ste 1100
Milwaukee, WI 53202
American Board of Clinical Neurophysiology,
Phone: 414-918-9804
Inc. (ABCN)
Fax: 414-276-3349
Booth #17
2509 W Iles Ave - Ste 102
Website: www.acmegs.org
Springfield, IL 62704
Contact: Ms. Megan Kelley
Phone: 217-726-7980
ACMEGS is a non-profit association whose
Fax: 217-726-7989
membership includes clinical MEG facilities in
the US. Founded by physicians committed to
Website: www.abcn.org
high-quality care of patients with epilepsy,
Contact: Ms. Janice Walbert
ACMEGS now advocates for patients with
The ABCN has a 65 year history of promoting
neurological conditions who may benefit from
excellence in Clinical Neurophysiology and
MEG by educating policymakers about
offers examinations with added competency
recommended standards of care,
in Epilepsy Monitoring or Neurophysiologic
reimbursement, and provider regulations.
Intraoperative Monitoring. Visit our booth or
the ABCN website for outlines and Practice
American Clinical Neurophysiology Society
Exam order form. Exams are computer(ACNS)
based. International testing is available.
Booth #7
555 E Wells St - Ste 1100
American Board of Psychiatry and
Milwaukee, WI 53202
Neurology
Phone: 414-918-9803
Booth #533
Fax: 414-276-3349
2150 E Lake Cook Rd - #900
Buffalo Grove, IL 60089
Website: www.acns.org
Phone: 847-229-6500
Contact: Ms. Megan Kelley
Fax: 847-229-6600
The American Clinical Neurophysiology Society
(ACNS) is a professional association
Website: www.abpn.com
dedicated to fostering excellence in clinical
Contact: Ms. Karen Back
neurophysiology and furthering the
The American Board of Psychiatry and
understanding of central and peripheral
Neurology serves the public interest and the
nervous system function in health and disease
professions of psychiatry and neurology by
through education, research, and the provision
promoting excellence in practice through its
of a forum for discussion and interaction.
certification and maintenance of certification
EXHIBITORS
For over 25 years, Epilepsy Centers have
made Ad-Tech their choice for invasive
electrodes for brain mapping and epilepsy
monitoring. We offer a large variety of
electrodes and accessories to meet you and
your patients needs. Visit our booth to
discover why Ad-Tech is your best choice.
The North American AED Pregnancy
Registry’s goal is to determine the frequency
of major malformations in the infants
exposed during pregnancy to anticonvulsant
drugs. Visit our booth to learn more about
how you and your patients can help!
Monday, December 9: 10:00 a.m.-3:30 p.m.
Prize Drawing & Grand Prize Drawing:
3:00 p.m.
75
EXHIBITORS
Booth #2
342 N Main St
West Hartford, CT 06117-2507
Phone: 860-586-7505
Fax: 860-586-7550
Website: www.AESnet.org
Contact: Ms. Cheryl-Ann Tubby
The American Epilepsy Society promotes
research and education for professionals
dedicated to the prevention, treatment and
cure of epilepsy. Stop by the Epilepsy
Resource Center for information on
membership, publications and research
funding.
Angel Wings Foundation
Booth #12
2134 Baldwin Ct
Hanover Park, IL 60133
Phone: 630-550-1049
Website: www.angelwingsfoundation.net
Contact: Ms. Debbie Flader
The Angel Wings Foundation is dedicated to
enhancing the lives of those affected by
epilepsy and allowing them to reach their full
potential by living independently in the
community. Angel Wings Foundation’s vision
is to implement person-centered living; a way
of life centered on personal preferences and
values that stress dignity, individuality, and
choice.
Anita Kaufmann Foundation, The
Booth #16
1786 Lilbet Rd
Teaneck, NJ 07666
Phone: 201-655-0420
Toll Free: 866-596-4973
Fax: 866-303-3219
Website: www.akfus.org
Contact: Ms. Debra Josephs
AKF is a 501C3 charity with a grassroots
mission to educate the public not to fear
people with epilepsy, seizures or brain
trauma. We offer our 5th Grade Education
Program, our Heads Up For Vets Program &
free awareness materials for public use. As
the global sponsor for Purple Day® — World
Epilepsy Day™, we & our advocates organize
events around the globe.
ASET – The Neurodiagnostic Society
Booth #20
402 E Bannister Rd - Ste A
Kansas City, MO 64131
Phone: 816-931-1120
Fax: 816-931-1145
Website: www.aset.org
Contact: Ms. Lucy Sullivan
ASET – The Neurodiagnostic Society
represents more than 4,000 allied health
professionals who perform neurodiagnostic
procedures. ASET provides education and
advocacy, creates greater awareness of the
profession, and establishes standards and
best practices to ensure quality patient
76
care. Stop by our booth to see our newest
publications for the bedside caregiver.
Athena Diagnostics, Inc.
Booth #132
377 Plantation St
Worcester, MA 01605
Phone: 508-756-2886
Toll Free: 800-394-4493
Fax: 508-753-5601
Website: www.athenadiagnostics.com
Contact: Ms. Brenda Bowling
BIOPAC Systems, Inc.
Booth #138
42 Aero Camino
Goleta, CA 93117
Phone: 805-685-0066
Fax: 805-685-0067
Website: www.biopac.com
Contact: Ms. Mallory MacDougall
BIOPAC provides physiological data
acquisition and analysis systems for human
and small animal research applications. Stop
by to see wired and wireless solutions for
EEG including BioNomadix and B-Alert X10
wireless EEG Systems. Use AcqKnowledge
software for automated EEG analysis. The
fNIR100 Spectroscopy System monitors
hemodynamic changes in the human
prefrontal cortex.
Blackrock NeuroMed
Booth #437
630 Komas Drive, Ste 200
Salt Lake City, UT 84108
Phone: 801-994-5661
Fax: 877-623-6027
Website: www.blackrockneuromed.com
Contact: Ms. Shanna Ryan
Blackrock NeuroMed’s Cervello EEG/LTM
systems provide advanced EEG monitoring
technology including remote monitoring
capabilities, Bluetooth connectivity and
flexible integration for basic to advanced
clinical studies. Furthermore, all systems
include a comprehensive service package with
start-to-finish integration and comprehensive
IT support.
Cadwell Laboratories, Inc.
Booth #337
909 N Kellogg St
Kennewick, WA 99336
Phone: 509-735-6481
Toll Free: 800-245-3001
Fax: 509-783-6503
Website: www.cadwell.com
Contact: Ms. Lori Kaufman
Cadwell has developed useful instruments for
neurologists and technologists since 1979.
The Easy product family includes EEG for the
clinic, EMU and ICU, Ambulatory EEG with
our exclusive Q-Video Mobile for 72 hour in
home or lab monitoring all in a multi-modality
platform that adds full PSG capability.
Carolinas HealthCare System
Booth #350
c/o Physician Services, PO Box 32861
Charlotte, NC 32861
Phone: 704-401-8896
Fax: 704-355-5033
Website: www.choosecarolinashealthcare.org/
Contact: Ms. Sarah Foster
Currently seeking adult and pediatric
epileptolgists for the Charlotte, NC area.
Carolinas Pediatric Neurology Care at Jeff
Gordon Children’s Hospital has the state’s
only NAEC Level 3 Peds Dedicated EMU.
Northeast Neurology provides coverage for
the CMC-NorthEast Neuroscience Unit and
Adult EMU. The epilepsy program is Joint
Commission Disease-Specific Care Certified.
Charlie Foundation, The & Ice Epilepsy
Booth #11
1325 Victoria Cir. S.
Elm Grove, WI 53122
Phone: 262-754-8706
Fax: 262-754-1369
Website: www.charliefoundation.org
Contact: Beth Ann Zupec-Kania
The Charlie Foundation supports ketogenic
diet therapies for epilepsy through training
seminars. Our KetoCalculator program &
website are accessed by thousands worldwide. ICE Alliance (www.ice-epilepsy.org)
provides drug information, advocacy for
appropriate medical treatment & education,
a patient registry, & funding of research for
intractable childhood epilepsies.
Child Neurology Foundation
Booth #336
201 Chicago Ave - Ste 200
Minneapolis, MN 55431
Phone: 612-636-8600
Website: www.childneurologyfoundation.org
Contact: Mr. Steven Peer
The Child Neurology Foundation funds the
research, education, and collaboration
needed to cure and treat the one-in-four
children with a neurologic disorder.
Clever Sys, Inc.
Booth #142
11425 Isaac Newton Square - Ste 202
Reston, VA 20190
Phone: 703-787-6946
Fax: 703-757-7467
Website: www.cleversysinc.com
Contact: Ms. Naili Zhang
Clever Sys Inc. is a premier bioinformatics
software company utilizing patented Behavior
Recognition technology for automated
behavioral research systems. We offer
complete hardware and software solutions
for animal behavior data acquisition in a
variety of research areas and species.
Products include HomeCageScan,
SeizureScan, TopScan, GaitScan and many
more!
EXHIBITORS
Compumedics Limited
Booth #243
6605 WT Harris Blvd
Charlotte, NC 28269
Phone: 704-749-3200
Toll Free: 877-717-3975
Fax: 704-749-3299
Website: www.compumedics.com
Contact: Marjie Cummings
Compumedics Limited provides solutions for
epilepsy monitoring. NEUVO LTM and Grael
EEG Systems with CURRY-SCAN 7
Neuroimaging Suite meet requirements for
routine and ambulatory recordings as well as
LTM / Neuro-ICU monitoring. Compumedics
addresses ultra-high density and extended
frequency-range recordings for HFO, source
localization and source imaging.
Courtagen Life Sciences, Inc.
Booth #253
12 Gill Street - Suite 3700
Woburn, MA 01801
Phone: 617-999-4122
Fax: 617-892-7199
Website: www.courtagen.com
Contact: Lori Emrick
Courtagen Life Sciences, Inc. is a CLIA
certified and CAP accredited laboratory
providing genetic testing services for
neurological and metabolic disorders.
Courtagen delivers comprehensive sequence
analysis and reporting to enable clinicians to
make better decisions regarding patient care.
CURE (Citizens United for Research in
Epilepsy)
Booth #3
430 W Erie St - Ste 210
Chicago, IL 60654
Phone: 312-255-1801
Fax: 312-255-1809
Website: www.CUREepilepsy.org
Contact: Ms. Tracy Dixon-Salazar
Cyberonics, Inc.
Booth #315
100 Cyberonics Boulevard
Houston, TX 77058
Phone: 281-228-7200
Toll Free: 800-332-1375
Fax: 281-218-9332
Website: www.cyberonics.com
Contact: Renee Adams
DClamp Software and IEEG Portal
Booth #8
114 16th St - Ste 2600
Charlestown, MA 02129
Phone: 617-643-0364
Fax: 617-643-0141
Website: www.ieeg.org
Contact: Waldemar Swiercz
IEEG Portal-Sharing, collaborating, and
analyzing data on the cloud. DClamp - Free
automatic seizure detection software.
Optimized to analyze in-vivo EEG recordings
from rats and mice and in-vitro recordings
from acute and organotypic slices. New
version has updated detection routines and
allows for batch processing of multiple files.
Supported by AES and NINDS.
Demos Medical Publishing
Booth #415
11 W 42nd St - 15th Fl
New York, NY 10036
Phone: 212-683-0072
Toll Free: 800-532-8663
Fax: 212-941-7842
Website: www.demosmedpub.com
Contact: Mr. Thomas Hastings
Demos Medical is a publishing leader in clinical
neurology and related disciplines. Visit us in
Booth 415 to preview our current list of
premier print and new digital products
including Adult EEG on DVD, Second Edition,
Pediatric EEG DVD, Neurology Video Textbook,
Handbook of ICU EEG Monitoring, and more.
DigiTrace EEG Services
Booth #333
200 Corporate Place - Ste 5
Peabody, MA 01960
Phone: 978-536-6101
Fax: 978-536-6401
Website: www.sleepmedinc.com
Contact: Stuart Tuthill
DigiTrace EEG products and services are used
by dozens of comprehensive epilepsy centers
throughout the U.S. In addition, there are
over 40 SleepMed Service Centers around the
country where physicians can refer their
patients for ambulatory EEG testing. We are
noted for unique capabilities including our
lightweight head-mounted preamplifier that
minimizes motion artifact.
Dravet Syndrome Foundation
Booth #13
11 Nancy Dr
Monroe, CT 06468
Phone: 203-880-9456
Website: www.dravetfoundation.org
Contact: Ms. Lori O’Driscoll
Dravet syndrome and related epilepsies;
to increase awareness of these
catastrophic conditions; and to provide
support to affected individuals and
families. Since our inception in 2009, we
have awarded over $1.5M in research
grant awards.
Eisai Inc.
Booth #203
100 Tice Blvd
Woodcliff Lake, NJ 07677
Phone: 201-746-2527
Fax: 201-746-3196
Website: www.eisai.com
Contact: Ms. Shirley Hunt
Eisai Inc. is the U.S. pharmaceutical
operation of Eisai Co., Ltd., a researchbased human health care (HHC) company
that discovers, develops and markets
products throughout the world.
Headquartered in Woodcliff Lake, New
Jersey, Eisai’s key areas of commercial
focus are neurology and oncology. For
more information, please visit
www.eisai.com/US.
Electrical Geodesics, Inc.
Booth #343, 444
1600 Millrace Drive, Suite 200
Eugene, OR 97403
Phone: 541-687-7962
Fax: 541-687-7963
Website: www.egi.com
Contact: Diana Aguilar
EGI brings next-generation clinical EEG
systems, tools, and workflows to
hospitals and clinics worldwide. EEG
Systems feature EGI’s Geodesic Sensor
Net for rapid application and
unprecedented comfort. Your choice of
routine EEG systems or dense array
systems for source estimation.
ELEKTA Oy
Booth #215
Siltasaarenkatu 18-20
00530 Helsinki, Finland
Phone: 358-975-6240-22
Fax: 358-975-6240-11
Website: www.elekta.com/MEG
Contact: Ms. Riitta Pietilä
Elekta is the global leader in advanced
magnetoencephalography (MEG)
instrumentation. MEG is a highly sensitive
and completely non-invasive technology
increasingly used for localizing the
epileptogenic zone(s) and adjacent
eloquent cortex in pre-surgical evaluation
of epileptic patients.
Cyberonics, Inc. is the leader in device
solutions for epilepsy and is committed to
consistently delivering innovative and effective The mission of Dravet Syndrome Foundation is
solutions for physicians, caregivers and people to aggressively raise research funds for
77
EXHIBITORS
CURE (Citizens United for Research in
Epilepsy) is a nonprofit organization dedicated
to finding a cure for epilepsy by raising funds
for research and by increasing awareness of
the prevalence and devastation of this
disease. CURE funds seed grants to young
and established investigators to explore new
areas and collect the data necessary to apply
for further funding.
with epilepsy. Cyberonics’ VNS Therapy® is the
only FDA-approved device for the treatment of
refractory epilepsy, with more than 70,000
patients implanted worldwide.
EXHIBITORS
Elsevier, Inc.
Booth #110
1600 John F Kennedy Blvd - Ste 1800
Philadelphia, PA 19103
Phone: 215-239-3491
Fax: 215-239-3494
Website: www.elsevierhelath.com
Contact: Mr. Jeffrey Francis
Elsevier is a leading publisher of health
science publications, advancing medicine by
delivering superior reference information and
decision support tools to doctors, nurses,
health practitioners and students. With an
extensive media spectrum — print, online and
handheld — we are able to supply the
information you need in the most convenient
format.
Emfit, Corp.
Booth #542
PO Box 342394
Austin, TX 78734
Phone: 512-266-6950
Toll Free: 877-323-6348
Fax: 512-266-7203
Website: www.emfitcorp.com
Contact: Christine Ocean-Rintala
A world-leading manufacturer of movement
activity monitors for home & institutional
care. Featuring the Movement Monitor, an
intelligent bed monitor that continuously
monitors movements and alerts upon the
onset of repetitive muscle spasms & the
MM2: connects to Emfit servers through a
cell network. Events are recorded and
accessed from browser with user name and
password.
emka TECHNOLOGIES INC.
Booth #443
307 Annandale Road Suite 203
Falls Church, VA 22042
Phone: 703-237-9001
Fax: 703-237-9006
Website: www.emkatech.com
Contact: Ms. Virginie Brechet
Smaller, lighter, and even more signals! Check
out the all new non-invasive and tetherless
monitoring system: rodentPACK v2. This
wireless, head-mounted device measures
EEG, EMG, ECG, temperature, and activity
from up to 32 single or group housed
subjects simultaneously. rodentPACK v2 is an
affordable, reusable, and versatile solution,
brought to you by emka TECHNOLOGIES.
Emory Genetics Laboratory
Booth #530
2165 N Decatur Rd
Decatur, GA 30033
Phone: 404-778-8499
Toll Free: 855-831-7447
Fax: 404-778-8559
Website: www.geneticslab.emory.edu
Contact: Ms. Kelli Martin
Emory Genetics Laboratory (EGL) is a
worldwide leader in clinical genetic testing
78
for neurological disorders. EGL’s biochemical,
cytogenetics, and molecular laboratories
provide integrated and comprehensive
testing for neurologically-related genetic
disorders such as epilepsy and offers a nextgeneration sequencing panel featuring 130
genes associated with the disorder.
Epilepsy Centers of Excellence, Department
of Veterans Affairs
Booth #4
4150 Clement St (127E)
San Francisco, CA 94121
Phone: 415-221-4810
Fax: 415-379-5666
Website: www.epilepsy.va.gov
Contact: Mr. Ryan Rieger
Epilepsy Foundation
Booth #1, 505
8301 Professional Place
Landover, MD 20785
Phone: 301-918-3729
Toll Free: 800-332-1000
Website: www.epilepsy.com
Contact: Paul Scribner
The Epilepsy Foundation of America® is the
national voluntary agency dedicated solely to
the welfare of the more than 2 million people
with epilepsy in the U.S. and their families.
We work to ensure that people with seizures
are able to participate in all life experiences;
and to prevent, control and cure epilepsy
through services, education, advocacy and
research.
Epilepsy Life Links
Booth #152
820 2nd Ave - Ste 6C
New York, NY 10017
Phone: 212-661-7460
Fax: 212-661-7496
Website: www.epilepsylifelinks.com
Contact: Ms. Melissa Fleming
Epilepsy Life Links is the patient advocacy
branch of the Northeast Regional Epilepsy
Group in NY, NJ, and CT. Our services include
providing patient support groups, patient
education conferences & webinars, wellness
programs , community activities & our
Northeast Regional Epilepsy Group team
participates in national and local epilepsy
walks throughout the year.
EpiNet Study Group
Booth #19
Neurology Department, Auckland City
Hospital
Auckland, New Zealand
Phone: 6421480920
Fax: 6493078912
Website: epinet.co.nz
Contact: Mr. Peter Bergin
EpiNet is a platform to encourage clinical
research in epilepsy. A secure, on-line
database has been created to facilitate
cohort studies and pragmatic clinical trials.
Studies are initiated by investigators, and all
data remains under control of the
investigators. Epileptologists and
neurologists from anywhere in the world are
welcome to join.
EUROIMMUN US
Booth #251
1100 The American Rd
Morris Plains, NJ 07950
Phone: 973-656-1000
Toll Free: 800-913-2022
Fax: 973-656-1098
Website: www.euroimmun.us
Contact: Mrs. Lauren Popelka
EUROIMMUN produces a wide range of
reagents for medical laboratory diagnosis.
The main focus is on test systems for
antibodies in patient serum. These allow
highly sensitive and specific diagnosis of
autoimmune diseases, infectious diseases
and allergies. EUROIMMUN is an FDA
registered facility and is ISO 9000 certified.
GeneDx
Booth #146
481 Edward H Ross Dr
Elmwood Park, NJ 07407
Phone: 301-519-2100
Toll Free: 800-229-5227
Fax: 301-519-2892
Website: www.genedx.com
Contact: Ms. Marianne Sansing
GeneDx offers tests for more than 350 rare
Mendelian disorders using DNA sequencing
and del/dup analysis of the associated
gene(s), and oligonucleotide microarray-based
tests and next-generation sequencing based
panels for inherited cardiac, mitochondrial,
and neurodevelopmental disorders. GeneDx
specializes in prenatal diagnosis and
maternal/fetal risk assessment.
GlaxoSmithKline
Booth #123
7545 Hartman Industrial Way
Austell, GA 30168
Phone: 215-751-3572
Toll Free: 866-475-8222
Fax: 215-751-6520
Website: www.gsk.com
Contact: Mr. Barak Bright
Global Neuro-Diagnostics
Booth #358
2670 Firewheel Dr Ste B
Flower Mound, TX 75028
Phone: 214-532-3757
Fax: 972-692-8389
Website: www.globalneuro.net
Contact: Janice Shock
Global Neuro-Diagnostics is the gold
standard for in-home Ambulatory Video EEG
testing. Our level of expertise, server based
access, registered technologists and
wireless video technology cannot be matched
in our industry. We are proudly accredited by
The Joint Commission. Full compliance with
CPT codes including 95951 & 95957.
EXHIBITORS
GLUT1 Deficiency Foundation
Booth #14
PO Box 945
Westfield, IN 46074
Phone: 859-585-2538
Website: www.g1dfoundation.org
Contact: Ms. Glenna Steele
Lippincott Williams & Wilkins
Booth #431
Two Commerce Square 2001 Market Street
Philadelphia, PA 19103
Phone: 215-521-8300
Fax: 215-521-8493
Website: www.lww.com
Contact: Ms. Joey-Rose Jester
pharmaceutical industry, in the field of
electrophysiology. We provide solutions for
extracellular recordings with microelectrode
arrays in vitro and in vivo with the MEASystem and the ME-System as well as for
electrical stimulation with the STG series.
EXHIBITORS
MVAP Medical Supplies, Inc.
Booth #457
1415 Lawrence Drive
Lippincott Williams & Wilkins (Philadelphia, PA)
Newbury Park, CA 91320
is a leading global provider of information,
Phone: 877-735-6827
business intelligence and point-of-care
Fax: 877-735-7213
solutions for the healthcare industry. Serving
more than 150 countries and territories
Website: www.mvapmed.com
worldwide, Lippincott customers include
Contact: Brenda Jo Hocking
professionals, institutions and students in
Integra LifeSciences Corporation
medicine, nursing, allied health and pharmacy. After 20+ years in the industry, MVAP is
Booth #249
proud to announce that we will continue to
313 Enterprise Dr
Lundbeck Pharmaceuticals
offer our customers one-stop-shop for all
Plainsboro, NJ 08536
Booth #114, 115
EEG, EMG, IOM, cardiology, sleep medicine,
Phone: 609-275-0500
Four Parkway N - Ste 200
and respiratory products. We will maintain
Toll Free: 800-762-1574
Deerfield, IL 60015
our promise to offer all the latest products
Fax: 609-799-3297
Phone: 847-282-1000
at the most competitive prices, and offer an
Fax: 847-282-1001
unmatched customer service team! Our
Website: www.integralife.com
customer satisfaction is foremost!
Contact: Jon Trout
Website: www.lundbeckus.com
Contact: Ms. Margaret Trempe
National Association of Epilepsy Centers
Integra LifeSciences, a world leader in
Booth #511
medical devices, is dedicated to limiting
Headquartered in Deerfield, Illinois, with a
600 Maryland Ave SW - Ste 835W
uncertainty for surgeons, so they can
portfolio specialty central nervous system
Washington, DC 20024
concentrate on providing the best patient
(CNS) therapies and a robust pipeline of
Phone: 202-484-1100
care. Integra offers a vast portfolio of
promising CNS compounds, Lundbeck is
implants, devices, instruments and systems
committed to providing innovative therapies
used in neurosurgery and neuro critical care. that fulfill unmet medical needs of people with Website: www.naec-epilepsy.org
Contact: Ms. Johanna Gray
CNS disorders, including rare diseases for
John Libbey EUROTEXT
which few, if any, effective treatments are
The National Association of Epilepsy Centers
Booth #118
available.
is a non-profit 501(c)(6) trade association
127 Avenue de la Republique
with a membership of more than 190
92120 Montrouge, France
Medikidz
specialized epilepsy centers in the United
Phone: 330-146-7306-79
Booth #536
States. With the goal of no seizures and no
Fax: 330-140-8409-99
100 Tice Blvd
side effects, NAEC strives to make high
Woodcliff Lake, NJ 07677
quality healthcare available to and affordable
Website: www.jle.com
Phone: 201-692-1100
for epilepsy patients across the country.
Contact: Mr. Gilles Cahn
Fax: 201-692-1804
National Institute of Neurological
LGS (Lennox-Gastaut Syndrome) Foundation Website: www.eisai.com
Disorders & Stroke (NINDS)
Booth #9
Contact: Ms. Shirley Hunt
Booth #556
192 Lexington Ave. Suite 216
31 Center Dr - Bldg 31 - Rm 8A07
The Medikidz are five energetic, larger-thanNew York, NY 10016
Bethesda, MD 20892
life superheroes on a mission to help young
Phone: 718-374-3800
Phone: 301-496-5751
people understand illness and medical
Toll Free: 800-352-9424
concepts. Eisai Inc., a leader in the epilepsy
Website: www.lgsfoundation.org
Fax: 301-402-2186
community, is proud to support MediKidz in
Contact: Ms. Christina San Inocencio
the creation of the “MediKidz Explain
Website: www.ninds.nih.gov
The LGS Foundation is a non-profit
Epilepsy” comic book to educate young people
Contact: Ms. Natalie Frazin
organization dedicated to providing
about epilepsy, increase awareness of the
information about Lennox-Gastaut Syndrome disease and eliminate the stigma often
The National Institute of Neurological
while raising funds for research, programs
associated with it.
Disorders & Stroke (NINDS) supports basic,
and services for individuals living with LGS
translational, and patient-oriented research
and their families.
Multi Channel Systems
on epilepsy prevention, diagnosis and
Booth #144
treatment, including mechanisms underlying
Lifelines Neurodiagnostic Systems, Inc.
60 Marine St
seizures and epileptogenesis, gene discovery
Booth #256
Farmingdale, NY 11735
and targeted therapeutics, epidemiology,
611 Riggin Rd
Phone: 631-393-6401
psychosocial and behavioral consequences,
Troy, IL 62294
Fax: 631-393-6407
and development of new therapies.
Phone: 618-667-6445
Fax: 618-667-1982
Website: www.multichannelsystems.com
Contact: Ms. Margaret Badon
Website: www.lifelinesneuro.com
Multi Channel Systems develops precision
Contact: Ms. Elizabeth Thompson
measuring instrumentation & equipment for
research groups at universities & for the
The GLUT1 Deficiency Foundation is a
volunteer, non-profit family organization
dedicated to educating others about Glut1
Deficiency, increasing awareness of and
advocacy for Glut1 Deficiency, and supporting
and funding researchers as they work for
better treatments and an ultimate cure.
79
EXHIBITORS
Natus Neurology Incorporated
Booth #423
1850 Deming Way
Middleton, WI 53562
Phone: 608-829-8500
Toll Free: 800-356-0007
Fax: 608-829-8737
Website: www.natus.com
Contact: Ms. Julie Phillips
neurological diseases. The company’s first
product is the RNS® System, a cranially
implanted responsive neurostimulator for the
treatment of medically intractable partial
onset seizures in adults.
Nihon Kohden America, Inc.
Booth #223
15353 Barranca Parkway
Irvine, CA 92618
Phone: 949-580-1555
Natus Neurology is a leading provider of
Toll Free: 800-325-0283
healthcare products used for the detection
Fax: 949-271-5319
and monitoring of neurological dysfunction,
epilepsy and sleep disorders; neurophysiologic
Website: www.nkusa.com
research, and cerebral vascular disorders.
Contact: Ms. Jeannie Callahan
ALPINE BIOMED ● DANTEC ● DELTAMED ●
For over 60 years Nihon Kohden has been the
EMBLA ● GRASS TECHNOLOGIES ●NICOLET
trusted neurology solution for epilepsy
● SCHWARZER ● STELLATE ● TECA ● XLTEK
monitoring, electroencephalography, EEG &
PSG wireless & ambulatory recording,
Neuralynx, Inc
polysomnography, out of center sleep
Booth #222
testing/PSG, Electromyography, evoked
105 Commercial Dr
potentials, intra-operative and cEEG ICU
Bozeman, MT 59715
monitoring. Serving the best minds in
Phone: 406-585-4542
neurology for over sixty years.
Fax: 406-585-9034
Novartis Pharmaceuticals
Website: www.neuralynx.com
Booth #456
Contact: Ms. Kathy Walsh
One Health Plaza Bldg 335
Neuralynx is an internationally recognized
East Hanover, NJ 07936
provider of electrophysiology recording
Phone: 862-778-2159
systems and solutions for neuroscience
Fax: 973-781-6118
research. The ATLAS clinical research system
is designed to record the entire range of
Website: www.novartis.com
human electrophysiology from surface EEG to
Contact: Ms. Marianne LaRosa
single unit activity via micro-wire electrodes.
Novartis Oncology has emerged as a global
This makes ATLAS the logical choice for
leader in oncology through targeted research
clinical research.
and open partnership in the pursuit of new
therapies capable of transforming outcomes
Neuro Quest LLC
for people with cancer. Our research is driven
Booth #257
by a distinctive scientific and clinical strategy,
S75 W17317 Janesville Rd
focusing on unmet medical needs and disease
Muskego, WI 53150
pathways.
Phone: 855-516-3876
Toll Free: 855-516-3876
Nuro Pharma Inc.
Fax: 855-777-8378
Booth #116
6380 Polaris Ave Unit B
Website: www.neuroquestllc.com
Las Vegas, NV 89118
Contact: Ms. Mindy Gersonde
Phone: 702-269-1941
There’s no place like home to have your EEG,
Fax: 702-269-4428
especially since we make house calls.
NeuroQuest LLC is the premier provider of
Website: www.nuropharma.com
extended, in-home ambulatory, video and nonContact: Mr. Ed Kessig
video EEGs. Our goal is to provide the highest
quality, most convenient, cost-effective EEGs. Nuro Pharma is a specialty pharmaceutical
We’re fully staffed and equipped to administer company focused on neurology. We have a
mail order pharmacy that provides single
AEEGs in patients’ homes, a clinic, office or
source generic anti-convulsants to patients
institution.
suffering with seizure disorders. Nuro
Pharma is also developing three antiNeuroPace, Inc.
convulsants, the first of which we anticipate
Booth #523
launching in 2014.
455 N. Bernardo Avenue
Mountain View, CA 94043
Optima Neuroscience, Inc.
Phone: 650-279-1496
Booth #442
Toll Free: 877-676-3876
11930 Research Circle
Fax: 650-237-2701
Alachua, FL 32615
Phone: 352-371-8281
Website: www.neuropace.com
Fax: 382-462-5365
Contact: Kathy Miller
NeuroPace was founded to create implantable
Website: www.optimaneuro.com
responsive neurostimulation devices to treat
Contact: Hannah Schauer
80
Optima Neuroscience produces medical
devices for the diagnosis of neurological
disorders. Drawing on years of research in
EEG analysis, Optima creates innovative
technologies to improve patient care.
Currently, Optima is developing the
CereScope™ Brain Function Monitor, designed
to provide rapid and accurate brain function
monitoring for emergency rooms and ICUs.
Oxford University Press
Booth #112
2001 Evans Rd
Cary, NC 27513
Phone: 212-726-6000
Toll Free: 800-451-7556
Fax: 212-726-6494
Website: www.oup.com/us
Contact: Ms. Robin Hesselink
Featuring Oxford’s leading list including: Engle
Seizures and Epilepsy; Shorvon Oxford
Textbook of Epilepsy and Epileptic Seizures;
Misulis Atlas of EEG, Seizure Semiology, and
Management, and much more! Browse our
journal selection and ask about our online
offerings in medicine.
PCDH19 Alliance
Booth #10
6 Wisteria Ct
Novato, CA 94945
Phone: 415-892-5794
Website: www.PDCH19info.org
Contact: Ms. Julie Walters
Our mission is to improve the lives of children
and families affected by PCDH19 Female
Epilepsy. We raise and direct funds to
scientific research with the goal of finding
better, more effective treatments and,
ultimately, a cure; providing information and
support and assisting the efforts of the
medical community, so that no family suffers
without a diagnosis.
Persyst
Booth #156
12625 High Bluff Dr - Ste 213
San Diego, CA 92130
Phone: 858-461-4542
Fax: 858-461-4531
Website: www.persyst.com
Contact: Ms. Ann Shambo
For more than twenty years Persyst
Development Corporation has produced the
most trusted and innovative EEG analysis
products. Today, Persyst is the world’s
leading supplier of seizure detection, spike
detection, and quantitative analysis software
to every leading EEG manufacturer for
continuous EEG monitoring, LTM and
ambulatory EEG.
EXHIBITORS
Pinnacle Technology, Inc.
Booth #130
2721 Oregon St
Lawrence, KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Website: www.pinnaclet.com
Contact: Ms. Linda Lane
Pinnacle Technology provides preclinical
research tools. Our analysis software,
Sirenia® Seizure Pro, automatically finds,
identifies, and marks seizure events. We have
3- and 4-channel EEG/EMG systems capable
of adding biosensor channels to measure
neurotransmitters including glutamate,
glucose, lactate, ethanol, and choline.
Synchronized video recording also available.
PMT Corporation
Booth #122
1500 Park Rd
Chanhassen, MN 55317
Phone: 952-470-0866
Toll Free: 800-626-5463
Fax: 952-470-0865
Website: www.pmtcorp.com
Contact: Amanda Bammert
PMT Corporation’s commitment to innovative
products and customer satisfaction has
made PMT a leader in epilepsy monitoring.
PMT utilizes the finest quality materials in
the manufacturing process of their Cortac,
cortical surface electrodes and Depthalon,
depth electrodes. PMT’s nationwide direct
sales force is available 24 hours a day.
Questcor Pharmaceuticals, Inc.
Booth #330, 432
26118 Research Rd
Hayward, CA 94545
Phone: 510-400-0700
Toll Free: 800-411-3065
Fax: 510-400-0799
Website: www.questcor.com
Contact: J.T. Thomas
Rhythmlink International, LLC
Booth #514
PO Box 2045
Columbia, SC 29202
Phone: 803-252-1222
Toll Free: 866-633-3754
Fax: 803-252-1111
Website: www.rhythmlink.com
Contact: Leah Hanson
Ripple LLC
Booth #237
2015 S 1100 E
Salt Lake City, UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Website: www.rppl.com
Contact: Mr. Rob Nash
Ripple provides high performance
neurophysiology data acquisition systems for
recording and stimulation. Our systems are
compact, portable, and heavily optimized for
real-time, closed-loop control applications
with up to 512 channels of EMG, EEG / ECoG
and microelectrode data. Our software is
cross platform, and can be run on Windows,
Mac OS X, and Linux.
Rogue Research Inc.
Booth #459
4398 St-Laurent Suite 206
Montreal, QC H2W 1Z5 Canada
Phone: 514-284-3888
Fax: 514-284-6750
Website: www.rogue-research.com
Contact: Diane Gariepy
SeizureTracker.com
Booth #15
PO Box 10738
Alexandria, VA 22310
Phone: 703-339-8448
Fax: 703-339-8430
Website: www.seizuretracker.com
Contact: Mr. Robert Moss
Smart Monitor Corp.
Booth #531
6203 San Ignacio Ave. Suite 112
San Jose, CA 95119
Phone: 408-754-1695
Toll Free: 888-334-5045
Fax: 408-351-0154
Website: www.smart-monitor.com
Contact: Ms. Sheri Becker
Smart Monitor provides monitoring solutions
for people with chronic health conditions.
Smart Monitor fuses sensor, mobile and cloud
technologies with big-data analytics.Our
product, the SmartWatch, is an easy-to-use,
non-invasive wristwatch that continuously
monitors movements and instantly alerts
family and caregivers upon the onset of
repetitive, shaking motion.
Booth #323
84 Waterford Dr
Marlborough, MA 01752
Phone: 508-787-4279
Toll Free: 888-866-6500
Fax: 508-357-7490
Rogue Research manufactures the Brainsight
family of neuronavigation for brain stimulation
Website: www.sunovion.com
and fNIRS imaging products for neuroscience
Contact: Mr. Chris Fanale
research. As partners in Rogue Resolutions,
we offer the line of neuroConn DC stimulators Sunovion is a leading pharmaceutical company
dedicated to discovering, developing and
and EEG products.
commercializing therapeutic products that
advance the science of medicine in the
RSC Diagnostic Services
Psychiatry, Neurology and Respiratory
Booth #157
disease areas and improve the lives of
101 E Park Blvd - Ste 910
patients and their families. Sunovion is a
Plano, TX 75074
subsidiary of Dainippon Sumitomo Pharma
Phone: 813-416-4155
Co., Ltd. To learn more, visit
Toll Free: 877-333-2575
www.sunovion.com.
Fax: 800-840-8626
Website: www.rscdiagnosticservices.com
Booth #131
Contact: Mr. Luke Irish
1550 E Gude Dr
RSC Diagnostic Services team is a group of
Rockville, MD 20850
devoted health care specialists who are
Phone: 301-838-2500
committed to helping those in need of
neurodiagnostic testing services. Our
Website: www.supernus.com
services include video ambulatory EEG and
Contact: Mr. Tilton Conner
continuous EEG monitoring for the ICU. It is
our goal to assist physicians and hospitals in Supernus is a specialty pharmaceutical
company focused on the development and
providing the highest quality EEG services
commercialization of products for the
possible for better patient outcomes.
treatment of epilepsy and other central
nervous system (CNS) disorders. For further
information please contact Tilton Conner at
(301) 838-2500 or [email protected].
EXHIBITORS
At Questcor, we are a biopharmaceutical
company focused on the treatment of
patients with serious, difficult-to-treat
autoimmune and inflammatory disorders. Our
efforts are currently focused on the fields of
neurology and nephrology, areas of medicine
which have significant unmet medical needs.
For questions, please contact Questcor
customer service at 1.800.411.3065.
for IONM, epilepsy, critical care, EEG, EP, ICU
and PSG settings. Rhythmlink is the first to
receive FDA clearance of Disposable MR
Conditional Electrodes. Visit our booth to
learn about Disposable MR Conditional Cups
and our new, innovative Disposable PressOn™
Electrodes.
Rhythmlink designs, manufactures and
distributes medical devices and accessories
81
EXHIBITORS
related disorders, autism spectrum and
dedicated to its mission of Advancing
developmental delay disorders, chromosomal
Pharmacotherapy. Improving Life™. With
abnormalities, scoliosis and inherited diseases. capabilities ranging from early-stage research
to delivering on-market products, UpsherTriangle BioSystems, Inc.
Smith is committed to developing quality
Booth #148
products that enable people to live life to its
2224 Page Rd - Ste 108
greatest potential.
Durham, NC 27703
Phone: 919-361-2663
Visualase, Inc.
Fax: 919-544-3061
Booth #527
8058 El Rio St
Sutter Health is one of the nation’s leading
Website: www.trianglebiosystems.com
Houston, TX 77054
community-based, not-for-profit health care
Contact: Ms. Carol Alexander
Phone: 832-577-7773
networks of hospitals, physician
Fax: 713-741-0122
organizations, and other health care services. Miniaturized stimulation and recording
Sutter Health facilities are located from the
solutions for rodent and other animal models. Website: www.visualaseinc.com
Pacific Coast to the Sierra Foothills in
Wireless Stim headstage (2-16 ch).
Contact: Mr. Andre Marquette
Northern CA. Contact Physician Recruitment Recording headstages for single unit, EEG
at 800-650-0625 or
and other signals: tethered, multiplexed or
The Visualase Thermal Therapy System is an
[email protected] for details on
signature wireless headstages (5–128 ch).
MRI-guided, minimally invasive laser ablation
opportunities.
Software: Neuroware™ acquisition, Optimap™ system which allows for continuous
video tracking, StimWare™. Custom
monitoring of an ablation in real-time. The
Tenet Hospital System – South Florida
electrophysiology engineering solutions.
system is FDA-cleared for the ablation of soft
Booth #458
tissue, including for use in neurosurgical
9960 Central Park Blvd, North Suite 400
Tuberous Sclerosis Alliance
procedures. More than US 25 centers have
Boca Raton, FL 33428
Booth #5
performed >225 epileptogenic foci and >175
Phone: 561-288-5511
801 Roeder Rd - Ste 750
brain tumor ablations.
Fax: 866-764-6850
Silver Spring, MD 20910-4467
Phone: 301-562-9890
Vitaflo USA
Website: www.tenetflorida.com
Toll Free: 800-225-6872
Booth #158
Contact: Lane Mitnick
Fax: 301-562-9870
316 Montgomery St
Alexandria, VA 22314
The Tenet Florida Advanced Neuroscience
Website: www.tsalliance.org
Phone: 571-733-8574
Network includes over 40 physicians, 10
Contact: Ms. Katie Smith
Toll Free: 888-848-2356
award winning hospitals and multiple full
Fax: 631-693-2002
service outpatient centers across MiamiEmail: [email protected]
Dade, Broward and Palm Beach Counties. Our The Tuberous Sclerosis Alliance is the only
national organization dedicated to finding a
Website: www.vitaflousa.com
team provides comprehensive neurological &
cure for tuberous sclerosis complex (TSC)
Contact: Ms. Katrina Bellan
ancillary services and features some of the
while improving the lives of those affected.
leading neurologists in S. Florida. More
We work to stimulate and sponsor research; Vitaflo provides innovative specialized medical
info:www.tenetfloridaphysicianservices.com
develop programs, services and resources;
foods for metabolic disorders, nutrition
and increase awareness among professionals support and other areas of disease specific
Texas Children’s Hospital
and the public.
nutrition. We aim to offer products that
Booth #356
combine cutting edge research with lifestyle
1919 S. Braeswood, Suite 6226
UCB, Inc.
demands of modern living. Vitaflo continues to
Houston, TX 77030
Booth
#101
develop products which offer patients choice
Phone: 832-824-2143
1950 Lake Park Dr
and support compliance with restrictive
Fax: 832-825-2624
Smyrna, GA 30080
therapeutic diets.
Phone:
770-970-7500
Website: www.texaschildrens.org
Toll Free: 800-477-7877
Wiley
Contact: Karen Wilkinson
Fax: 770-970-8917
Booth #338
Texas Children’s Hospital, is committed to
350 Main St
creating a community of healthy children
Website: www.ucb-group.com
Malden, MA 02148
through excellence in patient care, education Contact: Ms. Kathleen Margalit
Phone: 781-388-7200
and research. Consistently ranked among the
Toll Free: 800-216-2522
UCB,
Brussels,
Belgium
(www.ucb.com)
is
a
top children’s hospitals in the US, Texas
Fax: 781-388-8212
global biopharmaceutical company focused on the
Children’s has recognized Centers of
discovery
and
development
of
innovative
Excellence in multiple pediatric subspecialties,
Website: www.wiley.com
medicines
and
solutions
to
transform
the
lives
of
and operates the largest primary pediatric
Contact: Ms. Daisy Guerrero
people living with severe diseases of the immune
care network in the country.
system or of the central nervous system.
Wiley is the leading society publisher. We
Sutter Health
Booth #128
2750 Gateway Oaks Suite 200
Sacramento, CA 95833
Phone: 916-643-6670
Toll Free: 800-650-0625
Fax: 916-503-6831
Website: www.checksutterfirst.org/
Contact: Rosemary Navarro
Transgenomic, Inc.
Booth #126
12325 Emmet St
Omaha, NE 68164
Phone: 402-452-5400
Fax: 402-452-5401
Website: www.transgenomic.com
Contact: Ms. Becky Kreifels
Transgenomic offers genetic testing for
mitochondrial disorders, epilepsy and seizure82
Booth #447, 513
6701 Evenstad Dr
Maple Grove, MN 55369
Phone: 763-315-2000
Toll Free: 800-654-2299
Fax: 763-315-2244
Website: www.upsher-smith.com
Contact: Ms. Becky Bouley
Upsher-Smith Laboratories, Inc., founded in
1919, is a growing pharmaceutical company
publish on behalf of more societies and
membership associations than anybody else,
and offer libraries and individuals 1250 online
journals, thousands of books and e-books,
reviews, reference works, databases, and
more. For more information, visit
www.wiley.com, or our online resource:
onlinelibrary.wiley.com.
ABSTRACT AUTHOR INDEX
A
Allen, C. 1.060
Alloway, R. 1.229, 3.212
Allred, E. 2.108
Almane, D. 2.223
Almashaikhi, T. 1.096
Alonso, M. 1.294
Alonso-Vanegas, M. 1.049
Altaye, M. 3.179
Althaus, A. 1.009, 3.004
Alvarez, V. 2.010
Alves-Leon, S. 2.311
Alzeir, M. 2.028
Amaral, M. 2.105
Amaro Jr, E. 2.080
Amiri, M. 1.199
Ammanuel, S. 1.063
Amrom, D. 3.268, 3.269
An, D. 1.191
An, S. 2.108, 3.080, 3.161, B.02
Andermann, E. 3.265, 3.268, 3.269
Andermann, F. 3.265, 3.268, 3.269
Anders, B. 1.219, 1.220, 1.221,
2.116, 2.117, 2.157, 3.214
Anderson, A. 1.038, 1.282, 3.029,
3.039
Anderson, A.W. 3.183
Anderson, C. 2.238
Anderson, R. 1.115
Anderson, W.S. 1.047
Ando, N. 1.171, 3.172
Andrade, D. 1.302, 3.271, 3.274,
3.275
Andrade, J. 2.309
Andrade, N. 1.247
André, V. 1.204
Andresen, E.N. B.06
Andresen, L. C.04
Andrews, N. 2.046
Andriola, M. 3.136
Andrisova, J. 2.053
Anghelina, E. 1.253
Anwar, A. 1.061
Apfel, A. 2.066
Applegate, C. 3.277
Appleton, R. 1.292
Aradhya, S. A.08
Arain, A. 2.047, 2.072, 3.129
Araki, K. 3.261
Araki, Y. 3.261
Aranda, J. 3.081
Arantes, P.R. 2.080
Archer, J. 1.188, A.04
Arcot Desai, S. 3.105
Ardekani, B. 3.177
Ardini, M.A. 2.260
Arehart, E. 2.306, 3.278
Arenas Cabrera, C. 2.298
Arican, N. 3.109
Arif, H. 2.019
Arkilo, D. 1.224, 1.238
Arndt, D. 2.015, 2.021, B.03
Arnedo, V. 2.211
Arnold, S. 1.219, 1.221, 1.223,
2.233, 2.236, 3.077
Arnold, S.S. 1.218
Aronica, E. C.06
Arora, J. 1.184
Arslan, N. 3.229
Artieda, J. 1.114
Artinger, K. 1.013
Arya, R. B.02
Arzimanoglou, A. 1.096, IW.11
Asadi-Pooya, A. 3.220
Asano, E. 1.113, 1.122, 1.138, 3.113
Asato, M. 2.219
Asconape, J. 2.154
Asensio Asensio, M. 1.239
Assaad, B. 1.083, 1.159
Assirati, J.A. 3.283
Atkinson, P. 2.212
Atta, C. 1.195
Auerbach, D.S. C.02
Auvin, S. 3.146
Avila, E. 2.158
Aylett, S. 2.212
Ayoub, K. 1.124
Azar, N. 2.047, 3.129
Azuma, Y. 1.171, 3.172
Azzam, R. 2.047
B
Baba, H. 1.250, 2.188
Baba, K. 3.261
Babtain, F. 1.158, 2.168
Bacher, M. 1.217
Bacskai, B. 3.005
Bagher-Ebadian, H. 1.169
Bagul, M. 2.148, 3.211
Bahceci, M. 3.109
Bahlo, M. 1.303
Bai, D. 1.294
Bai, X. 1.194, 3.194
Bailey, C. 1.194, 3.194
Bailey, J. 1.294
Bailey, L. 2.186
Baillet, S. 1.088, 2.094
Bainbridge, J. 2.149, 2.150, 2.171,
2.172, 3.153
Bakaki, P. 2.104, 2.107
Baker, E. 2.253
Baker, G. 2.213
Baki, S.A. 3.081
Balanescu, B. 1.099
Balcerzak, M. 3.140, 3.141
Baldin, E. 2.110
Balding, D. 3.267
Balena, T. 1.025
Balestri, M. 2.016
Baltar, A. 2.311
Baltuch, G. 1.274
Banaskiwitz, N.H. 1.270
Bandt, S. 1.124
Bandyopadhyay, S. 2.072
Bangalore Vittal, N. 2.072
Bannout, F. 2.153
Baraban, S. 1.013
Baram, T. 1.001, 1.065, 1.066, 3.011
Barborica, A. 1.099
Barker, G. 3.186
Barker-Haliski, M. 3.013
Barkley, G. 1.082, 1.083, 1.159, B.05,
A.02
Barnes, M.L. 3.201
Baroldi, P. 2.119, 2.120, 2.121, 3.206
Barr, W. 3.177
Barragan, E. 1.111
Barrett, L. 3.189
Barrios, E. 1.051
Barron, D. 3.070
Barry, J. 1.066
Bartha, R. 1.189, 2.078
Bartley, M. 2.027
Basha, M. 2.009, 2.151, 2.160,
2.265, 2.270, 3.282
Bassett, A.S. 1.302
Bast, T. 1.217, 1.254, 3.213
Basu, I. 1.047
Basu, T. 3.099
Batista, C. 1.021
Batista, D. 3.277
Battaglia, G. 3.050, 3.056
Batten, S.R. 3.052
Bauer, C. 1.040
Bauer, S. 3.060
Bauerschmidt, A. 1.050
Baulac, M. 1.271
Baumgartner, C. 2.017
Baumgartner, J. 1.256, 2.095, 2.196,
3.076, 3.083
Bausch, S. 3.012
Baykara, Y. 1.050
Bayly, M.A. 1.297
Bazil, C. B.05
Beach, R. 2.169
Beaulieu, C. 3.175
Becerra Zegarra, A. 1.173
Bech, P. 1.199
Beck, H. 1.209
Becker, D. 1.274
Beem, P. 2.219
Beers, C. 1.192, 3.195
Begley, C. 1.198, 2.229
Begnaud, J. 1.048, 3.066, 3.116
Belaidi, H. 1.305
Belan, V. 2.053
Belanger, S. 2.043
Bell, M.J. IW.08
Bellavoine, V. 3.146
Beller, C. 2.129
Bello-Espinosa, L.A. 1.081, 3.136
Bellows, S. 1.297
Beltramini, G.C. 3.175
Bena, J. 2.141
Benbadis, S. 1.137, 2.005, 2.197,
2.202, 3.094
Beniczky, S. 1.073
Benjamin, C. 2.208
Benke, T. 1.104, 1.110
Ben-Menachem, E. 2.148
Bensalem-Owen, M. 2.152
Berdichevsky, Y. 1.012, 1.205
Beretta, S. 2.067
Berg, A. 1.139, 1.149, 1.160, 2.110,
2.216, 2.264, 2.275, IW.10
Berg, M. 1.229, 3.120, 3.212, B.05,
A.02
Bergey, G. 3.085, 3.122, B.05, A.02
Bergin, A. 1.233, 1.236, 3.080
Bergin, P. 2.067
Aaron, G. 3.036
Abbott, D.F. 1.188, A.04
Abdel-Latief, O. 3.063
Abdelmoity, A. 1.077, 2.258, 3.226,
3.227, 3.228, 3.234, 3.235
Abdelmoity, S. 1.077, 3.227
Abdelwahab, M. 3.241
Abdi, A. 3.220
Abdulla, F. 2.235
Abel, T.J. 1.269
Abend, N. 2.015, 2.021, B.02, B.03,
IW.08
Abou-Khalil, B. 2.087, 2.118, 2.126,
2.128, 3.129, 3.183
Abramson, E.L. 2.242
Abubakr, A. 1.133
Aceves, A. 2.167
Ackhar, C. 1.300, 2.108
Acton, E. 2.238
Adams, E. 2.189, 2.215, 2.224
Adcock, J. 1.052
Adda, C. 1.270, 3.253
Adhami, S. 2.055
Afawi, Z. 1.309
Afeefy, H.H. 2.277
Agadi, S. B.02
Agarwal, N. 1.132
Agbe-Davies, O. 2.245, 2.248
Aghakhani, Y. 1.192, 3.162, 3.195
Agha-Khani, Y. 2.235
Agin, H. 3.217, 3.229, 3.233
Agostini, M. 1.164, 2.180, 2.206
Ahern, D. 2.204
Ahishali, B. 3.109
Ahmann, H. 1.077
Ahmed, O.J. C.08, IW.12
AhMu, M. 3.226
Ahrens, C. 2.166
Akalan, N. 1.251
Akarcan, S. 3.217
Akhan, G. 3.061
Akhondi-Asl, A. 3.171
Akiyama, T. 1.112, 1.115, 3.180
Akman, O. 1.212
Al Ghamdi, S. 1.158
Al Hamrany, M. 2.168
Al Kasab, S. 2.019
Al Saluli, M. 1.158
Alareddy, A. 1.088
Alcala, R. 3.052
Alegre, M. 1.114
Alessi, R. 1.197, 2.115
Alexander, A. 1.206
Alexander, G. 3.031
Alexandre, F.P. 1.201
Alexopoulos, A. 1.024, 1.032, 1.084,
1.089, 3.078, A.01
Algara, J. 1.111
Alghassab, N.S. 2.028
Ali, A. 2.282, 3.271, 3.274, 3.275
Ali, N. A.09
Ali, S. 1.027, 1.214
Alkawadri, R. 3.078, 3.110
Alkhachroum, A.M. 2.195
Al-Kaylani, M. 3.129
83
Bergqvist, C. 1.058
Berk, T. 2.245, 2.248
Berkovic, S. 1.296, 1.297, 1.303,
3.266, A.07
Berl, M. 3.189
Bermejo, P. 2.133
Bermeo-Ovalle, A. A.03
Bermudez, C. 3.087
Bernal, B. 1.279
Bernard, C. IW.03
Bernard, P. 1.110
Bertram, E. 1.044
Bertrand, O. 1.096
Besio, W. 1.064
Best, C. 2.227
Betting, L. 3.187, 3.254
Bhatia, H. 1.158, 2.168
Bhatia, P. 1.228
Bhattacharjee, R. B.09
Bhuyan, P. 1.013, 3.002, 3.025
Bickel, S. 1.098, 3.112
Biesecker, K. 2.002
Bilal, M. 1.076
Bilginer, B. 1.251
Bingaman, W. 1.259, 1.273, 3.284,
B.08, B.06
Biraben, A. 2.128, 3.130, 3.210
Bird, J. 2.282
Birg, L. 2.035
Birnbaum, A. 2.140, 2.162
Biro, A. 3.213
Biton, V. 2.049, 2.127, 3.201, 3.208
Bittel, B. 3.156
Bizen, T. 3.065
Blackmon, K. 3.177
Blaikie, L. 1.195
Blasque, W.P. 3.254
Blatt, I. 1.222, 1.223, 2.116, 2.117
Bleasel, A. 2.027, 2.106
Blichowski, M. 1.106
Blinston, C. 2.250
Blount, J. 2.088, 2.183, 2.225
Blue, M.E. 1.063
Bluemcke, I. 3.157
Blum, A. C.08
Blum, D. 1.228, 2.126, 2.127, 2.128,
2.139, 3.202, 3.208, 3.209, 3.210
Blumenfeld, H. 1.050, 1.194, 2.227,
3.048, 3.106, 3.107, 3.194, C.07
Boatman, D. 2.228
Bock, E. 1.088, 2.094
Bodamer, M.F. 2.299
Boelman, C. 3.273
Boerkoel, C.F. 1.019
Boggs, J. 2.058, 2.060
Bohlmann, K. 1.196
Bolger, P. 1.229, 3.212
Bollu, V. 2.137, 2.146, 2.147, 2.230
Bolton, J. 1.233, 1.236
Bonafina, M. 2.130
Bonelli, S. 2.090
Bonet, M. 2.136
Bonifácio, M. 1.209
Bonilha, L. 1.284, IW.09
Bonroy, B. 2.290
Bookheimer, S. 2.208
84
Boon, P. 1.048, 3.069, 3.157, 3.168
Boop, F. 2.035
Borges, K. 3.003, 3.242
Borges, M.G. 3.281
Bortz, J. 2.305
Boscariol, M. 2.105
Bottiglieri, T. 1.051
Boudreau, M. 1.132, 2.295
Boudreaux-Bartels, G.F. 1.064
Boudria, Y. 1.064
Boulay, C. 1.254, 2.024
Bourdon, O. 3.146
Bourgeois, B. 1.233
Bouthillier, A. 2.176, 2.291
Bouyssières, C. 1.211
Bowden, S.C. 2.226
Bowen, J. 2.240, 2.241
Bower, R. 2.190
Bowyer, S. 1.082, 1.083
Boychuk, J. 1.003, 1.015
Boyer, K. 3.088
Bozik, A. 2.227
Bozorg, A. 1.137, 2.202, 3.094
Bradshaw, K. 1.154
Braga, A.M. 3.254
Bragin, A. 3.041
Bramble-Browne, K.A. 2.282
Bramerio, M. 3.056
Brandt, C. 1.043, 2.278
Braun, C. 2.086, 3.193
Braun, K. 1.093
Braun, S. 1.194, 3.194
Bravo, K. 2.002
Brazdil, M. 1.242, 3.090
Bream, G. 1.226
Breeden, M. 3.245
Breia, P. 2.304
Brennan, G.P. 3.011
Brewster, A. 1.038, 1.282, 3.039
Brian, A.M. 3.236
Briggs, S. 3.006
Brinkmann, B. 1.116, 2.081, 2.084,
2.089
Brittain, S. 1.225, 2.119, 2.120,
2.121, 2.122, 3.206
Britton, J. 2.081, 2.310, 3.251
Brock, M. 1.227
Bromley, R. 2.213
Bronen, J. 1.050
Brooks-Kayal, A. 1.010, 1.015, 3.017,
3.028
Brotherstone, R. 1.136
Brouwer, O. 2.030
Brown, E. 1.122, 3.113
Brown, E.C. 1.113
Brown, L. 1.213
Browne, K. 1.039
Browning, N. 2.213
Brunklaus, A. 2.041
Brunn, J. 3.151
Brunner, P. 3.083
Buchanan, G. 3.051
Buchfelder, M. 3.157
Buchhalter, J. 1.081, 2.124, 3.147
Buchsbaum, R. 2.144
Buck, L. 2.189, 2.215
Buckley, S. 1.126
Buckmaster, P. 3.009
Buelow, J. 1.157
Bulacio, J. 1.070, 2.096, 3.284
Bulloch, A.G. 1.195, 2.266
Bunch, R. 3.147
Bundy, D. 1.124
Burch, E.A. 2.236
Burch, V. 2.212
Burgess, R. 1.070, 1.084, 1.089,
3.037, A.01
Burneo, J.G. 1.163, 1.173, 1.189,
2.067, 2.078, 2.240, 2.250, 2.307,
IW.07
Busch, R. 1.273, 2.109, 3.284, B.06
Buse, D. 2.066
Bush, B. 3.045
Butler, C. 1.003, 1.015
Butler, E. A.08
Butler, R. 2.113, 2.247
Byeon, J. 1.035, 3.131
Byrne, R. 3.188
Byrnes, W. 2.145
Byun, J.I. 2.142, 3.154
C
Chow, E.W. 1.302
Cabacar, D. 2.260
Cabral, P. 1.241
Cadieux-Dion, M. 3.265
Cahill, K.E. B.04
Caller, T. 1.201, 2.257
Calvert, S. 2.303
Camfield, C.S. 2.075, 3.165
Camfield, P. 2.075
Campos Blance, D. 1.239
Campos, A. 1.267
Campos, B.M. 3.175, 3.178
Campos, M. 1.263
Canas, N. 1.241
Canevini, M. 1.073
Cantu, D. C.04
Capecchi, M.R. 1.034
Caplan, R. 1.180, 1.288, 2.110, 2.112
Cara, C. 1.304
Carbone, L. 1.287
Carbonell, A. 1.283
Cardin, J.A. 3.106, 3.107
Carlotti, C.G. 3.283
Carlsen, J. 1.010
Carlson, C. 2.245, 2.248
Carmichael, D. 1.187, 2.085, 3.190
Carney, P. 1.188
Caron, J. 1.247, 2.296
Carpenter, J. 2.015, 2.021, B.03, B.02
Carrazana, E. 1.226
Carrel, A. 1.010
Carreno, M. 1.304
Carrette, E. 3.069, 3.157
Carroll, C. 1.195
Carsin-Nicol, B. 3.130
Carson, J. 2.221
Carter, A. 1.282
Carter, D. 2.184, 2.185, 2.191
Carter, V. 2.146, 2.147
Cartwright, T. 2.225
Carvalho, B.S. 3.281
Carvalho, K. 3.059, 3.086
Carvill, G. 1.297, A.07
Casali, R. 2.105
Cascino, G. 1.262, 2.081, 2.198,
3.250
Cash, S. C.08
Casillas-Espinosa, P. 1.005
Castano, A.M. 1.104, 1.110
Castelli, E. 2.016
Castellucci, G. 1.194, 3.194
Castelo-Branco, M. 3.089
Castillo, A. 1.234, 2.136
Castillo, E. 1.092, 2.095
Castillo, R. 2.167
Castro, L. 1.270, 2.080, 3.253
Catarino, C. 1.174
Catterall, W. 1.202
Cavaretta, J. 2.249
Cavazos, J. 2.037, 3.070
Cebrián, E. 2.163
Cendes, F. 1.301, 3.175, 3.178
Centeno, M. 2.085
Ceronie, B. 1.094, 1.101
Cerqueira, A.T. 3.254
Cerqueira, P. 2.309
Cervenka, M. 2.228, 3.085, 3.122,
3.221
Ceulemans, B. 2.290
Cha, B. 2.074
Chachua, T. 3.027, 3.047
Chae, J. 2.059, 2.065
Chakraborty, B. 3.209
Chakraborty, P.K. 3.073
Chambers, A. 2.240
Chambers, K. 1.178
Chan, V. 3.230
Chancharme, L. 1.232
Chandran Pillai, A. 2.107
Chang, E.F. 1.261
Chang, J.M. 2.222
Chang, W. 3.108
Chapieski, L. 1.281
Chapin, J. 1.273
Chapman, K. 1.235, 1.290, 2.015,
2.021, 2.132, B.03, B.02
Chapman, M. 2.227
Chari, G. 3.081
Chau, V. 2.043, 3.185
Chaudhary, U.J. 1.187, 3.190
Cheah, C.S. 1.202
Chee, C. 1.058
Chen, B. 2.144
Chen, C. 2.251
Chen, D. 2.042, 2.297
Chen, E. 1.050
Chen, H. 2.180
Chen, J. 3.066
Chen, L. 1.153
Chen, P. 1.128, 1.256, 2.095, 2.196,
3.076, 3.083, B.09
Chen, T.T. 3.034
Chen, W. 1.050, 2.227
Chen, Y. 1.065
Cheng, C. 1.185, 2.097
Cheng, H. 2.128, 3.209, 3.210
Colciaghi, F. 3.050, 3.056
Cole, A. 3.247, B.05, A.02
Cole, A.J. 2.283
Coles, L. 3.045
Collela-Santos, M.F. 2.105
Collins, J.F. 2.162
Collins, S. IW.01
Conley, C. 3.087
Connelly, A. 3.184
Conner, C. A.06
Connolly, M. 1.156, 1.166, 1.253,
3.224
Conry, J. 1.131, 3.134, 3.204
Consolatore, M. 2.275
Constable, T. 1.184, 1.194, 3.194
Constantinou, J. 1.159
Contreras, G. 3.239
Cook, J. 1.128, 2.095, 3.076, 3.083
Cook, L. 2.007
Cooper, E. 1.022, 1.029, 3.022
Cooper, P. 1.061
Cordeiro, I. 1.267
Corines, J. 2.228
Cornett, K. 2.015, 2.021, B.03
Corny, J. 3.146
Corredera, E. 2.163
Cortez, M. 1.106
Cosgrove, G.R. 1.244, C.08
Coslett, H.B. 3.068
Cossecq, M. 2.131
Cossette, P. 1.305, 3.265, 3.279
Cotter, R. 3.036
Coulter, D. 1.105, 3.101
Couture, D. 2.058, 2.060, 2.193,
2.198
Cox, F. 2.279
Cracco, J. 3.081
Crainiceanu, C.M. 1.063
Crawford, J. 1.237
Crepeau, A. 2.310
Crisan, E. 3.097
Crisp, E.D. 2.167
Crompton, D. 1.296
Crone, N. 2.228, 3.085
Cross, J. 2.085
Crowder Skarpaas, T. 1.151, 3.245
Crowley, M.J. 1.194, 3.194
Cruz Del Angel, Y. 1.010, 1.015,
3.017, 3.028
Cruz, A. 2.133
Cukovic, D. 1.021
Cullen, D.K. 1.039
Cunningham, C. 1.050, 2.227
Cuppens, K. 2.290
Curry, D. 1.252, 1.255, 2.198
Curry, R. 2.158
Cushner Weinstein, S. 2.260
Cusick, M.F. C.05
Czlapinski, R. 2.278
D
Dabbs, K. 1.175, 1.178, 1.284
Dagley, A.S. 2.087, 3.183
Dahle, E. 3.013
Daif, A. 2.195
Dalal, S.N. 2.233, 2.236
Damiano, J. 3.266
Damle, S. 3.059
D'Andrea-Meira, I. 2.311
D'Cruz, O. 1.227, 2.145
D'Souza, W. 2.067, 2.226
D'Souza-Li, L. 1.014
Dang, N. 2.067
Daniel, P. 3.090
Daniele, O. 3.257
Daniels, A. 3.203
Daniluk, J. 2.125, 3.207
Danish, S. 2.100, 2.198
Danzer, S. 1.018
Daoud, H. 1.305
Daras, M. 2.158
Das, K. 2.212
Dasgupta, A. A.09
Datta, A. 1.081
Dauwe, I. 3.069, 3.168
Dave, H. 1.240
Davis, A.R. B.04
Davis, K. 1.274, 3.104
Davis, V. 3.052
Day, B.J. 3.025
Day, B.K. 3.199
de Almeida, J. 2.080
De Backer, M. 1.231
De Bellescize, J. 1.096
de Haan, M. 3.057
De Herdt, V. 3.069
de Kovel, C.G. 1.309
De La Pena Mayor, P. 1.239
De Marco, A. 2.237
de Melis, M. 1.061
De Ribaupierre, S. 1.173, 2.250
De Saint-Martin, A. 1.254, 2.024
De Taeye, L. 3.069
De Tiege, X. 1.280
Dea, K. 2.146
Dean, B.C. 3.084
Dean, J.C. 1.060
Dean, S. 2.234
DeCan, E.D. 3.023
Deck, G. 2.161
DeCoster, C. 2.234
Dedeken, P. 2.259
Deel, M. 3.033
Deisseroth, K. 3.023, 3.106, 3.107
Del Villar Igea, A. 2.136
Delbeuck, X. 3.258
Delgado, H. 1.241
Delgado-Escueta, A. 1.294
Deliens, G. 1.280
Delil, S. 1.067
DeLorenzo, R. 1.033, 2.056
Demos, M. 1.156
Dengler, C. 1.105
Dentel, C. 2.036
Depondt, C. 2.040
Depositario-Cabacar, D. 1.131, 3.134
Derambure, P. 2.255, 2.261, 3.258
DeRossett, S. 2.125, 3.207
Derry, C. 1.136
Desai, S. 1.255
Deshpande, L. 1.033
Desrochers, J. 1.075
Desurkar, A. 1.292
Dettloff, S. 3.001
Detyniecki, K. 2.144, 2.227
Devinsky, O. 1.055, 1.157, 1.232,
3.177
DeVries-Rizzo, M. 2.001
Dewar, S. 2.208, 2.252, 3.174, 3.252
Dexter, M. 2.027
Dezort, C. 2.216
Dhakar, M. 2.265, 2.270
Dhaliwal, H. 2.235
Di Cristo, G. 3.279
Diaz, M. 1.053
Dibbens, L. 1.296, 1.297
Dick, N. 2.282
Dickens, D. 1.090
Diehl, B. 1.187, 3.190
DiGruccio, M. 3.020
Dikeos, D. 2.046
Dilley, D. 3.201, 3.203
Dilsiz, P. 1.055
Dimova, S. 1.231
Dinday, M. 1.013
Ding, K. 1.164, 2.180, 2.206
Ding, L. 3.033
Ding, M. 3.243
Ding, Y. 1.055, 3.243
Ding, Z. 3.183
Dingledine, R. IW.05
Dinkelacker, V. 1.271
Dion, P. 1.305
Dionne-Laporte, A. 1.305
Diosy, D. 1.163
Disabato, J.A. 2.006
DiVentura, B. 3.214
Divino, V. 2.137
Dlugos, D. 1.295, 2.015, 2.021, B.03
Dobesberger, J. 2.044, 2.164
Dobson, K. 1.195
Doesburg, S. 1.115
Doescher, J. 1.090, 2.189, 2.215
Doherty, C. 2.068
Dombkowski, A. 1.021
Donahue, D. 2.186
Donato, K. 2.184, 2.185, 2.191
Donishi, T. 2.083
Donner, E. 1.079, 1.115, 1.162, 3.230
Donohue, K. 3.118
Donos, C. 1.099
Dorfman, A.B. B.06
Doss, J. 2.189, 2.215
Doss, R. 2.111
Doty, P. 1.231
Doucet, G. 2.082
Downes, M. 1.249
Downtain, C. A.08
Doyle, W. 3.177
Drabek, J. 1.053
Drane, D. 2.198, B.07
Drazkowski, J. 2.305
Cheng, J. 2.073, 3.167
Chez, M. 1.243
Chika-Nwosuh, O. 1.006
Chin, J. C.07
Chin, R. 2.033, 2.212, 2.221, 3.057,
3.170, 3.173, 3.182
Chiruvella, M. 1.108
Chitayat, D. 3.273
Cho, B. 3.055
Cho, I. 1.030
Cho, Y. 1.030
Chochoi, M. 2.255, 2.261
Choezom, T. 2.227
Choi, H. 1.289, 2.144, 3.163
Choi, J. 2.059, 2.065, 3.251
Choi, Y. 3.021, 3.117
Cholleti, S. 2.019
Chong, K. 3.173
Choudhury, M. 3.279
Chow, E. 3.063
Chowdhury, F. 1.094, 2.025
Choy, M. 1.001, 1.065, 1.066
Chrastina, J. 1.242
Christian, C. C.01
Christodoulides, N. A.09
Chu, J. 2.297
Chu, K. 1.134, 2.142, 3.154
Chu, V. 2.227
Chuang, D. 2.199
Chudnow, R. 2.222
Chugani, D. 1.021, 3.071
Chugani, H. 1.021, 1.138, 1.232,
3.071, 3.073, 3.264
Chung, C. 1.119, 1.123, 3.114
Chung, H. 1.109, 2.249, 3.021, 3.117
Chung, N. 3.055
Chung, S.S. 1.144, 1.221, 1.222,
2.048, 2.117
Chung, W.K. 1.310, 3.263, 3.270
Cicora, K. 3.245
Cienfuegos, J. 1.049
Cieza Ortiz, S. 1.114
Cilio, M.R. 2.016
Cimbalnik, J. 1.116, 3.090
Ciobanu, M.I. 3.238
Ciricillo, S. 1.243
Cisneros-Franco, J. 1.049
Ciurea, J. 1.099
Clark, A.M. 1.220, 1.222, 1.223,
2.116, 2.157
Clark, C. 2.085, 3.182
Clark, M. 1.249
Clarke, D. 2.282, 3.237
Claus, S. 1.073, 1.117
Clawson, B.C. C.02
Clayden, J. 2.085
Clayton-Smith, J. 2.213
Cloostermans, M. 2.012, 2.013, C.03
Cloutier, M. 2.146, 2.147
Cloyd, J. 3.045
Coan, A. 3.175, 3.178
Cohen, J. 2.286
Cohen, M. 2.213, 3.262
Cohen, M.S. 1.170
Cohen, R. 1.309
85
Drees, C. 2.002, 2.171, 2.172, 2.179,
3.153
Du, X. 1.009
Dubé, C. 1.001, 1.065, 1.066
Dubeau, F. 1.191
Dubinsky, J. 1.207
Dubynin, V. 3.103
Duchowny, M. 1.248, 1.279, B.05
Duckrow, R. 1.186, B.05
Dudasova, K. 2.053
Dudek, F. 3.287
Dugan Stocks, J. 2.119, 2.120, 2.121,
3.206
Dulla, C. C.04, IW.02
Dumont, C. 1.211
Dumpelmann, M. 2.039
Duncan, J. 1.187, 2.090, 3.190
Duncan, S. 1.136, 2.033, 2.204
Dunham, C. 1.253
Dunin-Wasowicz, D. 3.140, 3.141
Dunlap, S.D. 2.150
Dunn, J. 2.091
Dunn, M. 1.090
Duong, T.Q. 3.192
Dupont, P. 3.197
Dupont, S. 1.271
Dupuy, R. 2.009
Duran, F. 3.239
Duran, M. 1.078
Durgin, T. 2.279
Dustin, I. 1.078, 1.193, 3.072
Dutra-Andrade, B.F. 3.007
Duveau, V. 1.211
Duzgun, G. 1.251
Dzhala, V. 1.028, 3.014
E
Echeverria, V. 1.229
Economo, M.N. 1.034
Economou, N. 2.046
Edwards, J. B.05, A.02
Edwards, S. 2.125, 3.207
Edwards, W. 3.159
Egawa, K. 3.014
Eguchi, Y. 1.079
Ehrenberg, J. 2.019
Ehrens, D. 2.281, 3.064, A.03
Eisenschenk, S. B.05, A.02
Eksioglu, Y. 2.184, 2.185, 2.191,
3.219
Ekstrand, J. 3.287
Elder, E. 1.229, 3.212
Elgammal, F.S. 1.006
Elger, C. 1.048
El-Hagrassy, M. 2.169
Eliashiv, D. 2.208, 3.252
Elisevich, K. 3.249
Elisevich, K.V. 1.169
Elitt, C. 2.108
Elizabeth, K. 1.079
Ellis, R. 2.041
Elpidorou, M. 3.075
Elsayed, M. 1.083, 1.159
Elshahabi, A. 2.086, 3.193
Elwes, R. 1.094, 2.025
Emeriau, M. 1.280
86
Enatsu, R. 2.096
Engbers, J. 1.268, 1.272
Engel, J. 3.041, 3.174
Engelhard, G. 2.285
Englot, D. 1.261, C.07
Enoki, H. 2.159, 2.201
Entezam, A. A.08
Entz, L. 1.098
Eom, S. 2.216, 2.289
EPGP Investigators and Epi4K
Investigators, 2.077
Epi4K Investigators, 1.295
Erdogan Bakar, E. 1.251
Eryigit, T. 1.044
Escalaya, A. 2.307
Escalza, I. 2.136
Escobar, F. 1.114
Escudero, I. 2.298
Eskandar, E.N. C.08
Espinosa, F.B. 2.003
Esquenazi Levy, Y. 1.245, 3.148
Estevo, A.M. 3.240
Ettinger, A. 1.146, 2.050, 2.137
Eun, B. 1.035, 3.131
Evankovich, K. 1.281
Evans, M. 2.210
Everhart, A. 2.273
Eversole, M. 2.217
Evrard, C. 2.070
Eyring, C. 1.063, 3.035
Eze, C. 1.078, 1.193
Ezeani, C. 1.050
F
Fabres, L. 1.263
Fabris, R. 3.250
Faghfoury, H. 3.275
Fain, R. 1.146, 1.230, 2.050
Faingold, C. 3.038
Faithe, M. 3.153
Fakhoury, T.A. 1.219, 1.221, 2.117
Falcone, T. 2.007, 2.113, 2.247
Fan, Y. 2.109
Fanciulli, M. 1.308
Fang, Y. 2.137
Fant, R.V. 1.154
Farid, R. A.09
Farmer, K.C. 2.268
Farooq, O. 1.132
Farooque, P. 1.186
Farwell Gonzalez, K.D. 1.306
Faught, E. 2.175
Faught, R. 2.279
Faulkner, M. 2.165
Faulknor, J. 3.209
Fecske, E. 2.258, 3.226, 3.228,
3.234, 3.235
Federico, P. 1.192, 2.079, 2.091,
2.235, 3.195
Feltane, A. 1.064
Fenton, C. 1.058
Feoli, E. 3.260
Ferastraoaru, V. 2.039
Ferguson, A. 3.224
Ferguson, E. 2.240
Ferguson, R.J. 1.201
Fernandez, C. 3.059
Fernández-Pajarín, G. 2.163
Fernando, J. 1.249
Ferreira, A.E. 1.014
Ferreira, J.C. 1.241
Ferreira, L.P. 3.187
Ferreira, N. 2.304
Ferrier, C. 1.093, 1.097
Ferro, M. 2.276, 3.165
Ferry, J. 1.140, 1.141, 1.143, 1.154,
2.063
Fertig, E. 2.130, 3.276
Feucht, M. 1.152
Feyissa, A.M. 2.312
Fiedler, A. 3.213
Fiedler, B. 3.213
Fiest, K. 1.195, 1.268, 1.272, 2.266
Fifer, M. 2.228
Figueroa-Garcia, A. 2.273
Filiano, J. 3.159
Finardi, A. 3.050, 3.056
Finnegan, S. 1.132
Fiol, M. 2.022
Fisch, B. 2.232
Fisher, B. 2.216
Fitzpatrick, A. 1.061
Fleming, J. 2.171
Fleming, M. 2.210
Fleury, M. 2.036
Flink, R. 3.138
Floden, D.P. 1.273
Florendo, E. 2.218
Focke, N. 2.086, 3.193
Fodeh, S. 2.278
Foldvary-Schaefer, N. 2.046, 2.141
Foley, K. 2.143
Fong, J. 1.089, 2.141
Fonseca, N. 3.058
For the SVIP Consortium, 1.300
Forcelli, P. 1.213, 3.067
Ford, P. 3.246
Foreman, B. 2.023, 3.286
Fortin, J. 1.059
Fountain, N. 2.057, 2.277, B.05, A.02
Fowler, K.M. B.04
Fox, P.T. 3.070, 3.192
Franaszczuk, P. 2.228, 3.085
Francois, D. 3.219
Franks, R. 2.042
Franz, D.N. 1.232
Fraser, R. 1.198
Frausto, S.F. 1.105
Frei, M. 3.116
French, C. 1.203
French, J. PL.01
French, J.A. 1.227, 3.214
Frey, L. 1.015, 2.002, 2.171, 2.172,
3.153, 3.222
Fridhandler, J.D. 3.275
Friedlander, L. 3.222
Friedman, D. 1.157, 2.293, 3.155
Friedman, L.K. 1.027, 1.214, 1.216
Friedman, W. 3.010
Friedo, A.L. 1.196
Fritz, P. 2.279
Frndova, H. 2.011
Frol, A.B. 2.206
Frontera, A. 1.137, 2.273, 3.094
Frost, M. 1.090, 3.150, 3.151
Fu, X. 1.020, 3.127
Fu, Y. 3.127
Fuerst, D. 1.113
Fuhr, P. B.01
Fujimoto, A. 2.159, 2.201, 3.091
Fujinami, R.S. C.05
Fujiwara, H. 1.087, 1.278
Fukasawa, T. 1.171, 3.095, 3.172
Fukuyama, H. 1.086, 2.093, 2.194,
3.255
Fulton, S. 2.035
Fumuro, T. 2.093
Fürbass, F. 2.017, 3.121
Fureman, B. IW.10
Furman, M. 2.227, 3.048, 3.106,
3.107, C.07
Furtado, M. 1.210
G
Gabbett, M. 2.303
Gaddam, S. 1.159
Gadeyne, S. 3.069
Gahl, W.A. 1.019
Gahlot, M. 3.123
Gaillard, W. 1.020, 1.131, 2.182,
2.260, 3.134, 3.189, B.02
Gainza, M. 1.156, 3.224
Galanopoulou, A.S. 1.212, 3.006,
IW.11
Gale, K. 1.213, 3.067
Gale, S. 1.177, 1.276
Galer, S. 1.280
Galimberti, C. 2.128, 3.210
Gallagher, M. 3.033
Gallentine, W. 2.015, 2.021, B.03
Gallo, A. 2.259
Galvez, N. 1.150, 1.200
Galvis-Alonso, O. 3.007
Gandhi, R. 2.302
Gandomi, S. 1.306
Gano, L.B. 3.002
Gao, W. 1.265
Garces, M. 2.136
Garcés, M. 1.234
Garcia Gracia, C. 1.150, 1.200, 2.302
Garcia, P. 2.019
Garcia, P.A. 1.261
Garcia-Sosa, R. 2.061
Garic, I. 2.026
Garrity, L. 2.170
Garzon, E. 2.309, 3.240, 3.272
Gaspard, N. 2.023, 3.078, 3.110
Gatali, J. 2.259
Gattaz, W.F. 3.058
Gauthier, J. 1.305
Gavrilovici, C. 1.107
Gaxiola Valdez, I. 1.192, 2.079, 3.195
Gazzola, D. 2.245, 2.248
Gebre, R. 1.050
Gedela, S. 2.092
Gee, J. 1.034
Gee, M. 2.148, 3.211
Geerts, A. 2.030
Goodman, R. 1.265
Goodwin, S. 2.276
Goodyear, B. 2.079
Gorman, C. 3.068
Gossett, D. 3.082
Gotman, J. 1.191
Goubran, M. 2.250
Goy, E. 2.070
Goyal, M. 2.038, 2.225
Gozubatik-Celik, G. 1.067
Grabenstatter, H.L. 1.010, 3.028
Grace, T. 1.128
Graciani, R.D. 3.007
Grant, A. 2.211
Gravel, M. 3.265
Graves, D. 3.077
Gray, K. 1.190
Greenaway, R. 1.249
Greenberg, D. 3.047
Greenfield, J. 1.078, 2.300
Greenway, L. 2.204
Greiner, H. 2.246, 3.125, IW.06
Greiner, M.V. 3.125
Griessenauer, C. 2.183
Griffin Cascino, T. 3.250
Grigg-Damberger, M. 3.158
Grinnell, T. 1.228, 2.126, 2.127,
2.128, 2.139, 3.202, 3.208
Grinspan, Z. 2.242
Gritsch, G. 3.121
Groppe, D. 1.098, 3.112
Gross, D. 3.175
Gross, R. 1.108, 2.175, 2.198, 3.105,
B.05, B.07, A.02
Grovola, M. 1.039
Gruber, A. 2.017
Guan, Y. 2.054
Guaranha, M.B. 3.240, 3.272
Guarda, C. 2.304
Guenot, M. 1.096
Guerin, A. 2.146, 2.147
Guerreiro, C.A. 2.105
Guerreiro, M. 1.286, 1.301, 2.105
Guger, C. 3.076
Guillamon, E. 1.234
Guimarães, C.A. 1.286
Guinan, H. 2.155
Guiraud-Diawara, A. 2.131
Gullapalli, R. 3.049
Gummadavelli, A. 3.048, C.07
Gumnit, R. 2.014
Gump, W. 1.057
Gunasekara, R.C. 3.219
Gunter, S.A. 1.054
Guo, J. 1.194, 3.194
Gupta, A. 1.006, 2.029, B.08
Gupta, P. 1.164, 2.180, 2.206
Gupta, V. 2.181
Guptill, J. 2.145
Gurbani, S. 1.180, 1.288, 2.112
Gurses, C. 3.109
Gustafson, M. 1.224, 1.238, 3.226,
3.228, 3.234, 3.235
Gutekunst, C.A. 1.108
Gutierrez Ceniseros, M. 3.137
Gutierrez, C. 2.062
Guvenc, G. 3.061
Guzel, O. 3.217, 3.229, 3.233
Gwinn, R. B.05, A.02
H
Haas, K. 1.226, 1.240, 2.023
Haberlandt, E. 1.152, 3.213
Hacohen, Y. 2.030
Haegelen, C. 3.130
Hãfler, J. 2.044
Hageman, J. 2.061
Hagge, M. 3.060
Hahn, C. 2.011, 2.015, 2.021, B.03,
IW.08
Hahn, J. 3.055
Hajek, M.A. 3.051
Hakimi, A. 2.256
Halamek, J. 3.090
Haldar, A. 2.031
Hale, D. 3.238
Halford, J.J. 1.075, 2.017, 3.084,
3.116
Halliday, W. 3.285
Hallinan, S. 2.137
Halvorsen, M.B. 1.220, 1.221, 1.222,
1.223, 2.116, 2.157, 3.214
Hamano, S. 1.298
Hamberger, M. 1.275
Hamdan, F. 1.305
Hamer, H. 3.060, 3.157
Hamid, H. 2.278
Hamilton, R.H. 3.068
Hamiwka, L.D. 1.232, 2.217
Hammers, A. 1.190
Hammond, N. 3.156
Hammond, R. 2.250
Hampton, D. C.04
Haneef, Z. 2.252
Haney, M. 3.009
Hansen, C. 2.051
Hansen, C.P. 1.199
Hanson, D. 2.081
Hanson, K. 1.177
Hanson, K.D. 1.276
Harden, C. 1.098, 2.198
Harden, J. 2.033
Harding, A. 2.229
Hardison, H. 3.059
Hardwick, J.M. 3.244
Harini, C. 1.233, 1.236, 1.290, 2.055,
2.132, 2.187, 3.080, 3.088
Harkness, W. 1.249
Harnod, T. 1.168
Harrington, J. 1.201, 2.257
Harrison, A. 2.088
Harrison, D. 2.268
Harry, L.P. 2.299
Hart, E. 2.108
Hart, S. 2.203
Hartl, E. 1.174
Hartman, A. 3.244
Hartmann, M. 2.017, 3.121
Harvey, J. 3.208, 3.210
Hasegawa, H. 3.092
Hashim, A. 1.069, 1.071
Hastings, W. 2.167
Hasulak, N. 3.245
Hattiangady, B. 1.062
Hauser, W.A. B.04
Haut, J. B.06
Haut, S. 2.039, 2.064, 2.066
Havens, K. 2.182, 2.260, 3.134
Hawa, Z. 3.235
Hayasaka, K. 1.298
Hayat, M. 3.163
Hays, R. 1.164, 2.180, 2.206
He, B. 2.084, 2.089
He, J. 1.051
He, X. 3.031
Heath, J. 2.108
Heavin, S. 1.293, A.07
Heck, C. 1.153, B.05, A.02
Hecox, K. 1.118
Hedegärd, E. 3.138
Hegazy, M. 2.166
Heiman, G. 3.163
Heinzen, E. 3.266
Helbig, I. 1.309
Helmers, S.L. 2.175, 2.198, 2.279
Hempel, A. 1.285
Hempstead, B.L. 3.010, 3.017
Hemza, J. 1.242
Hendson, G. 1.253
Heng, K. 3.009
Henney III, H.R. 1.226
Hennion, S. 3.258
Henry, B. 3.221
Heo, K. 1.030
Hepner, A. 3.203
Herges, A. 2.209
Herlopian, A. 2.300
Hermann, B. 1.175, 1.178, 1.284,
2.223, IW.09
Hernandez Ronquillo, L. 1.126, 1.127,
1.148, 3.223
Hernandez, A. 1.232, 2.186
Hernandez, O. 3.239
Heroux, J. 2.146, 2.147
Herren, C. 3.082
Herta, J. 2.017
Herzog, A. B.04
Hesdorffer, D. 1.310, 3.263, 3.270
Hesdorffer, D.C. 2.110, 2.260
Hess, S. 2.184, 2.185, 2.191, 3.219
Hessling, A. 2.170
Heyer, G.L. 3.144
Hibbard, K. 2.214, A.05
Hicks, A. 1.005
Hildebrand, M. 1.303, 3.266
Hill, A. 2.002, 2.043, 3.185
Hill, S.W. 1.276
Hindriks, R. C.03
Hirsch, E. 1.254, 2.024, 2.036
Hirsch, L. 1.050, 1.186, 2.023, 2.144,
3.078, 3.163, A.02
Hoch, D. 3.247
Hochberg, L. C.08
Hocker, S. 3.221
Hodgson, B.L. 1.296
Hodson, M.P. 3.242
Hoeppner, T. A.03
Geertsema, E. 1.117
Geller, E. B.05, A.02
Genari, C.M. 2.284
Genc Acikgoz, D. 1.251
Geocadin, R. 3.221
Gerard, E. 2.026
Gerber, D. 3.023
Gerhardt, G. 3.052
Ghassemi, A. 1.243
Ghatan, S. 1.265
Ghearing, G. 1.266, 2.288, 3.251
Ghisdal, P. 1.204
Ghoneim, D. 2.294
Giacino, J. 2.227
Gibson, K.M. 1.051, 3.072
Gidal, B. 1.143, 1.229, 2.063, 2.139,
3.202, 3.212
Giehl, J. 2.086
Gilbert, T. 2.099
Gill, J. 1.027
Gillberg, C. 2.212, 3.057
Gilles, N. 2.040
Gilligan, J. 1.111
Gil-Nagel, A. 1.073, 1.304
Giner, P. 1.234, 2.136
Girard, H. 1.185, 2.097
Girot, M. 2.255, 2.261
Girouard, M. 2.037
Giza, C. 2.015, 2.021, 3.041, B.03
Glaser, C. 1.237
Glauser, T. 1.036, 1.230, 2.214, A.05,
B.02
Glaze, D.G. 2.267
Gliske, S. 3.053
Go, C. 1.079, 1.176
Goeree, R. 2.240, 2.241
Goffin, K. 3.197
Goh, Y. 2.178
Gois, S.L. 2.254
Golby, A. 2.198
Gold, J. 1.237
Goldberg, E. 3.101
Goldenholz, D. 1.120
Goldenthal, M. 3.059
Goldfinger, M.S. 1.098
Goldman, A. 1.053, A.02
Goldsmith, C. 2.229
Goldsmith, J. 1.310, 3.263, 3.270
Goldstein, D. 3.266
Goldstein, J. 2.015, 2.021, B.03
Goldstein, P. 2.261
Gole, G. 2.303
Goletiani, C. 3.027, 3.047
Goli, V. 2.118
Gomez, A. 1.163
Gonçalves Ferreira, A. 1.267
Goncharova, I. 3.078, 3.110
Gong, H. 3.158
González de la Aleja, J. 1.239
Gonzalez Giraldez, B. 1.234, 1.239,
2.138
Gonzalez, J. 1.304
Gonzalez-Martinez, J. 2.096, 3.246,
3.284, B.08
Goodkin, H. 3.020, 3.032, B.02
Goodman, J. 3.245
87
Hoerth, M. 2.305
Hoffmann, K. 1.215
Höfler, J. 2.164
Hofmeijer, J. 2.012, 2.013, C.03
Hogan, R.E. 1.219, 2.116, 3.199
Hohenstein, J. A.09
Holland, K. 1.018, 3.125
Holmes, G. 3.054, 3.159
Holmes, G.L. 1.066
Holmes, M. 2.099
Hondmann, D. 1.059
Hong, H. 1.172
Hong, J. 1.193
Hong, S. 1.091
Hong, S.B. 2.128, 3.210,
Hooker, G. 2.242
Hope, O. 1.245, 2.229, 3.148
Hopp, J. 1.135, 3.262
Hopyan, T. 3.209
Horinek, D. 2.081
Hoskin, C. 3.150
Hosoyama, H. 3.261
Hou, J. 2.099
Howard, M. 1.269
Howard, T. 1.159
Howell, K. 2.077
Hsin, Y. 1.167, 1.168
Hsu, D. 1.175, 1.178, 1.284, 2.223
Hsu, F.P. 1.166
Hsu, M. 2.158
Hu, S. 1.027, 1.214
Hu, W. 3.251
Huang, B.A. 1.033
Huang, S. 2.048
Huang, Y. 3.031
Hubert, H. 2.261
Huckins, S. 2.184, 2.185, 2.191
Hudson, J. 2.145
Hughes, I. 2.294
Huguenard, J. 1.206, C.01
Huh, L. 1.253, 3.224
Huiskamp, G. 1.093, 1.097, 2.192
Hummelova, Z. 1.242
Hunt, R. IW.12
Huq, A.M. 3.264
Hurst, C. 2.275
Husain, A. 2.020, 2.263
Hussain, S. 1.072
Hussein, Z. 1.141
Hutchens, J. 2.060
Hutchison, J. 2.011
Hutton, L. 2.006
Hwang, E.S. 1.170
Hwang, H. 2.059, 2.065
Hwang, K.J. 1.091
Hwang, P. 3.218
Hwang, S. 1.098
Hwang, Y. 2.059, 2.065
Hyder, F. 3.048, C.07
I
Iasemidis, L. 1.084
Ibrahim, G. 1.115
Ibrahim, Z. 3.081
88
Ida, K. 3.180
Ihle, M. 2.039
Ikeda, A. 1.086, 2.093, 2.194, 3.255
Ikeda, H. 3.232
Ilea, A. 3.146
Ilyas, M. 1.138
Im, C. 1.246
Imai, K. 3.232
Imamura, H. 1.086, 3.255
Inano, R. 1.086, 2.194
Inati, S. 1.078, 1.193
Innis, R. 1.193
Inouchi, M. 2.093
Inoue, Y. 3.232, 3.261
Iori, V. C.06
Iragui-Madoz, V. 2.097
Irani, S.R. 1.052
Iriarte, J. 1.114
Irwin, A. B.08
Irwin, M. 3.238
Irwin, Z. 3.053
Isguder, R. 3.217, 3.229, 3.233
Ishihara, E. 3.232
Ishihara, N. 1.171, 3.172, 3.181
Ishiyama, A. 3.145
Isojarvi, J. 2.123, 2.124, 2.131,
3.204, 3.205, 3.215
Isom, L. 2.251, C.02
Issa, A. 1.260
Issema, R. 2.249
Ito, S. 1.089
Ivanisevic, M. B.07
Iwasaki, M. 1.258
Iyengar, S.S. 3.010
Iyer, A.M. C.06
Iyers, S. 3.011
J
Jackson, D. 1.175, 1.178, 2.223
Jackson, G.D. 1.188, 3.184, A.04
Jacob, C. 3.093
Jacob, M. 1.008
Jacobson, M.P. 1.228, 2.008, 2.062,
3.202
Jahodova, A. 1.248
Jain, S. 1.155
Jaisani, Z. A.01
Jalota, A. 3.188
Jamuar, S. 1.293
Jan, L.Y. 1.109
Janati, A.B. 2.028
Jani, R. 1.132
Jansen, L. 1.054
Jarosz, D. 1.077
Jauregui, J. 1.058
Javid, A. 2.144, 3.163
Jayakar, P. 1.248
Jefferys, J. 3.102
Jeffreys, A. 1.005
Jehi, L. 2.109, 3.246, B.08
Jenko, K. 1.193
Jenks, K.R. 1.066
Jensen, F. 1.011
Jeong, G. 2.059
Jethva, R. 3.059
Jette, N. 1.195, 1.268, 1.272, 2.234,
2.235, 2.266, 2.269, 3.162
Jezberova, M. 2.053
Jhun, S. 1.194, 3.194
Ji, C. 3.021, 3.117
Jiang, J. IW.12
Jiang, W. 3.200, 3.216
Jih, J. 2.203
Jillella, D. 3.161
Jin, B. 3.132
Jin, K. 1.258
Jiruska, P. 3.102
Joaquim, H.P. 3.058
Jobst, B. 1.183, 1.201, 2.257, 3.054,
B.05, A.02
Johnson, E. 1.198
Johnson, J. 2.119, 2.120, 3.206
Johnson, M.I. 1.050, 3.158, 3.267
Johnston, M. 1.063, 3.035
Jolleff, N. 1.249
Jones, D. 2.081, 2.131
Jones, J. 1.175, 1.178, 2.003, 2.223
Jones, K. 1.229, 2.152, 3.212
Jones, M. 1.037
Jones, S.E. 2.096, A.01
Jones, T.D. 3.024
Jones-Gotman, M. 3.256
Jongeling, A. 2.023, 3.286
Jorge, C. 1.270, 2.080, 3.253
Joshi, S. 1.026, 3.026
Jouan, L. 1.305
Jouny, C. 3.085, 3.122
Joy, M. 3.237
Jozwiak, S. 3.140, 3.141
Julich, K. 2.108
Jun, S. 3.021, 3.117
Jung, H. 1.172
Jung, J. 1.096
Jung, K. 1.134, 2.142, 3.154
Jung, S. 1.121, 3.024
Jurak, P. 3.090
Jus, A. 3.140, 3.141
K
Kabir, A. 2.292
Kadam, S. 1.063, 3.035
Kadis, D. 1.278
Kadish, N.E. 1.233
Kahana, M.J. 1.274
Kahane, P. 1.073
Kaiboriboon, K. 2.104, 2.107, 2.195
Kaiser, M. IW.09
Kajita, Y. 3.181
Kalamangalam, G. 1.245, 3.148, A.09
Kalayjian, L. 1.153, 2.213
Kaley, T. 2.158
Kalitzin, S. 1.117
Kalnins, R. 1.303
Kalume, F. 1.202
Kameyama, S. 2.093
Kanazawa, S. 3.180
Kandiah, P. 2.019
Kane, J. 3.237
Kaneoke, Y. 2.083
Kang, A. 3.195
Kang, B. 2.142, 3.154
Kang, H. 1.265, 3.126, 3.139, 3.196,
3.225
Kang, J. 1.023
Kang, S. 3.035
Kankirawatana, P. 2.038, 2.088, 2.225
Kanner, A. 2.213
Kao, A. 1.131, 2.182
Kapeller, C. 3.076
Kaplan, L. 2.243
Kaplan, P. 2.023, 3.160, 3.221, B.01
Kapur, J. 1.026, 3.026
Karakaya, M. 1.251
Karakis, I. 2.283
Karimi, S. 2.165
Karkar, K. 1.247, 2.037, 2.296,
3.169, 3.192
Karkare, S. 3.093
Karli Oguz, K. 1.251
Kaspar, J. 2.257
Kasradze, S. 1.181
Kato, M. 1.298
Kato, T. 2.093
Kaufer, D. IW.02
Kauffman, M. 1.301
Kaufmann, W. 2.267
Kaushal, R. 2.242
Kaushal, S. 1.071
Kawara, T. 1.095
Kawasaki, H. 1.269
Kaya, M. 3.109
Kayyali, H. 3.226, 3.227
Keator, C. 2.186
Keereman, V. 3.168
Kehrli, P. 1.254
Keller, C. 1.098, 3.112
Keller, L. 1.217
Keller, S. 2.025, 2.178, 3.186
Kelley, K. 2.061
Kelly, K.M. 1.041, 3.123, 3.259
Kelly, P. 2.263
Kelly, V. 1.137
Kemmotsu, N. 1.185, 2.097
Kendirli, M. 1.044
Kenmuir, C. 1.266
Kennedy, J. 2.026
Kenney, C. B.06
Kenny, R.A. 2.068
Keo Kosal, P. 1.096
Kern, L.M. 2.242
Kern, R. 1.075, 3.116
Kerr, M. 2.262
Kerr, S. 1.132
Kerr, W. 1.170
Kervyn, S. 2.156
Kessler, S. 1.300, 2.135, 3.068
Kestler, B. 1.018
Khaldi, K. 1.305
Khan, A. 1.173, 2.250
Khan, F. 1.130, 2.173
Khan, M.U. 2.028
Khan, O. 2.061, 2.167
Khan, S. 1.139, 1.149, 2.264
Kharlamov, E.A. 1.041
Khodabakhsh, K. 1.265
Kobulashvili, T. 1.181
Kobylarz, E.J. 1.183
Kocol, B. 3.097
Koeberl, D. 2.306
Koeleman, B.P. 1.309
Koepp, M. 2.090
Koh, S. 1.016, 1.042
Kojima, K. 1.113, 1.122, 3.113
Kok, F. 3.272
Komaki, H. 3.145
Kommajosyula, S.P. 3.038
Kondratyev, A. 1.213
Konikkara, J.J. 1.164, 2.206
Konuskan, B. 1.251
Korb, P. 2.019
Koren, J. 2.017
Korgaonkar, A. 1.007
Korman, B. 1.279
Korn, M. 3.015
Kornmeier, R. 1.217
Korostenskaja, M. 1.092, 1.128,
1.256, 2.095, 2.196, 3.076, 3.083
Koroukian, S. 2.104, 2.107
Korzeniewska, A. 2.228, 3.085
Kosaras, B. 1.011
Kossoff, E. 3.221, 3.277
Kotagal, P. 2.029
Kothare, S. 1.233
Kouzmitcheva, E. 1.162
Kowacs, P. 2.128, 3.210,
Kraemer, H. 3.164
Kramer, H. 1.052
Kramska, L. 3.248
Krassman, C. 2.235
Kratochvil, Z. 1.050
Krause, A. 2.238
Krauss, G. 1.226, 2.127, 2.148,
3.208
Krigbaum, G. 3.147
Krings, T. 1.302, 3.271, 3.275
Krishnan, A. 3.173
Krishnan, B. 1.070, 1.084, A.01
Kroner, B. 2.260
Krook-Magnuson, E. IW.12
Krsek, P. 1.248, 1.279
Krumholz, A. 2.102, 2.292, 3.216
Krupp, L.B. 2.207
Kuang, C. 1.059
Kuba, R. 1.242
Kubikova, R. 1.242
Kubota, T. 1.171, 3.095, 3.172
Kucewicz, M. 1.116
Kuchukhidze, G. 1.181, 2.044
Kucuk, M. 3.109
Kucukboyaci, N. 1.185, 2.097
Kudr, M. 1.248
Kuhlenbäumer, G. 1.309
Kulick, C. 1.213
Kulwicki, P. 2.009
Kumar, A. 3.073
Kumar, D. 2.148, 3.211
Kumari, S. 2.073
Kumthekar, P. 2.026
Kundishora, A. 1.194, 3.194
Kunieda, T. 1.086, 2.194, 3.255
Kunnakkat, S.D. 2.211
Kupsky, W. 3.282
Kurako, K. 1.150, 1.200
Kurian, M.A. 1.292, 3.277
Kurlemann, G. 3.213
Kuruba, R. 1.045
Kutluay, E. 2.177, 3.084
Kuzniecky, R. 3.177
Kwon, O. 1.121, 2.301
Kwon, Y.N. 1.100
Kwong, G. 1.072
Kyllo, H. 2.200
Kyncl, M. 1.248
L
La Vega-Talbott, M. 1.265, 3.149
Labar, D. B.05
Labiner, D. 2.195, 2.198
Lacey, A.S. 2.262
Lachance-Touchette, P. 1.305, 3.279
Lackland, D.T. 2.103
LaCoursiere, C. 1.293
Ladino, L.D. 1.148, 3.223
Laffan, A. 2.068
LaFrance, W. 2.278
LaFrancois, J.J. 3.010
Lagae, L. 2.290
Lahjouji, F. 1.305
Lai, Y. 3.029
Laine, D. 1.219, 1.221, 2.117, 3.214
Lajoie, J. 3.135
Lakshminarayan, G. 2.232
Lam, S. 2.166
Lambrinos, A. 2.276
Lamghari, H. 1.305
Lancaster, J. 3.070
Lancaster, J.L. 3.192
Lancman, M. 1.291, 2.130, 2.210,
3.260
Lancman, M.E. 1.291, 2.205, 2.210,
3.260
Landman, B.A. 3.183
Lane, C.J. 2.218
Lane, J.B. 2.267
Lang, B. 1.052
Langan, Y. 2.068
Langer, J. 2.057
Laoprasert, P. 3.124
Laroche, S. 2.019, 2.023
Lascelles, K. 1.292
Lassalle, V. 3.130
Laurenza, A. 1.140, 1.141, 1.142,
1.143, 1.144, 1.145, 1.146, 1.147,
1.154, 1.230, 2.048, 2.049, 2.050,
2.063
Laux, L. 1.232
Lawrence, J. 3.023
Lawrence, W. 3.029
Lawson, B. 1.219, 1.222
Laxer, K. A.02
Laxpati, N. 1.108, 3.105
Laxton, A. 2.060
Le Guern, M.E. 1.232
Le, C. 1.260
Leary, L. 2.037, 2.296
Leavy, Y. 2.204
Lebeau, K. 2.205, 2.210
Leblanc, S. 2.255, 2.261
Leclère, N. 1.204
Lee, B. 1.030, 3.021, 3.117
Lee, C. 3.238
Lee, D. 2.071, 2.123, 2.124, 3.204,
3.205, 3.215
Lee, E. 3.225
Lee, H. 1.172, 1.289, 3.021, 3.117,
C.07
Lee, I. 3.055
Lee, J. 1.172, 2.023, 2.045, 2.098,
2.140, 2.220, 3.055, 3.126, 3.139,
3.196, 3.225
Lee, J.S. 1.100
Lee, K. 1.109
Lee, K. 1.125, 1.128, 1.134, 1.256,
1.283, 2.095, 2.142, 2.196, 2.249,
3.076, 3.083
Lee, M. 2.071, 2.220, 3.046
Lee, R. 1.262
Lee, S. 1.119, 1.123, 1.134, 2.142,
2.289, 3.021, 3.114, 3.117, 3.154
Lee, W.L. 1.282
Lee, Y. 3.142
Lee, Y.H. 1.091
Leftridge, A. 1.287
Legido, A. 3.059, 3.086
Legros, B. 2.040, 2.067
Lehesjoki, A. 3.268
Lehmkuhle, M. 3.287
Leijten, F. 1.093, 1.097, 2.192
Leite, J. 3.283
Leitinger, M. 2.164
Leiz, S. 3.213
Leland, M. 1.040
Lemieux, L. 1.187, 2.085, 3.190
Lenck-Santini, P. 1.066, 3.054
Lenne, X. 2.255, 2.261
Leonard, A. 3.278
Lepage, C. 1.243
Leppik, I. 1.142, 2.014, 2.140, 2.162,
3.045
Leproult, R. 1.280
Lerche, H. 2.086, 2.125, 3.193, 3.207
Lerner, B.A. 3.106, 3.107
Lerner, J. 1.072, 2.015, 2.021, B.03
Lervik, K. 2.150
LeSure, S.M. 2.282
Leszczynski, A. 2.234
Leuthardt, E. 1.124
Levin, L. 2.240
Levin, S. 3.165
Levisohn, P. 2.006, 2.007
Levitt, J. 1.180, 1.288
Levy-Cooperman, N. 3.209
Lewis, E. 1.129
Ley, D. 1.109
Lhatoo, S. 2.195
Li, D. 3.066
Li, G. 1.227
Li, H. 1.058
Li, L. 3.022
Li, L.M. 2.284
Li, N. 1.050, 3.029
Li, P. 1.132, 2.295
Li, T. 3.008
Li, V. 2.295
Khurana, D. 3.059, 3.086
Khursheed, F. 3.133
Kidokoro, H. 1.171, 3.172, 3.181
Kiehl, T. 1.302
Kikuchi, K. 1.298
Kikuchi, T. 1.086, 2.194, 3.255
Kilit Yilmaz, A. 3.061
Kilit, A. 3.233
Kim, B. 2.289
Kim, D. 1.091, 1.121, 2.271, 3.046,
3.241
Kim, E. 1.109, 1.289, 2.249, 3.021
Kim, G. 1.035, 3.131
Kim, H. 1.030, 2.038, 2.059, 2.065,
2.088, 2.225, 2.289, 3.055, 3.126,
3.139, 3.196, 3.225, 3.231
Kim, J. 1.091, 3.021, 3.117, 3.196
Kim, K. 2.059, 2.065, B.06
Kim, M. 3.131
Kim, P. 1.153
Kim, R. 1.194, 3.081, 3.194
Kim, S. 1.172, 1.246, 1.289
Kim, S. 2.071
Kim, S. 3.021, 3.055, 3.117
Kim, S. 3.152
Kim, S. 3.166, 3.174
Kim, S.T. 3.035
Kim, T.J. 2.142
Kim, W. 1.030, 1.246
Kim, W.J. 3.152
Kim, Y. 1.246, 2.142, 3.142, 3.152,
3.154
Kimia, A. 3.080
King, E. 2.246
King-Stephens, D. B.05, A.02
Kinnaman, B. 1.077
Kinoshita, T. 1.298
Kirchner, A. 3.099
Kirmani, B. 2.167
Kishi, Y. 3.065
Kistner, B.M. 2.140
Kivity, S. 1.296
Klaas, P. 1.085, B.06
Klamer, S. 2.086, 3.193
Klassen, T.L. 1.053, 3.034
Kleen, J. 2.257
Klehm, J. 1.074, 1.236, 1.290, 2.069,
2.132, 3.161, 3.171
Klein, K. 1.309
Klein, P. 3.201
Kleineschay, T. 1.092
Kleneschay, T. 2.095
Klitgaard, H. 2.156, IW.01
Klotz, I.S. 2.244
Kluge, T. 2.017, 3.121
Kluger, D. 1.050
Kluger, G. 3.213
Knape, K. 1.040
Kneen, R. 1.292
Knowlton, R. 1.245
Knupp, K. 1.139, 1.149, 1.235
Ko, D. 1.147, 1.153
Ko, T. 3.046
Kobayashi, J. 3.230
Kobayashi, K. 3.180, 3.255
Kobayashi, R. 2.159, 2.201
89
Li, W. 3.048, 3.106, 3.107, C.07
Li, Y. 1.007
Li, Z. 1.088, 2.094
Liang, L. 3.002, 3.025
Liang, S. 1.056
Libbey, J.E. C.05
Libenson, M. 1.233, 1.236, 2.187
Licchetta, L. 1.296
Lie, O. 2.037, 2.296, 3.192
Liebenthal, J. 2.280
Ligon, K. 2.098
Lillis, K. 1.004, 3.005, 3.014
Lim, B. 2.059, 2.065
Lim, C. 2.162
Lim, J.A. 2.142, 3.154
Lim, M. 2.030, 2.241
Lim, S. 1.246, 3.152
Limon, S. 2.002
Lin, J. 1.165, 1.166, 1.175, 1.284,
IW.09
Linane, A. 1.166
Lindo, S. 3.012
Lindo-Gibbs, J. A.09
Liporace, J. 2.213
Lisa, I. 2.053
Liscak, R. 3.248
Lispi, M.L. 2.016
Litt, B. 1.274, 3.062, 3.104
Liu, C. 1.153
Liu, E. 3.203
Liu, G. C.07
Liu, J. 1.020
Liu, J.V. 1.183
Liu, M. 2.269, 3.175
Liu, X. 3.162
Liu, Y. 3.230
Lizama, G.A. 2.278
LLanes-Durán, A. 1.046
Loddenkemper, T. 1.074, 1.233, 1.236,
1.290, 2.015, 2.021, 2.069, 2.108,
2.132, 3.080, 3.161, 3.171, B.03,
B.02
Lodder, S. 3.111
Loeb, J. 3.001
Loeb, R. 1.308
Loesch, A. 1.174
Loewen, J. 3.013
Lomidze, G. 1.181
Long-Henson, T. 2.287
Longo, D. 2.016
Lopes, R. 3.258
Lopes-Cendes, I. 1.301, 3.281
López, F. 1.234, 1.239, 2.136, 2.163
Lopez, M. 2.273
López-Gomáriz, E. 1.234
López-Meraz, M. 1.046
LoPresti, A. 1.146, 2.050
Loring, D. 2.213, B.07
Loscher, W. 1.043, 1.215
Lotay, N. 2.125, 3.207
Loughman, A. 2.226
Lowden, A. 3.077
Lowe, H. 3.230
Lowerison, M. 1.268, 1.272, 2.234
Lozano, A. 3.275
Lu, Q. 2.157
90
Lu, Y. 2.084, 2.089
Lu, Z. 3.201
Luan, G. 2.054, 3.008
Lucas, T. 1.274
Ludwig, E. 2.157
Lugo, J. 1.282, IW.04
Lukavsky, J. 3.248
Lumley, L.A. 1.210
Luniova, A. 3.227
Lushbough, C. 2.211
Luu, P. 2.099
Lykissa, E. A.09
Lyons, E.J. 2.299
Lyons, P.D. 2.299
Lyons, R.A. 2.262
M
Ma, C. 3.106, 3.107
Ma, N.S. 2.108
Ma, T. 1.144, 1.230
Mabbott, D. 1.176
Maccotta, L. 3.199
Macdonald, R. 1.023
Macey, P. 3.174
Machado, F.M. 1.244
Macken, M. 2.026
MacKenzie, G. 1.103
Macrodimitris, S. 1.195, 2.234, 2.235
Madabhushi, A. 2.100
Madden, C. 1.164
Mader, E. 3.133
Madhavan, D. 2.200
Madou, M. 2.077
Madsen, J. 2.069, 2.198, 3.176
Madsen, J.R. 2.187
Madsen, S. 3.174
Maetzold, D. 2.098
Maganti, R. 1.037, 2.063
Magge, S. 2.182
Maglakelidze, G. 3.047
Magovern, D. 2.219
Maguire, J. 1.103
Maheshwari, A. 1.102
Mahmood, N. 1.159
Mahmoudi, B. 3.105
Maideniuc, C. 2.009
Mail, M. 1.028, 3.005
Maio, V. 2.143
Majmudar, S. 2.297
Makic, M. 2.002
Makin, C. 2.137
Maksabo, J.S. 3.071, 3.264
Malek, A. 2.103
Malik, M. 2.130
Malik, S. 2.186
Malikova, H. 3.248
Malinowska, U. 3.122
Malmenas, M. 2.230
Malmgren, K. 3.138
Malone, S. 2.303
Maloney, T. 2.214, 3.179, A.05
Malpe, C. 1.150, 1.200, 2.302
Malyshev, A. 3.103
Mancuso, M. 2.002
Mandle, H.B. B.04
Mandrekar, J. 1.262, 3.250
Manganaro, S. 3.136
Manganas, L. 1.050
Manreza, M.G. 2.254, 2.309
Manzo, J. 1.046
Marawar, R. 2.208
Marceau, E. 3.023
Marchette, J.C. 3.254
Marcion, S.C. 2.003
Marcus, J. 3.128
Marin de Carvalho, R. 3.080
Marinic, T. 3.010
Marquette, P. 3.143
Marsch, S. 3.160, B.01
Marsh, E. 3.087
Marsh, R. 1.116, 1.262, 2.198, 3.250
Marsh, S. 2.048, 3.044
Marshall, A. 3.049
Marson, A. 2.178, 3.267
Martin, E. 1.293
Martin, R.F. 3.049
Martinez Agredano, P. 2.298
Martinez, P. 3.097
Martínez-Juárez, I.E. 1.064, 1.294
Martinos, M. 3.057, 3.182
Martins, B.P. 3.007
Martins-Castro, B. 2.080
Martz, G. 2.101, 3.084
Masao-Buentello, M. 1.049
Mason, K.M. 1.082, 1.083
Mason, P. 2.251
Massey, A. B.05
Masuda, H. 2.093
Matagne, A. 2.156
Matas, C.G. 2.105
Mathews, K. 1.217
Mathur, A. 1.155
Matos, A. 3.281
Matsuda, K. 3.261
Matsuhashi, M. 1.086
Matsumoto, A. 1.116
Matsumoto, J. 1.072, 1.116, 2.015,
2.021, B.03
Matsumoto, N. 1.298
Matsumoto, R. 1.086, 2.093, 2.194,
3.255
Matsuo, F. 3.079
Matsushima, M. 1.095
Matsuura, M. 1.095
Matsuura, R. 1.298
Matsuzaki, N. 1.113, 1.122
Mattingly, M. 2.202
Mattos, M.F. 3.007
Matuk-Pérez, Y. 1.182
Mauguiere, F. 1.190
Maulisova, A. 1.279
Mauri Fábregas, L. 2.298
Mauri, J. 1.234, 1.239
Maury, R. 1.211
May, R. 2.213
Mayer, T. 1.218
Mayes, L.C. 1.194, 3.194
Maytal, J. 3.135
Mazurkiewicz-Beldzinska, M. 3.140,
3.141
McAuley, J. 2.203
McBain, K. 2.011, 2.015, 2.021, B.03
McCarter, R. 1.051
McCarthy, A. 2.135
McCarthy, D. 2.253
McCarthy, T.C. 2.140
McClelland, S. 3.011
McCloskey, D. 3.018, 3.074
McClurkin, M. 2.227
McConathy, J. 3.199
McCormick, J. 3.098
McCracken, C. 2.274
McDermott, D. 2.172, 3.153
McDevitt, J. A.09
McDonald, C. 1.185, 2.097
McDonald, M. 1.299, 2.306
McDonald, T. 3.003, 3.242
McDorman, J.W. 3.044
McDougall, N. 2.006
McEachran, K. 3.234
McEvoy, A. 1.187, 3.190
McGee, J. 2.154
McGoldrick, P. 1.265, 2.155, 3.149
McGregor, A. 2.035
McGuire, R. 1.048, 3.116
McKee, H. 3.052
McKnight, D. A.08
McLachlan, R. 1.163, 3.218
McLellan, A. 2.033, 2.221
McMahon, J. A.07
McMullen, D. 2.228
McNamara, J. 3.031
McQuitty, W.J. 2.088
McShea, C. 1.231
McTague, A. 1.292, 3.277
Meador, K.J. 2.213, 2.283, B.07
Medin, K.L. 2.207
Medina, M. 1.294
Meeus, C. 2.040
Mefford, H. 1.295, 1.297, A.07
Mégevand, P. 1.098, 3.112
Mehrotra, K. 3.219
Mehta, A. 1.098, 2.198, 3.112
Meisler, M. C.02
Mejia, J. 3.007
Melvin, J. 3.059
Memarian, N. 3.174
Meng, J. 3.106, 3.107
Menon, U. 1.130, 1.260, 2.173
Merrill, S. 2.149
Messenger, E.A. 3.004
Meurs, A. 3.069
Meyer, E. 1.292, 3.277
Meyer, F. 1.116, 1.262, 3.250
Meyer, J.F. 1.102
Meyers, E.E. 3.286
Micallef, C. 1.187
Michelson, M. 1.160
Michelucci, R. 1.308
Michoulas, A. 1.156, 1.253, 3.224
Mickey, B. 1.164
Mikati, M. 1.232, 1.299, 2.306,
3.278, B.02, PL.02
Mikdashi, J. 2.102
Mikuni, N. 1.086, 2.194, 3.255
Miles, L. IW.06
Miles, M. IW.06
Miletich, R. 2.295
Morris, G. 3.102
Morris, M. 3.063
Morris, S.C. 1.034
Morrison, S. 2.141
Morse, R. 3.159
Morse, R.P. 1.232
Morton, W. 2.004
Moseley, A. 3.031
Moseley, B. 2.208, 2.252, 3.252
Moshé, S.L. 1.212, IW.11
Mosher, J. 1.070, 1.084, 1.085,
1.089, A.01
Motelow, J. 3.048, 3.106, 3.107,
C.07
Motil, K.J. 2.267
Moufawad El Achkar, C. 2.187
Mountz, J. 2.092
Moura, L. 3.247
Mouthaan, B. 1.097
Mu, J. 3.157
Mudigoudar, B. 2.035
Mueller, W. 1.088, 2.177
Muir, K. 3.185
Mullan, H. 3.005
Mullatti, N. 1.048
Mullen, J. 2.004
Mullen, S. 1.296, 1.297
Müller, A. 3.213
Muller, M. 1.144
Muma, E. 1.159
Munoz, J. 3.077
Munyandamutsa, N. 2.259
Murakami, H. 2.093
Murakami, Y. 1.298
Murphy, G. 3.004
Murphy, W. 2.235
Murr, N. 3.096
Murro, A. B.05
Murugesan, A. A.01
Muse, W.T. 1.210
Muthaffar, O. 2.174
Muzik, O. 3.073
Myers, L. 2.130, 2.205, 2.210, 3.260
Myers, T. 3.226, 3.228, 3.234, 3.235
Mysore, C. 3.096
Mytinger, J.R. 3.144
N
Nagaraddi, V.N. 1.223, 2.116
Nair, D. 2.096, B.05, B.08, A.02
Najm, I. 1.024, 1.032, 1.273, 2.096,
3.284, B.08, A.01
Nakagawa, E. 3.145
Nakaharada, L. 3.240, 3.272
Nakai, Y. 2.083
Nakamura, M. 1.095
Nakanishi, D.H. 2.254
Nakao, N. 2.083
Nakasato, N. 1.258
Nakhutina, L. 2.211
Nalbandian, K. 3.174
Nam, H.J. 1.100
Nam, S. 3.142
Namer, I.J. 1.254
Nangia, S. 1.161
Nanivadekar, A.C. 1.274
Nanjireddy, R. 2.151
Narayana, S. 2.035
Naritoku, D. 3.115
Narwani, G. 2.151
Nascimento, F.A. 3.275
Naseer, Z. 1.027, 1.214, 1.216
Nash, K. 2.015, 2.021, B.03
Nashef, L. 1.094, 2.025
Nasir, S. 1.133
Nathwani, N. 3.245
Natsume, J. 1.171, 3.172, 3.181
Nazarenko, O. 1.089
Nazem-Zadeh, M. 1.169
Ndiaye, I. 2.259
Neary, M.A. 2.240
Nedelska, Z. 3.251
Negishi, M. 1.194, 3.194
Negoro, T. 1.171, 3.095, 3.172, 3.181
Nei, M. 2.199
Neils, A. 2.286
Nelson, C. 2.089
Nemes, A. 1.024, 1.032
Nespeca, M. 1.237
Neul, J.L. 2.267
Neville, B. 1.249, 2.212, 3.057,
3.173, 3.182
Newmark, M. 2.229
Ng, K. 2.306
Ng, M. 2.032
Ng, Y. 2.256, 2.268, 3.204
Ngo, L. 1.135
Ngoh, A. 3.277
Nguyen, C.N. 2.222
Nguyen, D. 2.176, 2.291, 3.265
Nguyen, L. 1.038, 3.039
Nguyen, R.T. 2.222
Nguyen, S.T. 2.222
Nica, A. 3.130
Nichol, K. 3.205
Nickels, K. 1.257, 2.076
Nicolas, J. 2.156
Niespodziany, I. 1.204
Nievera, C. 2.177
Nikanorova, M. 3.213
Nikolova, S. 1.189, 2.078
Nishibayashi, H. 2.083
Nitulescu, R. 2.147
Noachtar, S. 1.174, 3.089
Noack-Rink, M. 1.218
Nobile, C. 1.308
Nobili, P. 3.050, 3.056
Noé, E. 2.136
Noe, K. 2.305, B.05
Noebels, J. 1.053, 1.102
Noh, B.H. 3.231
Noh, J. 2.074
Nonclercq, A. 1.280
Norden, A. 2.098
Nordli, D. 1.139, 1.161, 2.264
Nourski, K.V. 1.269
Novak, H. 2.164
Novak, V. 1.279
Noviawaty, I. 2.177
Novotny, E. 2.198
Nunes, T. 2.128, 3.210
O
O’Brien, C. 2.172, 3.153, 3.164
O’Brien, T. 1.005, 1.227
O’Donovan, C. 2.058, 2.060, 2.193,
B.05
O’Dowd, D. 1.111
O’Dwyer, R. 1.032, 3.037
O’Hara, B. 3.118
O’Leary, H. 1.104
O’Leary, R. 2.287
O’Malley, H.A. 2.251
O’Muircheartaigh, J. 3.186
O’Neal, W. 3.206
O’Riordan, K. 3.099
O’Roak, B. A.07
Oakley, J.C. 1.202
Oberst, E. 2.092
Obuchowski, N. 2.109
Ochi, A. 1.079, 1.112, 1.115, 3.285
Ochoa, J. 3.115
Oddo, M. 2.010
ODriscoll, C. 1.063
Oertel, W. 3.060
Ogawa, C. 1.171, 3.172
Ogiwara, I. C.02
Ogura, M. 2.083
Oh, A. 2.088
Oh, C. 3.153
Oh, K. 1.125
Oh, M. 3.196
Ohata, K. 3.198
Ohta, K. 1.095
Ojemann, J. 1.054, 2.198
Okanari, K. 1.079, 1.162
Okanishi, T. 1.079, 1.112, 1.115
Okeke, J.O. 1.310, 3.263, 3.270
Okujava, M. 1.181
Okumura, M. 1.095
Olasin, R. 2.155
Olejniczak, P. 3.133, B.05
Olin, B. 3.116
Oliveira, E. 1.014
Oliveira, R.L. 3.007
Olmes, D.G. 3.060
Olsen, M. 1.002
Olson, H. 1.233, 1.293
Olson, L. 2.274
Onat, F. 1.044
Ono, T. 1.250, 2.188
Oommen, B. 3.062
Opperman, C. 2.215, 2.224
Orhan, N. 3.109
Orjuela, K. 2.034
Orozco-Suãrez, S. 1.049
Orth, M. 1.101
Osawa, S. 1.258
Ošlejšková, H. 1.152
Osorio, I. 1.179
Oster, J. 1.244
Oster, M. 3.060
Ostrowsky-Coste, K. 1.096
Otayza, F. 1.263
Otsubo, H. 1.079, 1.112, 1.115,
1.162, 3.285
Otsuki, T. 3.145
Miller, D. 3.246
Miller, D.B. 1.210
Miller, E.R. 1.041
Miller, I. 1.248, A.02
Miller, M.J. 2.268
Miller, S. 1.016, 1.203
Miller, S.P. 2.043, 3.185
Miller, V.S. 2.222
Miller, W. 1.157
Millett, D. 1.153
Millichap, J. 1.161, 2.264, 3.022
Milosevic, M. 2.290
Milsap, G. 2.228
Mima, T. 1.086, 2.093
Mims, K. 2.020
Minassian, B. 3.273
Mindruta, I. 1.099
Mintzer, S. 2.139, 2.143
Miquel, M. 1.046
Mirchandani, N. 2.207
Mireles, P. 2.222
Mirro, E. A.02
Mirsattari, S. 1.163
Mirsky, D. 3.124
Mishra, A. C.07
Miskin, C. 3.086
Mistry, H. 1.194, 3.194
Mittal, M. 2.268
Mittal, S. 1.113, 2.160, 3.282
Miyajima, M. 1.095
Miyamoto, S. 1.086, 2.194, 3.255
Miziara, C. 2.254
Mizrahi, E. B.05
Mlsna, L.M. 1.042
Mnatsakanyan, L. 1.166
Modi, A. 1.036
Modur, P. 1.164, 2.180, 2.206, 3.119
Mogul, D. 3.019
Mohamed, I. 2.176, 2.291
Mohan, C. 3.219
Molet, J. 1.065
Molins Albanell, A. 1.234, 1.239
Mollet, L. 3.069
Moloney, T. 1.052
Monette, C. 3.150, 3.151
Monica, N. 2.281
Monroe, T. 3.245
Montavont, A. 1.096
Montenegro, M.A. 1.301
Montouris, G.D. 2.161, 2.283
Moodley, M. 1.259, 2.029
Moon, C. 1.125
Moon, H. 3.154
Moon, J. 1.134, 2.142, 3.154
Moon, K.W. 2.282
Moran, J. 1.082, 1.083
Moreno, A. 1.239
Morgan, L. 1.247, 2.037, 2.296
Morgan, V. 2.087, 3.183
Mori, Y. 1.079
Morino, M. 3.198
Morita, A. 3.065
Morita, D. 2.214, 3.179, A.05
Morita, T. 3.180
Morrell, M. 1.151, A.02, B.05, IW.01
91
Ottman, R. 1.308, 1.310, 3.263,
3.270
Ouazzani, R. 1.305
Ouled Amar Bencheikh, B. 1.305
Oya, H. 1.269
Ozkara, C. 1.067
P
Paciorkowski, A. 2.294, 3.120
Packwood, S. 1.277
Padow, V. 3.010
Page, R.L. 2.149
Palau Bargues, J. 1.234
Pan, J. 1.186
Panageas, K. 2.158
Pandolfo, M. 1.296
Papacostas, S. 3.075
Papanastassiou, A. 1.247, 2.296
Papanicolaou, A. 2.035
Papathanasiou, E. 3.075
Papon, A. 3.146
Pardini, J. 2.219
Pardoe, H. 3.177
Parent, J. 1.009, 3.004, 3.015, C.02
Parente, A. B.09
Parisotto, S. 3.276
Park, H.S. 1.091
Park, J. 2.308, 3.021, 3.117
Park, K. 3.142
Park, S. 1.119, 1.123, 2.071, 3.114
Park, Y. A.02
Parks, P. 2.038
Parrent, A. 1.173, 2.250
Parris, R. 3.081
Partikian, A. 2.218
Paschoalato, R.P. 3.187
Pascoal, V. 3.281
Pascual, F. 2.256
Pasini, E. 1.308
Passe, T. 1.090
Passen, N. 2.203
Patel, A. 1.198, 2.108, 2.231, 2.279
Patel, D.C. C.05
Patel, K. 2.214
Patel, M. 1.013, 3.002, 3.025, IW.05
Patel, P. 2.207
Patel, S. 2.014
Paterson, S. 1.303
Pathmanathan, J. 2.253
Patil, V. 2.034, 3.097
Pato, A. 2.163
Patten, A. 1.141
Patten, S. 1.195, 1.268, 1.272, 2.266
Patterson, C. 2.092
Patterson, E. 3.045
Patterson, K. 1.001
Pattipaka, T. 2.230
Patton, D. 3.246
Pauli, E. 3.157
Paulson, K.E. 1.008
Pavelock, R. 1.060
Pavlov, J. 1.263
Pavlova, M. 2.032
Pawar, K. 1.077
Pawley, A.D. 1.094, 1.101, 2.025
Payne, E. 2.011, 2.015, 2.021, B.03
92
Pazdera, L. 1.228
Peariso, K. B.02
Pearl, P. 1.051, 1.131, 2.182, 3.072,
3.134
Pearson, C. 1.177, 1.276, 1.277,
2.209
Pearson, S. 2.171, 2.172, 3.153
Pedro, H. 3.276
Peigneux, P. 1.280
Peixoto-Santos, J.E. 3.283
Pellock, J. 2.056, 2.064
Pendziwiat, M. 1.309
Peng, G. 3.204
Peng, S. 1.168
Pennell, P. 2.213
Penovich, P. 1.264, 3.150, 3.151,
3.256
Pepersack, T. 2.040
Perani, S. 1.187, 2.085
Percy, A.K. 2.267
Pereira, P. 2.304
Pereira, V. 2.311
Pérez, J.M. 3.137
Perko, H. 2.017, 3.121
Pernell, M.D. 2.233
Perrine, K. 2.130
Perry, M. 2.186
Perucca, E. 3.211
Pestana Knight, E. 2.113, 2.247
Peters, J. 1.233, 1.236, 1.290,
2.132, 3.171
Peters, T. 1.173, 2.250
Petrilla, A.A. 2.137
Petrovski, S. 3.266
Phelan, J.C. 1.310, 3.263, 3.270
Phillips, K.F. 1.033
Piazzon, F.B. 3.272
Picard, R. 1.074, 2.069
Pickrell, W. 2.262
Pierson, T.M. 1.019
Pike, V. 1.193
Pillay, N. 2.235, 3.218
Pilz, G. 2.164
Pimentel, J. 1.267
Pinheiro-Martins, A. 3.284
Pinto, A.R. 1.241
Pinto, L. 1.270
Piper, R. 3.170
Piperidou, C. 2.283
Pires, N. 1.209
Pirone, A. 1.008
Pita, I. 2.239
Pittman, D.J. 1.192, 3.195
Pittman, Q. 3.100
Pixton, G.C. 2.118
Plegue, M. 1.287
Podell, M. 3.045
Poduri, A. 1.233, 1.236, 1.293,
1.295, 1.300, 2.077, 2.187
Poh, M. 1.074, 2.069
Polak, E. 2.066
Polczynska, M. 2.208
Politsky, J. 2.210
Pollard, J. 1.274, 2.238
Polli, J. 3.200, 3.216
Pongeluppi, R.I. 3.007
Poolos, N.P. 3.024, IW.01
Popescu, M. 1.179
Popli, G. 2.060, 2.193, 2.198
Porter, B. 3.022, 3.087
Poskitt, K.J. 2.043, 3.185
Potschka, H. 1.215
Potter, N.S. C.08
Poukas, V. 2.008
Pouladian, A. 2.176
Pourtois, G. 3.069
Pouyatos, B. 1.211
Powell, A.D. 3.102
Powell, E. 3.049
Powell, K. 1.005
Powell, R. 2.090
Poza, J. 1.304
Prasittisopin, B. 2.162
Prayson, B. 1.273
Prazak, E. 3.256
Press, C. 1.235
Pressler, R. 2.085
Price, M. B.07
Pristasova, E. 2.053
Pritchard, J. 3.262
Privitera, M. 1.229, 2.066, 2.213,
3.212
Pro, S. 2.016
Probasco, J. 3.221
Probst, L. 3.219
Proddutur, A. 1.006
Proteasa, S. 3.135
Prueckl, R. 3.076
Prusa, C. 2.203
pSERG, B.02
Puccioni, M. 2.200
Pugh, M. 2.278
Pugnaghi, M. 1.187
Pujar, S. 3.057, 3.170, 3.173, 3.182
Pun, R. 1.018
Puri, V. 1.080
Pustina, D. 2.082
Putman, M. 2.108
Puttachary, S. 3.040
Q
Qi, Y. 3.127
Qian, R. 3.127
Quan, H. 2.269
Quddusi, S. 1.065
R
Rabinowicz, A.L. 1.226
Raedt, R. 3.069, 3.168,
Raffelt, D. 3.184
Raghavan, M. 1.088, 2.094, 2.177
Rahman, Z. 2.106
Raible, D. 1.015
Raizer, J. 2.026
Rajasekaran, K. 1.026, 3.026
Rallis-Frutos, D. 1.193
Ramachandran Nair, R. 2.240
Raman, K.R. 1.170
Ramgopal, S. 1.233
Ramirez, M. B.06
Ramos Rivera, G.A. 1.152
Rampp, S. 3.157
Ramsay, E. 1.130
Ramsay, R. 2.162, 2.173
Randall, M. 3.038
Ranganathan, R. 1.021
Ranta, A. 1.303
Rao, X. 1.062
Raol, Y. 3.043
Rarick, J. 2.140
Rasina, A. 1.099
Rathore, J. 2.109
Rathouz, P.J. 2.223
Ravizza, T. 1.001, C.06
Razavi, A. 3.220
Razumkina, E. 3.103
Ream, M. 1.299, B.02
Reavey, E. 2.041
Reddy, D. 1.045
Redshaw, N. 1.303
Reed, U.C. 2.309
Reenan, R. 1.111
Rees, M. 2.262
Reeves-Tyer, P. 3.072
Regan, B. 1.296, 3.266
Rehman, R. 2.263, 2.273
Reid, A. 3.041
Reilly, C. 2.212
Reinsberger, C. 1.074, 2.069
Rektor, I. 1.242
Remi, J. 1.174, 3.089
Ren, L. 3.251
Rendahl, A. 3.045
Resnick, T. 1.248
Rey, G. 1.279
Reynolds, B. 1.059
Rezaie, R. 2.035
Rheims, S. 1.096
Rho, J.M. 1.037, 1.081, 1.107, 3.241
Rhone, A.E. 1.269
Rhoney, D.H. 2.160
Riazi, K. 3.100
Richard, G. A.08
Richardson, M.P. 1.094, 1.101, 1.266,
2.025, 2.178, 3.186
Richerson, G. 3.051
Riela, A.R. 2.222
Rigney, J. 2.043
Riley, D. 2.273
Riley, J. 1.165, 1.166, 1.175
Rincon Flores, N. 1.137
Rinehardt, E. 2.202
Riordan, K. 1.050
Rios, C. 2.275
Rios, L. 1.263
Risse, G. 3.256
Ristic, A. A.01
Ritacco, D.G. 1.161
Rittase, W.B. 3.012
Ritter, F. 1.090, 1.224, 1.264, 2.215,
2.224
Ritter, F.J. 1.238
Rizvi, S.A. 1.127
Robbins, A. 1.066, 3.054
Roberts, J. 2.269
Rocha, C.S. 3.281
Rocha, L. 1.049
Roden, W.H. 1.054
Rodgers-Neame, N. 2.202
S
Sabharwal, P. 2.245, 2.248
Sachdev, R.N. C.07
Sackellares, J. 1.075
Sadamoto, K. 3.065
Sadleir, L. 1.303
Sadler, T. A.02
Safi-Harab, M. 1.191
Sagastume, R. 2.173
Saghyan, A. 3.245
Saindane, A.M. B.07
Sainz, V. 3.239
Saito, T. 3.145
Saito, Y. 3.145
Saitsu, H. 1.298
Saiz Diaz, R. 1.239
Sajobi, T. 1.268, 1.272
Sakamoto, A. 1.301
Sakuma, S. 1.079, 3.285
Salah, A. 1.055
Salam, M. 1.069, 1.071
Salam, S. 2.183
Salamon, N. 1.170
Salanova, V. B.05, A.02
Salas Puig, J. 1.239
Salas, J. 1.234
Salazar, P. 2.095
Sales, F. 3.089
Salinas, C. 1.128, 1.283, 3.083
Salinas, F. 3.169, 3.192
Salinsky, M. 2.070
Salmon, C.G. 3.283
Salpekar, J. 2.260
Sammour, M. 2.028
Sampath, D. 3.043
Samson, R. 2.090
Samson, S. 1.271
San Luciano, M. 2.283
Sanchez Carpintero, R. 1.114
Sánchez Fernández, I. 1.233, 1.236,
1.290, 2.015, 2.021, 2.132, 3.161,
3.171, B.03, B.02
Sanchez, A. 2.292
Sanchez, L. 2.239
Sanchez, S. 2.015, 2.021, B.03
Sanchez-Alvarez, J. 1.239, 1.304
Sandoval, A. 2.218
Saneto, R.P. 1.232
Sanganahalli, B. 3.048, C.07
Sanguansermsri, C. 1.253
Sankar, R. 1.072, 2.112
Sankaraneni, R.R. 2.165
Santhakumar, V. 1.006, 1.007
Santos, A.P. 3.253
Santos, C. 1.301, 3.283
Santos, P. 3.244
Saponjian, Y. 1.028, 1.205
Sarkis, R. 1.074, 2.069
Sarkisova, K. 3.103
Sasaki, M. 3.145
Sasano, T. 1.095
Sato, S. 1.078
Satpute, S. 2.042
Saul, K. 1.008
Sauro, K. 2.234, 2.235
Savva, Y. 1.111
Sawamoto, N. 2.093
Sazgar, M. 1.166
Scandiuzzi, R.C. 3.283
Scantlebury, M. 1.081
Schaal, A. 3.083
Schalk, G. 3.083
Scharfman, H.E. 3.010, IW.05
Schauwecker, P. 3.280
Scheffer, I. 1.293, 1.295, 1.296,
1.297, 1.303, 3.266, A.07
Scheinost, D. 1.184
Scheuer, T. 1.202
Schiemann, J. 3.201
Schildt, C. 3.118
Schlachter, K. 3.213
Schmidt, C. 2.227
Schmitt, S. 1.274, 2.023
Schnabel, K. 1.075, 2.017
Schnabel, L. 2.224
Schneider, L. 1.013
Schoedel, K.A. 3.209
Schoenberg, M. 2.202
Schoene-Bake, J.C. 2.178
Schoenike, B. 3.099
Scholl, E. 3.287
Scholly, J. 1.217, 1.254
Scholtz, H. 3.239
Schomer, M. 2.108
Schooff, D. 2.273
Schrader, D. 1.156
Schramke, C. 3.123, 3.259
Schreiber, J. 1.078, 1.193, 3.072
Schuck, E. 2.063
Schuele, S. 2.026
Schuelke, A. 1.229, 3.212
Schuh, L. 1.159
Schultz, L.R. 1.083, 1.159, 3.249
Schultz, M.K. 1.210
Schultz, R.J. 3.143
Schulze-Bonhage, A. 1.048, 2.039,
2.134
Schusse, C. 2.179
Schutte, R.J. 1.111
Schutte, S.S. 1.111
Schwab, M. 2.139
Schwabe, M. 1.118
Schwabe, S. 1.225
Schwalb, J. 3.249
Schwalb, J.M. 1.169
Schwartz, J.E. 1.210
Scott, C. 1.187
Scott, R. 1.066, 2.212, 3.054, 3.057,
3.173, 3.182
Sebera, F. 2.259
Secore, K. 1.201, 2.257
Seegmuller, C. 2.024
Segal, E. 1.291, 3.276
Seidenberg, M. 1.175, 1.178, 2.223
Seif Eddeine, H. 1.177, 1.226
Seinfeld, S. 2.056, 2.064
Selassie, A. 2.101, 2.103, 2.114
Selassie, A.W. 2.272
Selby, K. 3.224
Selch, C. 3.213
Sell, E. 1.129
Seltzer, L. 3.120
Selvakumar, T. 1.031
Selwa, L. 1.198
Selway, R. 1.249
Sen-Gupta, I. 1.160
Seo, J. 1.128, 1.256, 2.095, 2.196
Sepeta, L. 3.189
Serafini, R. 3.001
Serrano, P. 1.239, 1.304
Serrano, V.G. 2.254
Serratosa, J. 1.234, 1.239, 1.294,
2.138
Sethi, N.K. 3.128
Seyal, M. 1.120, C.09
Shah, A. 1.113, 2.151, 2.160, 2.265,
2.270, 3.282
Shahdad, N. 1.076
Shahmirzadi, L. 1.306
Shain, C. 1.293
Shang, E. 3.047
Shanmugham, A. A.08
Shao, L. 3.012
Shapiro, J.S. 2.242
Sharan, A. 2.082, 2.198, 2.199
Sharkey, K.A. 3.100
Sharma, R. 2.011
Sharon, R. 2.286
Shaw, A. 1.160
Shaw, S. 1.153
Sheffield, R. 3.164
Shegog, R. 2.229
Sheidley, B. 1.293
Shellhaas, R. 1.287
Shen, L. 1.106
Shen, V. 2.124, 2.131
Shendure, J. A.07
Shephard, A. 1.106
Sherer, K. 2.249
Sheriff, H. 1.237
Sherman, N.A. 2.118
Sherman, W. 2.026
Sherr, E. 1.295, 1.300, 2.077
Shetty, A. 1.062, 1.252
Shiau, D. 1.075, 3.116
Shibata, S. 1.086, 2.194
Shields, D. B.05
Shields, W. A.02
Shih, J. 2.181, 2.198, 3.211
Shih, S. 2.260
Shihabuddin, B. 2.300
Shimizu, N. 3.180
Shimoda, Y. 1.258
Shimotake, A. 2.093, 3.255
Shin, D. 1.068
Shin, J. 1.134, 2.142, 3.154
Shin, W. 1.100
Shin, Y. 2.142
Shirka, R. 1.050
Shneker, B. 2.203
Shohatee, T.A. 3.074
Shon, Y. 1.246, 3.152
Shorten, A. 2.227
Shostak, S. 1.310, 3.263, 3.270
Shreiber, J. 1.051
Shrestha, A. 2.171, 2.172, 3.153
Shuai, B. 1.062
Shukla, R.B. 2.118
Shukla, U. 1.021
Shunney, C. 2.237
Shvarts, V. 1.082
Shyu, B. 3.108
Rodionov, R. 1.187, 3.190
Rodriguez Osorio, X. 2.163
Rodriguez Uranga, J. 1.234, 1.239
Rodriguez, A. 1.150, 1.200, 2.302
Rodríguez-Fernandez, J. 1.194, 3.194
Rodriguez-Leyva, I. 1.182
Roehl, K. 3.221
Roers, E. 2.121
Roessler, K. 3.157
Rogin, J.B. 2.118, 2.126, 2.128,
2.139
Rogozinskaya, E. 3.103
Rohmer, D. 2.036
Roland, C.L. 2.118
Roland, E. 2.043, 3.185
Rolle, I. 1.018
Roman, R. 3.090
Romero, C. 1.241
Rong, L. 3.094
Roopchansingh, V. 3.189
Roopra, A. 3.099
Roper, S. 1.059, 3.042
Rose, D. 1.087, 1.278
Rosen, A.R. 1.300
Rosenbaum, R. 2.257
Rosenfeld, W. 3.205
Rosenow, F. 1.309, 3.060
Rossetti, A.O. 2.010
Rossi, M. 2.281, 3.064, 3.188, A.02
Rotenberg, A. 1.233, 1.236, IW.02
Roth, R.M. 1.201
Rothermel, M. 1.034
Rothermel, R. 1.113
Rothman, S. 1.207
Rothner, A.D. 1.259, 2.029
Roucard, C. 1.211
Rouleau, G. 1.305
Rowles, J. 1.002
Rowley, S. 1.013, 3.002
Royston, S. 1.109
Rozzelle, C. 2.088, 2.225
Rubboli, G. 1.073
Rubio, E. 3.239
Rubio-Nazábal, E. 2.163
Ruble, T. 2.166
Rudolf, G. 2.036
Rudzinski, L. 2.019
Rueda, C.H. 1.036
Rueegg, S. 3.160
Ruegg, S. B.01
Runge, U. 1.218
Russek, S. 1.010, 1.015, 3.017,
3.028
Rutecki, P. B.05, A.02
Rutka, J. 1.115
Ryan, K. 3.002
Rydenhag, B. 3.138
Ryu, H. 2.059, 2.065, 2.289
Ryvlin, P. 1.073, 1.096, 1.190
Rzezak, P. 1.286
93
Siddarth, P. 1.180, 1.288, 2.112
Sidyelyeva, G. 3.027, 3.047
Sierra-Marcos, A. 2.010
Silva, L.A. 1.270
Simons, R. 3.164
Simonson, C. 3.224
Simontacchi, K. 2.145, 2.279
Singh, G. 2.307
Singh, J. 1.069, 1.071
Singh, K. 3.080
Singh, P. 2.072, 3.129
Singh, S. 2.165
Singhal, A. 1.253
Singh-Cadieux, G. 1.115
Singleton, M. 1.013
Sinha, S. 2.018, 2.020
Sirsi, D. 3.082
Sirven, J. 2.305
Sivakumar, S. 2.265, 2.270
Sivaswamy, L. 1.138
Skidmore, C. 2.082, B.05
Skinner, S.A. 2.267
Skjei, K. 1.057, 3.236
Skocic, J. 1.176
Skyrud, D.W. 3.024
Slater, J. 1.245, 2.198, 3.148
Slevin, J. 2.152, 3.052
Slomko, A.M. 1.027, 1.214, 1.216
Slone, E. 2.091
Smeland, O. 3.003
Smirnakis, S. 1.102
Smith, B. 1.003, 1.015, 3.249
Smith, C. 2.269
Smith, E. 2.186
Smith, G. 2.114
Smith, K. 1.303, 2.179
Smith, M. 3.165, B.05
Smith, M.A. 1.111
Smith, M.L. 1.176
Smith, P. 2.262
Snead, O.C. 1.106, 1.115, 1.176,
2.240, 2.241
Snutch, T.P. 1.005
Snyder, J. 1.159, 2.098
So, E. 1.262, 2.081
So, G. 2.222
So, N. 2.166, 3.078
Soares Da Silva, P. 1.209, 2.128,
3.210
Sobayo, T. 3.019
Soderblom, E. 3.031
Sogawa, Y. 2.052, 2.092
Solari, F. 1.263
Solomon, G. 3.128
Soltanian-Zadeh, H. 1.169
Sommerville K, K. 2.118
Song, H. 1.068
Song, Y. 1.012
Soni, N. 2.211
Sonnewald, U. 3.003
Sontheimer, H. IW.02
Sood, S. 1.113, 1.138
Soper, C. 1.213, 3.067
Sorge, S. 1.310, 3.263, 3.270
Soster, L.A. 3.240
Sotero de Menezes, M. 1.232
94
Soto, A. 3.239
Sousa, R. 2.126, 2.127, 2.139, 3.202,
3.208
Soussou, W. 3.084
Souza, D.A. 1.301
Souza, M. 2.311
Soylemezoglu, F. 1.251
Spaeth, C. 2.246
Spanaki, M. 1.159, 3.249
Sparks, J.D. 3.236
Speechley, K. 2.276, 3.165
Speed, D. 3.267
Spencer, D. 1.184, 1.186, 3.078,
B.05, A.02
Spencer, K. 2.108
Sperling, M.R. 1.226, 2.082, 2.198,
2.199, 3.210, 3.215, 3.220, A.02
Sperry, L. 2.113, 2.247
Spiegel, R. 2.207
Spiegelman, D. 1.305
Spitz, M. 2.171, 2.172, 3.153
Spitz, M.A. 2.024
Squillacote, D. 2.049, 3.164
Srinivaskumar, P. 1.155
St Pier, K. 2.085
Staack, A.M. 1.217
Staba, R. 3.041, 3.174
Staber, C. 1.111
Stacey, W. 3.053
Stack, C. 1.160, 1.161
Staelens, L. 2.156
Stafstrom, C. 1.175, 1.178, 1.284,
2.223
Staley, K. 1.004, 1.012, 1.017, 1.025,
1.028, 1.205, 3.005, 3.014, IW.05
Stanek, A. 1.129
Staudt, M. 3.213
Stead, M. 1.116, 3.090
Stefan, H. 1.073, 3.157
Steinbok, P. 1.253
Steinborn, B. 3.140, 3.141
Steindler, D. 1.059
Steinhoff, B.J. 1.073, 1.217
Stence, N. 3.124
Stephani, C. 2.308
Stephani, U. 3.213
Stephens, M.L. 3.052
Stern, J. 1.170, 2.252
Steven, D. 1.173, 2.250
Stewart, S.B. 2.218
Stino, A. 2.009
Stockis, A. 3.203
Stoica, A. 3.279
Stoll, K. 3.023
Stoll, S. 1.198
Stone, M.F. 1.210
STOP SUDEP Program Network 1.053
Storme, T. 3.146
Storzbach, D. 2.070
Stowe, R. 1.080
Straub, H.B. 1.196
Striz, M. 3.118
Strobl, K. 1.254
Stroescu, I. 2.209
Strom, L. 2.150, 2.171, 2.172, 3.153,
3.222
Stufflebeam, S. 3.176
Suchdev, K. 3.282
Suddes, M. 2.235
Sugai, K. 3.145
Sulc, V. 2.081, 3.251
Sullivan, J.E. 1.232
Sun, F. 1.151, B.05, A.02
Sun, H. 1.011, 3.032
Sun, J. 3.026
Sunaert, S. 3.197
Sundaram, S. 3.071
Sundaram, S.K. 3.264
Sunderam, S. 3.118, 3.119
Superak, H. 2.279
Sutter, R. 3.160, B.01
Sutton, R. 1.061
Suzuki, N. 3.191
Suzuki, T. 1.294
Suzuki, Y. 1.095
Sveinsson, O. 1.053
Swann, J. IW.04
Sweitek, B. 1.006
Swiercz, W. 1.004, 1.205, 3.005
Swisher, C. 2.018
Symms, M. 2.090
Synowiec, A. 3.123
Szabo, C. 1.040, 1.247, 2.037, 2.296,
3.169, 3.192
Szaflarski, J. 2.023
Szrama, N. 1.124
Szurhaj, W. 3.258
Szuster, S. 2.205, 3.260
T
Tahir, R. 3.249
Tai, T.Y. 3.024
Takahashi, E. 3.176
Takahashi, J. 2.194
Takahashi, R. 1.086, 3.255
Takahashi, Y. 3.232
Takamori, H. 3.065
Takano, H. 1.105
Takaya, S. 1.086
Takayama, R. 1.298, 3.232
Takeoka, M. 1.233, 1.236, 2.187,
2.198, 3.080, 3.088
Takeuchi, C.A. 3.272
Takeuchi, T. 1.171, 3.172
Takumi, I. 3.065
Talib, L.L. 3.058
Tall, M.K. 1.128
Talos, D. 1.055
Tam, E.W. 3.185
Tamber, M. 2.092
Tan, H.J. 2.067
Tan, K. 3.003, 3.242
Tanaka, M. 1.294
Tanaka, N. 3.176
Tandon, N. 1.245, 2.198, 3.070,
3.148, A.06
Tang, S. 1.306
Tangel, V. 1.310, 3.263, 3.270
Tao, J. 2.280
Tarallo, T. 3.213
Tarquinio, D.C. 2.267
Tarride, J. 2.241
Tasker, R. B.02
Taskiran, E. 3.109
Tatum, W. 2.181
Tayah, T. 2.291
Taylor, A. C.04
Tcheng, T. 3.245
Teasdale, E. 1.136
Tecoma, E. 2.097
Tedeschi, H. 1.014
Teigland, C. B.09
Telecka, S. 1.242
Tellez-Zenteno, J. 1.126, 1.127, 1.148,
3.223
Tenney, J. 1.087, 2.214, A.05
Teocchi, M. 1.014
Tepley, N. 1.082
Terada, K. 3.261
Terada, M. 2.083
Terra, V. 1.301
Terrill, M. 3.091
Terry, D. 2.217
Tesar, G. 2.109
Tesco, G. C.04
Tesoro, O. 2.092
Testa, S. 3.262
Teter, B. 1.076
Teuwen, D. 2.259
Thakur, K. 3.221
Thaler, A. 2.238
Thawani, S. 2.245, 2.248
Theodore, W. 1.051, 1.078, 1.193,
3.072, 3.189
Thesen, T. 3.177
Thio, K. 3.120
Thippeswamy, T. 3.040
Thodeson, D. 2.052
Thomas, A. 3.017
Thomas, D.I. 2.154
Thomas, G.P. 1.183
Thomas, L. 2.237
Thomas, R. 2.262
Thome-Souza, S. 1.074, 1.233, 1.236,
1.290, 2.069, 2.132
Thompson, D. 3.063
Thompson, D.M. 2.268
Thompson, L. 3.226
Thompson, M. 2.225
Thompson, N. 1.198, 2.285
Thompson, P. 2.090, 3.174
Thompson, S. 1.070
Thomson, J. 1.050
Thomson, K. 1.036
Thornton, R. 1.187, 3.190
Thurman, D. 2.279
Tierney, T. 1.031
Timarova, G. 2.053
Timmons Mitchell, J. 2.113, 2.247
Ting, T. 2.102, 3.200, 3.216
Titiz, A. 3.054
Tiwari, P. 2.100
Tiwari, V. 3.073, 3.264
Tobochnik, S. 2.062
Toda, K. 1.250, 2.188
Todd, W.M. 1.219
Todorovic, S. 3.020
Toledo, M. 1.234, 1.239
U
Uchegbu, G. 2.007
Uda, T. 3.198
Ueda, K. 3.113
Ueda, Y. 1.307, 3.232
Uematsu, M. 1.258
Ulyanova, A.V. 1.039
Unal, N. 3.217, 3.229, 3.233
Unalp, A. 3.217
Unterberger, I. 2.044
Upchurch, K. 2.253
Ura, H. 3.065
Urbain, C. 1.280
Urrestarazu, E. 1.114
Usami, K. 2.093, 3.255
Usui, K. 3.261
Usui, N. 3.261
Uwacu, B. 2.259
Uysal, U. 1.179, 2.277, 3.156
V
Vadivelu, S. 1.255
Vaidya, U. 3.260
Vale, F. 1.137, 2.197, 2.202
Valencia, I. 1.232, 3.059, 3.086
Valente, K. 1.197, 1.286, 2.115,
3.058
Valenti-Hirsch, M.P. 1.254
Valenti-Hirsch, P. 2.024
Valeriano, J.P. 3.123, 3.259
Valerio, R. 1.270, 2.080, 3.253
Valiante, T. 2.240
Van Bochove, M. 3.069
Van Bogaert, P. 1.280
Van de Vel, A. 2.290
Van Emde Boas, W. 1.073
Van Grunderbeek, W. 1.048
Van Hemert, H. 1.073
Van Huffel, S. 2.290
van Klink, N. 1.093, 2.192
Van Meurs, B. 2.224
van Mierlo, P. 3.168
Van Ness, P. 1.164, 2.180, 2.206,
B.05, A.02
Van Paesschen, W. 3.197
Van Poppel, K. 2.035
van Putten, M.J. 2.012, 2.013, 3.111,
C.03
van Rijckevorsel, K. 1.048
Van Zandt, M. 3.036
Vandenberghe, S. 3.168
Vanhove, C. 3.168
Vannan, D. 1.074, 2.069
Vannest, J. 2.214, 3.179, A.05
Vanrumste, B. 2.290
van't Klooster, M. 1.093, 1.097, 2.192
Vara, R. 2.004
Vargas-Mendez, D.A. 1.182
Vats, A. 2.274
Vaughan, D. 3.184
Vazquez, B. 1.145
Vega, C. 1.290, 2.132
Velasco, T.R. 3.283
Velez, F. 2.137, 2.146, 2.147, 2.230
Velis, D. 1.073, 1.117
Velisek, L. 3.027, 3.046, 3.047
Veliskova, J. 3.027, 3.047
Velmurugan, M. 1.158, 2.168
Venkatesan, A. 3.221
Venkatesan, C. 1.161
Verbel, D.A. 1.143, 2.063
Verguts, T. 3.069
Verpillat, P. 2.131
Vest, M. 1.109
Vezzani, A. 1.001, C.06
Victoria Costa Caetano, E. 2.309
Vieira, A.S. 3.281
Vigevano, F. 2.016
Villafuerte Espinoza, M. 2.307
Villanueva Haba, V. 1.234, 1.239,
2.136
Villemarette-Pittman, N. 3.133
Viltz, L.M. 1.054
Vincent, A. 1.052, 2.030
Vincentiis, S. 3.058
Vinette, S. 2.091
Virag, N. 1.061
Visser, G. 1.117
VIte, C. 3.045
Vitkovskiy, P. 1.050
Vivas, A. 2.197
Vlachos, I. 1.084
Voets, N. B.07
Vojtech, Z. 3.248
Vollmar, C. 1.174
von Dobeln, U. 1.053
Vonck, K. 1.048, 3.069
VonDran, M.W. 3.010
Vossler, D. 1.208
Vulliemoz, S. 1.187, 3.190
W
Wachowiak, M. 1.034
Wagenaar, J. 3.062
Wagner, F. 2.240
Wagner, G. 1.048
Wagner, J. 2.007, 2.114
Wagoner, J. 2.008
Walczak, E.G. 2.014
Walczak, P. 2.002
Walczak, T. 2.014
Walker, E. 2.285
Walker, K. C.04
Walker, M. 1.187, 3.190
Wallace, E. 1.037
Wallendorf, M. 1.155
Waller, L. 2.279
Walser, G. 2.044
Walsh, C. 1.293
Walton, J. 1.229
Wan, W. 1.027, 1.214, 3.245
Wang, C. 3.245
Wang, S. 1.237, 3.132, 3.243
Wang, T. 3.277
Wang, X. 2.296
Wang, Y. 2.228
Wang, Z. 1.017, 1.084, A.01
Wannamaker, B. 2.103
Warfield, S. 3.171
Warner, L.N. 3.024
Warren, A. 1.188, A.04
Wasade, V. 1.159, 3.249
Wassermann, E.M. 3.072
Watanabe, K. 1.171, 3.172, 3.181
Watanabe, S. 1.191, 1.298
Waters, C.G. 3.084
Watson, C. 2.183
Weber, A. 3.144
Weber, B. 2.178
Weber, P. A.02
Wechsler, R. 1.142, 1.227, 2.129,
2.139
Wehrens, X.H. 3.029
Wei, X. 3.127
Weinand, M. 2.198
Weiner, H. 1.055
Weinkopf, M. 2.017, 3.121
Weinstein, S. 1.131
Weinstock, A. 1.076, 1.132, 2.295
Weir, A. 2.221
Welty, T. 1.229, 3.212
Wempe, M.F. 1.010
Wen, P. 2.098
Wennberg, R. 3.275
Wentworth, J. A.09
Wentzensen, I. 3.277
Werhahn, K. 1.231
West, P.J. 3.030
Westenbroek, R.E. 1.202
Westerveld, M. 1.128, 1.283, 3.076,
3.083
Westmoreland, B. 2.310
Westover, M. 2.023
Wetjen, N. 1.262, 2.190
Wexler, J. 1.259, 2.029
Wey, H.Y. 3.192
Whalley, C.E. 1.210
Wharen, R. 2.181, 2.198, B.05, A.02
Wheless, J. 2.035, 2.118, 2.123,
3.140, 3.141
White, A. 3.043, 3.124
White, H. 1.036, 3.013, IW.01
White, J. 1.034, 1.264, 2.111
White-James, J. 3.044
Whiting, S. 2.240
Wichter, M. 2.060
Widjaja, E. 1.176
Wiebe, S. 1.195, 1.268, 1.272, 2.234,
2.235, 2.266, 2.269, 3.162, 3.165
Wiel, E. 2.261
Wiener, M. 3.068
Wiggs, E. 1.051
Wijayath, M. 2.027
Wikler, K. 2.002
Wilcox, K. 1.034, 3.013, IW.11
Wilfong, A. 1.252, 1.255, 2.198
Wilfong, A.A. 3.143
Wilk, M. 2.291
Wilkening, G. 1.290, 2.132
Williams, A.C. 1.275
Williams, B. 1.140, 1.141, 1.142,
1.143, 1.144, 1.145, 1.146, 1.147,
1.154, 1.230, 2.048, 2.049, 2.050,
2.063
Williams, F. 3.133
Williams, J. 1.040
Williams, K. 2.015, 2.021, B.03
Williams, P. 1.227, 2.145
Williams, S. 2.092
Williamson, J. 3.026
Williate, P. 2.255, 2.261
Willie, J. 2.175, 2.198, B.07
Töllner, K. 1.043, 1.215
Tom, M. 2.022
Tominaga, T. 1.258
Tomlinson, S. 3.087
Tomson, T. 1.053
Tonberg, A. 2.033
Tonegawa, S. 3.023
Topcu, M. 1.251
Tornabene, K. 2.184, 2.185, 2.191,
3.219
Torres Delgado, F. 3.133
Torres Muller, C. 1.263
Torres, F. 1.301
Torres, N. 1.234, 2.136
Tottori, T. 3.261
Tournier, J. 3.184
Tousseyn, S. 3.197
Tovar, D. 1.265, 2.155
Tovar-Spinoza, Z. 2.184, 2.185, 2.191
Towgood, K. 3.186
Toyoda, G. 1.122
Tracy, J. 2.082
Tran, B. 1.022, 3.022
Tran, C.T. 2.233, 2.236
Tran, T. 2.263
Tran, Y.T. 2.291
Tranel, D. 1.269
Traynelis, S.F. 1.019
Traynor, C. 3.186
Trefler, A. 1.170
Treiman, D. 3.044
Treiman, L. 3.044
Tringham, E. 1.005
Trinka, E. 1.073, 2.044, 2.164
Tripathi, M. 2.067
Triplett, R. 2.219
Trobliger, R. 1.291, 2.130, 2.205
Truccolo, W. C.08
Tseng, P. 2.153
Tsuchida, T. 1.131
Tsunoda, M. 1.079
Tsuyuguchi, N. 3.198
Tucker, D. 2.099, 3.091
Tumkur, A. 2.020
Tummala, S. 2.312
Tung, J. 1.108
Turanli, G. 1.251
Ture, S. 3.061
Turner, M. 2.170
Tuttle, E. 2.294
Tuzun, E. 1.067
Tvrdik, P. 1.034
Twele, F. 1.043, 1.215
Tyer, P. 1.078
Tyrlik, M. 1.242
Tyrlikova, I. 1.242
Tytgat, D. 2.156
Tyvaert, L. 2.255, 2.261, 3.258
95
Willner, A. 3.074
Wilson, D.A. 2.101, 2.103, 2.114,
2.272
Wilson, T. 2.200
Winawer, M. 1.310, 3.263, 3.270
Winnik, S. 3.036
Winstanley, F. 1.184
Wirrell, E. 1.139, 1.149, 1.232,
1.257, 1.262, 2.076, 2.190
Wisniewski, I. 1.217
Witcher, M. 2.193
Witten, I.B. 3.106, 3.107
Wolf, J.A. 1.039
Wolf, S. 1.265
Wolf, S.M. 2.155, 3.149
Wolff, C. 1.204
Wolff, M. 3.213
Wolff, U. 1.196
Wolgemuth, D. 3.047
Wolter, K. 2.118
Wong, C. 2.027, 2.106, A.01
Wong, D.S. 3.185
Wong, M. 2.106, 3.016, IW.04
Wong, S. 2.198
Wong-Kisiel, L. 1.257, 2.076, 2.081
Wongvravit, J.P. 1.027, 1.214
Wood, M. 2.303
Woodard, V. 2.058, 2.060
Woods, S. 3.179
Woodward, K.E. 2.079
Worrell, G. 1.116, 1.262, 2.081,
2.084, 2.089, 2.198, 3.251, B.05,
A.02
Worster, A. 2.241
Wozniak, A. 1.063
Wright, L. 1.209
Wright, S. 2.030
Wu, C. 3.104
Wu, E.Q. 2.146, 2.147
Wu, J. 1.072
Wu, N. 3.271, 3.274
Wu, X. 1.045
Wulsin, D. 3.104
X
Xiao, W.R. 1.194, 3.194
Xiao, Y. 1.059
Xin, X. 1.271
Xing, D. 1.147
Xu, B. 3.189
Xu, D. 1.016
Xu, M. 1.022, 1.029, 3.022
Xu, Q. 2.043, 3.185
Xu, R. 2.087, 3.183
Xu, S. 3.049
Y
Yaghouby, F. 3.118, 3.119
Yalnizoglu, D. 1.251
Yamaguchi, T. 3.232
Yamakawa, K. 1.294, C.02
Yamamoto, H. 1.171, 3.172, 3.181
Yamamoto, T. 2.159, 2.201, 3.091
Yamao, Y. 1.086, 2.194
Yamashita, S. 3.187, 3.254
Yamazaki, M. 3.091
Yamazoe, T. 2.159, 2.201
Yang, G. 1.184
96
Yang, H. 1.140, 1.141, 1.142, 1.143,
1.144, 1.145, 1.146, 1.147, 1.154,
1.230, 2.048, 2.049, 2.050, 2.063
Yang, S. 1.167, 3.021, 3.117
Yang, T. 1.121, 2.301
Yang, X. 1.207
Yankam Njiwa, J. 1.190
Yardi, R. B.08
Yasuda, C. 3.175, 3.178
Yates, S. 2.129, 2.145
Yaun, A. 1.020
Ybarra, M. 3.237
Ye, S. 2.293, 3.155
Yee, A. 1.008
Yee, K. 3.246
Yeni, N. 1.067
Yenugadhati, V. 1.041
Yetkin, Z. 1.164
Yi, F. 3.023
Yilmaz, C. 3.109
Yilmaz, U. 1.208, 3.217
Ying, Z. 1.024, 1.032
Yogarajah, M. 2.090
Yoke, J. 2.228
Yokoi, S. 1.171, 3.172
Yokota, T. 2.159, 2.201
Yoo, J. 1.050
Yoon, J. 3.225
Yoong, M. 3.170
Yorns, W. 3.059
Yoshida, N. 1.095
Yoshinaga, H. 3.180
Youngblood, M.W. 1.050
Yourick, D.L. 1.210
Yu, F.H. 1.202
Yu, H. 2.220
Yu, R. 3.139
Yu, T.W. 1.293
Yu, Y. 3.072
Yuan, H. 1.019
Yuan, Y. 2.251
Yuceer, N. 3.061
Yum, M. 3.027, 3.046
Yuskaitis, C. 2.077
Z
Zabad, R. 3.096
Zaghloul, K. 1.193
Zaheer, F. 2.152
Zajac, J. 2.186
Zak, M. 3.230
Zanchi, C. 2.067
Zanotti-Fregonara, P. 1.193
Zanotto, F. 3.224
Zavala-Tecuapetla, C. 1.049
Zaveri, H. 3.078, 3.110
Zayyad, Z. C.07
Zelleke, T. 1.131, 2.260
Zelmann, R. 2.192
Zempel, J. 1.155
Zeng, L. 3.016
Zeng, Z. 1.203
Zentner, J. 1.254
Zerbs, A. 2.164
Zhan, Q. 3.048, 3.106, 3.107, C.07
Zhang, H. 1.009, 2.084, 2.089, 3.004,
3.016
Zhang, R. 3.163
Zhang, S. 1.056
Zhang, T. 3.118
Zhang, W. 1.090
Zhang, Z.W. 1.107
Zhao, Q. 2.223
Zhao, X. 2.011
Zheng, T. 1.059
Zhou, C. 1.023, 3.033
Zhou, F. 1.059, 3.042
Zhou, J. 2.054
Zhou, S. 1.140, 1.142, 1.145, 1.146,
2.049, 2.050
Zhu, J. 1.135, 3.262
Ziai, W. 3.160
Zijlmans, M. 1.093, 1.097, 1.117,
2.192
Zillgitt, A. 1.082, 1.083, 1.159
Zions, M. 3.018
Zoghbi, S. 1.193
Zou, G. 3.165
Zrik, A. 2.195
Zuberi, S. 2.041
Zuercher, U. 3.037
Zummo, L. 3.257
Zurita Santamaría, J. 2.138
COMMERCIAL SUPPORTER RECOGNITION
All as of October 21, 2013
Leader Level
Special thanks to:
Eisai Inc.
for supporting:
SUPPORTER LEVELS
• Exhibit
• Epilepsy Currents Ads
• Educational Grant – Annual Course,
Professionals in Epilepsy Care Symposium,
Epilepsy Specialist Symposium,
AET Symposium
• AES Fellows/Epi-PORT
• AES Named Fellowship (Sustained)
• Young Investigator Awards
• Nurse Awards
• Innovation Pavilion (Monday)
97
Leader Level
Special thanks to:
Lundbeck
Pharmaceuticals,
Inc.
for supporting:
•
•
•
•
•
Exhibit
Scientific Exhibit
Innovation Pavilion (Saturday/Sunday)
Epilepsy Currents Ads
AES Fellows/Epi-PORT (Sustained)
• Educational Grant – Annual Fundamentals Symposium,
Epilepsy Specialist Symposium, Professionals in Epilepsy
Care Symposium, Pediatric State of the Art Symposium
• Program Book Ad
• Seed Grant
• Door Drop
98
Leader Level
Special thanks to:
UCB, Inc.
for supporting:
•
•
•
•
Exhibit
Scientific Exhibit
Program Book Ad
Educational Grant – Annual Course and AET
Symposium
• AES Annual Meeting
SUPPORTER LEVELS
99
Leader Level
Special thanks to:
Sunovion
Pharmaceuticals
Inc.
for supporting:
• Exhibit
• Scientific Exhibit
• Educational Grant – AET Symposium and
Annual Course
• Lunch in Exhibit Hall (Saturday)
• SIGs (2)
• Poster Session Breakfast (Sunday/Monday)
• Exhibit Hall Coffee Break (Sunday)
• Program Book Ad
• Innovation Pavilion (Monday)
• Cell Phone Charging Station (2)
• Cyber Café (3 days)
• Passport to Prizes
• Door Drops
100
Partner Level
Special thanks to:
Upsher-Smith
Laboratories, Inc.
for supporting:
•
•
•
•
•
•
•
•
•
•
•
Exhibit
Hoyer Lecture
Program Book Ad
Scientific Exhibit
AES Fellows/Epi-PORT
Seed Grant
Subspecialty Exam Prep Support
Young Investigators Awards
Nurse Awards
Passport to Prizes
Door Drop
SUPPORTER LEVELS
101
Supporter Level
Special thanks to:
for supporting:
Questcor
Pharmaceuticals,
Inc.
• Exhibit
• SIGs (2)
• Innovation Pavilion
(Sunday/Monday)
• Program Book Ad
• AES Fellows/Epi-PORT
• Pediatric State of the Art
Symposium
• Door Drop
Supporter Level
102
Special thanks to:
for supporting:
Cyberonics, Inc.
• Exhibit
• Educational Grant –
Annual Course
• Named Fellow
• AES Fellow/Epi-PORT
Supporter Level
Special thanks to:
for supporting:
Supernus
Pharmaceuticals,
Inc.
•
•
•
•
•
•
•
•
Exhibit
Program Book Ad
AES Fellows/Epi-PORT
Door Drop
Virtual Bag Banner
Scientific Exhibit (2)
Passport to Prizes
Exhibit Hall Reception
“Suds for Scientists”
Supporter Level
Special thanks to:
for supporting:
Pfizer Inc.
• Annual Meeting
SUPPORTER LEVELS
103
Contributor Level
Contributor Level
Special thanks to:
Special thanks to:
Nihon Kohden
America, Inc.
Acorda Therapeutics
for supporting:
for supporting:
• Exhibit
• Exhibit
• Auction of Video EEG machine
• Program Book Ad
• AES Fellows /Epi-PORT
Contributor Level
Special thanks to:
Compumedics
Limited
for supporting:
• Exhibit
104
Advocate Level
Special thanks to these companies for supporting:
NeuroPace
• Exhibit
• Innovation Pavilion
Natus Neurology
Incorporated
• Exhibit
Cadwell
Laboratories, Inc.
• Exhibit
Medtronic, Inc.
• Exhibit
GlaxoSmithKline
• Exhibit
• Year Round Education
Electrical Geodesics,
Inc.
• Exhibit
• Exhibit Hall Reception “Suds for
Scientists”
• Passport for Prizes
Patron Level
Special thanks to these
companies for supporting:
Visualase, Inc.
• Exhibit
Ad Tech Medical
Instrument Corp.
• Exhibit
Lifelines
Neurodiagnostics
Systems, Inc.
• Exhibit
Neurolynx, Inc
• Exhibit
PMT Corporation
• Exhibit
Ripple LLC
• Exhibit
Epilepsy Foundation
• Exhibit
SUPPORTER LEVELS
• Young Investigators Awards
ELEKTA
Blackrock Neuromed
• Exhibit
105
GENERAL INFORMATION
AES 2013 Annual Meeting
The American Epilepsy Society (AES) is one of 108 Chapters of the
International League Against Epilepsy (ILAE). The Annual Meeting of the
American Epilepsy Society is the largest meeting and exhibition in the world
for those who share the common scientific and clinical interests of epilepsy
and clinical neurophysiology. Each year over 4,000 attendees gather who are
dedicated to improving the quality of life for those afflicted with epilepsy. This
meeting will be the top forum to examine common concerns and to gain
insight from leading authorities.
Mission Statement
The American Epilepsy Society promotes research and education for
professionals dedicated to the prevention, treatment and cure of epilepsy.
Target Audience
Basic: Those new to epilepsy treatment or whose background is limited, e.g.,
students, residents, general physicians, general neurologists and
neurosurgeons, other professionals in epilepsy care, administrators.
Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons,
“mid-level” providers with experience in epilepsy care (e.g., advanced practice
nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic
and translational researchers.
Advanced: Symposium will address highly technical or complex topics
(e.g., neurophysiology, advanced imaging techniques, advanced treatment
modalities, including surgery).
Policy on Commercial Support and Conflict
of Interest
The American Epilepsy Society maintains a policy on the use of commercial
support, which ensures that all educational activities sponsored by the AES
provide in-depth presentations that are fair, balanced, independent and
scientifically rigorous. All faculty, planning committee members, editors,
managers and other individuals who are in a position to control content are
required to disclose any relevant relationships with any commercial interests
related to the activity. The existence of these interests or relationships is not
viewed as implying bias or decreasing the value of the presentations. All
educational materials are reviewed for fair balance, scientific objectivity and
levels of evidence. This information will also be made available through
syllabus materials and faculty presentations.
Disclosure of Unlabeled / Unapproved Uses
This educational program may include references to the use of products for
indications not approved by the FDA. These discussions are noted on the
faculty’s disclosure forms as well as during their presentations. Opinions
expressed with regard to unapproved uses of products are solely those of the
faculty and are not endorsed by the American Epilepsy Society or any other
manufacturers of pharmaceuticals.
Abstracts
Abstracts from the 2013 Annual Meeting will be available on the AES website
and as an online supplement to Epilepsy Currents.
Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to offer continuing medical education
for physicians.
Nurses: EDUPRO Resources LLC is an approved provider of continuing
nursing education by Pennsylvania State Nurses Association, an accredited
approver by the American Nurses Credentialing Center’s Commission on
Accreditation.
EDUPRO is also an approved provider by the California Board of Registered
Nursing, provider number CEP-14387.
Nurses who participate in selected AES programs can receive up to 30.75
contact hours. To successfully complete the activities, nurses will be required
to complete evaluations for each session attended and to access the Medical
Education Evaluator to claim credit.
Pharmacists: Extension Services in Pharmacy at the University of
Wisconsin-Madison School of Pharmacy is accredited by the
Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy education. Selected portions of this Annual
Meeting are approved for pharmacy CE credit. Specific hours of credit for
approved presentations and Universal Program numbers assigned to those
presentations are found elsewhere in program materials. Credit is based on
documented program attendance, on-line completion of a Program
Evaluation/Assessment.
Those seeking pharmacy CE credit will be required to access the ESP website
and complete the on-line assessments/evaluations for each accredited
session. No CE credit will be provided beyond January 15, 2014. Note that
further information regarding the CPE Monitor program and unique identifier
number can be found at www.pharmacy.wisc.edu/esp
International Credits: The American Medical Association has determined
that non-U.S. licensed physicians who participate in this CME activity are
eligible for AMA PRA Category 1 Credits TM.
CME / CE Certificates
The Medical Education Evaluator® is an online system that allows any
attendee to self-manage the process of completing course evaluations,
tracking educational credits and printing out the CME or nursing certificate.
Pharmacy certificates are available separately as noted above.
Once you have accessed the Medical Education Evaluator®, you will be asked
to enter your “myAES number” and password. The certificate(s) are saved to
your personal account page which is cumulative. You may print the
certificate(s) in PDF format at any time.
To help support this process, attendees who want educational credits will be
asked to pay:
Member Fees:
Non-member Fees:
$50 through January 17, 2014
$75 January 18 – February 28, 2014
$75 through January 17, 2014
$100 January 18 – February 28, 2014
The online evaluator will be left open through February 28, 2014, so
you must complete the evaluations and credit tracking by that date.
By completing this information online, attendees greatly assist the Council on
Education and Annual Meeting Committee with important needs assessment
data whereby the AES can further plan and address educational gaps to meet
the needs of our learners.
A meeting attendance certificate will be available at the registration desk for
international meeting attendees.
Insurance, Liabilities
Handouts
Credit Designation
Questions? Please contact virtualTotebag Support Desk at 410.402.1062
AES cannot be held responsible for any personal injury, loss, damage,
accident to private property or additional expenses incurred as a result of
delays or changes in air, rail, sea, road, or other services, strikes, sickness,
weather, acts of terrorism and any other cause. All participants are
encouraged to make their own arrangements for health and travel insurance.
Physicians: The American Epilepsy Society designates this live activity for a
maximum of 30.75 AMA PRA Category 1 CreditsTM. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
Physician Assistant: AAPA accepts certificates of participation for
educational activities certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 35.25 hours of Category 1
credit for completing this program.
106
Handouts for the educational symposia will be available
via the virtualTotebag. For instructions: please refer to
the flyer provided in your meeting bag or go to the AES
website for details at www.AESnet.org/meetings-andevents.
GENERAL INFORMATION
Audience Response System
AES will be utilizing the Audience Response System (ARS) in all of the
symposia. Faculty will have ARS questions throughout their presentations with
multiple choice answers. To participate, you will use your cell phone to text
your reply. When a question appears in a presentation, simply text your
answer (a 5 or 6 digit code) to “22333.” Standard text rates will apply. The
ARS will allow for interactive audience participation as well as real time,
immediate feedback to enhance the learning environment and ensure that we
are meeting the learning objectives set forth by each symposium.
Program Changes
AES cannot assume liability for any changes in the program due to external or
unforeseen circumstances.
Commercial Exhibits (page 73)
The Exhibit Hall is an integral part of the learning experience. Meeting
participants will have an ideal opportunity to learn about the latest in
pharmaceuticals, publications, scientific equipment, and technology relevant
to the fields of epilepsy and neurophysiology. Please check the AES website
for an updated listing of exhibiting companies and organizations. To ensure
safety and security, no children, strollers, carriages, wheeled luggage or
wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours.
Sunday, December 8
Monday, December 9
Noon - 6:00 p.m.
10:00 a.m. - 6:00 p.m.
10:00 a.m. - 3:30 p.m.
Scientific Exhibits (page 21)
AES has approved guidelines for industry-sponsored, Scientific Exhibits at the
Annual Meeting. Scientific Exhibits differ from traditional poster presentations
in that a broad range of material can be presented as a collection of topics,
such as results of various clinical trials, or a thematic presentation of one
aspect of drug development. Scientific Exhibits will be displayed on Sunday,
December 8 and Monday, December 9. An application to register for a
Scientific Exhibit was emailed to interested companies in May. Reservations
will be reviewed and accepted on a first-come, first-served basis until space
is sold out. Send inquiries of interest to JoLynn Amsden at
[email protected].
Cyber Café
Open during Exhibit Hall hours
The Cyber Café will be available at the Convention Center with email and
Internet access. Check in with family members and colleagues, and conduct
online research while attending the Meeting. You will also be able to complete
the course evaluations and obtain your CME certificate online. Material presented
at the AES Annual Meeting is not to be reproduced in any format without the
express written consent of the AES. For your convenience, Wi-Fi will also be
available in the Convention Center.
Language
The official language of the Annual Meeting is English.
Photography and Recording of Programs
Attendees acknowledge and agree that commercial or promotional
distribution, publishing or exploitation of speaker sessions, content, or
materials from the AES Annual Meeting is strictly prohibited unless you have
received the express prior written permission from AES or the otherwise
applicable rights holder.
When you attend an American Epilepsy Society (AES) event or program,
you enter an area where photography, audio, and video recording may occur.
By entering the event premises, you consent to photography and its release,
publication, exhibition, or reproduction to be used for news, newsletters,
promotional purposes, advertising, inclusion on websites, or any other
purpose by AES and representatives. You release AES, its officers and
employees, and each and all persons involved from any liability connected
with the taking, digitizing, or publication of photographs and computer images.
You have been fully informed of your consent, waiver of liability, and release
before entering the event.
AES offers meeting information and assistance for journalists reporting on
epilepsy studies, educational presentations, and special reports at this
meeting. The AES on-site Press Room staff works with journalists to develop
stories, research facts and information, and connect with experts and
presenters. The on-site Press Room is also available to sponsors and
exhibitors for the display and distribution of relevant press releases and media
kits. For more information. contact Peter Van Haverbeke 703-927-9639 or
Natalie Judd 203-605-9515 [email protected].
Friday, December 6 ..................................................
Saturday, December 7 ..............................................
Sunday, December 8 ................................................
Monday, December 9 ..............................................
Tuesday, December 10..............................................
11:00 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 2:30 p.m.
A series of media briefings on the following topics will be held in the press
room from Friday, December 6 through Tuesday, December 10. Details will be
posted in Room 209A, Level Two at the Walter E. Washington Convention
Center and in advance on the AES website Press Room after December 1.
Some of the featured press topics include:
• New Reports on Genetic Causes of Epilepsy
• Home Monitoring Tests
• New Findings on Women and Epilepsy
• Efficacy of Epilepsy Surgery
• Drug Equivalency
• Burden of Epilepsy in Veterans
• Risks of AED Withdrawal
• Impact of Prolonged Childhood Seizures
• Changing Landscape of Epilepsy Surgery
Hotel Information
Early Departure Policy
Guests who check out of the hotel prior to their scheduled departure date will
be charged a penalty of one night’s room rate and tax.
Renaissance Washington, D.C. Downtown Hotel (Headquarters Hotel)
999 Ninth Street, NW, Washington, D.C. 20001
Telephone: 202.898.9000
Courtyard by Marriot D.C. Convention Center
900 F Street, NW, Washington, D.C. 20004
Telephone: 202.638.4600
Embassy Suites Washington, D.C. – Convention Center
900 10th Street, NW, Washington, D.C. 20001
Telephone: 202.739.2001
Grand Hyatt Washington, D.C.
1000 H Street, NW, Washington, D.C.
Telephone: 202.582.1234
Hampton Inn Washington Downtown
Telephone: 202.842.2500
Washington Marriott at Metro Center
Telephone: 202.737.2200
Meeting Location
Walter E. Washington Convention Center
801 Mt Vernon Place NW, Washington, D.C. 20001
Business Centers
Two full-service business centers are available at the following locations:
The Capital Business Center offers an array of high demand services and
products tailored to meet your needs. On-site services include shipping,
mailing, faxing and photocopying. The center is located in the Walter E.
Washington Convention Center on the Street Level across from Salon F.
Phone: 202.289.5233 Emails: [email protected]
GENERAL INFORMATION
AES strictly prohibits all photography (flash, digital, or otherwise), audio and /
or videotaping during the Annual Meeting. Equipment will be confiscated.
Press Room
107
GENERAL INFORMATION
FedEx Office is located in the Renaissance Washington, D.C. Downtown Hotel
on the Ballroom level. Please visit their website for details at
http://local.fedex.com/dc/washington/office-5041/ or call 202.789.1015.
Safety and Security Information
No Smoking Policy
• Pick up any Convention Center house phone located in the facility and dial
3333 or 202.249.3333. Uniformed Convention Center employees have
radios and are ready to assist you. Advise the dispatcher of the exact
location within the Convention Center.
For the comfort and health of all attendees, smoking is not permitted at
any AES function. This includes educational sessions, meetings and all
food functions. Both the Convention Center and the Renaissance are smokefree facilities. Also, smoking is not permitted in public buildings, restaurants or
bars.
Meeting Attire
AES promotes casual business attire for the duration of the Annual Meeting.
Consider bringing a light jacket or sweater with you since meeting room
temperatures and personal comfort levels vary.
Information for International Travelers
Consulates and Embassies
All international embassies from other countries to the United States are
located in Washington, D.C. Call directory information in Washington, D.C.
(phone: 202.555.1212) for the number of your national embassy.
Gratuities
The following security measures have been designed to further enhance your
personal and professional safety.
We respectfully request that you do NOT call 911 directly.
• An EMT will be on duty in the Convention Center throughout the meeting.
• A government-issued photo identification is required to receive a badge
and to replace a lost badge.
• Convention Center Security may randomly check packages and bags at the
Convention Center entrances, meeting rooms and in the Exhibit Hall.
• You will be asked to always clearly display your name badge and to use
only approved Convention Center entrances and exits.
• Appropriate badges will be required to enter all educational sessions,
Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire
regulations, doors will be closed to all session rooms that fill to capacity.
Gratuities are not automatically added to the bill, except in some cases for
large groups. Servers are usually given 15% to 20% of the bill. Taxi drivers
usually receive 15% of the fare and door attendants, skycaps and porters are
normally tipped $1 per bag.
• Throughout the meeting, you will notice security staff presence to monitor
the safety of all participants.
Registration and Security
• Please report any suspicious activity to security staff or to the AES
registration desk staff.
The American Epilepsy Society is committed to providing a secure meeting
environment. A formal security plan is in place with the Security Department
at the Convention Center. All meeting attendees will be required to produce
government-issued photo identification prior to receiving their badge and
registration materials. Appropriate badges must be worn at all times while in
attendance at the meeting and are required for admittance to all meeting
activities. Special security procedures are also in place for exhibition materials
and all deliveries to the AES meeting.
General Safety Tips
• Remove your badge once you leave the meeting facilities.
• Carry important telephone numbers with you.
• Do not display or carry large amounts of cash.
• Walk in groups, especially at night.
• Lock your hotel room door.
• Always verify hotel room repair or service calls.
Contact Information
• Do not disclose your room number to anyone.
342 North Main Street
West Hartford, CT 06117-2507
Phone:
Meeting Fax:
E-mail:
Website:
• Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.)
in any area of the Convention Center or hotel.
• Never give your personal information (credit card, room number, etc.) over
the phone; instead, go to the front desk if the hotel calls with questions.
860.586.7505
860.586.7550
[email protected]
www.AESnet.org
Faculty Ready Room and Photos
Location: Convention Center – Room 209B, Level Two
Faculty need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint
presentations have already been uploaded through the AES Faculty Development Room. All faculty must stop by
to reconfirm their presentation with an audiovisual technician.
Thursday, December 5
Friday, December 6
..............................
..................................
4:00 p.m. - 8:00 p.m.
8:00 a.m. - 6:00 p.m.
Saturday, December 7 .............................. 8:00 a.m. - 6:00 p.m.
Sunday, December 8
................................
8:00 a.m. - 6:00 p.m.
Monday, December 9 ................................ 8:00 a.m. - 6:00 p.m.
Tuesday, December 10
108
..........................
8:00 a.m. - 11:00 a.m.
MAP OF WASHINGTON, D.C.
109
WALTER E. WASHINGTON CONVENTION CENTER
Street Level
Level Two
110
WALTER E. WASHINGTON CONVENTION CENTER
Level Three
Ballroom B
General Sessions
111
RENAISSANCE WASHINGTON, D.C. DOWNTOWN HOTEL
112
NOTES
113
113
NOTES
114
Stay informed with
Look to The Lancet Neurology for original research, expert reviews, informative commentary, and breaking news – all with a
clear, independent perspective – and stay well informed about the developments shaping the clinical neurology field today.
Whether you are a reader or an author, The Lancet Neurology has valuable time-saving resources for you:
Read breakthrough research, reviews, and news at thelancet.com/neurology
Download our new Lancet iPad app at apple.com/iTunes
Stay informed with e-tables of contents and news alerts at thelancet.com
Gain greater insight from monthly podcasts available on iTunes and at thelancet.com
Submit a manuscript at ees.elsevier.com/thelancetneurology
Get your original research fast-track published within 8 weeks from submission
SPECIAL CONFERENCE OFFER!
Benefit from a 25% discount on your choice of either an online or a print with online subscription.
Visit www.thelancet.com/subscribe-laneur and enter promo code PA217 to ensure your discount.
In delivering science
for better health
www.thelancet.com/neurology
THE LANCET® is a registered trademark of Reed Elsevier Properties S.A., used under licence.
115
116
117
118
119
120
121
Driven by Our Commitment
to Patients and Healthcare Professionals
VIMPAT ® is a registered trademark under license from Harris FRC Corporation.
©2013, UCB, Inc., Smyrna, GA 30080. All rights reserved. Printed in U.S.A.
LCM-PRM-025861-0913
Scan the code or
visit www.vimpat.com/steps
to find out more.

2013 AES Annual Meeting, Washington, D.C

Transcription

Similar documents

Seafood and Sandals

our profile from the December 2015

I want to do one or two films a year

KORB-Seizure - Hospitalist Presentation with Cases [31576].pptx

Absence seizures in children

Headlines - Epilepsy Foundation of Michigan

Headlines - Epilepsy Foundation of Michigan

Lecture 52-Epilepsy

here - Brain Canada